A tetrazole c1 g0">derivative of formula (I) ##STR1## wherein R is H, alkyl, alkoxy, carbocyclic ring, alkyl or alkoxy substituted by carbocyclic ring;

AA1 and AA2 is a bond or ##STR2## and ##STR3## respectively, or AA1 and AA2, together, may have the formula (a); ##STR4## and Y is formula (b) ##STR5## wherein the Tet ring is tetrazole; Z is alkylene, alkenylene, O, S, SO, SO2, NR26, methylene in alkylene replaced by O, S, --SO--, --SO2 -- or --NR26 --; and E is H, alkyl, or COOR27.

PTO Wrapper PDF
Dossier Espace Google
Patent
   6136834
Priority
Dec 27 1995
Filed
Jun 29 1998
Issued
Oct 24 2000
Expiry
Dec 26 2016
Inventors
Tanaka, Ma…
Assg.orig
ONO PHARMA…
Assg.curr
ONO Pharma…
Entity
Large
Referenced by
23
References
7
Maint.:
EXPIRED
FIELD OF THE INVENTI…
BACKGROUND OF THE IN…
RELATED ARTS
PURPOSE OF THE INVEN…
COMPARISON OF THE IN…
SUMMARY OF THE INVEN…
PROCESSES FOR THE PR…
Application for Phar…
BEST MODE TO PRACTIC…
EXAMPLE 1
Example 1(1)
Example 1(2)
EXAMPLES 1(3)-1(6)
Example 1(3)
Example 1(4)
Example 1(5)
Example 1(6)
Example 2(1)
EXAMPLES 2(2)-2(6)
Example 2(2)
Example 2(3)
Example 2(4)
Example 2(5)
Example 2(6)
EXAMPLES 3(1)-3(7)
Example 3(1)
Example 3(2)
Example 3(3)
Example 3(4)
Example 3(5)
Example 3(6)
Example 3(7)
EXAMPLES 4(1)-4(7)
Example 4(1)
Example 4(2)
Example 4(3)
Example 4(4)
Example 4(5)
Example 4(6)
Example 4(7)
Reference Example 1
Reference Example 1(…
Reference Example 2
Reference Example 3
Reference Example 4
Reference Example 5
Reference Example 6
Reference Example 7
EXAMPLES 5(1)-5(160)
Example 5(1)
Example 5(2)
Example 5(3)
Example 5(4)
Example 5(5)
Example 5(6)
Example 5(7)
Example 5(8)
Example 5(9)
Example 5(10)
Example 5(11)
Example 5(12)
Example 5(13)
Example 5(14)
Example 5(15)
Example 5(16)
Example 5(17)
Example 5(18)
Example 5(19)
Example 5(20)
Example 5(21)
Example 5(22)
Example 5(23)
Example 5(24)
Example 5(25)
Example 5(26)
Example 5(27)
Example 5(28)
Example 5(29)
Example 5(30)
Example 5(31)
Example 5(32)
Example 5(33)
Example 5(34)
Example 5(35)
Example 5(36)
Example 5(37)
Example 5(38)
Example 5(39)
Example 5(40)
Example 5(41)
Example 5(42)
Example 5(43)
Example 5(44)
Example 5(45)
Example 5(46)
Example 5(47)
Example 5(48)
Example 5(49)
Example 5(50)
Example 5(51)
Example 5(52)
Example 5(53)
Example 5(54)
Example 5(55)
Example 5(56)
Example 5(57)
Example 5(58)
Example 5(59)
Example 5(60)
Example 5(61)
Example 5(62)
Example 5(63)
Example 5(64)
Example 5(65)
Example 5(66)
Example 5(67)
Example 5(68)
Example 5(69)
Example 5(70)
Example 5(71)
Example 5(72)
Example 5(73)
Example 5(74)
Example 5(75)
Example 5(76)
Example 5(77)
Example 5(78)
Example 5(79)
Example 5(80)
Example 5(81)
Example 5(82)
Example 5(83)
Example 5(84)
Example 5(85)
Example 5(86)
Example 5(87)
Example 5(88)
Example 5(89)
Example 5(90)
Example 5(91)
Example 5(92)
Example 5(93)
Example 5(94)
Example 5(95)
Example 5(96)
Example 5(97)
Example 5(98)
Example 5(99)
Example 5(100)
Example 5(101)
Example 5(102)
Example 5(103)
Example 5(104)
Example 5(105)
Example 5(106)
Example 5(107)
Example 5(108)
Example 5(109)
Example 5(110)
Example 5(111)
Example 5(112)
Example 5(113)
Example 5(114)
Example 5(115)
Example 5(116)
Example 5(117)
Example 5(118)
Example 5(119)
Example 5(120)
Example 5(121)
Example 5(122)
Example 5(123)
Example 5(124)
Example 5(125)
Example 5(126)
Example 5(127)
Example 5(128)
Example 5(129)
Example 5(130)
Example 5(131)
Example 5(132)
Example 5(133)
Example 5(134)
Example 5(135)
Example 5(136)
Example 5(137)
Example 5(138)
Example 5(139)
Example 5(140)
Example 5(141)
Example 5(142)
Example 5(143)
Example 5(144)
Example 5(145)
Example 5(146)
Example 5(147)
Example 5(148)
Example 5(149)
Example 5(150)
Example 5(151)
Example 5(152)
Example 5(153)
Example 5(154)
Example 5(155)
Example 5(156)
Example 5(157)
Example 5(158)
Example 5(159)
Example 5(160)
Example 6(1)
EXAMPLES 6(2)-6(160)
Example 6(2)
Example 6(3)
Example 6(4)
Example 6(5)
Example 6(6)
Example 6(7)
Example 6(8)
Example 6(9)
Example 6(10)
Example 6(11)
Example 6(12)
Example 6(13)
Example 6(14)
Example 6(15)
Example 6(16)
Example 6(17)
Example 6(18)
Example 6(19)
Example 6(20)
Example 6(21)
Example 6(22)
Example 6(23)
Example 6(24)
Example 6(25)
Example 6(26)
Example 6(27)
Example 6(28)
Example 6(29)
Example 6(30)
Example 6(31)
Example 6(32)
Example 6(33)
Example 6(34)
Example 6(35)
Example 6(36)
Example 6(37)
Example 6(38)
Example 6(39)
Example 6(40)
Example 6(41)
Example 6(42)
Example 6(43)
Example 6(44)
Example 6(45)
Example 6(46)
Example 6(47)
Example 6(48)
Example 6(49)
Example 6(50)
Example 6(51)
Example 6(52)
Example 6(53)
Example 6(54)
Example 6(55)
Example 6(56)
Example 6(57)
Example 6(58)
Example 6(59)
Example 6(60)
Example 6(61)
Example 6(62)
Example 6(63)
Example 6(64)
Example 6(65)
Example 6(66)
Example 6(67)
Example 6(68)
Example 6(69)
Example 6(70)
Example 6(71)
Example 6(72)
Example 6(73)
Example 6(74)
Example 6(75)
Example 6(76)
Example 6(77)
Example 6(78)
Example 6(79)
Example 6(80)
Example 6(81)
Example 6(82)
Example 6(83)
Example 6(84)
Example 6(85)
Example 6(86)
Example 6(87)
Example 6(88)
Example 6(89)
Example 6(90)
Example 6(91)
Example 6(92)
Example 6(93)
Example 6(94)
Example 6(95)
Example 6(96)
Example 6(97)
Example 6(98)
Example 6(99)
Example 6(100)
Example 6(101)
Example 6(102)
Example 6(103)
Example 6(104)
Example 6(105)
Example 6(106)
Example 6(107)
Example 6(108)
Example 6(109)
Example 6(110)
Example 6(111)
Example 6(112)
Example 6(113)
Example 6(114)
Example 6(115)
Example 6(116)
Example 6(117)
Example 6(118)
Example 6(119)
Example 6(120)
Example 6(121)
Example 6(122)
Example 6(123)
Example 6(124)
Example 6(125)
Example 6(126)
Example 6(127)
Example 6(128)
Example 6(129)
Example 6(130)
Example 6(131)
Example 6(132)
Example 6(133)
Example 6(134)
Example 6(135)
Example 6(136)
Example 6(137)
Example 6(138)
Example 6(139)
Example 6(140)
Example 6(141)
Example 6(142)
Example 6(143)
Example 6(144)
Example 6(145)
Example 6(146)
Example 6(147)
Example 6(148)
Example 6(149)
Example 6(150)
Example 6(151)
Example 6(152)
Example 6(153)
Example 6(154)
Example 6(155)
Example 6(156)
Example 6(157)
Example 6(158)
Example 6(159)
Example 6(160)
Example 7
EXAMPLES 7(1)-7(3)
Example 7(1)
Example 7(2)
Example 7(3)
Example 8(1)
EXAMPLES 8(2)-8(4)
Example 8(2)
Example 8(3)
Example 8(4)
Example 9(1)
EXAMPLES 9(2)-9(4)
Example 9(2)
Example 9(3)
Example 9(4)
EXAMPLES 10(1)-10(8)
Example 10(1)
Example 10(2)
Example 10(3)
Example 10(4)
Example 10(5)
Example 10(6)
Example 10(7)
Example 10(8)
Example 11
Example 12
Reference Example 8
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Reference Example 8(…
Example 13(1)
EXAMPLES 13(2)-13(12)
Example 13(2)
Example 13(3)
Example 13(4)
Example 13(5)
Example 13(6)
Example 13(7)
Example 13(8)
Example 13(9)
Example 13(10)
Example 13(11)
Example 13(12)
EXAMPLES 14(1)-14(10…
Example 14(1)
Example 14(2)
Example 14(3)
Example 14(4)
Example 14(5)
Example 14(6)
Example 14(7)
Example 14(8)
Example 14(9)
Example 14(10)
Example 14(11)
Example 14(12)
Example 14(13)
Example 14(14)
Example 14(15)
Example 14(16)
Example 14(17)
Example 14(18)
Example 14(19)
Example 14(20)
Example 14(21)
Example 14(22)
Example 14(23)
Example 14(24)
Example 14(25)
Example 14(26)
Example 14(27)
Example 14(28)
Example 14(29)
Example 14(30)
Example 14(31)
Example 14(32)
Example 14(33)
Example 14(34)
Example 14(35)
Example 14(36)
Example 14(37)
Example 14(38)
Example 14(39)
Example 14(40)
Example 14(41)
Example 14(42)
Example 14(43)
Example 14(44)
Example 14(45)
Example 14(46)
Example 14(47)
Example 14(48)
Example 14(49)
Example 14(50)
Example 14(51)
Example 14(52)
Example 14(53)
Example 14(54)
Example 14(55)
Example 14(56)
Example 14(57)
Example 14(58)
Example 14(59)
Example 14(60)
Example 14(61)
Example 14(62)
Example 14(63)
Example 14(64)
Example 14(65)
Example 14(66)
Example 14(67)
Example 14(68)
Example 14(69)
Example 14(70)
Example 14(71)
Example 14(72)
Example 14(73)
Example 14(74)
Example 14(75)
Example 14(76)
Example 14(77)
Example 14(78)
Example 14(79)
Example 14(80)
Example 14(81)
Example 14(82)
Example 14(83)
Example 14(84)
Example 14(85)
Example 14(86)
Example 14(87)
Example 14(88)
Example 14(89)
Example 14(90)
Example 14(91)
Example 14(92)
Example 14(93)
Example 14(94)
Example 14(95)
Example 14(96)
Example 14(97)
Example 14(98)
Example 14(99)
Example 14(100)
Example 14(101)
Example 14(102)
Example 14(103)
Example 14(104)
Example 14(105)
Example 14(106)
EXAMPLES 15(1)-15(10…
Example 15(1)
Example 15(2)
Example 15(3)
Example 15(4)
Example 15(5)
Example 15(6)
Example 15(7)
Example 15(8)
Example 15(9)
Example 15(10)
Example 15(11)
Example 15(12)
Example 15(13)
Example 15(14)
Example 15(15)
Example 15(16)
Example 15(17)
Example 15(18)
Example 15(19
Example 15(20)
Example 15(21)
Example 15(22)
Example 15(23)
Example 15(24)
Example 15(25)
Example 15(26)
Example 15(27)
Example 15(28)
Example 15(29)
Example 15(30)
Example 15(31)
Example 15(32)
Example 15(33)
Example 15(34)
Example 15(35)
Example 15(36)
Example 15(37)
Example 15(38)
Example 15(39)
Example 15(40)
Example 15(41)
Example 15(42)
Example 15(43)
Example 15(44)
Example 15(45)
Example 15(46)
Example 15(47)
Example 15(48)
Example 15(49)
Example 15(50)
Example 15(51)
Example 15(52)
Example 15(53)
Example 15(54)
Example 15(55)
Example 15(56)
Example 15(57)
Example 15(58)
Example 15(59)
Example 15(60)
Example 15(61)
Example 15(62)
Example 15(63)
Example 15(64)
Example 15(65)
Example 15(66)
Example 15(67)
Example 15(68)
Example 15(69)
Example 15(70)
Example 15(71)
Example 15(72)
Example 15(73)
Example 15(74)
Example 15(75)
Example 15(76)
Example 15(77)
Example 15(78)
Example 15(79)
Example 15(80)
Example 15(81)
Example 15(82)
Example 15(83)
Example 15(84)
Example 15(85)
Example 15(86)
Example 15(87)
Example 15(88)
Example 15(89)
Example 15(90)
Example 15(91)
Example 15(92)
Example 15(93)
Example 15(94)
Example 15(95)
Example 15(96)
Example 15(97)
Example 15(98)
Example 15(99)
Example 15(100)
Example 15(101)
Example 15(102)
Example 15(103)
Example 15(104)
Example 15(105)
Example 15(106)
EXAMPLES 16(1)-16(4)
Example 16(1)
Example 16(2)
Example 16(3)
Example 16(4)
EXAMPLES 17(1)-17(4)
Example 17(1)
Example 17(2)
Example 17(3)
Example 17(4)
Reference Example 9(…
Reference Example 9(…
Reference Example 9(…
Reference Example 9(…
Example 18(1)
EXAMPLES 18(2)-18(28)
Example 18(2)
Example 18(3)
Example 18(4)
Example 18(5)
EXAMPLES 18(6) AND 1…
Example 18(8)
Example 18(9)
Example 18(10)
Example 18(11)
EXAMPLES 18(12) AND …
Example 18(14)
Example 18(15)
Example 18(16)
Example 18(17)
Example 18(18)
Example 18(19)
Example 18(20)
Example 18(21)
Example 18(22)
Example 18(23)
Example 18(24)
Example 18(25)
Example 18(26)
Example 18(27)
Example 18(28)
EXAMPLES 19(1)-19(26)
Example 19(1)
Example 19(2)
Example 19(3)
Example 19(4)
Example 19(5)
Example 19(6)
Example 19(7)
Example 19(8)
Example 19(9)
Example 19(10)
Example 19(11)
Example 19(12)
Example 19(13)
Example 19(14)
Example 19(15)
Example 19(16)
Example 19(17)
Example 19(18)
Example 19(19)
Example 19(20)
Example 19(21)
Example 19(22)
Example 19(23)
Example 19(24)
Example 19(25)
Example 19(26)
EXAMPLES 20(1)-20(2)
Example 20(1)
Example 20(2)
Reference Example 10
Example 21 (1)
Example 22(1) and Ex…
Example 22(1)
Example 22(2)
Example 23(1)
Example 23(2)
Reference Example 11…
Reference Example 11…
Reference Example 11…
EXAMPLES 24(1)-24(12)
Example 24(1)
Example 24(2)
Example 24(3)
Example 24(4)
Example 24(5)
Example 24(6)
Example 24(7)
Example 24(8)
Example 24(9)
Example 24(10)
Example 24(11)
Example 24(12)
EXAMPLES 25(1)-25(11)
Example 25(1)
Example 25(2)
Example 25(3)
Example 25(4)
Example 25(5)
Example 25(6)
Example 25(7)
Example 25(8)
Example 25(9)
Example 25(10)
Example 25(11)
EXAMPLE 26(1) and EX…
Example 26(1)
Example 26(2)
EXAMPLES 27(1)-27(9)
Example 27(1)
Example 27(2)
Example 27(3)
Example 27(4)
Example 27(5)
Example 27(6)
Example 27(7)
Example 27(8)
Example 27(9)
EXAMPLES 28(1)-28(7)
Example 28(1)
Example 28(2)
Example 28(3)
Example 28(4)
Example 28(5)
Example 28(6)
Example 28(7)
Example 29(1)
EXAMPLES 29(2)-29(74)
Example 29(2)
Example 29(3)
Example 29(4)
Example 29(5)
Example 29(6)
Example 29(7)
Example 29(8)
Example 29(9)
Example 29(10)
Example 29(11)
Example 29(12)
Example 29(13)
Example 29(14)
Example 29(15)
Example 29(16)
Example 29(17)
Example 29(18)
Example 29(19)
Example 29(20)
Example 29(21)
Example 29(22)
Example 29(23)
Example 29(24)
Example 29(25)
Example 29(26)
Example 29(27)
Example 29(28)
Example 29(29)
Example 29(30)
Example 29(31)
Example 29(32)
Example 29(33)
Example 29(34)
Example 29(35)
Example 29(36)
Example 29(37)
Example 29(38)
Example 29(39)
Example 29(40)
Example 29(41)
Example 29(42)
Example 29(43)
Example 29(44)
Example 29(45)
Example 29(46)
Example 29(47)
Example 29(48)
Example 29(49)
Example 29(50)
Example 29(51)
Example 29(52)
Example 29(53)
Example 29(54)
Example 29(55)
Example 29(56)
Example 29(57)
Example 29(58)
Example 29(59)
Example 29(60)
Example 29(61)
Example 29(62)
Example 29(63)
Example 29(64)
Example 29(65)
Example 29(66)
Example 29(67)
Example 29(68)
Example 29(69)
Example 29(70)
Example 29(71)
Example 29(72)
Example 29(73)
Example 29(74)
EXAMPLES 30(1)-30(74)
Example 30(1)
Example 30(2)
Example 30(3)
Example 30(4)
Example 30(5)
Example 30(6)
Example 30(7)
Example 30(8)
Example 30(9)
Example 30(10)
Example 30(11)
Example 30(12)
Example 30(13)
Example 30(14)
Example 30(15)
Example 30(16)
Example 30(17)
Example 30(18)
Example 30(19)
Example 30(20)
Example 30(21)
Example 30(22)
Example 30(23)
Example 30(24)
Example 30(25)
Example 30(26)
Example 30(27)
Example 30(28)
Example 30(29)
Example 30(30)
Example 30(31)
Example 30(32)
Example 30(33)
Example 30(34)
Example 30(35)
Example 30(36)
Example 30(37)
Example 30(38)
Example 30(39)
Example 30(40)
Example 30(41)
Example 30(42)
Example 30(43)
Example 30(44)
Example 30(45)
Example 30(46)
Example 30(47)
Example 30(48)
Example 30(49)
Example 30(50)
Example 30(51)
Example 30(52)
Example 30(53)
Example 30(54)
Example 30(55)
Example 30(56)
Example 30(57)
Example 30(58)
Example 30(59)
Example 30(60)
Example 30(61)
Example 30(62)
Example 30(63)
Example 30(64)
Example 30(65)
Example 30(67)
Example 30(68)
Example 30(69)
Example 30(70)
Example 30(71)
Example 30(72)
Example 30(73)
Example 30(74)
Example 31 (1)
Example 32(1)
EXAMPLE 33(1) AND EX…
Example 33(1)
Example 33(2)
Example 34(1)
Example 35(1)
Example 36(1)
Example 37(1)
Example 38(1)
Example 39(1)
Example 39(2)
Example 40(1)
Reference Example 13
Reference Example 14
Example 41(1)
Example 42(1)
Example 42(2)
FORMULATION EXAMPLE
Formulation Example 2
1. A tetrazole c1 g0">derivative of formula (I), a non-toxic salt thereof, an acid addition salt thereof, or a hydrate thereof: ##STR2045## wherein R is a hydrogen atom, ##STR2046## and in which J is a bond, c1-6 alkylene, c1-6 oxyalkylene, c1-6 aminoalkylene, c1-6 thioalkylene, C2-6 alkenylene, or carbocyclic ring, wherein the carbocyclic ring may be substituted by c1-4 alkyl with the proviso that when J contains an oxygen atom, a nitrogen atom or a sulfur atom, and wherein the oxygen atom, the nitrogen atom or the sulfur atom is bonded to C═O or S(O)m group in R);
R1 is
1) c1-8 alkyl,
2) c1-8 alkoxy,
3) C2-8 alkenyl,
4) C2-8 alkenyloxy,
5) c1-8 alkylamino,
6) di(c1-8 alkyl)amino,
7) c1-8 alkylthio,
8) Cyc1 in which Cyc1 is a carbocyclic ring which may be substituted by 1 to 5 substituents selected from the group consisting of a hydrogen atom, c1-8 alkyl, phenyl, phenyloxy, c1-8 alkyl substituted by phenyl, a halogen atom, nitro, trifluoromethyl, nitrile, keto, --OR2, --NR2 R3, --S(O)R2, --SO2 R2, --COOR2 or --COR2, wherein R2 is a hydrogen atom, c1-8 alkyl, phenyl or c1-4 alkyl substituted by phenyl, R3 is a hydrogen atom, c1-8 alkyl, phenyl or c1-4 alkyl substituted by phenyl, or C2-5 acyl,
9) Cyc1 --O-- wherein Cyc1 is the same as hereinbefore defined,
10) Cyc1 --S-- wherein Cyc1 is the same as hereinbefore defined,
11) Cyc1 --CO-- wherein Cyc1 is the same as hereinbefore defined,
12) c1-8 alkyl, c1-8 alkoxy, c1-8 alkylamino, di(c1-8 alkyl)amino or c1-8 alkylthio mono or di-substituted by Cyc1, Cyc1 --O--, Cyc1 --S--, or Cyc1 --CO-- wherein Cyc1 is the same as hereinbefore defined,
13) trifluoromethyl,
14) Cyc1 --CO--NH--CH2 -- wherein Cyc1 is the same as hereinbefore defined,
15) amino,
16) benzyloxycarbonyl,
17) C2-5 acylamino, or
18) c1-8 alkoxy substituted by c1-8 alkoxy;
m is 0 or 1-2,
with the proviso that
(1) when m is 0, then --S(O)m -- is not directly bonded to a nitrogen atom or a sulfur atom, and
(2) when m is 1, then S(O)m -- is not directly bonded to a sulfur atom;
AA1 is
1) a bond or
2) ##STR2047## in which R4 is (1) a hydrogen atom,
(2) c1-8 alkyl,
(3) Cyc2 in which Cyc2 is a carbocyclic ring which may be substituted by 1 to 5 substituents selected from the group consisting of a hydrogen atom, c1-8 alkyl, phenyl, c1-4 alkyl substituted by phenyl, a halogen atom, nitro, trifluoromethyl, nitrile, tetrazole, --OR5, --NR5 R6, --SR5, --COOR5 or --COR5, wherein R5 and R6 each, independently, is a hydrogen atom, c1-4 alkyl, phenyl or c1-4 alkyl substituted by phenyl or
(4) c1-8 alkyl substituted by a substituent selected from --OR7, --NR7 R8, --SR7, --COOR7, --COR7, --CONH2, --NR7 --CO--NR7 R8, guanidino or Cyc2 in which R7 and R8 each, independently, is a hydrogen atom, c1-4 alkyl, phenyl or c1-4 alkyl substituted by phenyl and Cyc2 is the same as hereinbefore defined;
AA2 is
1) a bond or
2) ##STR2048## in which R9 and R10 each, independently, is (1) a hydrogen atom,
(2) c1-8 alkyl,
(3) Cyc3 in which Cyc3 is a carbocyclic ring or hetero ring, and Cyc3 which may be substituted by 1 to 5 substituents selected from the group consisting of a hydrogen atom, c1-8 alkyl, phenyl, c1-4 alkyl substituted by phenyl, a halogen atom, nitro, trifluoromethyl, nitrile, tetrazole, --OR11, --NR11 R12, --SR11, --COOR11 or --COR11, wherein R11 and R12 each, independently, is a hydrogen atom, c1-4 alkyl, phenyl or c1-4 alkyl substituted by phenyl, or
(4) c1-8 alkyl substituted by a substituent selected from --OR13, --NR13 R14, --SR13, --COOR13, --COR13, --CONH2, --NR13 --CO--NR13 R14, guanidino or Cyc3 in which R13 is a hydrogen atom, c1-4 alkyl, phenyl or c1-4 alkyl substituted by phenyl, R14 is a hydrogen atom, c1-4 alkyl, phenyl, c1-4 alkyl substituted by phenyl, t-butyloxycarbonyl or benzyloxycarbonyl and Cyc3 is the same as hereinbefore defined;
AA1 and AA2, together, may have the formula: ##STR2049## in which R19 is a hydrogen atom, c1-8 alkyl, phenyl or c1-4 alkyl substituted by phenyl;
n is 1-4; ##STR2050## is ##STR2051## or ##STR2052## Z is 1) c1-6 alkylene,
2) C2-6 alkenylene,
3) oxygen atom,
4) sulfur atom,
5) --CO--,
6) --SO--,
7) --SO2 --,
8) --NR26 -- in which R26 is a hydrogen atom, c1-4 alkyl, phenyl, c1-4 alkyl substituted by phenyl, or
9) a carbon atom in c1-6 alkylene replaced by an oxygen atom, sulfur atom, --CO--, --SO--, --SO2 -- or --NR26 -- in which R26 is the same as hereinbefore defined,
with the proviso that Z is bonded directly to the carbon atom on a tetrazole ring;
E is a hydrogen atom, a halogen atom, c1-4 alkyl, --COOR27 in which R27 is a hydrogen atom, c1-4 alkyl, phenyl, c1-4 substituted by phenyl, --CONR28 R29 in which R28 and R29 each, independently, is a hydrogen atom, c1-4 alkyl, phenyl, c1-4 substituted by phenyl or --NR28 R29 in which R28 and R29 are the same as hereinbefore defined, or ##STR2053## in which ##STR2054## is a carbocyclic ring substituted by --(R20)p wherein R20 is
1) a hydrogen atom,
2) c1-8 alkyl,
3) a halogen atom,
4) nitro,
5) trifluoromethyl,
6) nitrile,
7) --OR22,
8) --NR22 R23,
9) --SR22,
10) --COOR22,
11) --COR22,
12) --CONR28 R29 in which R28 and R29 are the same as hereinbefore defined,
13) Cyc4 in which Cyc4 is a carbocyclic ring which may be substituted by 1 to 5 substituents selected from the group consisting of a hydrogen atom, c1-8 alkyl, phenyl, c1-4 alkyl substituted by phenyl, a halogen atom, nitro, trifluoromethyl, nitrile, tetrazole, --OR24, --NR24 R25, --SR24, --COOR24 or --COR24 in which R24 and R25 each, independently, is a hydrogen atom, c1-4 alkyl, phenyl or c1-4 alkyl substituted by phenyl, or
14) c1-8 alkyl substituted by Cyc4 in which Cyc4 is the same as hereinbefore defined,
R22 is a hydrogen atom, c1-4 alkyl, phenyl or c1-4 alkyl substituted by phenyl,
R23 is a hydrogen atom, c1-4 alkyl, phenyl, c1-4 alkyl substituted by phenyl, C2-5 acyl or trifluoromethylcarbonyl;
p is 1-5; or
--Z--E is a halogen atom, trifluoromethyl, c1-4 alkyl di-substituted by phenyl or tri(c1-4 alkyl)silyl
with the proviso that
(1) when Z is c1-6 alkylene or C2-6 alkenylene, E is not a hydrogen atom or c1-4 alkyl, or
(2) when Z is --SO--, E is not a hydrogen atom.
2. The compound according to claim 1, wherein the E group in Y is a hydrogen atom, halogen atom, c1-4 alkyl, --COOR27, --CONR28 R29, or --NR28 R29 in which R27, R28 and R29 are defined as in claim 1.
3. The compound according to claim 1, wherein the E group in Y is ##STR2055## in which R20 and p are defined as in claim 1, and ##STR2056## is a 3-10 membered mono-cyclic or bi-cyclic carbocyclic ring.
4. The compound according to claim 1, wherein the --Z--E group in Y is a halogen atom, trifluoromethyl, diphenylmethyl or tri(c1-4 alkyl)silyl.
5. The compound according to claim 1, wherein AA1 is α-amino acid residue and AA2 is α-amino acid residue.
6. The compound according to claim 1, wherein AA1 is a bond and AA2 is α-amino acid residue.
7. The compound according to claim 1, wherein AA1 is a bond and AA2 is a bond.
8. The compound according to claim 1, which is
(1) N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(N,N-dimet hylamino)tetrazol-2-yl)pentanoic acid,
(2) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-methoxytetrazol-1-yl)pentanoic acid,
(3) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-methoxytetrazol-2-yl)pentanoic acid,
(4) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(ethoxycarbonylmethyl)tetrazol-2-yl )pentanoic acid,
(5) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylthiotetrazol-1-yl)pentanoic acid,
(6) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylthiotetrazol-2-yl)pentanoic acid,
(7) N-benzyioxycarbonyl-3-amino-4-oxo-5-(5-(ethoxycarbonylmethyl)tetrazol-1-yl )pentanoic acid,
(8) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxycarbonylethyl)tetrazol-2- yl)pentanoic acid,
(9) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxycarbonylethyl)tetrazol-1- yl)pentanoic acid,
(10) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloroethyl)tetrazol-2-yl)pentan oic acid,
(11) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloroethyl)tetrazol-1-yl)pentan oic acid,
(12) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-dimethylaminoethyl)tetrazol-2-yl )pentanoic acid,
(13) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-dimethylaminoethyl)tetrazol-1-yl )pentanoic acid,
(14) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(carboxymethyl)tetrazol-2-yl)pentan oic acid,
(15) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(carboxymethyl)tetrazol-1-yl)pentan oic acid,
(16) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-carboxyethyl)tetrazol-2-yl)penta noic acid,
(17) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-carboxyethyl)tetrazol-1-yl)penta noic acid,
(18) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfinyltetrazol-1-yl)pentanoi c acid,
(19) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfonyltetrazol-1-yl)pentanoi c acid,
(20) N-benzyioxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfinyltetrazol-2-yl)pentanoi c acid,
(21) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfonyltetrazol-2-yl)pentanoi c acid,
(22) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(methylaminocarbonylmethyl)tetrazol -2-yl)pentanoic acid, or
(23) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(methylaminocarbonylmethyl)tetrazol -1-yl)pentanoic acid,
an ester thereof, a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof.
9. A compound according to claim 1, which is
(1) N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichl orophenylmethyl)tetrazol-1-yl)pentanoic acid,
(2) N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichl orophenylmethyl)tetrazol-2-yl)pentanoic acid,
(3) N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(4-methylp henoxy)tetrazol-1-yl)pentanoic acid, or
(4) N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(4-methylp henoxy)tetrazol-2-yl)pentanoic acid,
an ester thereof, a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof.
10. A compound according to claim 1, which is
(1) N-(N-benzyloxycarbonyl-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmet hyl)tetrazol-2-yl)pentanoic acid,
(2) N-(N-benzyloxycarbonyl-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmet hyl)tetrazol-1-yl)pentanoic acid,
(3) N-(N-benzyloxycarbonyl-L-valyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-2-yl)pentanoic acid,
(4) N-(N-benzyloxycarbonyl-N'-t-butyloxycarbonyl-L-lysinyl)-3-amino-4-oxo-5-(5 -(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid,
(5) N-(N-benzyloxycarbonyl-L-lysinyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylme thyl)tetrazol-2-yl)pentanoic acid, or
an ester thereof, a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof.
11. A compound according to claim 1, which is
(1) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol- 1-yl)pentanoic acid,
(2) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol- 2-yl)pentanoic acid,
(3) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid,
(4) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol-2-yl)pentanoic acid,
(5) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenoxy)tetrazol-1-yl)pent anoic acid,
(6) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenoxy)tetrazol-2-yl)pent anoic acid,
(7) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-t-butylphenoxy)tetrazol-1-yl)pen tanoic acid,
(8) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-t-butylphenoxy)tetrazol-2-yl)pen tanoic acid,
(9) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-styryltetrazol-1-yl)pentanoic acid,
(10) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-styryltetrazol-2-yl)pentanoic acid,
(11) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylethyltetrazol-1-yl)pentanoic acid,
(12) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylethyltetrazol-1-yl)pentanoic acid,
(13) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N,N-dibenzylamino)tetrazol-2-yl)pe ntanoic acid,
(14) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-((4-chlorophenyl)thiomethyl)tetrazo l-2-yl)pentanoic acid,
(15) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-((4-chlorophenyl)thiomethyl)tetrazo l-1-yl)pentanoic acid,
(16) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-phenylpropyl)tetrazol-2-yl)penta noic acid,
(17) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-phenylpropyl)tetrazol-1-yl)penta noic acid,
(18) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyloxy)tetrazol-2-y l)pentanoic acid,
(19) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyloxy)tetrazol-1-y l)pentanoic acid,
(20) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenyloxymethyl)tetrazol-2 -yl)pentanoic acid,
(21) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenyloxymethyl)tetrazol-1 -yl)pentanoic acid,
(22) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-difluorophenylmethyl)tetrazol- 2-yl)pentanoic acid,
(23) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-difluorophenylmethyl)tetrazol- 1-yl)pentanoic acid,
(24) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylthio)tetrazol-2-yl)pentanoic acid,
(25) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylthio)tetrazol-1-yl)pentanoic acid,
(26) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol-2- yl)pentanoic acid,
(27) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol-1- yl)pentanoic acid,
(28) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylmethyl)tetrazol- 2-yl)pentanoic acid,
(29) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylmethyl)tetrazol- 1-yl)pentanoic acid,
(30) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylmethyl)tetrazol-2-yl)pen tanoic acid,
(31) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylmethyl)tetrazol-1-yl)pen tanoic acid,
(32) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenylthio)tetrazol-2-yl)p entanoic acid,
(33) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenylthio)tetrazol-1-yl)p entanoic acid,
(34) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylthio)tetrazol-2-yl)p entanoic acid,
(35) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylthio)tetrazol-1-yl)p entanoic acid,
(36) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,5-dichlorophenylthio)tetrazol-2- yl)pentanoic acid,
(37) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,5-dichlorophenylthio)tetrazol-1- yl)pentanoic acid,
(38) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylcarbonyl)tetrazol-2-yl)penta noic acid,
(39) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylcarbonyl)tetrazol-1-yl)penta noic acid,
(40) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-fluoro-phenylmethyl)tet razol-2-yl)pentanoic acid,
(41) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-fluoro-phenylmethyl)tet razol-1-yl)pentanoic acid,
(42) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylthio)tetrazol-2-yl)penta noic acid,
(43) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylthio)tetrazol-1-yl)penta noic acid,
(44) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methoxyphenylthio)tetrazol-2-yl) pentanoic acid,
(45) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methoxyphenylthio)tetrazol-1-yl) pentanoic acid,
(46) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetrazol-2-yl)p entanoic acid,
(47) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetrazol-1-yl)p entanoic acid,
(48) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dichlorophenylthio)tetrazol-2- yl)pentanoic acid,
(49) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dichlorophenylthio)tetrazol-1- yl)pentanoic acid,
(50) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-methylphenylthio)tetraz ol-2-yl)pentanoic acid,
(51) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-methylphenylthio)tetraz ol-1-yl)pentanoic acid,
(52) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylphenylthio)tetraz ol-2-yl)pentanoic acid,
(53) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylphenylthio)tetraz ol-1-yl)pentanoic acid,
(54) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-2-ylthio)tetrazol-2-yl) pentanoic acid,
(55) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-2-ylthio)tetrazol-1-yl) pentanoic acid,
(56) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-t-butylphenylthio)tetrazol-2-yl) pentanoic acid,
(57) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-t-butylphenylthio)tetrazol-1-yl) pentanoic acid,
(58) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethyloxyphenylthio)tet razol-2-yl)pentanoic acid,
(59) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethyloxyphenylthio)tet razol-1-yl)pentanoic acid,
(60) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio)tetrazol -2-yl)pentanoic acid,
(61) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio)tetrazol -1-yl)pentanoic acid,
(62) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dimethylphenylthio)tetrazol-2- yl)pentanoic acid,
(63) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dimethylphenylthio)tetrazol-1- yl)pentanoic acid,
(64) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,5-dichlorophenylthio)tetrazol-2- yl)pentanoic acid,
(65) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,5-dichlorophenylthio)tetrazol-1- yl)pentanoic acid,
(66) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-bromophenylthio)tetrazol-2-yl)pe ntanoic acid,
(67) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-bromophenylthio)tetrazol-1-yl)pe ntanoic acid,
(68) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio)te trazol-2-yl)pentanoic acid,
(69) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio)te trazol-1-yl)pentanoic acid,
(70) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,4-dichlorophenylthio)tetrazol-2- yl)pentanoic acid,
(71) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,4-dichlorophenylthio)tetrazol-1- yl)pentanoic acid,
(72) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-nitrophenylthio)tetrazol-2-yl)pe ntanoic acid,
(73) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-nitrophenylthio)tetrazol-1-yl)pe ntanoic acid,
(74) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-1-ylthio)tetrazol-2-yl) pentanoic acid,
(75) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-1-ylthio)tetrazol-1-yl) pentanoic acid,
(76) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-di-t-butylphenylthio)tetrazol- 2-yl)pentanoic acid,
(77) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-di-t-butylphenylthio)tetrazol- 1-yl)pentanoic acid,
(78) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxyphenylthio)tetrazol-2-yl) pentanoic acid,
(79) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxyphenylthio)tetrazol-1-yl) pentanoic acid,
(80) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophenyl thio)tetrazol-2-yl)pentanoic acid,
(81) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophenyl thio)tetrazol-1-yl)pentanoic acid,
(82) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3-dichlorophenylthio)tetrazol-2- yl)pentanoic acid,
(83) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3-dichlorophenylthio)tetrazol-1- yl)pentanoic acid,
(84) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylthio)tetrazol-2- yl)pentanoic acid,
(85) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylthio)tetrazol-1- yl)pentanoic acid,
(86) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-t-butylphenylthio)tetra zol-2-yl)pentanoic acid,
(87) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-t-butylphenylthio)tetra zol-1-yl)pentanoic acid,
(88) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N-phenyl-N-methylamino)tetrazol-2- yl)pentanoic acid,
(89) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N-phenyl-N-methylamino)tetrazol-1- yl)pentanoic acid,
(90) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-diisopropylphenylthio)tetrazol -2-yl)pentanoic acid,
(91) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-diisopropylphenylthio)tetrazol -1-yl)pentanoic acid,
(92) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methyl-4-t-butylphenylthio)tetra zol-2-yl)pentanoic acid,
(93) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methyl-4-t-butylphenylthio)tetra zol-1-yl)pentanoic acid,
(94) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio)t etrazol-2-yl)pentanoic acid,
(95) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio)t etrazol-1-yl)pentanoic acid,
(96) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophenyl thio)tetrazol-2-yl)pentanoic acid,
(97) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophenyl thio)tetrazol-1-yl)pentanoic acid,
(98) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-isopropylphenylthio)tetrazol-2-y l)pentanoic acid,
(99) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-isopropylphenylthio)tetrazol-1-y l)pentanoic acid,
(100) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4,6-trichlorophenylthio)tetrazol -2-yl)pentanoic acid,
(101) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4,6-trichlorophenylthio)tetrazol -1-yl)pentanoic acid,
(102) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-(1,1-dimethylpropyl )phenylthio)tetrazol-2-yl)pentanoic acid,
(103) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-(1,1-dimethylpropyl )phenylthio)tetrazol-1-yl)pentanoic acid,
(104) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-fluorophenylthio)tetraz ol-2-yl)pentanoic acid,
(105) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-fluorophenylthio)tetraz ol-1-yl)pentanoic acid,
(106) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylcarbonylaminophen ylthio)tetrazol-2-yl)pentanoic acid,
(107) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylcarbonylaminophen ylthio)tetrazol-1-yl)pentanoic acid,
(108) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfinylmethyl)tetra zol-2-yl)pentanoic acid,
(109) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfinylmethyl)tetra zol-1-yl)pentanoic acid,
(110) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfonylmethyl)tetra zol-2-yl)pentanoic acid,
(111) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfonylmethyl)tetra zol-1-yl)pentanoic acid,
(112) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetraz ol-2-yl)pentanoic acid,
(113) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetraz ol-2-yl)pentanoic acid,
(114) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol -2-yl)pentanoic acid,
(115) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol -2-yl)pentanoic acid,
(116) N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid,
(117) N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid,
(118) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-( 2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid,
(119) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-1-yl)pentanoic acid,
(120) N-(2,6-dichlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol- 1-yl)pentanoic acid,
(121) N-(2,6-dichlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylme thyl)tetrazol-2-yl)pentanoic acid,
(122) N-(3-phenylpropyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid,
(123) N-(3-phenylpropyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-1-yl)pentanoic acid,
(124) N-(4-phenylbutyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid,
(125) N-(4-phenylbutyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid,
(126) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylmethyl)tetrazol-2-yl)pentanoic acid,
(127) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylmethyl)tetrazol-1-yl)pentanoic acid,
(128) N-(2-(4-fluorophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-2-yl)pentanoic acid,
(129) N-(2-(4-fluorophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-1-yl)pentanoic acid,
(130) N-(2-(phenylmethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylmethyl)tetrazol-2-yl)pentanoic acid,
(131) N-(2-(phenylmethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylmethyl)tetrazol-1-yl)pentanoic acid,
(132) N-(2-(4-dimethylaminophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-2-yl)pentanoic acid,
(133) N-(2-(4-dimethylaminophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-1-yl)pentanoic acid,
(134) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio)tetra zol-2-yl)pentanoic acid,
(135) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio)tetra zol-1-yl)pentanoic acid,
(136) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio )tetrazol-2-yl)pentanoic acid,
(137) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio )tetrazol-1-yl)pentanoic acid,
(138) N-(3-phenylpropylthio)carbonyl-3-amino-4-oxo-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid,
(139) N-(3-phenylpropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-1-yl)pentanoic acid,
(140) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophe nylthio)tetrazol-2-yl)pentanoic acid,
(141) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophe nylthio)tetrazol-1-yl)pentanoic acid,
(142) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthi o)tetrazol-2-yl)pentanoic acid,
(143) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthi o)tetrazol-1-yl)pentanoic acid,
(144) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphe nylthio)tetrazol-2-yl)pentanoic acid,
(145) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphe nylthio)tetrazol-1-yl)pentanoic acid,
(146) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophe nylthio)tetrazol-2-yl)pentanoic acid,
(147) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophe nylthio)tetrazol-1-yl)pentanoic acid,
(148) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthi o)tetrazol-2-yl)pentanoic acid,
(149) N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthi o)tetrazol-1-yl)pentanoic acid,
(150) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethyla minophenylthio)tetrazol-2-yl)pentanoic acid,
(151) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethyla minophenylthio)tetrazol-1-yl)pentanoic acid,
(152) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlor ophenylthio)tetrazol-2-yl)pentanoic acid,
(153) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlor ophenylthio)tetrazol-1-yl)pentanoic acid,
(154) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4 -methylphenylthio)tetrazol-2-yl)pentanoic acid,
(155) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4 -methylphenylthio)tetrazol-1-yl)pentanoic acid,
(156) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4 -dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid,
(157) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4 -dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid,
(158) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4 -dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid,
(159) N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4 -dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid,
(160) N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlor ophenylthio)tetrazol-2-yl)pentanoic acid,
(161) N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlor ophenylthio)tetrazol-2-yl)pentanoic acid,
(162) N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4 -dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid,
(163) N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4 -dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid,
(164) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-2-yl)pentanoic acid,
(165) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-1-yl)pentanoic acid,
(166) N-(butylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol- 2-yl)pentanoic acid,
(167) N-(butylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol- 1-yl)pentanoic acid,
(168) N-(2-(4-methoxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylthio)tetrazol-2-yl)pentanoic acid,
(169) N-(2-(4-methoxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylthio)tetrazol-1-yl)pentanoic acid,
(170) N-(2-(4-acetylaminophenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylthio)tetrazol-2-yl)pentanoic acid,
(171) N-(2-(4-acetylaminophenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylthio)tetrazol-1-yl)pentanoic acid,
(172) N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol-2-y l)pentanoic acid,
(173) N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol-1-p entanoic acid,
(174) N-(propylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol -2-yl)pentanoic acid,
(175) N-(propylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol -1-yl)pentanoic acid,
(176) N-(isopropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetra zol-2-yl)pentanoic acid,
(177) N-(isopropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetra zol-1-yl)pentanoic acid,
(178) N-(2-methoxyethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-2-yl)pentanoic acid,
(179) N-(2-methoxyethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-1-yl)pentanoic acid,
(180) N-(2-cyclohexylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthi o)tetrazol-2-yl)pentanoic acid,
(181) N-(2-cyclohexylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthi o)tetrazol-1-yl)pentanoic acid,
(182) N-cyclohexylmethyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-2-yl)pentanoic acid,
(183) N-cyclohexylmethyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-1-yl)pentanoic acid,
(184) N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-2-yl)pentanoic acid,
(185) N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-1-yl)pentanoic acid,
(186) N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-acetylaminophenylthi o)tetrazol-2-yl)pentanoic acid,
(187) N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-acetylaminophenylthi o)tetrazol-1-yl)pentanoic acid,
(188) N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylthio)tetrazol-2-yl)pentanoic acid,
(189) N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylthio)tetrazol-1-yl)pentanoic acid,
(190) N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-m ethylphenylthio)tetrazol-2-yl)pentanoic acid,
(191) N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-m ethylphenylthio)tetrazol-1-yl)pentanoic acid,
(192) N-(2-methoxyethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid,
(193) N-(2-methoxyethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid,
(194) N-(2-(4-hydroxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylthio)tetrazol-2-yl)pentanoic acid,
(195) N-(2-(4-hydroxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylthio)tetrazol-1-yl)pentanoic acid,
(196) N-(2-(4-hydroxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylthio)tetrazol-2-yl)pentanoic acid,
(197) N-(2-(4-hydroxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylthio)tetrazol-1-yl)pentanoic acid,
(198) N-phenylthiomethylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(199) N-t-butoxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2 -yl)pentanoic acid,
(200) N-t-butoxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1 -yl)pentanoic acid,
(201) N-phenylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-y l)pentanoic acid,
(202) N-(2-phenylethylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(203) N-phenyloxymethylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(204) N-(2-methylbenzyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid,
(205) N-(3-chlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid,
(206) N-(2-propenoxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetra zol-2-yl)pentanoic acid,
(207) N-(naphthalen-2-ylmethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-2-yl)pentanoic acid,
(208) N-(naphthalen-1-ylmethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-2-yl)pentanoic acid,
(209) N-(4-t-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-1-yl)pentanoic acid,
(210) N-phenylmethylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetraz ol-2-yl)pentanoic acid,
(211) N-phenylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-p entanoic acid,
(212) N-(2-(naphthalen-1-yl)ethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-2-yl)pentanoic acid,
(213) N-(naphthalen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid,
(214) N-(naphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid,
(215) N-(2-phenylethenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid,
(216) N-(4-bromophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(217) N-butylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl )pentanoic acid,
(218) N-(5-dimethylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlor ophenylmethyl)tetrazol-2-yl)pentanoic acid,
(219) N-(4-nitrophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(220) N-phenylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-y l)pentanoic acid,
(221) N-(2-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(222) N-(4-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(223) N-(3-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmthyl)tet razol-2-yl)pentanoic acid,
(224) N-(2-bromophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(225) N-(4-methoxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid,
(226) N-(4-trifluoromethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid,
(227) N-(3-phenylpropyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(228) N-(2-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-1-yl)pentanoic acid,
(229) N-(4-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(230) N-(3-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(231) N-(2-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(232) N-(2-phenyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid,
(233) N-(2-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(234) N-(3-phenylpropyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-1-yl)pentanoic acid,
(235) N-(2-methoxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid,
(236) N-(2,6-difluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid,
(237) N-(4-cyanophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(238) N-(2-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(239) N-(4-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(240) N-(4-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(241) N-(5-dibutylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylmethyl)tetrazol-2-yl)pentanoic acid,
(242) N-(3-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmetyl)tet razol-2-yl)pentanoic acid,
(243) N-(4-acctylaminophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-2-yl)pentanoic acid,
(244) N-(4-t-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid,
(245) N-(5-dimethylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlor ophenylmethyl)tetrazol-1-yl)pentanoic acid,
(246) N-(4-phenyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid,
(247) N-(4-phenylthiophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid,
(248) N-octanylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2- yl)pentanoic acid,
(249) N-(4-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(250) N-(4-phenylcarbonylmethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylmethyl)tetrazol-2-yl)pentanoic acid,
(251) N-(2,2,2-trifluoroethylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-2-yl)pentanoic acid,
(252) N-(2-trifluoromethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid,
(253) N-(2-benzyloxycarbonylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylmethyl)tetrazol-2-yl)pentanoic acid,
(254) N-(4-acetylaminophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-1-yl)pentanoic acid,
(255) N-(4-phenylthiophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-1-yl)pentanoic acid,
(256) N-(2-nitrophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(257) N-(camphor-10-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(258) N-(4-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(259) N-(4-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-1-yl)pentanoic acid,
(260) N-(4-phenylsulfinylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-2-yl)pentanoic acid,
(261) N-(4-phenylsulfonylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-2-yl)pentanoic acid,
(262) N-(4-aminophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(263) N-(N,N-dibenzylamino)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-1-yl)pentanoic acid,
(264) N-(N-benzyl-N-methylamino)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-1-yl)pentanoic acid,
(265) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-aminophenylthio)tetrazol-2-yl)pe ntanoic acid,
(266) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-aminophenylthio)tetrazol-1-yl)pe ntanoic acid,
(267) N-(2-aminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid,
(268) N-(N-benzylamino)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid,
(269) N-(2-(2-methoxyethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylthio)tetrazol-2-yl)pentanoic acid,
(270) N-(2-(2-methoxyethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylthio)tetrazol-1-yl)pentanoic acid,
(271) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetra zol-2-yl)pentanoic acid,
(272) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetra zol-1-yl)pentanoic acid,
(273) N-(2-acetylaminoethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylt hio)tetrazol-2-yl)pentanoic acid,
(274) N-(2-acetylaminoethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylt hio)tetrazol-1-yl)pentanoic acid,
(275) N-(2-acetylaminoethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylth io)tetrazol-2-yl)pentanoic acid,
(276) N-(2-acetylaminoethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylth io)tetrazol-1-yl)pentanoic acid,
(277) N-(2-(2-methoxyethyloxy)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlor ophenylthio)tetrazol-2-yl)pentanoic acid,
(278) N-(2-(2-methoxyethyloxy)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlor ophenylthio)tetrazol-1-yl)pentanoic acid,
(279) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(phenylthio)tetrazol-2-yl )pentanoic acid,
(280) N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(phenylthio)tetrazol-1-yl )pentanoic acid,
(281) N-(2-diethylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-2-yl)pentanoic acid,
(282) N-(3-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid,
(283) N-(4-isopropylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid,
(284) N-(4-isopropylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-1-yl)pentanoic acid,
(285) N-(2-diethylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-1-yl)pentanoic acid,
(286) N-(4-butyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid, or
(287) N-(4-butyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid,
an ester thereof, a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof.
12. A compound according to claim 1, which is
(1) N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-trifluorom ethyltetrazol-2-yl)pentanoic acid,
(2) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trifluoromethyltetrazol-1-yl)pentan oic acid,
(3) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trifluoromethyltetrazol-2-yl)pentan oic acid,
(4) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-bromotetrazol-2-yl)pentanoic acid,
(5) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1,1-diphenylmethyl)tetrazol-2-yl)p entanoic acid,
(6) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1,1-diphenylmethyl)tetrazol-1-yl)p entanoic acid, or
(7) N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trimethylsilyltetrazol-2-yl)pentano ic acid,
an ester thereof, a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof.
13. A pharmaceutical composition which comprises, as an active ingredient, an effective amount of a compound of formula (I) according to claim 1, a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof, and a pharmaceutically acceptable carrier or coating.
14. A method for the treatment of a disease in an animal, including a human subject, said animal having at least one of the following diseases: insulin dependent diabetes (type I), multiple sclerosis, acute or delayed type hypersensitivity, infectious diseases, infectious complications, septic shock, arthritis, colitis, glomelular nephritis, hepatitis, hepatic cirrhosis, pancreatitis, reperfusion injury, cholangeitis, encephalitis, endocarditis, myocarditis, vasculitis, Alzheimer's disease, Parkinson's disease, dementia, cerebral vascular disturbance, neuro-degenerative diseases, bone or cartilage-resorption diseases, AIDS, ARC (AIDS related complex), adult T cell leukemia, hairy cell (pilocytic) leukemia, myelosis, respiratory dysfunction, arthropathy, uveitis, neoplasm, diffuse collagen diseases such as systemic lupus erythematosis or rheumatoid arthritis, ulcerative colitis, Sjogren's syndrome, primary biliary cirrhosis, idiopathic thrombocytopnic purpura, autoimmunohaemolytic anemia, severe myasthenia, osteodisplasia syndrome, periodic thrombocytopenia, aplastic anemia, idiopathic thrombocytopenia, various diseases accompanied with thrombocytopenia such as disseminated intravascular coagulation, adult dyspnea syndrome, byperplasia of the prostatic gland, mysoma of the uterus, asthma bronchiole, arteriosclerosis, nephritis, senile cataract, chronic fatigue syndrome, myodystrophy and peripheral nervous disturbance, and wherein said treatment comprises the administration to a subject, a therapeutically effective amount of a compound of formula (I) according to claim 1, a non-toxic salt thereof, a non-toxic acid addition salt thereof or a hydrate thereof.

This application is a 371 of PCT/JP96/03801 filed Dec. 26, 1996.

FIELD OF THE INVENTION

This invention relates to tetrazole compounds. More particularly, this invention relates to:

(1) tetrazole compounds having interleukin-1β converting enzyme inhibitory activity of the following formula (I): ##STR6## wherein all of the symbols have the same meanings as described hereinafter, or a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof;

(2) processes for the preparation thereof; and

(3) pharmaceutical agents containing such devivative as an active ingredient.

BACKGROUND OF THE INVENTION

Interleukin 1 (IL-1) is a key cytokine that directly or indirectly participates in the regulation of, for example, the immune system, hemopoietic system and neuroendocrine system, and thus, has a crucial physiological role. There are two types of IL-1, which have different isoelectric points (IL-1α:pl=5, IL-1β:pl=7). Both of these are produced as a precursor having molecular weight of 31 Kd. The IL-1β precursor does not bind to the IL receptor nor exerts a biological function. The IL-1β converting enzyme (ICE) cleaves the precursor protein between Asp 116 and Ala 117 and converts into an active IL-1β mature form having a molecular weight of 17 Kd. Following the cleavage, IL-1β is secreted, binds to the receptor and triggers various biological activities (Ref. The New England Journal of Medicine, 328, 106 (1993)).

The inhibition of ICE enzymatic activity leads to prevention of conversion of the IL-1β precursor into the mature form and hence results in blockage of IL-1 biological activity. There are many possible target diseases for ICE inhibitors, for example, prevention and/or treatment of insulin dependent diabetes (type I), autoimmune diseases, including multiple sclerosis, immune diseases, such as acute or delayed type hypersensitivity, infectious diseases, infection complications, septic shock, acute or chronic inflammatory diseases, such as arthritis, colitis, glomelular nephritis, hepatitis, pancreatitis, reperfusion injury, cholangeitis, encephalitis, endocarditis, myocarditis and vasculitis, neural diseases, such as Alzheimer's disease and Parkinson's disease, bone or cartilage-resorption diseases, Crohn's disease, osteo arthritis etc.

It is believed that ICE and/or ICE-like cystein proteases play important roles in cell death by apoptosis. Therefore it is possible that an ICE inhibitor may be used in the prevention and/or treatment of diseases resulting from apoptosis disorders, such as infection, reduction or enhancement of immune or central nervous system function, neoplasm etc. Diseases associated with apoptosis disorders are as follows; AIDS, ARC (AIDS related complex), adult T cell leukemia, hairy cell (pilocytic) leukemia, myelosis, respiratory dysfunction, arthropathy, HIV or HTLV-I related diseases, such as uveitis, virus related diseases, such as hepatitis C, neoplasm, diffuse collagen diseases, such as systemic lupus erythematosis or rheumatoid arthritis, autoimmune diseases, such as ulcerative colitis, Sjogren's syndrome, primary biliary cirrhosis, idiopathic thrombocytopnic purpura, autoimmonohaemolytic anemia, severe myasthenia, insulin dependent (type I) diabetes, osteodysplasia syndrome, periodic thrombocytopenia, aplastic anemia, idiopathic thrombocytopenia, various diseases which accompany thrombocytopenia, such as disseminated intravascular coagulation, hepatic diseases, including hepatitis (type C, A, B, or F virus borne or drug mediated) and hepatic cirrhosis, Alzheimer's disease, dementia, such as Alzheimer type senile dementia, cerebral vascular disturbance, neuro-degenerative diseases, adult dyspnea syndrome, infection, hyperplasia of the prostate, myoma of the uterus, asthma bronchiole, arteriosclerosis, various kinds of congenital teratoma, nephritis, senile cataract, chronic fatigue syndrome, myodystrophy, peripheral nervous disturbance, and so on (Ref. The New England Journal of Medicine, 328, 106-113 (1993), Arthritis & Rheumatism, 39, 1092 (1996)).

RELATED ARTS

Compounds having an inhibitory activity on IL-1β converting enzyme (ICE) are known. The sequence of the ICE cleavage site of pre-IL-1β (Tyr-Val-His-Asp) has high affinity with ICE. Substrate analog inhibitors which are chemically modified and based on the above substrate sequence, for example, a compound of formula (X): ##STR7## wherein YX is ##STR8## or ##STR9## R1X is (a) a substituted C1-12 alkyl (in which a substituent is hydrogen, hydroxy etc.) or

(b) an aryl C1-6 alkyl (in which aryl is phenyl, naphthyl, pyridyl, furyl, thienyl, thiazolyl, isothiazolyl, imidazolyl, benzoimidazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, benzothienyl, pyrazolyl, indolyl, purinyl or isooxazolyl), wherein the aryl can be mono-substituted or di-substituted (in which a substituent is a C1-6 alkyl, halogen, hydroxyl, C1-6 alkylcarbonyl etc.);

R2X is

(a) hydrogen, ##STR10## (in which R3X is (1) a substituted C1-12 alkyl (in which a substituent is hydrogen, hydroxy etc.), or

(2) an aryl C1-6 alkyl or substituted aryl C1-6 alkyl as hereinbefore defined (in which an aryl may be mono-substituted or di-substituted by C1-6 alkyl, halogen, hydroxyl, C1-6 alkylcarbonyl etc.);

R4X and R5X are each hydrogen, hydroxyl etc.; and

R6X is

(1) hydrogen,

(2) a substituted C1-6 alkyl (in which a substituent is hydrogen, hydroxyl etc.),

(3) an aryl C1-6 alkyl (in which alkyl is substituted by hydrogen, oxo, C1-3 alkyl etc., aryl has the same meaning as hereinbefore defined, said aryl is mono-substituted or di-substituted, said substituent is C1-6 alkyl, halogen, hydroxyl, C1-6 alkylcarbonyl etc.),

(4) a C1-6 alkylaminocarbonylC1-6 alkyl or C1-6 alkylcarbonylaminoC1-6 alkyl,

(5) an arylaminocarbonylC1-6 alkyl or arylcarbonylaminoC1-6 alkyl (in which aryl has the same meaning as hereinbefore defined, said aryl is mono-substituted or di-substituted, said substituent is C1-6 alkyl, halogen, hydroxyl, C1-6 alkylcarbonyl etc.) or

(6) an aryl C1-6 alkylaminocarbonyl C1-6 alkyl or aryl C1-6 alkylcarbonylamino C1-6 alkyl (in which aryl has the same meaning as hereinbefore defined, said aryl is mono-substituted or di-substituted, said substituent is C1-6 alkyl, halogen, hydroxyl, C1-6 alkylcarbonyl etc.) etc.;

AA1X is a bond etc.;

AA2X is a bond or ##STR11## and AA3X is a bond or ##STR12## (wherein R8X and R9X is (a) hydrogen,

(b) a substituted C1-6 alkyl (in which a substituent is hydrogen, hydroxyl etc.) or

(c) an aryl C1-6 alkyl (in which aryl has the same meaning as hereinbefore defined, said aryl is mono-substituted or di-substituted, said substituent is C1-6 alkyl, halogen, hydroxyl, C1-6 alkylcarbonyl, etc.))

(with the proviso that, definitions not related are omitted)

are disclosed as having an inhibitory activity on ICE (see EP 519748).

The compounds of formula (Y):

RY --[A1Y --A2Y ]nY --A3Y --A4Y --XY --A5Y (Y)

wherein RY is hydrogen, an amino protecting group or benzyloxy, which may be optionally substituted by a ring;

nY is 0 or 1;

A1Y is Val, Leu, Ala, Ile or trimethylsilyl-Ala;

A2Y is Phe or Tyr;

A3Y is Val, Leu, Ala, Ile, trimethylsilyl-Ala or a divalent radical group: ##STR13## (in which ring AY may be optionally substituted by hydroxy or C1-4 alkoxy);

A4Y is a bond or ##STR14## (in which R1Y is hydrogen or C1-4 alkyl, and Y1Y is a residue bonded to the α-carbon atom of an optionally protected α-amino acid);

wherein A3Y and A4Y together may form: ##STR15## (wherein Y1Y has the same meaning as hereinbefore defined, and R1Y and R1aY are combined to form --(CH2)mY -- (in which mY is 2, 3, 4 or 5));

XY is a divalent radical group: ##STR16## (wherein R6Y is hydrogen or C1-4 alkyl); and A5Y is hydrogen, CF3, --Z1Y --Z2Y --Y2Y (in which Z1Y and Z2Y is each, independently, a bond or an α-amino acid residue and Y2Y is NH2, C1-4 alkylamino, di-(C1-4 alkyl)amino or hetero ring bonded to the Z2Y nitrogen), --CH2 --X1Y --Y3Y (in which X1Y is O or S and Y3Y is heteroaryl) or --CH2 --Y3Y wherein Y3Y is as previously defined)

(with the proviso that, definitions not related are omitted)

have an inhibitory activity on IL-1β release (see WO 93/09135).

Further, it is disclosed that compounds of formula (Z):

RZ --A1Z --A2Z --XZ --A3Z (Z)

wherein RZ is hydrogen, an amino or hydroxy protecting group or benzyloxy which may be optionally substituted by a ring;

A1Z is an α-hydroxy acid, amino acid residue or thiocarbonyl analogue, each with an optionally protected side chain, or ##STR17## (in which ring AZ may be optionally substituted by hydroxy or C1-4 alkoxy and RaZ is CO or CS);

A2Z is an α-hydroxy acid, --NH--CHR3Z --CO-- (in which R3Z is an optionally protected side chain of an α-amino acid);

XZ is ##STR18## or ##STR19## (in which R7Z is --CO2 H, --CONHOH or a bioisosteric group); and

A3Z is --CH2 --X1Z --CO--Y1Z, --CH2 --O--Y2Z or --CH2 --S--Y3Z (in which X1Z is O or S, Y1Z is an aliphatic ring, optionally substituted with aryl, diphenylmethyl, optionally substituted by a ring, piperidino or optionally substituted mono, di or tricyclic heteroaryl, Y2Z is an aliphatic ring, diphenylmethyl, optionally substituted by a ring, or optionally substituted di or tricyclic heteroaryl etc. and Y3Z is an aliphatic ring, tri-(C1-4 alkyl)methylcarbonyl, di-(C1-4 alkyl) aminothiocarbonyl, 4-nitrophenyl, 2,6-dichloro-benzoyl, 2,3,6-trichloro-4-pyridyl, 5-membered heterocyclic ring containing a nitrogen atom or optionally substituted di or tricyclic heteroaryl, etc.) etc.; and

A1Z and A2Z may form ##STR20## (in which R1aZ and R5Z together make form C2-5 alkylene or C2-5 alkenylene and Y5Z is an optionally protected side chain of an α-amino acid, etc.)

(with the proviso that, definitions not related are omitted)

have an inhibitory activity on IL-1β release (see EP 618223).

Furthermore, it is disclosed that compounds of formula (W): ##STR21## wherein nW is 0-4; YW is ##STR22## wherein when R3W is O, YW is ##STR23## (in which R2W is hydrogen or deuterium; R3W is O, OH, OR6W, NR6W OR7W or NR6W R7W ;

R6W and R7W each, independently, is hydrogen, alkyl, aralkyl, heteroaralkyl, aryl or heteroaryl;

R4W is hydrogen or alkyl;

R5W is hydrogen, alkyl, alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, halogen, haloalkyl, nitro or cyano,

HETW is heteroaryl);

AAW is ##STR24## (in which R6W and R7W have the same meaning as hereinbefore defined and R11W is (CR6W R7W)0-6 --R12W (wherein R12W is aryl, heteroaryl or optionally selected from hereinbefore described R5W)) or an amino acid; and

R1W is R12W --CO-- or R12W SO2 -- (wherein R12W has the same meaning as hereinbefore defined)

(with the proviso that, definitions not related are omitted)

have an inhibitory activity on IL-1β converting enzyme (see CA 2125021).

PURPOSE OF THE INVENTION

Energetic investigations have been carried out to discover new compounds having inhibitory activity on IL-1β converting enzyme. As a result, the present inventors have achieved that goal by a tetrazole compound of formula (I).

COMPARISON OF THE INVENTION AND RELATED ARTS

The tetrazole compounds of the present invention are newly synthesized and therefore, are quite novel.

To summarize, in the compound of formula (X) known in the art (EP 519748), R6X of YX can represent aryl C1-6 alkyl. But, the aryl group does not include a tetrazole. On the other hand, in the compound of the present invention, Y essentially is the tetrazole group. Therefore, it can be said that the compounds of the present invention have a chemical structure quite different from the compounds of formula (X). A representative example of formula (X) is compound (X-1). ##STR25##

In the compound of formula (Y) of WO93/09135, Y3Y of A5Y can be a heteroaryl group. Further, exemplification of the heteroaryl group includes a tetrazole group. But, no substituents of the heteroaryl group are disclosed in detail in WO93/09135. On the other hand, a compound of the present invention has a ring essentially as substituents of the tetrazole of Y. It can be said that the compounds of the present invention have a chemical structure quite different from the compounds of formula (Y). Representative examples of formula (Y) are compounds (Y-1) and (Y-2). ##STR26##

Further, in a compound of formula (Z), EP 618223, Y3Z of A3Z can represent a heteroaryl group. Further, exemplification of the heteroaryl group includes a tetrazole. But, only C1-4 alkyl is disclosed as substituents of the heteroaryl group. On the other hand, a compound of the present invention has a ring as a substituent of the tetrazole of Y. Therefore, it can be said that the compounds of the present invention have a chemical structure quite different from the compounds of formula (Z). Furthermore, in the compounds of formula (Z), Y3Z as a heteroaryl group is essentially bonded to a hetero atom (oxygen or sulfur atom). On the other hand, in the present invention, the tetrazole group of Y is bonded to a carbon atom. Thus, for another reason, compounds of formula (I) of the present invention have a chemical structure quite different from a compound of formula (Z). A representative example of a compound of formula (Z) is compound (Z-1). ##STR27##

Furthermore, in the compounds of formula (W) of CA 2125021, HETW of YW can be a heteroaryl group. Further, exemplification of the heteroaryl group includes a tetrazole group. But, there are no preparative examples of compounds in which a heteroaryl group is a tetrazole. Additionally, in the compound of formula (W), HETW as a heteroaryl is bonded to a hetero atom (oxygen atom). On the other hand, in the present invention, the tetrazole group Y is bonded to a carbon atom. Thus, compounds of formula (I) of the present invention have a chemical structure quite different from compound of formula (W). A representative compound of formula (W) is compound (W-1). ##STR28##

Therefore, the compounds of the present invention have a chemical structure quite different from the compounds of formulae (X), (Y), (Z) and (W) known in the art. The instant compounds are novel and not previously described.

Therefore, the present inventors have found that tetrazole compounds of formula (I) have an inhibitory activity on IL-1β converting enzyme even if a hetero atom dose not exist between a ketone group and a ring. That observation is quite unexpected from what is known in the art, and has been confirmed from experiments by the present inventors for the first time.

SUMMARY OF THE INVENTION

The present invention is related to:

1) A tetrazole derivatives of the formula (I) ##STR29## wherein R is a hydrogen atom, ##STR30## (in which J is bond, C1-6 alkylene, C1-6 oxyalkylene, C1-6 aminoalkylene, C1-6 thioalkylene, C2-6 alkenylene, carbocyclic ring, or hetero ring, carbocyclic ring and hetero ring may be substituted by C1-4 alkyl, with the proviso that, when J contains oxygen, nitrogen or sulfur atom, it is bond to C═O or S(O)m group in R),

R1 is

1) C1-8 alkyl,

2) C1-8 alkoxy,

3) C2-8 alkenyl,

4) C2-8 alkenyloxy,

5) C1-8 alkylamino,

6) di(C1-8 alkyl)amino,

7) C1-8 alkylthio,

8) Cyc1 (in which Cyc1 is a carbocyclic ring or hetero ring, and Cyc1 may be substituted by 1 to 5 substituents selected from a hydrogen atom, C1-8 alkyl, phenyl, phenyloxy, C1-8 alkyl substituted by phenyl, a halogen atom, nitro, trifluoromethyl, nitrile, keto, --OR2, --NR2 R3, --S(O)R2, --SO2 R2, --COOR2 or --COR2, wherein R2 is a hydrogen atom, C1-8 alkyl, phenyl or C1-4 alkyl substituted by phenyl, R3 is a hydrogen atom, C1-8 alkyl, phenyl or C1-4 alkyl substituted by phenyl, C2-5 acyl, or R2 and R3, taken together bonded to nitrogen atom, represent hetero ring),

9) Cyc1 --O--,

10) Cyc1 --S--,

11) Cyc1 --CO--,

12) C1-8 alkyl, C1-8 alkoxy, C1-8 alkylamino, di(C1-8 alkyl)amino or C1-8 alkylthio mono or di-substituted by Cyc1, Cyc1 --O--, Cyc1 --S--, or Cyc1 --CO--,

13) trifluoromethyl,

14) Cyc1 --CO--NH--CH2 --,

15) amino,

16) benzyloxycarbonyl,

17) C2-5 acylamino, or

18) C1-8 alkoxy substituted by C1-8 alkoxy,

m is 0 or 1-2,

with the proviso that,

(1) when m is 0, then --S(O)m -- is not directly bonded to nitrogen or sulfur atom, and

(2) when m is 1, then --S(O)m -- is not directly bonded to sulfur atom,

AA1 is

1) a bond or

2) ##STR31## (in which R4 is (1) a hydrogen atom,

(2) C1-8 alkyl,

(3) Cyc2 (in which Cyc2 is a carbocyclic ring or hetero ring, and Cyc2 may be substituted by 1 to 5 substituents selected from a hydrogen atom, C1-8 alkyl, phenyl, C1-4 alkyl substituted by phenyl, a halogen atom, nitro, trifluoromethyl, nitrile, tetrazole, --OR5, --NR5 R6, --SR5, --COOR5 or --COR5, wherein R5 and R6 each, independently, is a hydrogen atom, C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl) or

(4) C1-8 alkyl substituted by a substituent selected from --OR7, --NR7 R8, --SR7, --COOR7, --COR7, --CONH2, --NR7 --CO--NR7 R8, guanidino or Cyc2 (in which R7 and R8 each, independently, is a hydrogen atom, C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl),

AA2 is

1) a bond or

2) ##STR32## (in which R9 and R10 each, independently, is (1) a hydrogen atom,

(2) C1-8 alkyl,

(3) Cyc3 (in which Cyc3 is a carbocyclic ring or hetero ring, and Cyc3 may be substituted by 1 to 5 substituents selected from a hydrogen atom, C1-8 alkyl, phenyl, C1-4 alkyl substituted by phenyl, a halogen atom, nitro, trifluoromethyl, nitrile, tetrazole, --OR11, --NR11 R12, --SR11, --COOR11 or --COR11, wherein R11 and R12 each, independently, is a hydrogen atom, C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl),

(4) C1-8 alkyl substituted by a substituent selected from --OR13, --NR13 R14, --SR13, --COOR13, --COR13, --CONH2, --NR13 --CO--NR13 R14, guanidino or Cyc3 (in which R13 is a hydrogen atom, C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl, R14 is a hydrogen atom, C1-4 alkyl, phenyl, C1-4 alkyl substituted by phenyl, t-butyloxycarbonyl or benzyloxycarbonyl) or

(5) R9 and R10, together, is a C1-6 alkylene or C2-6 alkenylene),

AA1 and AA2, together, may have the formula ##STR33## in which R15 and R16 each, independently, is a hydrogen atom, C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl (with the proviso that, C1-4 alkyl or phenyl may be substituted by C1-4 alkyl, C1-4 alkoxy, a halogen atom, trifluoromethyl or phenyl),

R17 is

(1) a hydrogen atom,

(2) C1-8 alkyl,

(3) Cyc3 (in which Cyc3 has the same meaning as hereinbefore defined) or

(4) C1-8 alkyl substituted by a substituent selected from --OR13, --NR13 R14, --SR13, --COOR13, --COR13, --CONH2, --NR13 --CO--NR13 R14, guanidino or Cyc3 (in which R13 and R14 have the same meaning as hereinbefore defined),

q is 2-12,

with the proviso that, a carbon atom in --(CH2)q -- may be replaced by an oxygen atom, sulfur atom, --SO--, --SO2 -- or --NR18 -- (in which R18 is a hydrogen atom, C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl), or

two hydrogen atom at ortho positions are replaced by a double bond and

Y is ##STR34## in which R19 is a hydrogen atom, C1-8 alkyl, phenyl or C1-4 alkyl substituted by phenyl,

n is 1-4, ##STR35## is ##STR36## or ##STR37## Z is 1) C1-6 alkylene,

2) C2-6 alkenylene,

3) oxygen atom,

4) sulfur atom,

5) --CO--,

6) --SO--,

7) --SO2 --,

8) --NR26 -- (in which R26 is a hydrogen atom, C1-4 alkyl, phenyl, C1-4 alkyl substituted by phenyl), or

9) a carbon atom in C1-6 alkylene replaced by an oxygen atom, sulfur atom, --CO--, --SO--, --SO2 -- or --NR26 -- (in which R26 is the same meaning as hereinbefore defined),

with the proviso that, Z is bonded directly to the carbon atom on a tetrazole ring,

E is a hydrogen atom, a halogen atom, C1-4 alkyl, --COOR27 (in which R27 is a hydrogen atom, C1-4 alkyl, phenyl, C1-4 substituted by phenyl), --CONR28 R29 (in which R28 and R29 each, independently, is a hydrogen atom, C1-4 alkyl, phenyl, C1-4 substituted by phenyl or R28 and R29, taken together, boned to nitrogen atom represent hetero ring), --NR28 R29 (in which R28 and R29 are the same meaning as hereinbefore defined), or ##STR38## (in which ##STR39## is carbocyclic ring or hetero ring, R20 is

1) a hydrogen atom,

2) C1-8 alkyl,

3) a halogen atom,

4) nitro,

5) trifluoromethyl,

6) nitrile,

7) --OR22,

8) --NR22 R23,

9) --SR22,

10) --COOR22,

11) --COR22,

12) --CONR28 R29 (in which R28 and R29 are the same meaning as hereinbefore defined),

13) Cyc4 (in which Cyc4 is a carbocyclic ring or hetero ring, and Cyc4 may be substituted by 1 to 5 substituents selected from a hydrogen atom, C1-8 alkyl, phenyl, C1-4 alkyl substituted by phenyl, a halogen atom, nitro, trifluoromethyl, nitrile, tetrazole, --OR24, --NR24 R25, --SR24, --COOR24 or --COR24 (in which R24 and R25 each, independently, is a hydrogen atom, C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl)), or

14) C1-8 alkyl substituted by Cyc4 (in which Cyc4 is the same meaning as hereinbefore defined),

R22 is a hydrogen atom, C1-4 alkyl, phenyl or C1-4 alkyl substituted by phenyl,

R23 is a hydrogen atom, C1-4 alkyl, phenyl, C1-4 alkyl substituted by phenyl, C2-5 acyl or trifluoromethylcarbonyl,

p is 1-5), or

--Z--E is a halogen atom, trifluoromethyl, C1-4 alkyl di-substituted by phenyl or tri(C1-4 alkyl)silyl,

with the proviso that,

(1) when Z is C1-6 alkylene or C2-6 alkenylene, then E is not a hydrogen atom or C1-4 alkyl, or

(2) when Z is --SO--, then E is not a hydrogen atom, or a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof, 2) processes for the preparation thereof and

3) pharmaceutical agents containing such a derivative as an active ingredient.

Throughout the specification, including claims, it may be easily understood by those skilled in the art, that all isomers are included in the present invention. For example, the alkyl, alkoxy and alkylene groups include straight-chain and also branched-chain ones. Accordingly, all isomers produced by the existence of asymmetric carbon atoms are included in the present invention when branched-chain alkyl, alkoxy, alkylene, etc. exist.

In formula (I), C1-8 alkyl represented by substituent of Cyc1, substituent of Cyc2, substituent of Cyc3, R1, R2, R3, R4, R9, R10, R17, R19 and R20, C1-8 alkyl mono or di-substituted by Cyc1, Cyc1 --O--, Cyc1 --S-- or Cyc1 --CO--, C1-8 alkyl substituted by Cyc4, C1-8 alkyl substituted by a group selected from --OR7, --NR7 R8, --SR7, --COOR7, --COR7, --CONH2, --NR7 --CO--NR8, guanidino and Cyc2 and C1-8 alkyl substituted by a group selected from --OR13, --NR13 R14, --SR13, --COOR13, --COR13, --CONH2, --NR13 --CO--NR14, guanidino and Cyc3 each means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and an isomer thereof.

In formula (I), C1-8 alkylamino represented by R1 and C1-8 alkylamino mono or di-substituted by Cyc1, Cyc1 --O--, Cyc1 --S-- or Cyc1 --CO-- each means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and an isomer thereof, which are substituted by an amino group.

In formula (I), di(C1-8 alkyl)amino represented by R1 and di(C1-8 alkyl)amino mono or di-substituted by Cyc1, Cyc1 --O--, Cyc1 --S-- or Cyc1 --CO-- each means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and an isomer thereof, which are each independently di-substituted by an amino group on nitrogen atom.

In formula (I), C1-8 alkylthio represented by R1 and C1-8 alkylthio mono or di-substituted by Cyc1, Cyc1 --O--, Cyc1 --S-- or Cyc1 --CO-- each means thiomethyl, thioethyl, thiopropyl, thiobutyl, thiopentyl, thiohexyl, thioheptyl, thiooctyl and an isomer thereof.

In formula (I), C1-8 alkoxy represented by R1 and C1-8 alkoxy mono or di-substituted by Cyc1, Cyc1 --O--, Cyc1 --S-- or Cyc1 --CO-- each means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and an isomer thereof.

In formula (I), C1-8 alkoxy substituted by C1-8 alkoxy represented by R1 means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and the isomer thereof, which are substituted by a methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and the isomer thereof.

In formula (I), C1-4 alkyl represented by a substituent of carbocyclic ring, substituent of hetero ring, substituent of R15, substituent of R16, R5, R6, R7, R8, R11, R12, R13, R14, R15, R16, R18, R22, R23, R24, R25, R26, R27, R28, R29 and E means methyl, ethyl, propyl, butyl and an isomer thereof.

In formula (I), C1-4 alkoxy represented by R15 and R16 mean methoxy, ethoxy, propoxy, butoxy and an isomer thereof.

In formula (I), C1-4 alkyl substituted by phenyl represented by substituent of Cyc2, substituent of Cyc3, substituent of Cyc4, R2, R3, R5, R6, R7, R8, R11, R12, R13, R14, R15, R16, R18, R19, R22, R23, R24, R25, R26, R27, R28 and R29 means methyl, ethyl, propyl, butyl and the isomer thereof, which are substituted by a phenyl group.

In formula (I), C1-8 alkyl substituted by phenyl represented by substituent of Cyc1 means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and the isomer thereof, which are substituted by a phenyl group.

In formula (I), a halogen atom represented by a substituent of R15 and R16, substituent of Cyc1, substituent of Cyc2, substituent of Cyc3, substituent of Cyc4, R20, E and --Z--E means fluorine, chlorine, bromine and iodine.

In formula (I), C1-6 alkylene represented by J, Z, and R9 and R10, taken together, means methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene and an isomer thereof.

In formula (I), C1-6 oxyalkylene represented by J means oxymethylene, oxyethylene, oxytrimethylene, oxytetramethylene, oxypentamethylene, oxyhexamethylene and an isomer thereof.

In formula (I), C1-6 aminoalkylene represented by J means aminomethylene, aminoethylene, aminotrimethylene, aminotetramethylene, aminopentamethylene, aminohexamethylene and an isomer thereof.

In formula (I), C1-6 thioalkylene represented by J means thiomethylene, thioethylene, thiotrimethylene, thiotetramethylene, thiopentamethylene, thiohexamethylene and an isomer thereof.

In formula (I), C2-6 alkenylene represented by J, Z, and R9 and R10, taken together, means vinylene, propenylene, butenylene, pentenylene, hexenylene, butadienylene, pentadienylene, hexadienylene, hexatrienylene and an isomer thereof.

In formula (I), C2-8 alkenyl represented by R1 means vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, hexatrienyl, heptatrienyl, octatrienyl and an isomer thereof.

In formula (I), C2-8 alkenyloxy represented by R1 means vinyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy, heptenyloxy, octenyloxy, butadienyloxy, pentadienyloxy, hexadienyloxy, heptadienyloxy, octadienyloxy, hexatrienyloxy, heptatrienyloxy, octatrienyloxy and an isomer thereof.

In formula (I), C2-5 acyl represented by R3 and R23 means acetyl, propionyl, butyryl, valeryl and an isomer thereof.

In formula (I), C2-5 acylamino represented by R1 means acetylamino, propionylamino, butyrylamino, valerylamino and an isomer thereof.

In formula (I), tri(C1-4 alkyl)silyl represented by --Z--E means each independent tri-substituted by methyl, ethyl, propyl, butyl and the isomer thereof, on silicon atom.

In formula (I), a carbocyclic ring represented by J Cyc1, Cyc2, Cyc3, Cyc4 and ##STR40## means a 3-10 membered mono-cyclic or bi-cyclic carbocyclic ring. For example, a 3-10 membered mono-cyclic or bi-cyclic carbocyclic ring include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentadiene, benzene, pentalene, indene, naphthalene, azulene ring etc.

In formula (I), a hetero ring represented by J, Cyc1, Cyc2, Cyc3, Cyc4 and ##STR41## means a 5-18 membered mono-cyclic, bi-cyclic or tri-cyclic hetero ring containing 1-2 nitrogen atoms, one oxygen atom or one sulfur atom. For example, a 5-18 membered mono-cyclic, bi-cyclic or tri-cyclic hetero ring containing 1-3 nitrogen atoms, one oxygen atom or one sulfur atom includes pyrrole, imidazole, triazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, oxazepine, thiophene, thiaine (thiopyran), thiepine, oxazole, isooxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzoimidazole, pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, tetrahydropyrimidine, tetrahydropyridazine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiaine (dihydrothiopyran), tetrahydrothiaine (tetrahydrothiopyran), dihydrooxazole, tetrahydrooxazole, dihydroisooxazole, tetrahydroisooxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, morpholine, thiomorpholine, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzoimidazole, perhydrobenzoimidazole, benzooxazepine, benzooxadiazepine, benzothiazepine, benzodithiazepine, benzoazepine, benzodiazepine, indolooxoazepine, indolotetrahydrooxazepine, indolooxadiazepine, indolotetrahydrooxadiazepine, indolothiazepine, indolotetrahydrothiazepine, indolothiadiazepine, indolotetrahydrothiadiazepine, indoloazepine, indolotetrahydroazepine, indolodiazepine, indolotetrahydrodiazepine, benzofurazan, benzothiadiazole, benzotriazole, camphere, imidazothiazole ring etc.

In formula (I), hetero ring represented by R2 and R3, taken together bonded to nitrogen atom, and R28 and R29, taken together bonded to nitrogen atom, means a 5-7 membered mono-cyclic hetero ring containing 1-2 nitrogen atoms, one oxygen atom or one sulfur atom. For example, a 5-7 membered mono-cyclic hetero ring containing 1-2 nitrogen atoms, one oxygen atom or one sulfur atom includes pyrroline pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, piperidine, piperazine, morpholine, thiomorpholine, tetrahydropyrimidine, tetrahydropyridazine ring etc.

In formula (I), ##STR42## represented by AA1 may be an α-amino acid residue. For example, glycine, alanine, serine, threonine, cystine, valine, methionine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, arginine, glutamine, lysine, histidine etc.

In formula (I), ##STR43## represented by AA2 may be an α-amino acid residue. For example, glycine, alanine, serine, threonine, cystine, valine, methionine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, arginine, glutamine, lysine, histidine, proline etc.

In formula (I), C1-4 alkyl di-substituted by phenyl represented by --Z--E means methyl, ethyl, propyl, butyl and the isomer thereof, which are di-substituted by phenyl group.

In formula (I), keto group represented by substituent of Cyc1 may be substituted at one carbon atom, one nitrogen atom, or one or two sulfar atom.

In the present invention, non-toxic salts includes all such salts. For example, the following salt, acid addition salt or hydrate, etc.

Salt

The compounds of formula (I) of the present invention in the case of free carboxylic acid or tetrazole may be converted into a corresponding non-toxic salt by methods known per se. Non toxic and water-soluble salts are preferable. Suitable salts, for example, are salts of an alkaline metal (potassium, sodium etc.), salts of an alkaline earth metal (calcium, magnesium etc.), ammonium salts and salts of pharmaceutically-acceptable organic amines (tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)amine, lysine, arginine, N-methyl-D-glucamine etc.).

Acid Additional Salt

The compounds of formula (I) of the present invention may be converted into a corresponding acid addition salt by methods known per se. Non toxic and water-soluble salts are preferable. Suitable acid addition salts include salts of inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and nitric acid, and salts with organic acids such as acetic acid, trifluoroacetic acid, lactic acid, tartaric acid, oxalic acid, fumaric acid, maleic acid, benzenesulfonic acid, toluenesulfonic acid, isethionic acid, glucuronic acid and gluconic acid.

Hydrate

The compounds of formula (I) or salts thereof of the present invention may be converted into a corresponding hydrate by methods known per se.

Preferred compounds of the present invention are as follows:

tetrazole derivative of formula I (1) ##STR44## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (2) ##STR45## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (3) ##STR46## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (4) ##STR47## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (5) ##STR48## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (6) ##STR49## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (7) ##STR50## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (8) ##STR51## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (9) ##STR52## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (10) ##STR53## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (11) ##STR54## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (12) ##STR55## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (13) ##STR56## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (14) ##STR57## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (15) ##STR58## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (16) ##STR59## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (17) ##STR60## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (18) ##STR61## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (19) ##STR62## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (20) ##STR63## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (21) ##STR64## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (22) ##STR65## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (23) ##STR66## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (24) ##STR67## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (25) ##STR68## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (26) ##STR69## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (27) ##STR70## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (28) ##STR71## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (29) ##STR72## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (30) ##STR73## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (31) ##STR74## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (32) ##STR75## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (33) ##STR76## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (34) ##STR77## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (35) ##STR78## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (36) ##STR79## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (37) ##STR80## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (38) ##STR81## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (39) ##STR82## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (40) ##STR83## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (41) ##STR84## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (42) ##STR85## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (43) ##STR86## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (44) ##STR87## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (45) ##STR88## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (46) ##STR89## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (47) ##STR90## (wherein R4, R9 and R10 have the same meaning as hereinbefore defined),

the compound of formula I (48) ##STR91## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (49) ##STR92## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (50) ##STR93## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (51) ##STR94## (wherein R15, R16, R17 and --(CH2)q -- have the same meaning as hereinbefore defined),

the compound of formula I (52) ##STR95## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (53) ##STR96## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (54) ##STR97## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (55) ##STR98## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (56) ##STR99## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (57) ##STR100## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (58) ##STR101## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (59) ##STR102## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (60) ##STR103## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (61) ##STR104## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (62) ##STR105## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (63) ##STR106## (wherein Y has the same meaning as hereinbefore defined), the compound of formula I (64) ##STR107## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (65) ##STR108## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (66) ##STR109## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (67) ##STR110## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (68) ##STR111## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (69) ##STR112## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (70) ##STR113## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (71) ##STR114## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (72) ##STR115## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (73) ##STR116## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (74) ##STR117## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (75) ##STR118## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (76) ##STR119## (wherein R1 has the same meaning as hereinbefore defined), the compound of formula I (77) ##STR120## (wherein R1 has the same meaning as hereinbefore defined) or a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof.

Examples of representative compounds of formula (I) of the present invention are listed in Table 1-77 or a non-toxic salt thereof, an acid addition salt thereof or a hydrate thereof and described in example.

TABLE 1
______________________________________
I (1)
#STR121##
-
No. Y
______________________________________
1
#STR122##
- 2
#STR123##
- 3
#STR124##
- 4
#STR125##
- 5
#STR126##
- 6
#STR127##
- 7
#STR128##
- 8
#STR129##
- 9
#STR130##
- 10
##STR131##
______________________________________
TABLE 2
______________________________________
I (2)
#STR132##
No. Y
______________________________________
1
#STR133##
- 2
#STR134##
- 3
#STR135##
- 4
#STR136##
- 5
#STR137##
- 6
#STR138##
- 7
#STR139##
- 8
#STR140##
- 9
#STR141##
- 10
##STR142##
______________________________________
TABLE 3
______________________________________
I (3)
#STR143##
No. Y
______________________________________
1
#STR144##
- 2
#STR145##
- 3
#STR146##
- 4
#STR147##
- 5
#STR148##
- 6
#STR149##
- 7
#STR150##
- 8
#STR151##
- 9
#STR152##
- 10
##STR153##
______________________________________
TABLE 4
______________________________________
I (4)
#STR154##
No. Y
______________________________________
1
#STR155##
- 2
#STR156##
- 3
#STR157##
- 4
#STR158##
- 5
#STR159##
- 6
#STR160##
- 7
#STR161##
- 8
#STR162##
- 9
#STR163##
- 10
##STR164##
______________________________________
TABLE 5
______________________________________
I (5)
#STR165##
No. Y
______________________________________
1
#STR166##
- 2
#STR167##
- 3
#STR168##
- 4
#STR169##
- 5
#STR170##
- 6
#STR171##
- 7
#STR172##
- 8
#STR173##
- 9
#STR174##
- 10
##STR175##
______________________________________
TABLE 6
______________________________________
I (6)
#STR176##
No. Y
______________________________________
1
#STR177##
- 2
#STR178##
- 3
#STR179##
- 4
#STR180##
- 5
#STR181##
- 6
#STR182##
- 7
#STR183##
- 8
#STR184##
- 9
#STR185##
- 10
##STR186##
______________________________________
TABLE 7
______________________________________
I (7)
#STR187##
No. Y
______________________________________
1
#STR188##
- 2
#STR189##
- 3
#STR190##
- 4
#STR191##
- 5
#STR192##
- 6
#STR193##
- 7
#STR194##
- 8
#STR195##
- 9
#STR196##
- 10
##STR197##
______________________________________
TABLE 8
______________________________________
I (8)
#STR198##
No. Y
______________________________________
1
#STR199##
- 2
#STR200##
- 3
#STR201##
- 4
#STR202##
- 5
#STR203##
- 6
#STR204##
- 7
#STR205##
- 8
#STR206##
- 9
#STR207##
- 10
##STR208##
______________________________________
TABLE 9
______________________________________
I (9)
#STR209##
No. Y
______________________________________
1
#STR210##
- 2
#STR211##
- 3
#STR212##
- 4
#STR213##
- 5
#STR214##
- 6
#STR215##
- 7
#STR216##
- 8
#STR217##
- 9
#STR218##
- 10
##STR219##
______________________________________
TABLE 10
______________________________________
I (10)
#STR220##
No. Y
______________________________________
1
#STR221##
- 2
#STR222##
- 3
#STR223##
- 4
#STR224##
- 5
#STR225##
- 6
#STR226##
- 7
#STR227##
- 8
#STR228##
- 9
#STR229##
- 10
##STR230##
______________________________________
TABLE 11
______________________________________
I (11)
#STR231##
No. Y
______________________________________
1
#STR232##
- 2
#STR233##
- 3
#STR234##
- 4
#STR235##
- 5
#STR236##
- 6
#STR237##
- 7
#STR238##
- 8
#STR239##
- 9
#STR240##
- 10
##STR241##
______________________________________
TABLE 12
______________________________________
I (12)
#STR242##
No. Y
______________________________________
1
#STR243##
- 2
#STR244##
- 3
#STR245##
- 4
#STR246##
- 5
#STR247##
- 6
#STR248##
- 7
#STR249##
- 8
#STR250##
- 9
#STR251##
- 10
##STR252##
______________________________________
TABLE 13
______________________________________
I (13)
#STR253##
No. Y
______________________________________
1
#STR254##
- 2
#STR255##
- 3
#STR256##
- 4
#STR257##
- 5
#STR258##
- 6
#STR259##
- 7
#STR260##
- 8
#STR261##
- 9
#STR262##
- 10
##STR263##
______________________________________
TABLE 14
__________________________________________________________________________
I (14)
#STR264##
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR265##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR266##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 67##
- 10
H Me 68##
- 11
H Me 69##
- 12
H Me270##
__________________________________________________________________________
TABLE 15
__________________________________________________________________________
I (15)
#STR271##
-
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR272##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR273##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 74##
- 10
H Me 75##
- 11
H Me 76##
- 12
H Me277##
__________________________________________________________________________
TABLE 16
__________________________________________________________________________
I (16)
#STR278##
-
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR279##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR280##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 81##
- 10
H Me 82##
- 11
H Me 83##
- 12
H Me284##
__________________________________________________________________________
TABLE 17
__________________________________________________________________________
I (17)
#STR285##
-
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR286##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR287##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 88##
- 10
H Me 89##
- 11
H Me 90##
- 12
H Me291##
__________________________________________________________________________
TABLE 18
__________________________________________________________________________
I (18)
#STR292##
-
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR293##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR294##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 95##
- 10
H Me 96##
- 11
H Me 97##
- 12
H Me298##
__________________________________________________________________________
TABLE 19
__________________________________________________________________________
I (19)
#STR299##
-
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR300##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR301##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 02##
- 10
H Me 03##
- 11
H Me 04##
- 12
H Me305##
__________________________________________________________________________
TABLE 20
__________________________________________________________________________
I (20)
#STR306##
-
No.
RSTR307##
17 No.
R17#
__________________________________________________________________________
1
Me 7 09##
Me R310##
- 2
Me 8 11##
Me R312##
- 3
Me 9 13##
Me R314##
- 4
Me 10 5##
Me R316##
- 5
Me 11 7##
Me R318##
- 6
Me 12 9##
MeTR320##
__________________________________________________________________________
TABLE 21
__________________________________________________________________________
I (21)
#STR321##
-
No.
RSTR322##
17 No.
R17#
__________________________________________________________________________
1
Me 7 24##
Me R325##
- 2
Me 8 26##
Me R327##
- 3
Me 9 28##
Me R329##
- 4
Me 10 0##
Me R331##
- 5
Me 11 2##
Me R333##
- 6
Me 12 4##
MeTR335##
__________________________________________________________________________
TABLE 22
__________________________________________________________________________
I (22)
#STR336##
-
No.
RSTR337##
17 No.
R17#
__________________________________________________________________________
1
Me 7 39##
Me R340##
- 2
Me 8 41##
Me R342##
- 3
Me 9 43##
Me R344##
- 4
Me 10 5##
Me R346##
- 5
Me 11 7##
Me R348##
- 6
Me 12 9##
MeTR350##
__________________________________________________________________________
TABLE 23
__________________________________________________________________________
I (23)
#STR351##
-
No.
RSTR352##
17 No.
R17#
__________________________________________________________________________
1
Me 7 54##
Me R355##
- 2
Me 8 56##
Me R357##
- 3
Me 9 58##
Me R359##
- 4
Me 10 0##
Me R361##
- 5
Me 11 2##
Me R363##
- 6
Me 12 4##
MeTR365##
__________________________________________________________________________
TABLE 24
__________________________________________________________________________
I (24)
#STR366##
-
No.
RSTR367##
17 No.
R17#
__________________________________________________________________________
1
Me 7 69##
Me R370##
- 2
Me 8 71##
Me R372##
- 3
Me 9 73##
Me R374##
- 4
Me 10 5##
Me R376##
- 5
Me 11 7##
Me R378##
- 6
Me 12 9##
MeTR380##
__________________________________________________________________________
TABLE 25
__________________________________________________________________________
I (25)
#STR381##
-
No.
RSTR382##
17 No.
R17#
__________________________________________________________________________
1
Me 7 84##
Me R385##
- 2
Me 8 86##
Me R387##
- 3
Me 9 88##
Me R389##
- 4
Me 10 0##
Me R391##
- 5
Me 11 2##
Me R393##
- 6
Me 12 4##
MeTR395##
__________________________________________________________________________
TABLE 26
______________________________________
I (26)
#STR396##
-
No. R1 No. R1
______________________________________
1 Me 10
#STR397##
- 2
11 R398##
#STR399##
- 3
12 R400##
#STR401##
- 4
13 R402##
#STR403##
- 5
14 R404##
#STR405##
- 6
15 R406##
#STR407##
- 7
16 R408##
#STR409##
- 8
17 R410##
#STR411##
- 9
18 R412##
##STR413##
______________________________________
TABLE 27
______________________________________
I (27)
#STR414##
No. R1 No. R1
______________________________________
1 Me 10
#STR415##
- 2
11 R416##
#STR417##
- 3
12 R418##
#STR419##
- 4
13 R420##
#STR421##
- 5
14 R422##
#STR423##
- 6
15 R424##
#STR425##
- 7
16 R426##
#STR427##
- 8
17 R428##
#STR429##
- 9
18 R430##
##STR431##
______________________________________
TABLE 28
______________________________________
I (28)
#STR432##
No. R1 No. R1
______________________________________
1 Me 10
#STR433##
- 2
11 R434##
#STR435##
- 3
12 R436##
#STR437##
- 4
13 R438##
#STR439##
- 5
14 R440##
#STR441##
- 6
15 R442##
#STR443##
- 7
16 R444##
#STR445##
- 8
17 R446##
#STR447##
- 9
18 R448##
##STR449##
______________________________________
TABLE 29
______________________________________
I (29)
#STR450##
No. R1 No. R1
______________________________________
1 Me 10
#STR451##
- 2
11 R452##
#STR453##
- 3
12 R454##
#STR455##
- 4
13 R456##
#STR457##
- 5
14 R458##
#STR459##
- 6
15 R460##
#STR461##
- 7
16 R462##
#STR463##
- 8
17 R464##
#STR465##
- 9
18 R466##
##STR467##
______________________________________
TABLE 30
______________________________________
I (30)
#STR468##
No. R1 No. R1
______________________________________
1 Me 10
#STR469##
- 2
11 R470##
#STR471##
- 3
12 R472##
#STR473##
- 4
13 R474##
#STR475##
- 5
14 R476##
#STR477##
- 6
15 R478##
#STR479##
- 7
16 R480##
#STR481##
- 8
17 R482##
#STR483##
- 9
18 R484##
##STR485##
______________________________________
TABLE 31
______________________________________
I (31)
#STR486##
No. R1 No. R1
______________________________________
1 Me 10
#STR487##
- 2
11 R488##
#STR489##
- 3
12 R490##
#STR491##
- 4
13 R492##
#STR493##
- 5
14 R494##
#STR495##
- 6
15 R496##
#STR497##
- 7
16 R498##
#STR499##
- 8
17 R500##
#STR501##
- 9
18 R502##
##STR503##
______________________________________
TABLE 32
______________________________________
I (32)
#STR504##
No. R1 No. R1
______________________________________
1 Me 10
#STR505##
- 2
11 R506##
#STR507##
- 3
12 R508##
#STR509##
- 4
13 R510##
#STR511##
- 5
14 R512##
#STR513##
- 6
15 R514##
#STR515##
- 7
16 R516##
#STR517##
- 8
17 R518##
#STR519##
- 9
18 R520##
##STR521##
______________________________________
TABLE 33
______________________________________
I (33)
#STR522##
No. R1 No. R1
______________________________________
1 Me 10
#STR523##
- 2
11 R524##
#STR525##
- 3
12 R526##
#STR527##
- 4
13 R528##
#STR529##
- 5
14 R530##
#STR531##
- 6
15 R532##
#STR533##
- 7
16 R534##
#STR535##
- 8
17 R536##
#STR537##
- 9
18 R538##
##STR539##
______________________________________
TABLE 34
______________________________________
I (34)
#STR540##
No. R1 No. R1
______________________________________
1 Me 10
#STR541##
- 2
11 R542##
#STR543##
- 3
12 R544##
#STR545##
- 4
13 R546##
#STR547##
- 5
14 R548##
#STR549##
- 6
15 R550##
#STR551##
- 7
16 R552##
#STR553##
- 8
17 R554##
#STR555##
- 9
18 R556##
##STR557##
______________________________________
TABLE 35
______________________________________
I (35)
#STR558##
No. R1 No. R1
______________________________________
1 Me 10
#STR559##
- 2
11 R560##
#STR561##
- 3
12 R562##
#STR563##
- 4
13 R564##
#STR565##
- 5
14 R566##
#STR567##
- 6
15 R568##
#STR569##
- 7
16 R570##
#STR571##
- 8
17 R572##
#STR573##
- 9
18 R574##
##STR575##
______________________________________
TABLE 36
______________________________________
I (36)
#STR576##
No. Y
______________________________________
1
#STR577##
- 2
#STR578##
- 3
#STR579##
- 4
#STR580##
- 5
#STR581##
- 6
#STR582##
- 7
#STR583##
- 8
#STR584##
- 9
#STR585##
- 10
##STR586##
______________________________________
TABLE 37
______________________________________
I (37)
#STR587##
No. Y
______________________________________
1
#STR588##
- 2
#STR589##
- 3
#STR590##
- 4
#STR591##
- 5
#STR592##
- 6
#STR593##
- 7
#STR594##
- 8
#STR595##
- 9
#STR596##
- 10
##STR597##
______________________________________
TABLE 38
______________________________________
I (38)
#STR598##
No. Y
______________________________________
1
#STR599##
- 2
#STR600##
- 3
#STR601##
- 4
#STR602##
- 5
#STR603##
- 6
#STR604##
- 7
#STR605##
- 8
#STR606##
- 9
#STR607##
- 10
##STR608##
______________________________________
TABLE 39
______________________________________
I (39)
#STR609##
No. Y
______________________________________
1
#STR610##
- 2
#STR611##
- 3
#STR612##
- 4
#STR613##
- 5
#STR614##
- 6
#STR615##
- 7
#STR616##
- 8
#STR617##
- 9
#STR618##
- 10
##STR619##
______________________________________
TABLE 40
______________________________________
I (40)
#STR620##
No. Y
______________________________________
1
#STR621##
- 2
#STR622##
- 3
#STR623##
- 4
#STR624##
- 5
#STR625##
- 6
#STR626##
- 7
#STR627##
- 8
#STR628##
- 9
#STR629##
- 10
##STR630##
______________________________________
TABLE 41
______________________________________
I (41)
#STR631##
No. Y
______________________________________
1
#STR632##
- 2
#STR633##
- 3
#STR634##
- 4
#STR635##
- 5
#STR636##
- 6
#STR637##
- 7
#STR638##
- 8
#STR639##
- 9
#STR640##
- 10
##STR641##
______________________________________
TABLE 42
______________________________________
I (42)
#STR642##
No. Y
______________________________________
1
#STR643##
- 2
#STR644##
- 3
#STR645##
- 4
#STR646##
- 5
#STR647##
- 6
#STR648##
- 7
#STR649##
- 8
#STR650##
- 9
#STR651##
- 10
##STR652##
______________________________________
TABLE 43
______________________________________
I (43)
#STR653##
No. Y
______________________________________
1
#STR654##
- 2
#STR655##
- 3
#STR656##
- 4
#STR657##
- 5
#STR658##
- 6
#STR659##
- 7
#STR660##
- 8
#STR661##
- 9
#STR662##
- 10
##STR663##
______________________________________
TABLE 44
__________________________________________________________________________
I (44)
#STR664##
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR665##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR666##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 67##
- 10
H Me 68##
- 11
H Me 69##
- 12
H Me670##
__________________________________________________________________________
TABLE 45
__________________________________________________________________________
I (45)
#STR671##
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR672##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR673##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 74##
- 10
H Me 75##
- 11
H Me 76##
- 12
H Me677##
__________________________________________________________________________
TABLE 46
__________________________________________________________________________
I (46)
#STR678##
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR679##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR680##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 81##
- 10
H Me 82##
- 11
H Me 83##
- 12
H Me684##
__________________________________________________________________________
TABLE 47
__________________________________________________________________________
I (47)
#STR685##
No. R4 R9
R10
__________________________________________________________________________
1 i-Pr H
#STR686##
- 2 i-Pr H --CH2 --OH
- 3 i-Pr H
#STR687##
- 4 i-Pr Me Me
5 i-Pr --(CH2)3 --
6 i-Pr --CH2 CH═CHCH2 --
7 Me H Me
8 i-Bu H Me
- 9
H Me 88##
- 10
H Me 89##
- 11
H Me 90##
- 12
H Me691##
__________________________________________________________________________
TABLE 48
__________________________________________________________________________
I (48)
#STR692##
-
No.
RSTR693##
17 No.
R17#
__________________________________________________________________________
1
Me 7 95##
Me R696##
- 2
Me 8 97##
Me R698##
- 3
Me 9 99##
Me R700##
- 4
Me 10 1##
Me R702##
- 5
Me 11 3##
Me R704##
- 6
Me 12 5##
MeTR706##
__________________________________________________________________________
TABLE 49
__________________________________________________________________________
I (49)
#STR707##
No.
RSTR708##
17 No.
R17#
__________________________________________________________________________
1
Me 7 10##
Me R711##
- 2
Me 8 12##
Me R713##
- 3
Me 9 14##
Me R715##
- 4
Me 10 6##
Me R717##
- 5
Me 11 8##
Me R719##
- 6
Me 12 0##
MeTR721##
__________________________________________________________________________
TABLE 50
__________________________________________________________________________
I (50)
#STR722##
No.
RSTR723##
17 No.
R17#
__________________________________________________________________________
1
Me 7 25##
Me R726##
- 2
Me 8 27##
Me R728##
- 3
Me 9 29##
Me R730##
- 4
Me 10 1##
Me R732##
- 5
Me 11 3##
Me R734##
- 6
Me 12 5##
MeTR736##
__________________________________________________________________________
TABLE 51
__________________________________________________________________________
I (51)
#STR737##
No.
RSTR738##
17 No.
R17#
__________________________________________________________________________
1
Me 7 40##
Me R741##
- 2
Me 8 42##
Me R743##
- 3
Me 9 44##
Me R745##
- 4
Me 10 6##
Me R747##
- 5
Me 11 8##
Me R749##
- 6
Me 12 0##
MeTR751##
__________________________________________________________________________
TABLE 52
______________________________________
I (52)
#STR752##
-
No. Y
______________________________________
1
#STR753##
- 2
#STR754##
- 3
#STR755##
- 4
#STR756##
- 5
#STR757##
- 6
#STR758##
- 7
#STR759##
- 8
#STR760##
- 9
#STR761##
- 10
##STR762##
______________________________________
TABLE 53
______________________________________
I (53)
#STR763##
No. Y
______________________________________
1
#STR764##
- 2
#STR765##
- 3
#STR766##
- 4
#STR767##
- 5
#STR768##
- 6
#STR769##
- 7
#STR770##
- 8
#STR771##
- 9
#STR772##
- 10
##STR773##
______________________________________
TABLE 54
______________________________________
I (54)
#STR774##
No. Y
______________________________________
1
#STR775##
- 2
#STR776##
- 3
#STR777##
- 4
#STR778##
- 5
#STR779##
- 6
#STR780##
- 7
#STR781##
- 8
#STR782##
- 9
#STR783##
- 10
##STR784##
______________________________________
TABLE 55
______________________________________
I (55)
#STR785##
No. Y
______________________________________
1
#STR786##
- 2
#STR787##
- 3
#STR788##
- 4
#STR789##
- 5
#STR790##
- 6
#STR791##
- 7
#STR792##
- 8
#STR793##
- 9
#STR794##
- 10
##STR795##
______________________________________
TABLE 56
______________________________________
I (56)
#STR796##
No. Y
______________________________________
1
#STR797##
- 2
#STR798##
- 3
#STR799##
- 4
#STR800##
- 5
#STR801##
- 6
#STR802##
- 7
#STR803##
- 8
#STR804##
- 9
#STR805##
- 10
##STR806##
______________________________________
TABLE 57
______________________________________
I (57)
#STR807##
No. Y
______________________________________
1
#STR808##
- 2
#STR809##
- 3
#STR810##
- 4
#STR811##
- 5
#STR812##
- 6
#STR813##
- 7
#STR814##
- 8
#STR815##
- 9
#STR816##
- 10
##STR817##
______________________________________
TABLE 58
______________________________________
I (58)
#STR818##
No. Y
______________________________________
1
#STR819##
- 2
#STR820##
- 3
#STR821##
- 4
#STR822##
- 5
#STR823##
- 6
#STR824##
- 7
#STR825##
- 8
#STR826##
- 9
#STR827##
- 10
##STR828##
______________________________________
TABLE 59
______________________________________
I (59)
#STR829##
No. Y
______________________________________
1
#STR830##
- 2
#STR831##
- 3
#STR832##
- 4
#STR833##
- 5
#STR834##
- 6
#STR835##
- 7
#STR836##
- 8
#STR837##
- 9
#STR838##
- 10
##STR839##
______________________________________
TABLE 60
______________________________________
I (60)
#STR840##
No. Y
______________________________________
1
#STR841##
- 2
#STR842##
- 3
#STR843##
- 4
#STR844##
- 5
#STR845##
- 6
#STR846##
- 7
#STR847##
- 8
#STR848##
- 9
#STR849##
- 10
##STR850##
______________________________________
TABLE 61
______________________________________
I (61)
#STR851##
No. Y
______________________________________
1
#STR852##
- 2
#STR853##
- 3
#STR854##
- 4
#STR855##
- 5
#STR856##
- 6
#STR857##
- 7
#STR858##
- 8
#STR859##
- 9
#STR860##
- 10
##STR861##
______________________________________
TABLE 62
______________________________________
I (62)
#STR862##
No. Y
______________________________________
1
#STR863##
- 2
#STR864##
- 3
#STR865##
- 4
#STR866##
- 5
#STR867##
- 6
#STR868##
- 7
#STR869##
- 8
#STR870##
- 9
#STR871##
- 10
##STR872##
______________________________________
TABLE 63
______________________________________
I (63)
#STR873##
No. Y
______________________________________
1
#STR874##
- 2
#STR875##
- 3
#STR876##
- 4
#STR877##
- 5
#STR878##
- 6
#STR879##
- 7
#STR880##
- 8
#STR881##
- 9
#STR882##
- 10
##STR883##
______________________________________
TABLE 64
______________________________________
I (64)
#STR884##
No. R1
______________________________________
1 Me
- 2
#STR885##
- 3
#STR886##
- 4
#STR887##
- 5
#STR888##
- 6
#STR889##
- 7
#STR890##
- 8
#STR891##
- 9
#STR892##
- 10
#STR893##
- 11
#STR894##
- 12
#STR895##
- 13
#STR896##
- 14
#STR897##
- 15
#STR898##
- 16
#STR899##
- 17
#STR900##
- 18
##STR901##
______________________________________
TABLE 65
______________________________________
I (65)
#STR902##
No. R1
______________________________________
1 Me
- 2
#STR903##
- 3
#STR904##
- 4
#STR905##
- 5
#STR906##
- 6
#STR907##
- 7
#STR908##
- 8
#STR909##
- 9
#STR910##
- 10
#STR911##
- 11
#STR912##
- 12
#STR913##
- 13
#STR914##
- 14
#STR915##
- 15
#STR916##
- 16
#STR917##
- 17
#STR918##
- 18
##STR919##
______________________________________
TABLE 66
______________________________________
I (66)
#STR920##
No. R1
______________________________________
1 Me
- 2
#STR921##
- 3
#STR922##
- 4
#STR923##
- 5
#STR924##
- 6
#STR925##
- 7
#STR926##
- 8
#STR927##
- 9
#STR928##
- 10
#STR929##
- 11
#STR930##
- 12
#STR931##
- 13
#STR932##
- 14
#STR933##
- 15
#STR934##
- 16
#STR935##
- 17
#STR936##
- 18
##STR937##
______________________________________
TABLE 67
______________________________________
I (67)
#STR938##
No. R1
______________________________________
1 Me
- 2
#STR939##
- 3
#STR940##
- 4
#STR941##
- 5
#STR942##
- 6
#STR943##
- 7
#STR944##
- 8
#STR945##
- 9
#STR946##
- 10
#STR947##
- 11
#STR948##
- 12
#STR949##
- 13
#STR950##
- 14
#STR951##
- 15
#STR952##
- 16
#STR953##
- 17
#STR954##
- 18
##STR955##
______________________________________
TABLE 68
______________________________________
I (68)
#STR956##
No. R1
______________________________________
1 Me
- 2
#STR957##
- 3
#STR958##
- 4
#STR959##
- 5
#STR960##
- 6
#STR961##
- 7
#STR962##
- 8
#STR963##
- 9
#STR964##
- 10
#STR965##
- 11
#STR966##
- 12
#STR967##
- 13
#STR968##
- 14
#STR969##
- 15
#STR970##
- 16
#STR971##
- 17
#STR972##
- 18
##STR973##
______________________________________
TABLE 69
______________________________________
I (69)
#STR974##
No. R1
______________________________________
1 Me
- 2
#STR975##
- 3
#STR976##
- 4
#STR977##
- 5
#STR978##
- 6
#STR979##
- 7
#STR980##
- 8
#STR981##
- 9
#STR982##
- 10
#STR983##
- 11
#STR984##
- 12
#STR985##
- 13
#STR986##
- 14
#STR987##
- 15
#STR988##
- 16
#STR989##
- 17
#STR990##
- 18
##STR991##
______________________________________
TABLE 70
______________________________________
I (70)
#STR992##
No. R1
______________________________________
1 Me
- 2
#STR993##
- 3
#STR994##
- 4
#STR995##
- 5
#STR996##
- 6
#STR997##
- 7
#STR998##
- 8
#STR999##
- 9
#STR1000##
- 10
#STR1001##
- 11
#STR1002##
- 12
#STR1003##
- 13
#STR1004##
- 14
#STR1005##
- 15
#STR1006##
- 16
#STR1007##
- 17
#STR1008##
- 18
##STR1009##
______________________________________
TABLE 71
______________________________________
I (71)
#STR1010##
No. R1
______________________________________
1 Me
- 2
#STR1011##
- 3
#STR1012##
- 4
#STR1013##
- 5
#STR1014##
- 6
#STR1015##
- 7
#STR1016##
- 8
#STR1017##
- 9
#STR1018##
- 10
#STR1019##
- 11
#STR1020##
- 12
#STR1021##
- 13
#STR1022##
- 14
#STR1023##
- 15
#STR1024##
- 16
#STR1025##
- 17
#STR1026##
- 18
##STR1027##
______________________________________
TABLE 72
______________________________________
I (72)
#STR1028##
No. R1
______________________________________
1 Me
- 2
#STR1029##
- 3
#STR1030##
- 4
#STR1031##
- 5
#STR1032##
- 6
#STR1033##
- 7
#STR1034##
- 8
#STR1035##
- 9
#STR1036##
- 10
#STR1037##
- 11
#STR1038##
- 12
#STR1039##
- 13
#STR1040##
- 14
#STR1041##
- 15
#STR1042##
- 16
#STR1043##
- 17
#STR1044##
- 18
##STR1045##
______________________________________
TABLE 73
______________________________________
I (73)
#STR1046##
No. R1
______________________________________
1 Me
- 2
#STR1047##
- 3
#STR1048##
- 4
#STR1049##
- 5
#STR1050##
- 6
#STR1051##
- 7
#STR1052##
- 8
#STR1053##
- 9
#STR1054##
- 10
#STR1055##
- 11
#STR1056##
- 12
#STR1057##
- 13
#STR1058##
- 14
#STR1059##
- 15
#STR1060##
- 16
#STR1061##
- 17
#STR1062##
- 18
##STR1063##
______________________________________
TABLE 74
______________________________________
I (74)
#STR1064##
No. R1
______________________________________
1 Me
- 2
#STR1065##
- 3
#STR1066##
- 4
#STR1067##
- 5
#STR1068##
- 6
#STR1069##
- 7
#STR1070##
- 8
#STR1071##
- 9
#STR1072##
- 10
#STR1073##
- 11
#STR1074##
- 12
#STR1075##
- 13
#STR1076##
- 14
#STR1077##
- 15
#STR1078##
- 16
#STR1079##
- 17
#STR1080##
- 18
##STR1081##
______________________________________
TABLE 75
______________________________________
I (75)
#STR1082##
No. R1
______________________________________
1 Me
- 2
#STR1083##
- 3
#STR1084##
- 4
#STR1085##
- 5
#STR1086##
- 6
#STR1087##
- 7
#STR1088##
- 8
#STR1089##
- 9
#STR1090##
- 10
#STR1091##
- 11
#STR1092##
- 12
#STR1093##
- 13
#STR1094##
- 14
#STR1095##
- 15
#STR1096##
- 16
#STR1097##
- 17
#STR1098##
- 18
##STR1099##
______________________________________
TABLE 76
______________________________________
I (76)
#STR1100##
No. R1
______________________________________
1 Me
- 2
#STR1101##
- 3
#STR1102##
- 4
#STR1103##
- 5
#STR1104##
- 6
#STR1105##
- 7
#STR1106##
- 8
#STR1107##
- 9
#STR1108##
- 10
#STR1109##
- 11
#STR1110##
- 12
#STR1111##
- 13
#STR1112##
- 14
#STR1113##
- 15
#STR1114##
- 16
#STR1115##
- 17
#STR1116##
- 18
##STR1117##
______________________________________
TABLE 77
______________________________________
I (77)
#STR1118##
No. R1
______________________________________
1 Me
- 2
#STR1119##
- 3
#STR1120##
- 4
#STR1121##
- 5
#STR1122##
- 6
#STR1123##
- 7
#STR1124##
- 8
#STR1125##
- 9
#STR1126##
- 10
#STR1127##
- 11
#STR1128##
- 12
#STR1129##
- 13
#STR1130##
- 14
#STR1131##
- 15
#STR1132##
- 16
#STR1133##
- 17
#STR1134##
- 18
##STR1135##
______________________________________
PROCESSES FOR THE PREPARATION

For compounds of formula (I) of the present invention, those in which R does not contain a COOH group, AA1 does not contain a COOH group, AA2 does not contain a COOH group and Y does not contain a COOH group, i.e., the compounds of formula (I-A) ##STR1136## wherein RA, AA1A, AA2A and YA have the same meaning as hereinbefore defined for R, AA1, AA2 and Y, respectively, provided that all of RA, AA1A, AA2A and YA do not contain a COOH group may be prepared by methods (a) to (b) as follows.

(a) For compounds of formula (I-A) of the present invention, those in which RA does not contain an amino group, AA1A does not contain an amino group, AA2A does not contain an amino group, YA does not contain an amino group and --Z--E group is bonded directly to a carbon atom of tetrazole of YA, i.e., the compounds of formula (I-A-a) ##STR1137## wherein RA-a, AA1A-a, AA2A-a and YA-a have the same meaning as hereinbefore defined for RA, AA1A, AA2A and YA, respectively, provided that all of RA-a, AA1A-a, AA2A-a and YA-a do not contain an amino group and --Z--E group is bonded directly to a carbon atom of tetrazole of yA-a may be prepared by methods (a-1), (a-2), (a-3) or (a-4) as follows.

(a-1) For compounds of formula (I-A-a) of the present invention, those in which --Z--E do not tri(C1-4 alkyl)silyl, i.e., the compounds of formula (I-A-a-1) ##STR1138## wherein YA-a-1 have the same meaning as hereinbefore defined for YA-a, provided that of YA-a-1 do not tri(C1-4 alkyl)silyl, the other symbols are the same meaning as hereinbefore defined may be prepared by reacting a compound of formula (II-a-1) ##STR1139## wherein R19A is C1-8 alkyl, phenyl or C1-4 alkyl substituted with phenyl, XA-a-1 is a leaving group known per se (e.g., chlorine, bromine or iodine atom, mesyl, tosyl group etc.) and the other symbols have the same meaning as hereinbefore defined with a compound of formula (III-a-1) ##STR1140## wherein ZA-a-1 and EA-a-1 has the same meaning as hereinbefore defined for Z and E, provided that --ZA-a-1 --EA-a-1 do not contain COOH, amino groups and tri(C1-4 alkyl)silyl group.

This reaction is known per se, and may be carried out, for example, in an organic solvent (e.g., N,N-dimethylformamide etc.), in the presence of potassium fluoride etc., at a temperature of from 20°C to 40°C

(a-2) For compounds of formula (I-A-a) of the present invention, those in which --Z--E represent tri(C1-4 alkyl)silyl, i.e., the compounds of formula (I-A-a-2) ##STR1141## wherein YA-a-2 have the same meaning as hereinbefore defined for YA-a, provided that of --Z--E group in YA-a-2 represent tri(C1-4 alkyl)silyl, the other symbols are the same meaning as hereinbefore defined may be prepared by reacting a compound of formula (II-a-2) ##STR1142## wherein G is C1-4 alkyl and the other symbols have the same meaning as hereinbefore defined with a compound of formula (III-a-2) ##STR1143## wherein RIII-a-2-1, RIII-a-2-2 and RIII-a-2-3 is each independently C1-4 alkyl.

This reaction is known per se, and may be carried out, for example, the same method described in Chem. Pharm. Bull., 30, 3450-3452 (1982). For example, this reaction carried out by reacting the compound of the formula (III-a-2) with alkylaminolithium (e.g., lithium diisobutylamide [LDA], etc.) in an inert organic solvent (e.g., diethyl ether, tetrahydrofuran etc.) under an atomoshere inert gas (e.g., argon, nitrogen, etc.) at a temperature of from -20°C to 0°C, and then by reacting the obtained lithium compound with the compound of the formula (II-a-2) at a temperature of from -20°C to 0°C

(a-3) For compounds of formula (I-A-a) of the present invention, those in which RA-a and NH group in AA1A-a or AA2A-a bonded to form amide bond, sulfonamide bond or sulfonylurea bond, i.e., the compounds of formula (I-A-a-3) ##STR1144## wherein RA-a-3, AA1A-a-3 and AA2A-a-3 have the same meaning as hereinbefore defined for RA-a, AA1A-a and AA2A-a, provided that of RA-a-3 and NH group in AA1A-a-3, AA2A-a-3 and YA-a bonded to form amide bond, sulfonamide bond or sulfonylurea bond, the other symbols are the same meaning as hereinbefore defined may be prepared by reacting a compound of formula (II-a-3)

RA-a --AA1A-a --AA2A-a --XA-a-3 (II-a- 3)

wherein XA-a-3 is a leaving group (e.g., chlorine, bromine or iodine atom etc.) or a hydroxy group and the other symbols have the same meaning as hereinbefore defined with a compound of formula (III-a-3)

H2 N--YA-a (III-a- 3)

wherein all the symbols have the same meaning as hereinbefore defined.

The reaction can be carried out as an amidation reaction, sulfonamidation reaction, sulfonylurea reaction and the like.

Amidation reactions are known per se and can be carried out by, for example:

(1) using an acid halide,

(2) using a mixed acid anhydride,

(3) using a condensing agent etc.

Each of those methods can be carried out, for example, as follows:

(1) the method using an acid halide may be carried out, for example, by reacting a carboxylic acid with an acid halide (e.g., oxalyl chloride, thionyl chloride etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at from -20°C to the reflux temperature of the solvent, and then by reacting the acid halide obtained with an amine in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at a temperature of from 0°C to 40°C,

(2) the method using a mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid and an acid halide (e.g., pivaloyl chloride, tosyl chloride, mesyl chloride etc.) or an acid derivative (e.g., ethyl chloroformate, isobutyl chloroformate etc.) in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at a temperature of from 0°C to 40°C, and then by reacting the mixture of acid anhydride obtained with an amine in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at a temperature of from 0°C to 40°C, or

(3) the method using a condensing agent (e.g., 1,3-dicyclohexyl carbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), 2-chloro-1-methylpyridinium iodide etc.) may be carried out, for example, by reacting a carboxylic acid with an amine using a condensing agent in the presence or absence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, dimethyl formamide, diethyl ether etc.) or without a solvent at a temperature of from 0°C to 40°C

The reactions (1), (2) and (3) hereinbefore described preferably may be carried out in an atmosphere of inert gas (e.g., argon, nitrogen etc.) under anhydrous conditions.

Sulfonamidation reactions are known pre se, and can be carried out, for example, by reacting a sulfonic acid derivatives with an acid halide (e.g., oxalyl chloride, thionyl chloride, phosphous trichloride, phosphous pentachloride etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at from -20°C to the reflux temperature of the solvent, and then by reacting the sulfonyl halide obtained with an amine in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at a temperature of from 0°C to 40°C

Formation of sulfonylurea reactions are known pre se, and can be carried out, for example, by reacting a aminosulfonic acid derivatives with an acid halide (e.g., oxalyl chloride, thionyl chloride, phosphous trichloride, phosphous pentachloride etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at from -20°C to the reflux temperature of the solvent, and then by reacting the aminosulfonyl halide obtained with an amine in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at a temperature of from 0°C to 40°C

(a-3) For compounds of formula (I-A-a) of the present invention, those in which RA-a and NH group in AA1A-a or AA2A-a bonded to form urea bond, i.e., the compounds of formula (I-A-a-4) ##STR1145## wherein R1A-a-3, JA-a-4, AA1A-a-4 and AA2A-a-4 have the same meaning as hereinbefore defined for R1, J, AA1A-a and AA2A-a, provided that of R1A-a-4 --JA-a-4 group do not contain an COOH, amino group, and carbonyl bonded to NH group in R1A-a-4 --JA-a-4, the other symbols are the same meaning as hereinbefore defined may be prepared by reacting a compound of formula (II-a-4) ##STR1146## wherein all the symbols have the same meaning as hereinbefore defined with a compound of formula (III-a-4)

R1A-a-4 --JA-a-4 --H (III-a-4)

wherein all the symbols have the same meaning as hereinbefore defined.

Formation of urea reactions are known pre se, and can be carried out, for example, in an inert organic solvent (e.g., dimethylformamide, dichloromethane, tetrahydrofuran etc.), using N,N'-carbodiimidazole, an amine in the presence or absence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.), at a temperature of from 0°C to 80°C

(b) For compounds of formula (I-A) of the present invention, those in which at least one of RA, AA1A, AA2A and YA represent contains an amino group i.e., the compounds of formula (I-A-b) ##STR1147## wherein RA-b, AA1A-b, AA2A-b and YA-b have the same meaning as hereinbefore defined for RA, AA1A, AA2A and YA, respectively, provided that at least one of RA-b, AA1A-b, AA2A-b and YA-b represent contains an amino group may be prepared by methods (b-1) or (b-2) as follows.

(b-1) For compounds of formula (I-A-b) of the present invention may be prepared by subjecting the amino protecting group to elimination, the compound prepared by the same methods (a-1), (a-2), (a-3) or (a-4) above and protecting an amino group as known per se (e.g., t-butyloxycarbonyl, benzyloxycarbonyl, triphenylmethyl, 2-(trimethylsilyl)ethoxymethyl or trifluoroacetyl etc.), i.e., the compound of formula (II-b-1) ##STR1148## wherein RA-IIb-1, AA1A-IIb-1, AA2A-IIb-1 and YA-IIb-1 have the same meaning as hereinbefore defined for RA-b, AA1A-b, AA2A-b and YA-b, respectively, provided that at least one of RA-IIb-1, AA1A-IIb-1, AA2A-IIb-1, and YA-IIb-1 represent contains a protected amino group with a known protecting group (e.g., t-butyloxycarbonyl, benzyloxycarbonyl, triphenylmethyl, 2-(trimethylsilyl) ethoxymethyl or trifluoroacetyl etc.)

The elimination of an amino protecting group May be carried out by methods known per se, and depends on the protecting group. For example, when the protecting group is t-butoxycarbonyl, triphenylmethyl or 2-(trimethylsilyl)ethoxymethyl, the reaction may be carried out in a water-miscible organic solvent (e.g., methanol, tetrahydrofuran, dioxane, acetone etc.) in the presence of aqueous solution of organic acid (e.g., acetic acid, trifluoroacetic acid etc.) or inorganic acid (hydrochloric acid, sulfuric acid etc.) or a mixture of them, at a temperature of from 0°C to 100°C

When the protecting group is a benzyloxycarbonyl group, the elimination of the protecting group can be carried out by hydrogenation. The hydrogenation reaction is known per se, and may be carried out, for example, in an inert solvent [ether (e.g., tetrahydrofuran, dioxane, diethoxyethane, diethyl ether etc.), alcohol (e.g., methanol, ethanol etc.), benzene analogues (e.g., benzene, toluene etc.), ketone (e.g., acetone, methyl ethyl ketone etc.), nitrile (e.g., acetonitrile etc.), amide (e.g., dimethylformamide etc.), water, ethyl acetate, acetic acid, mixture of two or more of them etc.], in the presence of a catalyst of hydrogenation (e.g., palladium on activated carbon, palladium black, palladium, palladium hydroxide on carbon, platinum oxide, nickel, Raney nickel (registered trade mark) etc.), in the presence or absence of an inorganic acid (e.g., hydrochloric acid, sulfuric acid, hypochlorous acid, boric acid, tetrafluoroboric acid etc.) or an organic acid (e.g., acetic acid, p-toluenesulfonic acid, oxalic acid, trifluoroacetic acid, formic acid etc.), at ordinary or additional pressure under an atmosphere of hydrogen, at a temperature of from 0°C to 200°C When using an acid, its salt may be used at the same time.

Furthermore, when the protecting group is a trifluoroacetyl group, may be carried out, for example, in a water-miscible organic solvent (e.g., methanol, tetrahydrofuran, dioxan, acetone etc.), using a hydroxide of an alkali metal (e.g., sodium hydroxide, potassium hydroxide, etc.), hydroxide of an alkaline earth metal (e.g., barium hydroxide, calcium hydroxide, etc.), or a carbonate of an alkali metal (e.g., sodium carbonate, potassium carbonate, etc.), or aqueous solution thereof, at a temperature of from 0°C to 40°C

It should be easily understood by those skilled in the art, that other amino protecting groups that can be used in the present invention are available and the choices are not limited only to t-butyloxycarbonyl, benzyloxycarbonyl, triphenylmethyl, 2-(trimethylsilyl) ethoxymethyl or trifluoroacetyl groups. Any group which can be easily and selectively eliminated essentially can be used. For example, a protecting group may be one described in Protective Groups in Organic Synthesis (T. W. Greene, Wiley, New York (1991)). The proposed compounds of the present invention may be easily prepared with those protecting group practicing known methods.

(b-2) For compounds of formula (I-A-b) of the present invention may be prepared by subjecting reduction, the compound prepared by the same methods (a-1), (a-2), (a-3) or (a-4) above and having nitro group, i.e., the compound of formula (II-b-2) ##STR1149## wherein RA-IIb-2, AA1A-IIb-2, AA2A-IIb-2, and YA-IIb-2, have the same meaning as hereinbefore defined for RA-b, AA1A-b, AA2A-b and YA-b, respectively, provided that at least one of RA-IIb-2, AA1A-IIb-2, AA2A-IIb-2 and YA-IIb-2 contains a nitro group.

Reduction of nitro group is known per se, and may be carried out, hydrogenation or reduction by using organic metal.

Hydrogenation may be carried out by the same method as hereinbefore described.

Reduction by using organic metal is known per se, and may be carried out, for example, in a water-miscible organic solvent (e.g., ethanol, methanol etc.), in the presence or absence of an aqueous solution of hydrochloric acid, by using organic metal (e.g., zinc, iron, tin, tin chloride, iron chloride, etc.), at a temperature of from 50°C to 150°C

For compounds of formula (I) of the present invention, those in which at least one of R, AA1, AA2 and Y represent contain a COOH group, i.e., the compounds of formula (I-B) ##STR1150## wherein RB, AA1B, AA2B and YB have the same meaning as hereinbefore defined for R, AA1, AA2 and Y, respectively, provided that at least one of RB, AA1B, AA2B and YB represent contains a COOH group may be prepared by, for example, hydrolysis of a t-butylester, hydrogenation, hydrolysis of an ester or a cleavage reaction of a 2,2,2-trichloroethylester group of a compound having at least one COOH group derivatized to contain a t-butylester, benzylester, alkylester or 2,2,2-trichloroethylester i.e., the compound of formula (I-A-1) ##STR1151## wherein RA-1, AA1A-1, AA2A-1 and YA-1 have the same meaning as hereinbefore defined for RA, AA1A, AA2A and YA, respectively, provided that at least one of RA-1, AA1A-1, AA2A-1 and YA-1 represent contains a t-butylester, benzylester, alkylester or 2,2,2-trichloroethylester group.

Hydrolysis of t-butylester is known per se, and may be carried out, for example, in an inert organic solvent (e.g., dichloromethane, chloroform, methanol, dioxane, ethyl acetate, anisole etc.) in the presence of an organic acid (e.g., trifluoroacetic acid etc.), or inorganic acid (e.g., hydrochloric acid etc.) or a mixture of them, at a temperature of from 0°C to 90°C

Hydrogenation may be carried out by the same method as hereinbefore described.

Hydrolysis of an ester is known per se, and may be carried out, for example, by hydrolysis in acid or under alkaline conditions. Hydrolysis under alkaline conditions may be carried out, for example, in an appropriate organic solvent (e.g., methanol, dimethoxyethane etc.), using a hydroxide or a carbonate of an alkali metal or alkaline earth metal, at a temperature of from 0°C to 40°C Hydrolysis under acidic conditions may be carried out by the same method as for hydrolysis of a t-butylester.

Cleavage of 2,2,2-trichloroethylester is known per se, and may be carried out, for example, in an acidic solvent (e.g., acetic acid, buffer of pH4.2-7.2 or a mixture of organic solvent (e.g. tetrahydrofuran etc.) and solution thereof etc.), in the presence of zinc powder, sonicated or not sonicated, at a temperature of from 0°C to 40°C

It should be easily understood by those skilled in the art that the carboxyl protecting group of the present invention are not to only t-butylester, benzylester or 2,2,2-trichloroethylester but any group which can be easily and selectively eliminated can be used in the present invention. For example, a protecting group described in Protective Groups in Organic Synthesis (T. W. Greene, Wiley, N.Y. (1991)) may be used. The proposed compounds of the present invention may be easily prepared using those protecting groups and practicing known methods.

For compounds of formula (I) of the present invention, those in which R does not contain a COOH and amino group, AA1 does not contain a COOH and amino group, AA2 does not contain a COOH and amino group, Y does not contain a COOH and amino group and Z or R20 group in Y represent amide group, i.e., the compounds of formula (I-C) ##STR1152## wherein RC, AA1C, AA2C and YC have the same meaning as hereinbefore defined for R, AA1, AA2 and Y, respectively, provided that all of RC, AA1C, AA2C and YC do not contain a COOH and amino group, and Z or R20 group in YC represent amide group may be prepared by subjecting the amidation, the compound prepared by the same methods (I-B) above and Z or R20 selectively represent --COOH, methylester or ethylester, i.e., the compound of formula (I-B-1) ##STR1153## wherein YC-B-1 has the same meaning as hereinbefore defined for YC, provided that Z or R20 in YC represent COOH with an amine compound of formula (III-C-1) ##STR1154## wherein all the symbols are the same meaning as hereinbefore defined.

Amidation of --COOH group and amine may be carried out by the same method as hereinbefore described.

Amidation of -methylester or ethylester and amine may be carried out, for example, in a water-miscible organic solvent (e.g., methanol, ethanol etc.), an aqueous solution of an amine compound of the formula (III-C-1), at room temperature.

For compounds of formula (I) of the present invention, those in which at least one of R, AA1, AA2 and Y represent contain a COOH and amino group and Z or R20 group in Y represent amide group, may be prepared by subjecting the amino protecting group to elimination hereinbefore described or the carboxy protecting group to elimination hereinbefore described, the compound prepared by the same methods (I-C) above.

A compound of formula (II-a-1) may be prepared by methods known per se. For example, the compound may be produced by methods described in the literature of J. Med. Chem., 37, 563 (1994) or in EP 0623592.

The products of such synthesis reactions may be purified in a conventional manner. For example, it may be carried out by distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

The starting materials and each reagents used in the process for the preparation of the present invention are known per se or may be easily prepared by known methods.

Effect

It has been confirmed that the compounds of formula (I) of the present invention have inhibitory activities on IL-1β converting enzyme. For example, in laboratory tests the following results were obtained.

Method

(1) Assay for IL-1β converting enzyme

The reaction mixture contains, for example, 20 mM of HEPES-NaOH pH7.4, 10 mM of KOH, 1.5 mM of MgCl2, 0.1 mM of EDTA and 10% glycerol. Various concentrations of test compounds (50 μl), human ICE solution (50 μl) and various concentrations of substrate (Ac-Tyr-Val-Ala-Asp-MCA) were mixed and incubated at 37°C Fluorescence intensity was measured at En=355 nm and Ex=460 nm. The compounds of the present invention have ICE inhibitory values less than 1 μM (for example, in Example 2(1), the compound has an IC50 of 0.03 μM).

In the aboved example method,

HEPES is 4-(2-Hydroxyethyl)-1-piperazineethane-sulfonic acid,

EDTA is Ethylenediamine tetraacetate, and

Ac-Tyr-Val-Ala-Asp-MCA is Acetyl-L-tyrosyl-L-valyl-L-alanyl-L-asparaginic acid 4-methyl-coumarinyl-7-amide.

Toxicity

The compounds of the present invention are substantially non-toxic. Therefore, the compounds of the present invention may be considered sufficiently safe and suitable for pharmaceutical use.

Application for Pharmaceuticals

Compounds of the present invention have an inhibitory activity on ICE in animals, including humans. Therefore the compounds are useful for prevention and/or treatment of insulin dependent diabetes (type I), multiple sclerosis, acute or delayed type hypersensitivity, infectious diseases, infection complications, septic shock, arthritis, colitis, glomerular nephritis, hepatitis, hepatic cirrhosis, pancreatitis, reperfusion injury, cholangeitis, encephalitis, endocarditis, myocarditis, vasculitis, Alzheimer's disease, Parkinson's disease, dementia, cerebral vascular disturbance, neuro-degenerative diseases, bone or cartilage-resorption diseases, AIDS, ARC (AIDS related complex), adult T cell leukemia, hairy cell (pilocytic) leukemia, myelosis, respiratory dysfunction, arthropathy, uveitis, neoplasm, diffuse collagen diseases such as systemic lupus erythematosis or rheumatoid arthritis, ulcerative colitis, Sjogren's syndrome, primary biliary cirrhosis, idiopathic thrombocytopnic purpura, autoimmonohaemolytic anemia, severe myasthenia, osteodisplasia syndrome, periodic thrombocytopenia, aplastic anemia, idiopathic thrombocytopenia, various diseases accompanied with thrombocytopenia such as disseminated intravascular coagulation, adult dyspnea syndrome, hyperplasia of the prostae gland, myoma of the uterus, asthma bronchiole, arteriosclerosis, various kinds of teratoma, nephritis, senile cataract, chronic fatigue syndrome, myodystrophy, peripheral nervous disturbance, Crohn's diseases and osteo arthritics etc. essentially disorders arising from or influenced by IL-1β activity.

For the purpose above described, the compounds of formula (I) of the present invention, non-toxic salts thereof, acid additional salts thereof and hydrates thereof may be normally administered systemically or partially, usually by oral or parenteral administration.

The doses to be administered are determined depending on age, body weight, symptom, the desired therapeutic effect, the route of administration, the duration of the treatment etc. In the human adult, the dose per person is generally between 1 mg and 1000 mg, by oral administration, up to several times per day, and between 0.1 mg and 100 mg, by parenteral administration, up to several times per day, or continuous administration between 1 and 24 hrs. per day intravenously.

As mentioned above, the doses to be used depend on various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

The compounds of the present invention can be administered as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parenteral administration.

Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders and granules. Capsules include hard capsules and soft capsules.

In such compositions, one or more of the active compound(s) is or are admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate etc.). The compositions also may comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (such as magnesium stearate etc.), disintegrating agents (such as cellulose calcium glycolate etc.), stabilizing agents (such as lactose etc.), and assisting agents for dissolving (such as glutamic acid, asparaginic acid etc.).

The tablets or pills may, if desired, be coated with a film of gastric or enteric material (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate etc.), or be coated with more than two films. Further, the coating may include containment within capsules of absorbable materials such as gelatin.

Liquid compositions for oral administration include pharmaceutically-acceptable solutions, emulsions, suspensions, syrups and elixirs. In such compositions, one or more of the active compound(s) is or are contained in inert diluent(s) commonly used in the art (purified water, ethanol etc.). Besides inert diluents, such compositions also may comprise adjuvants (such as wetting agents, suspending agents etc.), sweetening agents, flavouring agents, perfuming agents and preserving agents.

Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfate etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid etc.). For preparation of such spray compositions, for example, the method described in the U.S. Pat. Nos. 2,868,691 or 3,095,355 (herein incorporated in their entirety by reference) may be used.

Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. In such compositions, one more of active compound(s) is or are admixed with at least one inert aqueous diluent(s) (distilled water for injection, physiological salt solution etc.) or inert non-aqueous diluent(s) (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSORBATE80 (registered trade mark) etc.).

Injections may comprise other inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (lactose etc.), assisting agents, such as assisting agents for dissolving (glutamic acid, asparaginic acid etc.) etc.

They may be sterilized for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They may also be manufactured in the form of sterile, solid compositions, for example, by freeze-drying, which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use.

Other compositions for parenteral administration include liquids for external use, and endermic liniments, ointments, suppositories and pessaries which comprise one or more of the active compound(s) and may be prepared by per se known methods.

BEST MODE TO PRACTICE THE INVENTION

The following reference examples and examples illustrate the present invention, but should not be construed to limit the present invention.

The solvents in the parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations, TLC and HPTLC.

NMR in the parentheses show measured solvents. The TLC plate used was Merck 5715, and the HPTLC plate used was Merck 05642. Silica gel used was Merck 7734, except for specifically case.

EXAMPLE 1

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester (1) and N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichl orophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester (2) ##STR1155##

To a solution of N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-bromopentanoi c acid•t-butylester [The compound prepared by the method of J. Med. Chem., 37, 563 (1994)] (298 mg) in N,N-dimethylformamide (5 ml) was successively added potassium fluoride (144 mg) and 5-(2,6-dichlorophenylmethyl)tetrazole (249 mg). The reaction mixture was stirred for 1 days at room temperature. The mixture was quenched by addition of water and extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on NAM-600M silica gel (Nam research institute, registered trade mark) (chloroform:methanol=100:1→50:1) to give the compounds of example 1(1) (37 mg) and example 1(2) (147 mg) having the following physical dataly.

Example 1(1)

HPTLC: Rf 0.33 and 0.30 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.89 and 8.66 (total 1H, each d, J=7.9 Hz), 8.29 and 8.28 (total 1H, each d, J=7.9 Hz), 7.83 and 7.81 (total 1H, each d, J=7.9 Hz), 7.53 (2H, d, J=9.0 Hz), 7.41 (1H, t, J=9.0 Hz), 7.26-7.11 (5H, m), 5.86, 5.83, 5.79 and 5.75 (total 2H, each d, J=18.0 Hz), 4.85 and 4.64 (total 1H, each dt, J=7.9 Hz, 6.7 Hz), 4.35-4.06 (total 4H, m), 2.87-2.72, 2.72-2.57 and 2.57-2.35 (total 8H, m), 1.94-1.80 (1H, m), 1.40 and 1.39 (total 9H, each s), 1.28 and 1.25 (total 3H, each d, J=9.0 Hz), 0.80, 0.76 and 0.71 (total 6H, each d, J=6.7 Hz).

Example 1(2)

HPTLC: Rf 0.40 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.80 and 8.53 (total 1H, each d, J=7.9 Hz), 8.29 and 8.27 (total 1H, each d, J=7.9 Hz), 7.88 and 7.84 (total 1H, each d, J=7.9 Hz), 7.51 (2H, d, J=9.0 Hz), 7.36 (1H, t, J=9.0 Hz), 7.28-7.12 (5H, m), 5.89, 5.83, 5.79 and 5.71 (total 2H, each d, J=18.0 Hz), 4.78 and 4.56 (total 1H, each dt, J=7.9 Hz, 6.7 Hz), 4.50 and 4.49 (total 1H, each s), 4.22 and 4.21 (1H, each dq, J=9.0 Hz, 7.9 Hz), 4.16 and 4.14 (1H, each dd, J=9.0 Hz, 7.9 Hz), 2.83-2.70 and 2.70-2.36 (total 8H, m), 1.95-1.80 (1H, m), 1.36 and 1.37 (total 9H, each s), 1.24 and 1.22 (total 3H, each d, J=9.0 Hz), 0.82, 0.81 and 0.76 (total 6H, each d, J=6.7 Hz).

EXAMPLES 1(3)-1(6)

By the same procedure as provided in example 1, using corresponding tetrazole compounds instead of 5-(2,6-dichlorophenylmethyl)tetrazole, compounds of the present invention having the following physical data were obtained.

Example 1(3)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(4-methylph enoxy)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1156##

HPTLC: Rf 0.21 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.64-7.54 (1H, m), 7.35-7.12 (10H, m), 6.72-6.61 (1H, m), 6.07-6.00 (1H, m) 5.57 (1H, d, J=18.5 Hz), 5.25 (1H, d, J=18.5 Hz), 4.98-4.81 (1H, m), 4.50-4.30 (1H, m), 4.21-4.07 (1H, m), 3.03-2.84, 2.84-2.63 and 2.63-2.52 (total 8H, m), 2.34 (3H, s), 2.15-1.95 (1H, m), 1.42 (3H, d, J=8.0 Hz), 1.40 (9H, s), 0.87 and 0.82 (each 3H, each d, J=6.8 Hz).

Example 1(4)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(4-methylph enoxy)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1157##

HPTLC: Rf 0.27 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.79-7.67 (1H, m), 7.31-6.98 (10H, m), 6.40-6.29 (1H, m), 5.69 and 5.68 (total 1H, each d, J=17.0 Hz), 5.46 and 5.45 (total 1H, each d, J=17.0 Hz), 4.92-4.75 (1H, m), 4.59-4.38 (1H, m), 4.32-4.19 (1H, m), 3.01-2.83, 2.83-2.65 and 2.65-2.49 (total 8H, m), 2.33 (3H, s), 2.11-1.80 (1H, m), 1.41 (9H, s), 1.38 (3H, d, J=8.4 Hz), 0.92-0.73 (6H, m).

Example 1(5)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-trifluorome thyltetrazol-2-yl)pentanoic acid•t-butylester ##STR1158##

HPTLC: Rf 0.13 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 9.02-8.92 and 8.66-8.55 (total 1H, m), 8.36-8.24 (1H, m), 7.91-7.75 (1H, m), 7.30-7.05 (5H, m), 6.17-6.04 (2H, m), 4.91-4.74 and 4.68-4.50 (total 1H, m), 4.32-4.05 (2H, m), 2.90-2.65 and 2.65-2.27 (total 8H, m), 2.00-1.75 (1H, m) 1.38 and 1.37 (total 9H, each s), 1.28-1.12 (3H, m), 0.92-0.67 (6H, m).

Example 1(6)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(N,N-dimeth ylamino)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1159##

TLC: Rf 0.31 (chloroform:methanol=15:1); NMR (DMSO-d6): δ 8.78 and 8.54 (total 1H, each m), 8.29 (1H, m), 7.88 (1H, m), 7.21 (5H, m), 5.61 (2H, m), 4.79 and 4.58 (total 1H, each m), 4.19 (2H, m), 2.94 (6H, s), 2.88-2.35 (total 6H, m), 1.90 (1H, m), 1.40 (9H, s), 1.23 (3H, m), 0.80 (6H, m).

Example 2(1)

N-((N-(3-phenylpropio nyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetra zol-1-yl)pentanoic acid ##STR1160##

To a solution of compound (1) prepared in example 1 (23 mg) in thioanisole (0.17 ml) and m-cresole (0.1 5 ml) was added trifluoroacetic acid (2 ml). The reaction mixture was stirred for 30 min at room temperature. To the reaction mixture was added toluene, and then the mixture was concentrated. The residue was washed with diethyl ether, and dried over to give the compound of the present invention (17 mg) having the following physical data.

TLC: Rf 0.31 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.93-8.82 and 8.75-8.64 (total 1H, m), 8.33-8.20 (1H, m), 7.87-7.75 (1H, m), 7.65-7.32 and 7.32-7.05 (total 8H, m), 5.98-5.67 (2H, m), 4.83-4.57 (1H, m), 4.41-4.00 (2H, m), 2.95-2.66 and 2.66-2.25 (total 6H, m), 2.00-1.74 (1H, m), 1.35-1.15 (3H, m), 0.90-0.62 (6H, m).

EXAMPLES 2(2)-2(6)

By the same procedure as provided in example 2(1), and if necessary, by known methods converted to accommodate the corresponding salts, using the compounds of examples 1(2)-1(6) instead of compound (1) prepared in example 1, compounds of the present invention having the following physical data were obtained.

Example 2(2)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR1161##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.86-8.71 and 8.64-8.52 (total 1H, m), 8.33-8.18 (1H, m), 7.92-7.80 (1H, m), 7.57-7.43 and 7.43-7.30 (3H, m), 7.30-7.07 (5H, m), 6.00-5.75 (2H, m), 4.79-4.63 and 4.63-4.40 (total 1H, m), 4.50 (2H, s), 4.27-4.05 (2H, m), 2.78-2.66 and 2.66-2.25 (total 6H, m), 1.97-1.75 (1H, m), 1.31-1.15 (3H, m), 0.88-0.68 (6H, m).

Example 2(3)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(4-methylph enoxy)tetrazol-1-yl)pentanoic acid ##STR1162##

TLC: Rf 0.34 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.78-8.67 and 8.67-8.54 (1H, m), 8.32-8.16 (1H, m), 7.92-7.80 (1H, m), 7.33-7.08 (9H, m), 5.65-5.30 (2H, m), 4.77-4.55 (1H, m), 4.35-4.03 (2H, m), 2.77-2.66 and 2.66-2.37 (total 6H), 2.32 (3H, s), 1.98-1.75 (1H, m), 1.30-1.15 (3H, m), 0.87-0.67 (6H, m).

Example 2(4)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(4-methylph enoxy)tetrazol-2-yl)pentanoic acid ##STR1163##

TLC: Rf 0.51 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.86-8.71 and 8.62-8.52 (1H, m), 8.32-8.18 (1H, m), 7.93-7.79 (1H, m), 7.32-7.07 (9H, m), 5.91-5.58 (2H, m), 4.78-4.65 and 4.65-4.49 (1H, m), 4.30-4.06 (2H, m), 2.80-2.68 (2H, m), 2.68-2.34 (4H, m), 2.31 (3H, s), 2.00-1.75 (1H, m), 1.32-1.15 (3H, m),0.87-0.70 (6H, m).

Example 2(5)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-trifluorome thyltetrazol-2-yl)pentanoic acid ##STR1164##

TLC: Rf 0.28 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.98-8.84 and 8.71-8.59 (total 1H, m), 8.35-8.22 (1H, m), 7.92-7.77 (1H, m) 7.32-7.06 (5H, m), 6.26-5.90 (2H, m), 4.81-4.54 (1H, m), 4.35-4.07 (2H, m), 2.92-2.30 (6H, m) 2.01-1.85 (1H, m), 1.34-1.15 (3H, m), 0.93-0.69 (each 3H, m).

Example 2(6)

N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-(5-(N,N-dimeth ylamino)tetrazol-2-yl)pentanoic acid•trifluoroacetic acid salt ##STR1165##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 8.71 and 8.54 (total 1H, each d, J=10 Hz), 8.28 and 8.21 (total 1H, each d, J=6 Hz), 7.88 and 7.84 (total 1H, each d, J=10 Hz), 7.20 (5H, m), 5.70-5.46 (2H, m), 4.70 and 4.55 (total 1H, each m), 4.20 and 4.15 (total 2H, each m), 2.93 (6H, s), 2.80-2.40 (total 6H, m), 1.90 (1H, m), 1.23 (3H, m), 0.80 (6H, m).

EXAMPLES 3(1)-3(7)

By the same procedure as example 1, using corresponding tetrazole compound and 3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)am ino-4-oxo-5-bromopentanoic acid•t-butylester [The compound was prepared by the method of J. Med. Chem., 37, 563(1994)] instead of N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-bromopentanoi c acid•t-butylester, compounds of the present invention having the following physical data were obtained.

Example 3(1)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1166## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 3(3))

HPTLC: Rf 0.24 (benzene:ethyl acetate=1:1); NMR (CDCl3): δ 7.80 and 7.64-7.13 (total 10H, m), 5.82, 5.78, 5.60 and 5.52 (total 2H, each d, J=18.0 Hz), 5.06-4.78 (3H, m), 4.34 and 4.30 (total 2H, each s),3.56 (2H, m), 3.12-2.61 (2H, m), 2.33-1.10 (9H, m), 1.42 and 1.41 (total 9H, each s).

Example 3(2)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1167## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 3(4))

HPTLC: Rf 0.32 (benzene:ethyl acetate=1:1); NMR (CDCl3): δ 7.82 and 7.68-7.10 (total 10H, m), 5.85-5.50 (2H, m), 5.13-4.75 (3H, m), 4.60 and 4.57 (total 2H, each s), 3.51 (2H, m), 3.02-2.50 (2H, m), 2.30-1.20 (9H, m), 1.42 and 1.40 (total 9H, each s).

Example 3(3)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1168## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 3(1))

HPTLC: Rf 0.29 (benzene:ethyl acetate=1:1); NMR (CDCl3): δ 7.86-7.08 (10H, m), 5.85-5.38 (2H, m), 5.06 (1H, m), 4.96-4.72 (2H, m), 4.60, 4.57, 4.33 and 4.28 (total 2H, each s), 3.65-3.30 (2H, m), 3.02-2.50 (2H, m), 2.28-1.20 (18H, m).

Example 3(4)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1169## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 3(2))

HPTLC: Rf 0.42 (benzene:ethyl acetate=1:1); NMR (CDCl3): δ 7.85-7.10 (10H, m), 5.80-5.43 (2H, m), 5.10 (1H, m), 4.82 (2H, m), 4.56 (2H, s), 3.60-3.28 (2H, m), 2.87-2.54 (2H, m), 2.29-1.20 (6H, m), 1.46 (3H, d, J=8.0 Hz), 1.33 and 1.32 (total 9H, each s).

Example 3(5)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami ne-4-oxo-5-(5-trifluoromethyltetrazol-2-yl)pentanoic acid•t-butylester ##STR1170## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 3(6))

HPTLC: Rf 0.39 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.89-7.32 (5H, m), 6.05, 5.95, 5.76 and 5.69 (total 2H, each d, J=17.5 Hz), 5.15-4.75 (3H, m), 3.55 (2H, m), 3.08-2.56 (2H, m), 2.32-1.20 (6H, m), 1.48 (3H, d, J=7.5 Hz), 1.42 (9H, s).

Example 3(6)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-trifluoromethyltetrazol-2-yl)pentanoic acid•t-butylester ##STR1171## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 3(5))

HPTLC: Rf 0.27 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.79 and 7.62-7.28 (total 5H, m), 6.06, 6.03, 5.84 and 5.76 (total 2H, each d, J=17.5 Hz), 5.01-4.74 (3H, m), 3.55 (2H, m), 3.08-2.56 (2H, m), 2.32-1.20 (6H, m), 1.48 (3H, d, J=7.5 Hz), 1.42 (9H, s).

Example 3(7)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1172##

TLC: Rf 0.33 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.77-8.47 (1H, m), 8.22 (1H, d, J=6.6 Hz), 7.79 (2H, m), 7.46 (3H, m), 7.26 (5H, m), 5.65 (2H, m), 5.19-4.62 (3H, m), 4.10 (2H, m), 3.50 (2H, m), 2.80 (1H, m), 2.56 (1H, m), 1.99-1.50 (6H, m), 1.40 (9H, s), 1.36 (3H, m).

EXAMPLES 4(1)-4(7)

By the same procedure as provided in example 2(1), using the compounds of examples 3(1)-3(7) instead of compound (1) prepared in example 1, compounds of the present invention having the following physical data were obtained.

Example 4(1)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1173## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 4(3))

HPTLC: Rf 0.34 and 0.30 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 8.57-8.22 (2H, m), 7.80 (2H, m), 7.60-7.30 (6H, m), 5.89 (2H, m), 5.00-4.55 (3H, m), 4.32 (2H, m), 3.51 (2H, m), 2.60 (2H, m), 2.00-1.43 (6H, m), 1.31 (3H, m).

Example 4(2)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR1174## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 4(4))

HPTLC: Rf 0.41 and 0.32 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 8.46-8.26 (2H, m), 7.79 (2H, m), 7.60-7.29 (6H, m), 6.06-5.66 (2H, m), 4.96-4.54 (3H, m), 4.49 and 4.43 (total 2H, s), 3.50 (2H, m), 2.61-2.36 (2H, m), 1.98-1.45 (6H, m), 1.29 (3H, m).

Example 4(3)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1175## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 4(1))

HPTLC: Rf 0.37 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 8.53-8.26 (2H, m), 7.84 (2H, m), 7.48 (6H, m), 5.86 (2H, m), 5.15 (1H, m), 4.86 (1H, m), 4.66 (1H, m), 4.34 (total 2H, s), 3.5 (2H, m), 2.59 (2H, m), 2.02-1.53 (6H, m), 1.33 (3H, m).

Example 4(4)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR1176## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 4(2))

HPTLC: Rf 0.43 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 5 8.51-8.21 (2H, m), 7.86 (2H, m), 7.60-7.28 (6H, m), 6.00-5.68 (2H, m), 5.11 (1H, m), 4.89 (1H, m), 4.68 (1H, m), 4.50 and 4.48 (total 2H, s), 3.50 (2H, m), 2.53 (2H, m), 2.00-1.55 (6H, m), 1.33 (3H, m).

Example 4(5)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-trifluoromethyltetrazol-2-yl)pentanoic acid ##STR1177## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 4(6))

HPTLC: Rf 0.35 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 8.59-8.16 (2H, m), 8.00-7.76 and 7.65-7.40 (total 5H, m), 6.29-6.00 (2H, m), 5.13, 4.89 and 4.70 (total 3H, m), 3.6-3.1 (2H, m), 2.66-2.39 (2H, m), 2.00-1.51 and 1.48-1.05 (total 9H, m).

Example 4(6)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-trifluoromethyltetrazol-2-yl)pentanoic acid ##STR1178## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 4(5))

HPTLC: Rf 0.30 and 0.24 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 8.60-8.30 (2H, m), 8.00-7.70 and 7.60-7.30 (total 5H, m), 6.36-5.99 (2H, m), 4.95-4.50 (3H, m), 3.6-3.1 (2H, m), 2.65-2.40 (2H, m), 1.98-1.20 (9H, m).

Example 4(7)

3-(N-(2-(hexahydro-2-oxo-3S-(phenylcarbonylamino)azepin-1-yl))propionyl)ami no-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1179##

HPTLC: Rf 0.70 (chloroform:methanol water=6:4:1); NMR (DMSO-d6): δ 8.40 (2H, m), 7.85 (2H, m), 7.50 (3H, m), 7.27 (5H, s), 5.72 (2H, m), 5.22-4.58 (3H, m), 4.14 (2H, m), 3.45 (4H, m), 2.59 (2H, m), 1.96-1.50 (6H, m), 1.31 (3H, m).

Reference Example 1

5-(ethoxycarbonylmethyl)tetrazole ##STR1180##

The mixture of ethylcyanoacetate (1.53 g), trimethyltinazaide [(CH3)3 SnN3 ] (3.67 g) and toluene (20 ml) was refluxed for 14 h. After the reaction mixture was concentrated under reduced pressure, the residue was dissolved in ethanol (300 ml). To the thus obtained solution was added a 1N aqueous solution of hydrochloric acid (150 ml), and the mixture was stirred for 3 h at room temperature. To the reaction mixture was added a 1N aqueous solution of sodium hydroxide until a pH 3 or 4 was obtained, and the mixture was concentrated under reduced pressure. To the residue was added water, and the mixture was added chloroform and methanol, the precipitate solid was filtered, dried to give the title compound (783 mg) having the following physical data.

TLC: Rf 0.23 (chloroform:methanol=4:1); NMR (CD3 OD): δ 4.22 (2H, q, J=7.0 Hz), 4.12 (2H, s), 1.27 (2H, t, J=7.0 Hz).

Reference Example 1(1)

5-styryltetrazole ##STR1181##

By the same procedure as provided in reference example 1, using the compounds of cinnamonitrile instead of ethylcyanoacetate, compound having the following physical data was obtained.

TLC: Rf 0.25 (chloroform:methanol=19:1); NMR (CD3 OD): δ 7.74-7.55 (3H, m), 7.50-7.32 (3H, m), 7.20 (1H, d, J=16.8 Hz).

Reference Example 2

5-phenylethyltetrazole ##STR1182##

The mixture of the compound prepared in reference example 1(1) (1.0 g), 10% palladium on activated carbon (200 mg) and ethanol (40 ml) was stirred at room temperature for 4 h under an atmosphere of hydrogen gas. The reaction mixture was filtered through Celite (trade mark) and the filtrate was concentrated to give the title compound having the following physical data.

TLC: Rf 0.25 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 7.38-7.10 (5H, m), 3.26-3.12 (2H, m), 3.11-2.97 (2H, m).

Reference Example 3

1-(4-methoxyphenylmethyl)tetrazole ##STR1183##

The mixture of 4-methoxybenzylamine (27 g), trimethylorthoformate (52.4 ml), sodium azide (19.2 g) and acetic acid (176 ml) was stirred at 80°C for 14 h. The reaction mixture was concentrated under reduced pressure, the residue was dissolved in water and extracted with ethyl acetate. The extract was washed with a 1N aqueous solution of hydrochloric acid, water, a saturated aqueous solution of sodium hydrocarbonate and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=1:1) to give the title compound (17.6 g) having the following physical data.

TLC: Rf 0.34 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.46 (1H, s), 7.26 (2H, d, J=8.5 Hz), 6.92 (2H, d, J=8.5 Hz), 5.52 (2H, s), 3.81 (3H, s).

Reference Example 4

1-(4-methoxyphenylmethyl)-5-bromotetrazole ##STR1184##

To a solution of the compound prepared in reference example 3 (5.0 g) in tetrahydrofuran (112 ml) and N,N,N',N'-tetramethylethylenediamine (11 ml) was added 1.67 M of n-butyllithium in hexane solution (15.8 ml) at -68°C under an atmosphere of argon. After the mixture was stirred for 10 min, to the mixture was added dropwise the solution of bromine (1.36 ml) in tetrahydrofuran (8 ml) at same temperature. The mixture was stirred for 30 min at -78°C, and the mixture was warmed up at 0°C The mixture was concentrated under reduced pressure, the residue was dissolved in water and extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=2:1) to give the title compound (2.28 g) having the following physical data.

TLC: Rf 0.63 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.29 (2H, d, J=8.5 Hz), 6.87 (2H, d, J=8.5 Hz), 5.48 (2H, s), 3.80 (3H, s).

Reference Example 5

1-(4-methoxyphenylmethyl)-5-methoxytetrazole ##STR1185##

To a solution of the compound prepared in reference example 4 (507 mg) in methanol (5 ml) was added sodium methoxide (509 mg) at 0°C The mixture was stirred for 4 h at 0°C The mixture was concentrated under reduced pressure, the residue was dissolved in ice and a 1N aqueous solution of hydrochloric acid and extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on NAM-600M silica gel (Nam research institute, registered trade mark) (hexane:ethyl acetate=2:1) to give the title compound (335 mg) having the following physical data.

TLC: Rf 0.53 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.24 (2H, d, J=8.5 Hz), 6.87 (2H, d, J=8.5 Hz), 5.18 (2H, s), 4.22 (3H, s), 3.79 (3H, s).

Reference Example 6

5-methoxytetrazole ##STR1186##

To a solution of the compound prepared in reference example 5 (335 mg) in acetonitrile (8 ml) was added ammonium cerium nitrate [CAN] (4.41 g) in water (6 ml) at 0°C The mixture was stirred for 1 h at room temperature. The reaction mixture was poured into a saturated aqueous solution of sodium chloride and extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated. The residue was washed with diethylether to give the title compound (66 mg) having the following physical data.

TLC: Rf 0.20 (chloroform:methanol=4:1); NMR (CD3 OD): δ 4.15 (3H, s).

Reference Example 7

5-phenylmethyltetrazole ##STR1187##

The mixture of 5-(2,6-dichlorophenylmethyl)tetrazole (355 mg), 5% palladium on activated carbon (93 mg) and methanol (8 ml) was stirred for 1 h room temperature under an atmosphere of hydrogen gas. The reaction mixture was filtered through Celite (trade mark) and the filtrate was concentrated to give the title compound having the following physical data.

TLC: Rf 0.50 (chloroform:methanol:acetic acid=18:1:1).

EXAMPLES 5(1)-5(160)

By the same procedure as example 1, using N-benzyloxycarbonyl-3-amino-4-oxo-5-bromopentanoic acid•t-butylester [see EP 0623592, Example 1] instead of N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-bromopentanoi c acid•t-butylester and the corresponding tetrazole compounds (for example the compounds prepared in reference example 1, reference example 1(1), reference example 2, reference example 6 or reference example 7), the compounds of the present invention having the following physical data were obtained.

Example 5(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1 -yl)pentanoic acid•t-butylester ##STR1188##

TLC: Rf 0.45 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.44-7.15 (8H, m), 5.86 (1H, d, J=8.0 Hz), 5.69 (1H, d, J=18.7 Hz), 5.55 (1H, d, J=18.7 Hz), 5.20 (2H, s), 4.70-4.54 (1H, m), 4.33 (1H, d, J=16.4 Hz), 4.23 (1H, d, J=16.4 Hz), 3.10 (1H, dd, J=17.6, 4.4 Hz), 2.76 (1H, dd, J=17.6, 5.0 Hz), 1.41 (9H, s).

Example 5(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2 -yl)pentanoic acid•t-butylester ##STR1189##

TLC: Rf 0.66 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.40-7.10 (8H, m), 5.92 (1H, d, J=8.4 Hz), 5.76 (1H, d, J=17.7 Hz), 5.58 (1H, d, J=17.7 Hz), 5.16 (2H, s), 4.70-4.55 (3H, m), 2.99 (1H, dd, J=17.5, 5.0 Hz), 2.69 (1H, dd, J=17.5, 4.8 Hz), 1.41 (9H, s).

Example 5(3)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1190##

TLC: Rf 0.14 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.41-7.14 (10H, m), 5.87-5.73 (1H, m), 5.32 (2H, s), 5.15 (2H, s), 4.60-4.44 (1H, m), 4.25 and 4.04 (each 1H, d, J=17.0 Hz), 3.03 and 2.71 (each 1H, dd, J=17.0 Hz, 5.0 Hz), 1.43 (9H, s).

Example 5(4)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol-2-yl)pentanoic acid•t-butylester ##STR1191##

TLC: Rf 0.36 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.42-7.16 (10H, m), 6.05-5.90 (1H, m), 5.78 and 5.60 (each 1H, d, J=18.0 Hz), 5.16 (2H, s), 4.73-4.56 (1H, m), 4.26 (2H, s), 2.98 (1H, dd, J=17.4 Hz, 4.4 Hz), 2.70 (1H, dd, J=17.4 Hz, 5.0 Hz), 1.41 (9H, s).

Example 5(5)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenoxy)tetrazol-1-yl)penta noic acid•t-butylester ##STR1192##

NMR (CDCl3): δ 7.39 (5H, brs), 7.21 (4H, brs), 5.97 (1H, d, J=8.9 Hz), 5.53 (1H, d, J=18.3 Hz), 5.32 (1H, d, J=18.3 Hz),5.20 (2H, s), 4.78-4.56 (1H, m), 3.07 (1H, dd, J=17.5, 4.2 Hz), 2.72 (1H, dd, J=17.5, 4.9 Hz), 2.36 (3H, s), 1.39 (9H, s).

Example 5(6)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenoxy)tetrazol-2-yl)penta noic acid•t-butylester ##STR1193##

NMR (CDCl3): δ 7.38 (5H, brs), 7.18 (4H, brs), 5.95 (1H, d, J=9.0 Hz), 5.71 (1H, d, J=17.4 Hz), 5.54 (1H, d, J=17.4 Hz), 5.18 (2H, s), 4.76-4.58 (1H, m), 3.02 (1H, dd, J=17.6, 4.8 Hz), 2.70 (1H, dd, J=17.6, 4.8 Hz), 2.35 (3H, s), 1.42 (9H, s).

Example 5(7)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-butylphenoxy)tetrazol-1-yl)pentan oic acid•t-butylester ##STR1194##

NMR (CDCl3): δ 7.42-7.08 (9H, m), 5.97 (1H, J=8.8 Hz), 5.54 (1H, d, J=18.0 Hz), 5.33 (1H, d, J=18.0 Hz), 5.19 (2H, s), 4.74-4.60 (1H, m), 3.08 (1H, dd, J=18.0, 4.0 Hz), 2.72 (1H, dd, J=18.0, 4.0 Hz), 1.37 (9H, s), 1.31 (9H, s).

Example 5(8)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-t-butylphenoxy)tetrazol-2-yl)pent anoic acid•t-butylester ##STR1195##

NMR (CDCl3): δ 7.42-7.20 (8H, m), 7.06 (1H, 6 J=8.0 Hz), 5.95 (1H, d, J=9.4 Hz), 5.71 (1H, d, J=17.7 Hz), 5.55 (1H, d, J=17.7 Hz), 5.17 (2H, s), 4.73-4.55 (1H, m), 3.02 (1H, dd, J=17.5, 4.6 Hz), 2.71 (1H, dd, J=17.5, 4.9 Hz), 1.41 (9H, s), 1.31 (9H, s).

Example 5(9)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-styryltetrazol-1-yl)pentanoic acid•t-butylester ##STR1196##

NMR (CDCl3): δ 7.93 (1H, δ J=15.9 Hz), 7.59 (2H, brs), 7.54-7.18, (8H, m), 6.80 (1H, d, J=15.9 Hz), 5.80 (1H, d, J=8.6 Hz), 5.63 (2H, brs), 5.20 (2H, s), 4.66 (1H, brs), 3.24-3.00 (1H, m), 2.93-2.79 (1H, m), 1.41 (9H, s).

Example 5(10)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-styryltetrazol-2-yl)pentanoic acid•t-butylester ##STR1197##

NMR (CDCl3): δ 7.76 (1H, δ J=16.5 Hz), 7.68-7.31 (10H, m), 7.16 (1H, d, J=16.5 Hz) 5.98 (1H, d, J=9.6 Hz), 5.84 (1H, d, J=17.9 Hz), 5.67 (1H, d, J=17.9 Hz), 5.19 (2H, s), 4.80-4.62 (1H, m), 3.04 (1H, dd, J=17.4, 4.4 Hz), 2.74 (1H, dd, J=7.4, 4.9 Hz), 1.44 (9H, s).

Example 5(11)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1198##

NMR (CDCl3): δ 7.64-7.05 (10H, m), 5.72 (1H, d, J=9.1 Hz), 5.21 (1H, d, J=18.7 Hz), 5.18 (2H, s), 5.08 (1H, d, J=18.7 Hz), 4.65-4.45 (1H, m), 3.20-2.85 (5H, m), 2.71 (1H, dd, J=17.7, 5.0 Hz), 1.38 (9H, s).

Example 5(12)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1199##

NMR (CDCl3): δ 7.65-7.10 (10H, m), 5.94 (1H, d, J=9.1 Hz), 5.79 (1H, d, J=17.8 Hz), 5.62 (1H, d, J=17.8 Hz), 5.19 (2H, s), 4.77-4.57 (1H, m), 3.30 3.06 (4H, m), 3.01 (1H, dd, J=17.5, 4.5 Hz), 2.72 (1H, dd, J=17.5, 4.8 Hz), 1.43 (9H, s).

Example 5(13)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-methoxytetrazol-1-yl)pentanoic acid•t-butylester ##STR1200##

HPTLC: Rf 0.10 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.38 (5H, m), 5.95 (1H, brs), 5.35 and 5.13 (each 1H, each d, J=18.0 Hz), 5.18 (2H, s), 4.62 (1H, m), 4.18 (3H, s), 3.03 (1H, dd, J=17.0, 4.5 Hz), 2.70 (1H, dd, J=17.0, 5.0 Hz), 1.42 (9H, s).

Example 5(14)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-methoxytetrazol-2-yl)pentanoic acid•t-butylester ##STR1201##

HPTLC: Rf 0.33 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.38 (5H, m), 5.93 (1H, brs), 5.67 and 5.50 (each 1H, each d, J=18.5 Hz), 5.16 (2H, s), 4.65 (1H, m), 4.09 (3H, s), 3.02 (1H, dd, J=17.0, 4.5 Hz), 2.71 (1H, dd, J=17.0, 5.0 Hz), 1.42 (9H, s).

Example 5(15)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N,N-dibenzylamino)tetrazol-2-yl)pen tanoic acid•t-butylester ##STR1202##

TLC: Rf 0.65 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.23-7.15 (15H, m), 5.93 (1H, d, J=10.0 Hz), 5.61 and 5.45 (each 1H, d, J=17.5 Hz), 5.16 (2H, s), 4.72-4.50 (1H, m), 4.61 (4H, s), 2.99 and 2.70 (each 1H, dd, J=17.5 Hz, 5.0 Hz), 1.42 (9H, s).

Example 5(16)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trifluoromethyltetrazol-1-yl)pentano ic acid•t-butylester ##STR1203##

HPTLC: Rf 0.39 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39 (5H, m), 6.04-5.60 (3H, m), 5.20 (2H, s), 4.67 (1H, m), 3.09 (1H, dd, J=18.0, 4.5 Hz), 2.73 (1H, dd, J=18.0, 5.0 Hz), 1.42 (9H, s).

Example 5(17)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trifluoromethyltetrazol-2-yl)pentano ic acid•t-butylester ##STR1204##

HPTLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39 (5H, m), 6.04-5.68 (3H, m), 5.19 (2H, s), 4.69 (1H, m), 3.07 (1H, dd, J=18.0, 4.5 Hz), 2.73 (1H, dd, J=18.0, 5.0 Hz), 1.43 (9H, s).

Example 5(18)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(ethoxycarbonylmethyl)tetrazol-2-yl) pentanoic acid•t-butylester ##STR1205##

HPTLC: Rf 0.36 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.44-7.32 (5H, m), 5.94 (1H, d, J=8.0 Hz), 5.82 and 5.68 (each 1H, both d, J=18.0 Hz), 5.18 (2H, s), 4.66 (1H, m), 4.20 (2H, q, J=7.0 Hz), 4.00 (2H, s), 3.00 (1H, dd, J=18.0, 4.0 Hz), 2.73 (1H, dd, J=18.0, 5.0 Hz), 1.42 (9H, s), 1.27 (3H, t, J=7.0 Hz).

Example 5(19)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylthiotetrazol-1-yl)pentanoic acid•t-butylester ##STR1206##

TLC: Rf 0.38 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.39 (5H, m), 5.95 (1H, m), 5.50 (1H, d, J=16 Hz), 5.30 (1H, d, J=16 Hz), 5.20 (2H, s), 4.63 (1H, m), 3.30 (2H, q, J=7 Hz), 3.05 (1H, dd, J=17.5, 5 Hz), 2.70 (1H, dd, J=17.5, 5 Hz), 1.42 (12H, m).

Example 5(20)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylthiotetrazol-2-yl)pentanoic acid•t-butylester ##STR1207##

TLC: Rf 0.54 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.39 (5H, m), 5.95 (1H, m), 5.80 (1H, d, J=16 Hz), 5.60 (1H, d, J=16 Hz), 5.16 (2H, s), 4.63 (1H, m), 3.20 (2H, q, J=7 Hz), 3.01 (1H, dd, J=17.5, 5 Hz), 2.70 (1H, dd, J=17.5, 5 Hz), 1.41 (12H, m).

Example 5(21)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(ethoxycarbonylmethyl)tetrazol-1-yl) pentanoic acid•t-butylester ##STR1208##

HPTLC: Rf 0.26 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.44-7.30 (5H, m), 5.89-5.58 (3H, m), 5.17 (2H, s), 4.62 (1H, m), 4.18 (2H, q, J=7.0 Hz), 4.03 and 3.82 (each 1H, each d, J=17.0 Hz), 3.09 and 2.77 (each 1H, each dd, J=17.0, 5.0 Hz), 1.42 (9H, s), 1.27 (3H, t, J=7.0 Hz).

Example 5(22)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-((4-chlorophenyl)thiomethyl)tetrazol -2-yl)pentanoic acid•t-butylester ##STR1209##

TLC: Rf 0.62 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.38 (5H, m), 7.30 and 7.22 (total 4H, each d, J=9.0 Hz), 5.94 (1H, d, J=10.0 Hz), 5.79 (1H, d, J=17.5 Hz), 5.60 (1H, d, J=17.5 Hz), 5.18 (2H, s), 4.64 (1H, m), 4.28 (2H, s), 3.00 (1H, dd, J=17.5 Hz and 5.0 Hz), 2.70 (1H, dd, J=17.5 Hz and 5.0 Hz), 1.40 (9H, s).

Example 5(23)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-((4-chlorophenyl)thiomethyl)tetrazol -1-yl)pentanoic acid•t-butylester ##STR1210##

TLC: Rf 0.46 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.38 (5H, m), 7.22 (4H, m), 5.80 (1H, d, J=10.0 Hz), 5.75 (1H, d, J=17.5 Hz), 5.60 (1H, d, J=17.5 Hz), 5.20 (2H, s), 4.64 (1H, m), 4.28 and 4.08 (total 2H, each d, J=15.0 Hz), 3.10 (1H, dd, J=17.5 Hz and 5.0 Hz), 2.78 (1H, dd, J=17.5 Hz and 5.0 Hz), 1.40 (9H, s).

Example 5(24)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-phenylpropyl)tetrazol-2-yl)pentan oic acid•t-butylester ##STR1211##

TLC: Rf 0.36 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.98 (1H, d, J=9.5 Hz), 7.42-7.10 (10H, m), 5.91 (2H, s), 5.10 (2H, s), 4.75-4.57 (1H, m) 2.92-2.55 (6H, m), 2.10-1.90 (2H, m), 1.38 (9H, s).

Example 5(25)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-phenylpropyl)tetrazol-1-yl)pentan oic acid•t-butylester ##STR1212##

TLC: Rf 0.14 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.07 (1H, d, J=9.5 Hz), 7.42-7.08 (10H, m), 5.71 (2H, s), 5.11 (2H, s), 4.72-4.57 (1H, m), 2.87-2.54 (6H, m), 2.05-1.84 (2H, m), 1.38 (9H, s).

Example 5(26)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyloxy)tetrazol-2-yl )pentanoic acid•t-butylester ##STR1213##

HPTLC: Rf 0.55 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.44-7.12 (8H, m), 5.92 (1H, m), 5.70 and 5.53 (each 1H, each d, J=17.5 Hz), 5.16 (2H, s), 4.63 (1H, m), 3.01 and 2.69 (each 1H, each dd, J=17.0, 5.0 Hz), 1.41 (9H, s).

Example 5(27)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyloxy)tetrazol-1-yl )pentanoic acid•t-butylester ##STR1214##

HPTLC: Rf 0.44 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.47-7.14 (8H, m), 6.00 (1H, m), 5.69-5.26 (2H, m), 5.19 (2H, brs), 4.69 (1H, br), 3.08 and 2.73 (each 1H, each m), 1.40 (9H, s).

Example 5(28)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenyloxymethyl)tetrazol-2- yl)pentanoic acid•t-butylester ##STR1215##

TLC: Rf 0.62 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.38 (6H, m), 7.20 (1H, d, J=6.0 Hz), 7.10 (1H, d, J=6.0 Hz), 6.94 (1H, m), 5.95 (1H, d, J=10.0 Hz), 5.88 (1H, d, J=17.5 Hz), 5.70 (1H, d, J=17.5 Hz), 5.42 (2H, s), 5.18 (2H, s), 4.65 (1H, m), 3.01 (1H, dd, J=17.5 Hz and 5.0 Hz), 2.70 (1H, dd, J=17.5 Hz and 5.0 Hz), 1.42 (9H, s).

Example 5(29)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenyloxymethyl)tetrazol-1- yl)pentanoic acid•t-butylester ##STR1216##

TLC: Rf 0.48 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.38 (6H, m), 7.20 (1H, d, J=6.0 Hz), 6.98 (2H, m), 6.08 (1H, d, J=19.0 Hz), 5.88 (1H, d, J=10.0 Hz), 5.75 (1H, d, J=19.0 Hz), 5.50 and 5.30 (total 2H, each d, J=12.5 Hz), 5.18 (2H, s), 4.68 (1H, m), 3.01 (1H, dd, J=117.5 Hz and 5.0 Hz), 2.68 (1H, dd, J=17.5 Hz and 5.0 Hz), 1.25 (9H, s).

Example 5(30)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxycarbonylethyl)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1217##

TLC: Rf 0.50 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.45-7.30 (5H, m), 5.94 (1H, d, J=10.0 Hz), 5.76 (1H, d, J=17.0 Hz), 5.61 (1H, d, J=17.0 Hz), 5.18 (2H, s), 4.75-4.50 (1H, m), 3.70 (3H, s), 3.23 (2H, t, J=6.5 Hz), 3.00 (1H, dd, J=16.0 and 4.5 Hz), 2.86 (2H, t, J=6.5 Hz), 2.70 (1H, dd, J=16.0 and 5.0 Hz), 1.42 (9H, s).

Example 5(31)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxycarbonylethyl)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1218##

TLC: Rf 0.25 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.43-7.29 (5H, m), 5.96 (1H, d, J=9.0 Hz), 5.68 (1H, d, J=19.5 Hz), 5.55 (1H, d, J=19.5 Hz), 5.19 (2H, s), 4.72-4.51 (1H, m), 3.65 (3H, s), 3.06 (1H, dd, J=16.5 and 5.0 Hz), 2.92 (4H, brs), 2.73 (1H, dd, J=16.5 and 5.5 Hz), 1.42 (9H, s).

Example 5(32)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-methylpyrrol-2-ylmethyl)tetrazol- 2-yl)pentanoic acid•t-butylester ##STR1219##

TLC: Rf 0.65 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.46-7.28 (5H, m), 6.51 (1H, m), 5.98 (1H, m), 5.87 (1H, d, J=9.0 Hz), 5.73 (1H, d, J=17.8 Hz), 5.55 (1H, d, J=17.8 Hz), 5.11 (2H, s), 4.75-4.54 (1H, m), 4.18 (2H, s), 3.51 (3H, s), 2.94 (1H, dd, J=17.2 and 4.4 Hz), 2.64 (1H, dd, J=17.2 Hz and 4.8 Hz), 1.36 (9H, s).

Example 5(33)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-methylpyrrol-2-ylmethyl)tetrazol- 1-yl)pentanoic acid•t-butylester ##STR1220##

TLC: Rf 0.51 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.48-7.30 (5H, m), 6.56 (1H, m), 6.18-5.92 (2H, m), 5.83 (1H, d, J=9.1 Hz), 5.44 (1H, d, J=18.4 Hz), 5.30 (1H, d, J=18.4 Hz), 5.18 (2H, s), 4.64-4.45 (1H, m), 4.31 (1H, d, J=16.8 Hz), 4.12 (1H, d, J=16.8 Hz), 3.44 (3H, s), 2.97 (1H, dd, J=17.5 and 4.6 Hz), 2.66 (1H, dd, J=17.5 and 4.8 Hz), 1.43 (9H, s).

Example 5(34)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-2-ylmethyl)tetrazol-2-yl)pe ntanoic acid•t-butylester ##STR1221##

TLC: Rf 0.16 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.60-8.46 (1H, m), 7.71-7.54 (1H, m), 7.52-7.07 (7H, m), 5.99 (1H, d, J=8.8 Hz), 5.80 (1H, d, J=17.8 Hz), 5.65 (1H, dd, J=17.8 Hz), 5.16 (2H, s), 4.75-4.50 (1H, m), 4.48 (2H, s), 3.00 (1H, dd, J=17.6 and 4.8 Hz), 2.72 (1H, dd, 17.6 and 5.0 Hz), 1.41 (9H, s).

Example 5(35)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-2-ylmethyl)tetrazol-1-yl)pe ntanoic acid•t-butylester ##STR1222##

TLC: Rf 0.07 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.50-8.36 (1H, m), 7.71-7.56 (1H, m), 7.52-7.07 (7H, m), 6.00 (1H, d, J=8.2 Hz), 5.93 (1H, d, J=18.4 Hz), 5.70 (1H, d, J=18.4 Hz), 5.17 (2H, s), 4.77-4.54 (1H, m), 4.33 (2H, s), 3.03 (1H, dd, J=22.1 and 4.6 Hz), 2.74 (1H, dd, J=22.1 and 5.0 Hz), 1.39 (9H, s).

Example 5(36)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-3-ylmethyl)tetrazol-2-yl)pe ntanoic acid•t-butylester ##STR1223##

TLC: Rf 0.61 (chloroform:methanol:acetic acid=18:1:1); NMR (CDCl3): δ 8.80-8.30 (2H, m), 7.70-7.60 (1H, m), 7.50-7.21 (1H, m), 5.98 (1H, d, J=9.2 Hz), 5.80 (1H, d, J=17.7 Hz), 5.63 (1H, d, J=17.7 Hz), 5.17 (2H, s), 4.75-4.56 (1H, m), 4.27 (2H, s), 3.01 (1H, dd, J=17.4, 4.6 Hz), 2.71 (1H, dd, J=17.4, 4.9 Hz), 1.42 (9H, s).

Example 5(37)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-3-ylmethyl)tetrazol-1-yl)pe ntanoic acid•t-butylester ##STR1224##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=18:1:1); NMR (CDCl3): δ 8.75-8.35 (2H, m), 7.65-7.56 (1H, m), 7.50-7.04 (1H, m), 5.80 (1H, d, J=8.5 Hz), 5.47 (2H, s), 5.18 (2H, s), 4.66-4.52 (1H, m), 4.20 (1H, d, J=16.4 H), 4.02 (1H, d, J=16.4 Hz), 3.09 (1H, dd, J=17.6, 4.5 Hz), 2.77 (1H, dd, J=17.6, 5.2 Hz), 1.43 (9H, s).

Example 5(38)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-difluorophenylmethyl)tetrazol-2 -yl)pentanoic acid•t-butylester ##STR1225##

TLC: Rf 0.45 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.70-7.15 (6H, m), 7.03-6.70 (2H, m), 5.92 (1H, d, J=9.2 Hz), 5.76 (1H, d, J=17.9 Hz), 5.58 (1H, d, J=17.9 Hz), 5.16 (2H, s), 4.73-4.52 (1H, m), 4.31 (2H, s), 2.99 (1H, dd, J=17.3, 4.6 Hz), 2.69 (1H, dd, J=17.3, 4.9 Hz), 1.41 (9H, s).

Example 5(39)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-difluorophenylmethyl)tetrazol-1 -yl)pentanoic acid•t-butylester ##STR1226##

TLC: Rf 0.25 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.60-7.10 (6H, m), 7.00-6.85 (2H, m), 5.88 (1H, d, J=8.4 Hz), 5.66 (1H, d, J=18.7 Hz), 5.49 (1H, d, J=18.7 Hz), 5.19 (2H, s), 4.74-4.53 (1H, m), 4.07 (2H, s), 3.07 (1H, dd, J=17.5, 4.6 Hz), 2.75 (1H, dd, J=17.5, 4.9 Hz), 1.41 (9H, s).

Example 5(40)

N-benzyloxycarbonyi-3-amino-4-oxo-5-(5-(phenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1227##

TLC: Rf 0.26 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.62-7.49 and 7.43-7.29 (total 10H, m), 5.93 (1H, d, J=8.5 Hz), 5.79 and 5.62 (each 1H, each d, J=17.5 Hz), 5.16 (2H, s), 4.63 (1H, m), 3.00 and 2.70 (each 1H, each dd, J=17.5, 5.0 Hz), 1.40 (9H, s).

Example 5(41)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1228##

TLC: Rf 0.19 (hexane:ethyl acetate=2:1); NMR (CDC13): δ 7.58-7.28 (10H, m), 5.94 (1H, d, J=8.0 Hz), 5.58 and 5.42 (each 1H, each d, J=17.5 Hz), 5.19 (2H, s), 4.60 (1H, m), 3.04 and 2.70 (each 1H, each dd, J=17.5, 5.0 Hz), 1.41 (9H, s).

Example 5(42)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1229##

HPTLC: Rf 0.42 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.50-7.23 (8H, m), 5.93 (1H, d, J=8.0 Hz), 5.77 and 5.58 (each 1H, each d, J=17.5 Hz), 5.16 (2H, s), 4.62 (1H, m), 3.00 and 2.69 (each 1H, each dd, J=17.5, 5.0 Hz), 1.39 (9H, s).

Example 5(43)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1230##

HPTLC: Rf 0.30 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.50-7.25 (8H, m), 5.98 (1H, d, J=8.0 Hz), 5.69 and 5.52 (each 1H, each d, J=17.5 Hz), 5.21 (2H, s), 4.68 (1H, m), 3.10 and 2.75 (each 1H, each dd, J=17.5, 5.0 Hz), 1.43 (9H, s).

Example 5(44)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylmethyl)tetrazol-2 -yl)pentanoic acid•t-butylester ##STR1231##

TLC: Rf 0.71 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.46-7.20 (5H, m), 7.13-6.92 (2H, m), 5.93 (1H, d, J=8.6 Hz), 5.73 (1H, d, J=18.0 Hz), 5.55 (1H, d, J=18.0 Hz), 5.15 (2H, s), 4.72-4.64 (1H, m), 4.25 (2H, s), 2.98 (1H, dd, J=17.3, 4.4 Hz), 2.67 (1H, dd, J=17.3, 4.8 Hz), 2.38 (6H, s), 1.41 (9H, s).

Example 5(45)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylmethyl)tetrazol-1 -yl)pentanoic acid•t-butylester ##STR1232##

TLC: Rf 0.40 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.50-7.25 (5H, m), 7.18-6.95 (2H, m), 5.80 (1H, d, J=8.6 Hz), 5.45 (1H, d, J=18.6 Hz), 5.31 (1H, d, J=18.6 Hz), 5.17 (2H, s), 4.51-4.35 (1H, m), 4.05 (2H, s), 2.98 (1H, dd, J=17.7, 4.6 Hz), 2.69 (1H, dd, J=17.7, 4.9 Hz), 2.18 (6H, s), 1.40 (9H, s).

Example 5(46)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylmethyl)tetrazol-2-yl)pent anoic acid•t-butylester ##STR1233##

TLC: Rf 0.72 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.42-7.30 (5H, m), 5.95 (1H, d, J=9.0 Hz), 5.78 (1H, d, J=17.8 Hz), 5.61 (1H, d, J=17.8 Hz), 5.17 (2H, s), 4.72-4.50 (1H, m), 3.00 (1H, dd, J=17.4, 4.4 Hz), 2.84-2.62 (3H, m), 2.00-1.50 (6H, m), 1.42 (9H, s), 1.36-0.85 (5H, m).

Example 5(47)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylmethyl)tetrazol-1-yl)pent anoic acid•t-butylester ##STR1234##

TLC: Rf 0.46 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.45-7.30 (5H, m), 5.85 (1H, d, J=8.8 Hz), 5.49 (2H, s), 5.19 (2H, s), 4.68-4.54 (1H, m), 3.09 (1H, dd, J=17.4, 4.4 Hz), 2.75 (1H, dd, J=17.4, 5.2 Hz), 2.54 (2H, d, J=7.2 Hz), 2.00-1.51 (6H, m), 1.43 (9H, s), 1.37-0.80 (5H, m).

Example 5(48)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenylthio)tetrazol-2-yl)pe ntanoic acid•t-butylester ##STR1235##

TLC: Rf 0.65 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.48 (2H, d, J=8.0 Hz), 7.42-7.30 (5H, m), 7.17 (2H, d, J=8.0 Hz), 5.93 (1H, d, J=9.0 Hz), 5.77 (1H, d, J=17.8 Hz), 5.59 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.71-4.56 (1H, m), 3.00 (1H, dd, J=17.4, 4.4 Hz), 2.69 (1H, dd, J=17.4, 4.9 Hz), 2.35 (3H, s), 1.41 (9H, s).

Example 5(49)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4- methylphenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1236##

TLC: Rf 0.52 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.53-7.28 (7H, m), 7.18 (2H, d, J=8.0 Hz), 5.95 (1H, d, J=8.7 Hz), 5.57 (1H, d, J=18.4 Hz), 5.40 (1H, d, J=18.4 Hz), 5.19 (2H, s), 4.73-4.52 (1H, m), 3.04 (1H, dd, J=17.7, 4.6 Hz), 2.70 (1H, dd, J=17.7, 4.9 Hz), 2.35 (6H, s), 1.43 (9H, s).

Example 5(50)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylthio)tetrazol-2-yl)pe ntanoic acid•t-butylester ##STR1237##

TLC: Rf 0.63 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.50 (2H, d, J=8.6 Hz), 7.42-7.30 (5H, m), 7.33 (2H, d, J=8.6 Hz), 5.93 (1H, d, J=8.8 Hz), 5.80 (1H, d, J=17.6 Hz), 5.62 (1H, d, J=17.6 Hz), 5.17 (2H, s), 4.72-4.56 (1H, m), 3.02 (1H, dd, J=17.4, 4.4 Hz), 2.70 J=17.6 Hz), 5.17 (2H, s), 4.72-4.56 (1H, m), 3.02 (1H, dd, J=17.4, 4.4 Hz), 2.70 (1H, dd, J=17.4, 4.7 Hz), 1.41 (9H, s).

Example 5(51)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylthio)tetrazol-1-yl)pe ntanoic acid•t-butylester ##STR1238##

TLC: Rf 0.51 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.48 (2H, d, J=8.6 Hz), 7.43-7.28 (7H, m), 5.94 (1H, d, J=9.0 Hz), 5.60 (1H, d, J=18.3 Hz), 5.44 (1H, d, J=18.3 Hz), 5.20 (2H, s), 4.70-4.54 (1H, m), 3.06 (1H, dd, J=17.6, 4.2 Hz), 2.71 (1H, dd, J=17.6, 4.7 Hz), 1.43 (9H, s).

Example 5(52)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-4-yl)tetrazol-2-yl)pentanoi c acid•t-butylester ##STR1239##

TLC: Rf 0.55 (ethyl acetate); NMR (CDCl3): δ 8.58-8.48 (2H, m), 7.38 (5H, m), 7.27-7.18 (2H, m), 5.95 (1H, d, J=8.4 Hz), 5.83 (1H, d, J=17.6 Hz), 5.65 (1H, d, J=17.6 Hz), 5.18 (2H, s), 4.77-4.50 (1H, m), 4.27 (2H, s), 3.04 (1H, dd, J=17.4 and 4.6 Hz), 2.71 (1H, dd, J=17.4 and 4.8 Hz), 1.42 (9H, s).

Example 5(53)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-4-yl)tetrazol-1-yl)pentanoi c acid•t-butylester ##STR1240##

TLC: Rf 0.37 (ethyl acetate); NMR (CDCl3): δ 8.64-8.50 (2H, m), 7.38 (5H, brs), 7.25-7.11 (2H, m), 5.75-5.65 (1H, m), 5.58-5.31 (2H, m), 5.17 (2H, s), 4.69-4.45 (1H, m), 4.20 (1H, d, J=16.6 Hz), 4.01 (1H, d, J=16.6 Hz), 3.19-2.67 (2H, m), 1.43 (9H, s).

Example 5(54)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,5-dichlorophenylthio)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1241##

HPTLC: Rf 0.59 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.45-7.28 (8H, m), 5.94 (1H, d, J=8.5 Hz), 5.84 and 5.68 (each 1H, each d, J=17.5 Hz), 5.17 (2H, s), 4.66 (1H, m), 3.03 and 2.71 (each 1H, each dd, J=17.5, 5.0 Hz), 1.40 (9H, s).

Example 5(55)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,5-dichlorophenylihio)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1242##

HPTLC: Rf 0.46 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.46-7.30 (8H, m), 5.92 (1H, d, J=8.5 Hz), 5.64 and 5.48 (each 1H, each d, J=17.5 Hz), 5.19 (2H, s), 4.63 (1H, m), 3.07 and 2.73 (each 1H, each dd, J=17.5, 5.0 Hz), 1.42 (9H, s).

Example 5(56)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-methylpyrimidin-2,4-dion-3-ylmeth yl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1243##

TLC: Rf 0.38 (chloroform:methanol=20:1); NMR (CDCl3): δ 7.38 (5H, m), 7.15 (1H, d, J=8 Hz), 6.00 (1H, d, J=10 Hz), 5.79 (1H, d, J=8 Hz), 5.72 (1H, d, J=17 Hz), 5.62 (1H, d, J=17 Hz), 5.43 (2H, s), 5.18 (2H, s), 4.61 (1H, m), 3.40 (3H, s), 2.93 (1H, dd, J=18 and 5 Hz), 2.71 (1H, dd, J=15 and 5 Hz), 1.40 (9H, s).

Example 5(57)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-methylpyrimidin-2,4-dion-3-ylmeth yl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1244##

TLC: Rf 0.32 (chloroform:methanol=20:1); NMR (CDCl3): δ 7.40 (5H, m), 7.13 (1H, d, J=8 Hz), 5.93 (1H, d, J=10 Hz), 5.92 (1H, d, J=17 Hz), 5.75 (1H, d, J=17 Hz), 5.72 (1H, d, J=8 Hz), 5.30 (1H, d, J=16 Hz), 5.20 (2H, s), 5.09 (1H, d, J=16 Hz), 4.68 (1H, m), 3.39 (3H, s), 3.03 (1H, dd, J=17 and 5 Hz), 2.78 (1H, dd, J=17 and 5 Hz), 1.40 (9H, s).

Example 5(58)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloroethyl)tetrazol-2-yl)pentano ic acid•t-butylester ##STR1245##

TLC: Rf 0.68 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.39 (5H, m), 5.94 (1H, d, J=8.8 Hz), 5.82 (1H, d, J=17.8 Hz), 5.65 (1H, d, J=17.8 Hz), 5.18 (2H, s), 4.72-4.60 (1H, m), 3.92 (2H, t, J=7.0 Hz), 3.39 (2H, t, J=7.0 Hz), 3.02 (1H, dd, J=17.4 and 4.2 Hz), 2.72 (1H, dd, J=17.4 and 4.8 Hz), 1.43 (9H, s).

Example 5(59)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloroethyl)tetrazol-1-yl)pentano ic acid•t-butylester ##STR1246##

TLC: Rf 0.46 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.39 (5H, m), 5.79 (1H, d, J=8.2 Hz), 5.74-5.49 (2H, m), 5.20 (2H, s), 4.70-4.52 (1H, m), 3.92 (2H, t, J=7.0 Hz), 3.24-3.02 (3H, m), 277 (1H, dd, J=17.4 and 5.2 Hz), 1.44 (9H, s).

Example 5(60)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylcarbonyl)tetrazol-2-yl)pentan oic acid•t-butylester ##STR1247##

HPTLC: Rf 0.35 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.36 (2H, d, J=7.0 Hz), 7.73-7.29 (3H, m), 7.37 (5H, m), 6.11-5.74 (3H, m), 5.18 (2H, s), 4.73 (1H, m), 3.05 and 2.77 (each 1H, each dd, J=17.0, 5.0 Hz), 1.42 (9H, s).

Example 5(61)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylcarbonyl)tetrazol-1-yl)pentan oic acid•t-butylester ##STR1248##

HPTLC: Rf 0.47 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.42 (2H, d, J=7.0 Hz), 7.70 (1H, t, J=7.0 Hz), 7.54 (2H, t, J=7.0 Hz), 7.46-7.29 (5H, m), 6.12-5.74 (3H, m), 5.20 (2H, s), 4.78 (1H, m), 2.97 and 2.71 (each 1H, each dd, J=17.5, 5.0 Hz), 1.36 (9H, s).

Example 5(62)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-fluorophenylmethyl)tetra zol-2-yl)pentanoic acid•t-butylester ##STR1249##

TLC: Rf 0.74 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.46-7.30 (5H, m), 7.25-7.18 (2H, m), 7.10-6.95 (1H, m),5.94 (1H,d, J=8.6 Hz), 5.77 (1H, d, J=17.8 Hz), 5.58 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.70-4.55 (1H, m), 4.44 (2H, s), 2.99 (1H, dd, J=17.4, 4.5 Hz), 2.68 (1H, dd, J=17.4, 4.8 Hz), 1.41 (9H,s).

Example 5(63)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-fluorophenylmethyl)tetra zol-1-yl)pentanoic acid•t-butylester ##STR1250##

TLC: Rf 0.51 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.50-7.30 (5H, m), 7.30-7.16 (2H, m), 7.10-6.94 (1H, m), 5.88 (1H, d, J=9.1 Hz), 5.68 (1H, d, J=18.7 Hz), 5.52 (1H, d, J=18.7 Hz), 5.19 (2H, s), 4.70-4.55 (1H, m), 3.10 (1H, dd, J=17.6, 4.6 Hz), 2.76 (1H, dd, J=17.6, 4.8 Hz), 1.41 (9H, s).

Example 5(64)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylthio)tetrazol-2-yl)pentan oic acid•t-butylester ##STR1251##

TLC: Rf 0.42 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.44-7.30 (5H, m), 5.95 (1H, d, J=9.4 Hz), 5.79 (1H, d, J=17.8 Hz), 5.61 (1H, d, J=17.8 Hz), 5.18 (2H, s), 4.75-4.60 (1H, m), 3.72-3.50 (1H, m), 3.03 (1H, dd, J=17.4, 4.4 Hz), 2.71 (1H, dd, J=17.4, 4.8 Hz), 2.20-1.30 (10H, m), 1.42 (9H, s).

Example 5(65)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylthio)tetrazol-1-yl)pentan oic acid•t-butylester ##STR1252##

TLC: Rf 0.28 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.48-7.30 (5H, m), 5.96 (1H, d, J=8.4 Hz), 5.49 (1H, d, J=18.3 Hz), 5.31 (1H, d, J=18.3 Hz), 5.19 (2H, s), 4.72-4.57 (1H, m), 3.91-3.72 (1H, m), 3.06 (1H, dd, J=17.6, 4.3 Hz), 2.70 (1H, dd, J=17.6, 4.9 Hz), 2.20-1.20 (10H, m), 1.43 (9H, s).

Example 5(66)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methoxyphenylthio)tetrazol-2-yl)p entanoic acid•t-butylester ##STR1253##

TLC: Rf 0.50 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.56 (2H, d, J=8.9 Hz), 7.45-7.30 (5H, m), 6.90 (2H, d, J=8.9 Hz), 5.93 (1H, d, J=9.2 Hz), 5.75 (1H, d, J=17.8 Hz), 5.58 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.72-4.55 (1H, m), 3.81 (3H, s), 2.97 (1H, dd, J=17.3 4.3 Hz), 2.68 (1H, dd, J=17.3, 4.9 Hz), 1.41 (9H, s).

Example 5(67)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methoxyphenylthio)tetrazol-1-yl)p entanoic acid•t-butylester ##STR1254##

TLC: Rf 0.43 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.51 (2H, d, J=8.9 Hz), 7.45-7.32 (5H, m), 6.90 (2H, d, J=8.9 Hz), 5.97 (1H, d, J=9.2 Hz), 5.57 (1H, d, J=18.4 Hz), 5.40 (1H, d, J=18.4 Hz), 5.20 (2H, s), 4.71-4.55 (1H, m), 3.81 (3H, s), 3.05 (1H, dd, J=17.5, 4.4 Hz), 2.75 (1H, dd, J=17.5, 4.9 Hz), 1.43 (9H, s).

Example 5(68)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetrazol-2-yl)pe ntanoic acid•t-butylester ##STR1255##

TLC: Rf 0.52 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.51-7.16 (9H, m), 5.93 (1H, d, J=9.4 Hz), 5.84 (1H, d, J=17.8 Hz), 5.66 (1H, d, J=17.8 Hz), 5.18 (2H, s), 4.73-4.54 (1H, m), 3.03 (1H, dd, J=17.4 and 4.8 Hz), 2.71 (1H, dd, 17.4 and 4.6 Hz), 1.42 (9H, s).

Example 5(69)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetrazol-1-yl)pe ntanoic acid•t-butylester ##STR1256##

TLC: Rf 0.40 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.58-7.00 (9H, m), 5.95 (1H, d, J=9.0 Hz), 5.67 (J=18.4 Hz), 5.50 (1H, d, J=18.4 Hz), 5.20 (2H, s), 4.74-4.52 (1H, m), 3.05 (1H, dd, J=17.6 and 4.2 Hz), 2.71 (1H, dd, 17.6 and 5.0 Hz), 1.41 (9H, s).

Example 5(70)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dichlorophenylthio)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1257##

TLC: Rf 0.30 (hexane:ethyl acetate=4:1); NMR (CDCl3): δ 7.48 (1H, d, J=2.2 Hz), 7.46-7.31 (6H, m), 7.23 (1H, dd, J=8.4 and 2.2 Hz), 5.93 (1H, d, J=9.0 Hz), 5.84 (1H, d, J=17.8 Hz), 5.66 (1H, d, J=17.8 Hz), 5.18 (2H, s), 4.75-4.52 (1H, m), 3.03 (1H, dd, J=17.6 and 4.4 Hz), 2.71 (1H, dd, J=17.6 and 4.8 Hz), 1.42 (9H, s).

Example 5(71)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dichlorophenylthio)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1258##

TLC: Rf 0.23 (hexane:ethyl acetate=4:1); NMR (CDCl3): δ 7.53 (1H, d, J=8.4 Hz), 7.47 (1H, d, J=2.4 Hz), 7.45-7.32 (5H, m), 7.27 (1H, dd, J=8.4 and 2.4 Hz), 5.94 (1H, d, J=9.6 Hz), 5.68 (1H, d, J=18.6 Hz), 5.51 (1H, d, J=18.6 Hz), 5.20 (2H, s), 4.76-4.52 (1H, m), 3.07 (1H, dd, J=17.6 and 4.6 Hz), 2.72 (1H, dd, J=17.6 and 4.6 Hz), 1.41 (9H, s).

Example 5(72)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-methylphenylthio)tetrazo l-2-yl)pentanoic acid•t-butylester ##STR1259##

TLC: Rf 0.71 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.39-7.20 (8H, m), 5.92 (1H, d, J=8.8 Hz), 5.74 (1H, d, J=17.4 Hz), 5.55 (1H, d, J=17.4 Hz), 4.65-4.55 (1H, m), 3.00 (1H, dd, J=4.4, 17.4 Hz), 2.69 (1H, dd, J=4.6, 17.4 Hz), 2.52 (3H, s), 1.40 (9H, s).

Example 5(73)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-methylphenylthio)tetrazo l-1-yl)pentanoic acid•t-butylester ##STR1260##

TLC: Rf 0.55 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.43-7.23 (8H, m), 5.97 (1H, d, J=9.4 Hz), 5.66 (1H, d, J=18.6 Hz), 5.49 (1H, d, J=18.6 Hz), 4.70-4.60 (1H, m), 3.08 (1H, dd, J=4.4, 17.2 Hz), 2.74 (1H, dd, J=4.6, 17.2 Hz), 2.58 (3H, s), 1.43 (9H, s).

Example 5(74)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylphenylthio)tetrazo l-2-yl)pentanoic acid•t-butylester ##STR1261##

TLC: Rf 0.59 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.60 (s, 4H), 7.38 (s, 5H), 6.0-5.6 (m, 3H), 5.18 (s, 2H), 4.7-4.6 (m, 1H), 3.05 (dd, J=4.3, 17.5 Hz, 1H), 2.72 (dd, J=4.8, 17.5 Hz, 1H), 1.42 (s, 9H).

Example 5(75)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylphenylthio)tetrazo l-1-yl)pentanoic acid•t-butylester ##STR1262##

TLC: Rf 0.43 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.61 (s, 4H), 7.38 (s, 5H), 6.0-5.9 (m, 1H), 5.7-5.4 (m, 2H), 5.20 (s, 2H), 4.7-4.6 (m, 1H), 3.07 (dd, J=4.3, 17.6 Hz, 1H), 2.71 (dd, J=4.0, 17.5 Hz, 1H), 1.41 (s, 9H).

Example 5(76)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-2-ylthio)tetrazol-2-yl)p entanoic acid•t-butylester ##STR1263##

TLC: Rf 0.47 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 8.08 (1H, d, J=1.5 Hz), 7.87-7.73 (3H, m), 7.62-7.43 (3H, m), 7.41-7.25 (5H, m), 5.93 (1H, d, J=8.6 Hz), 5.79 (1H, d, J=17.7 Hz), 5.62 (1H, d, J=17.7 Hz), 5.15 (2H, s), 4.71-4.56 (1H, m), 3.00 (1H, dd, J=17.5, 4.4 Hz), 2.69 (1H, dd, J=17.5, 4.9 Hz), 1.39 (9H, s).

Example 5(77)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-2-ylthio)tetrazol-1-yl)p entanoic acid•t-butylester ##STR1264##

TLC: Rf 0.35 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 8.06 (1H, s), 7.88-7.75 (3H, m), 7.61-7.46 (3H, m), 7.43-7.30 (5H, m), 5.92 (1H, d, J=8.8 Hz), 5.59 (1H, d, J=18.3 Hz), 5.44 (1H, d, J=18.3 Hz), 5.17 (2H, s), 4.65-4.52 (1H, m), 2.98 (1H, dd, J=17.5, 4.4 Hz), 2.66 (1H, dd, J=17.5, 4.9 Hz), 1.42 (9H, s).

Example 5(78)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-t-butylphenylthio)tetrazol-2-yl)p entanoic acid•t-butylester ##STR1265##

TLC: Rf 0.49 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.51 (2H, d, J=8.6 Hz), 7.45-7.30 (7H, m), 5.94 (1H, d, J=8.8 Hz), 5.78 (1H, d, J=17.8 Hz), 5.60 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.70-4.56 (1H, m), 3.01 (1H, dd, J=17.4, 4.4 Hz), 2.69 (1H, dd, J=17.4, 4.8 Hz), 1.41 (9H, s), 1.30 (9H, s).

Example 5(79)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-t-butylphenylthio)tetrazol-1-yl)p entanoic acid•t-butylester ##STR1266##

TLC: Rf 0.34 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.47 (2H, d, J=8.7 Hz), 7.42-7.30 (7H, m), 5.95 (1H, d, J=9.2 Hz), 5.57 (1H, d, J=18.4 Hz), 5.41 (1H, d, J=18.4 Hz), 5.19 (2H, s), 4.68-4.53 (1H, m), 3.03 (1H, dd, J=17.4, 4.4 Hz), 2.69 (1H, dd, J=17.4, 4.9 Hz), 1.42 (9H, s), 1.30 (9H, s).

Example 5(80)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethyloxyphenylthio)tetr azol-1-yl)pentanoic acid•t-butylester ##STR1267##

TLC: Rf 0.31 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.7-7.5 (m, 2H), 7.5-7.3 (m, 5H), 7.3-7.2 (m, 2H), 5.94 (d, J=8.5 Hz, 1H), 5.63 (d, J=18.4 Hz, 1H), 5.46 (d, J=18.4 Hz, 1H), 5.20 (s, 2H), 4.7-4.6 (m, 1H), 3.10 (dd, J=4.4, 17.6 Hz, 1H), 2.71 (dd, J=4.9, 17.6 Hz, 1H), 1.42 (s, 9H).

Example 5(81)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethyloxyphenylthio)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1268##

TLC: Rf 0.37 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.7-7.5 (m, 2H), 7.5-7.3 (m, 5H), 7.3-7.2 (m, 2H), 6.0-5.9 (m, 1H), 5.86 (d, J=17.7 Hz, 1H), 5.68 (d, J=17.7 Hz, 1H), 5.17 (s, 2H), 4.7-4.6 (m, 1H), 3.00 (dd, J=4.4, 17.5 Hz, 1H), 2.70 (dd, J=4.8, 17.5 Hz, 1H), 1.41 (s, 9H).

Example 5(82)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio)tetrazol- 2-yl)pentanoic acid•t-butylester ##STR1269##

TLC: Rf 0.55 (benzene:diethylether=10:1); NMR (CDCl3): δ 7.51-7.35 (7H, m), 5.92 (1H, d, J=8.8 Hz), 5.78 (1H, d, J=17.8 Hz), 5.59 (1H, d, J=17.8 Hz), 5.17 (2H, s), 4.63-4.60 (1H, m), 3.08 (1H, dd, J=4.8, 17.6 Hz), 2.71 (1H, dd, J=5.0, 17.6 Hz), 1.41 (9H, s).

Example 5(83)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio)tetrazol- 1-yl)pentanoic acid•t-butylester ##STR1270##

TLC: Rf 0.37 (benzene:diethylether=10:1); NMR (CDCl3): δ 7.53-7.33 (7H, m), 5.98 (1H, d, J=9.4 Hz), 5.70 (1H, d, J=18.4 Hz), 5.54 (1H, d, J=18.4 Hz), 5.21 (2H, s), 4.76-4.64 (1H, m), 3.12 (1H, dd, J=4.4, 17.6 Hz), 2.76 (1H, dd, J=5.0, 17.6 Hz), 1.43 (9H, s).

Example 5(84)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dimethylphenylthio)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1271##

TLC: Rf 0.53 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.49 (1H, d, J=7.9 Hz), 7.45-7.30 (5H, m), 7.11 (1H, s), 7.01 (1H, d, J=7.9 Hz), 5.94 (1H, d, J=9.1 Hz), 5.76 (1H, d, J=17.8 Hz), 5.57 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.72-4.55 (1H, m), 3.01 (1H, dd, J=17.8, 4.4 Hz), 2.68 (1H, dd, J=17.8, 4.7 Hz), 2.39 (3H, s), 2.33 (3H, s), 1.41 (9H, s).

Example 5(85)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dimethylphenylthio)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1272##

TLC: Rf 0.36 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.46-7.31 (6H, m), 7.13 (1H, s), 7.02 (1H, d, J=7.7 Hz), 5.96 (1H, d, J=9.2 Hz), 5.56 (1H, d, J=18.4 Hz), 5.39 (1H, d, J=18.4 Hz), 5.20 (2H, s), 4.70-4.54 (1H, m), 3.05 (1H, dd, J=17.5, 4.4 Hz), 2.70 (1H, dd, J=17.5, 4.8 Hz), 2.37 (3H, s), 2.32 (3H, s), 1.42 (9H, s).

Example 5(86)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,5-dichlorophenylthio)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1273##

TLC: Rf 0.72 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.55-7.30 (6H, m), 7.30-7.17 (2H, m), 5.94 (1H, d, J=9.0 Hz), 5.87 (1H, d, J=17.5 Hz), 5.69 (1H, d, J=17.5 Hz), 5.18 (2H, s), 4.73-4.59 (1H, m), 3.05 (1H, dd, J=17.6, 4.0 Hz), 2.71 (1H, dd, J=17.6, 4.8 Hz), 1.42 (9H, s).

Example 5(87)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,5-dichlorophenylthio)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1274##

TLC: Rf 0.72 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.53 (1H, d, J=7.2 Hz 7.45-7.32 (5H, m) 7.30-7.24 (2H, m), 5.94 (1H, d, J=9.2 Hz), 5.69 (1H, d, J=18.3 Hz), 5.52 (1H, d, J=18.3 Hz), 5.20 (2H, s), 4.74-4.58 (1H, m), 3.08 (1H, dd, J=17.5, 4.3 Hz), 2.72 (1H, dd, J=17.5, 4.8 Hz), 1.42 (9H, s).

Example 5(88)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-bromophenylthio)tetrazol-2-yl)pen tanoic acid•t-butylester ##STR1275##

TLC: Rf 0.35 (hexane:ethyl acetate=4:1).

Example 5(89)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-bromophenylthio)tetrazol-1-yl)pen tanoic acid•t-butylester ##STR1276##

TLC: Rf 0.31 (hexane:ethyl acetate=3:1).

Example 5(90)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio)tet razol-2-yl)pentanoic acid•t-butylester ##STR1277##

TLC: Rf 0.47 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.42-7.29 (5H, m), 7.27 (2H, d, J=1.4 Hz), 5.92 (1H, d, J=8.8 Hz), 5.75 (1H, d, J=17.6 Hz), 5.57 (1H, d, J=17.6 Hz), 5.16 (2H, s), 4.70-4.55 (1H, m), 3.00 (1H, dd, J=17.4, 4.3 Hz), 2.69 (1H, dd, J=17.4, 4.8 Hz), 2.34 (3H, s), 1.42 (9H, s).

Example 5(91)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio)tet razol-1-yl)pentanoic acid•t-butylester ##STR1278##

TLC: Rf 0.34 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.45-7.31 (5H, m), 7.26 (2H, s), 5.98 (1H, d, J=9.1 Hz), 5.67 (1H, d, J=18.4 Hz), 5.50 (1H, d, J=18.4 Hz), 5.21 (2H, s), 4.75-4.62 (1H, m), 3.09 (1H, dd, J=17.5, 4.5 Hz), 2.74 (1H, dd, J=17.5, 4.8 Hz), 2.34 (3H, s), 1.43 (9H, s).

Example 5(92)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,4-dichlorophenylthio)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1279##

TLC: Rf 0.72 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.65 (1H, d, J=1.8 Hz), 7.45-7.33 (7H, m), 5.94 (1H, d, J=9.6 Hz), 5.83 (1H, d, J=18.0 Hz), 5.65 (1H, d, J=18.0 Hz), 5.17 (2H, s), 4.70-4.61 (1H, m), 3.04 (1H, dd, J=4.2, 17.4 Hz), 2.72 (1H, dd, J=4.6, 17.4 Hz), 1.41 (9H, s).

Example 5(93)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,4-dichlorophenylthio)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1280##

TLC: Rf 0.53 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.65 (1H, d, J=2.0 Hz), 7.47-7.34 (7H, m), 5.94 (1H, d, J=8.6 Hz), 5.63 (1H, d, J=18.6 Hz), 5.47 (1H, d, J=18.6 Hz), 5.20 (2H, s), 4.69-4.60 (1H, m), 3.09 (1H, dd, J=4.4, 17.6 Hz), 2.75 (1H, dd, J=5.0, 17.6 Hz), 1.43 (9H, s).

Example 5(94)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-bromotetrazol-2-yl)pentanoic acid•t-butylester ##STR1281##

TLC: Rf 0.26 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.39 (5H, m), 5.93 (1H, d, J=10.2 Hz), 5.86 (1H, d, J=17.6 Hz), 5.68 (1H, d, J=17.6 Hz), 5.18 (2H, s), 4.78-4.55 (1H, m), 3.04 (1H, dd, J=17.4 Hz, and 4.6 Hz), 2.72 (1H, dd, J=17.4 Hz and 4.8 Hz), 1.43 (9H, s).

Example 5(95)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-nitrophenylthio)tetrazol-2-yl)pen tanoic acid•t-butylester ##STR1282##

TLC: Rf 0.40 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.24-8.09 (2H, m), 7.62-7.48 (2H, m), 7.45-7.28 (5H, m), 5.94 (1H, d, J=8.4 Hz), 5.91 (1H, d, J=17.8 Hz), 5.72 (1H, d, J=17.8 Hz), 5.18 (2H, s), 4.78-4.58 (1H, m), 3.06 (1H, dd, J=17.6 and 4.4 Hz), 2.73 (1H, dd, J=17.6 and 4.8 Hz), 1.42 (9H, s).

Example 5(96)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-nitrophenylthio)tetrazol-1-yl)pen tanoic acid•t-butylester ##STR1283##

TLC: Rf 0.23 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.26-8.11 (2H, m), 7.69-7.50 (2H, m), 7.46-7.28 (5H, m), 5.90 (1H, d, J=9.0 Hz), 5.68 (1H, d, J=18.2 Hz), 5.51 (1H, d, J=18.2 Hz), 5.19 (2H, s), 4.75-4.48 (1H, m), 3.06 (1H, dd, J=17.6 and 4.4 Hz), 2.71 (1H, dd, J=17.6 and 5.0 Hz), 1.41 (9H, s).

Example 5(97)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-1-ylthio)tetrazol-2-yl)p entanoic acid•t-butylester ##STR1284##

TLC: Rf 0.77 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.39 (1H, d, J=7.0 Hz), 7.94-7.85 (3H, m), 7.59-7.43 (3H, m), 7.40-7.30 (5H, m), 5.89 (1H, d, J=9.0 Hz), 5.70 (1H, d, J=18.0 Hz), 5.52 (1H, d, J=18.0 Hz), 5.13 (2H, s), 4.71-4.56 (1H, m), 2.96 (1H, dd, J=17.0, 4.0 Hz), 2.65 (1H, dd, J=17.0, 5.0 Hz), 1.38 (9H, s).

Example 5(98)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-1-ylthio)tetrazol-1-yl)p entanoic acid•t-butylester ##STR1285##

TLC: Rf 0.70 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.32 (1H, d, J=8.0 Hz), 7.96-7.86 (3H, m), 7.64-7.47 (3H, m), 7.44-7.31 (5H, m), 5.92 (1H, d, J=9.0 Hz), 5.59 (1H, d, J=18.0 Hz), 5.43 (1H, d, J=18.0 Hz), 5.19 (2H, s), 4.65-4.52 (1H, m), 3.02 (1H, dd, J=17.0, 4.0 Hz), 2.69 (1H, dd, J=17.0, 4.0 Hz), 1.42 (9H, s).

Example 5(99)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-di-t-butylphenylthio)tetrazol-2 -yl)pentanoic acid•t-butylester ##STR1286##

TLC: Rf 0.48 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.50 (1H, d, J=2.2 Hz), 7.44 (1H, d, J=8.2 Hz), 7.38-7.35 (5H, m), 7.17 (1H, dd, J=2.2 and 8.2 Hz), 5.94 (1H, d, J=8.4 Hz), 5.76 and 5.59 (each 1H, each d, J=17.4 Hz), 5.16 (2H, s), 4.69-4.59 (1H, m), 2.99 (1H, dd, J=4.6 and 17.4 Hz), 2.69 (1H, dd, J=4.8 and 17.4 Hz), 1.53 (9H, s), 1.41 (9H, s), 1.31 (9H, s).

Example 5(100)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-di-t-butylphenylthio)tetrazol-1 -yl)pentanoic acid•t-butylester ##STR1287##

TLC: Rf 0.31 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.52 (1H, d-like), 7.41-7.34 (5H, m), 7.28-7.16 (2H, m), 5.95 (1H, d, J=8.8 Hz), 5.60 and 5.43 (each 1H, each d, J=18.4 Hz), 5.19 (2H, s), 4.69-4.59 (1H, m), 3.06 (1H, dd, J=4.6 and 17.4 Hz), 2.71 (1H, dd, J=4.6 and 17.4 Hz), 1.51 (9H, s), 1.42 (9H, s), 1.31 (9H, s).

Example 5(101)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imidazol-1-ylmethyl)tetrazol-2-yl)p entanoic acid•t-butylester ##STR1288##

TLC: Rf 0.50 (chloroform:methanol=10:1); NMR (CDCl3): δ 7.62 (1H, s), 7.40-7.30 (5H, m), 7.07 (1H, s), 7.05 (1H, s), 5.88 (1H, m), 5.84 (1H, d, J=18 Hz), 5.66 (1H, d, J=18 Hz), 5.39 (2H, s), 5.17 (2H, s), 4.64 (1H, m), 3.03 (1H, dd, J=4.4, 17 Hz), 2.71 (1H, dd, J=4.6, 17 Hz), 1.42 (9H, s).

Example 5(102)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imidazol-1-ylmethyl)tetrazol-1-yl)p entanoic acid•t-butylester ##STR1289##

TLC: Rf 0.44 (chloroform:methanol=10:1); NMR (CDCl3): δ 7.68 (1H, s), 7.40-7.30 (5H, m), 7.08 (1H, s), 7.00 (1H, s), 5.84 (1H, m), 5.60-5.26 (4H, m), 5.39 (2H, s), 5.18 (2H, s), 4.60 (1H, m), 3.10 (1H, dd, J=4.8, 18 Hz), 2.80 (1H, dd, J=5.0, 18 Hz), 1.42 (9H, s).

Example 5(103)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxyphenylthio)tetrazol-2-yl)p entanoic acid•t-butylester ##STR1290##

TLC: Rf 0.53 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.48-7.30 (7H, m), 6.98-6.90 (2H, m), 5.93 (1H, d, J=9.6 Hz), 5.78 (1H, d, J=17.8 Hz), 5.60 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.89-4.60 (1H, m), 3.81 (3H, s), 3.00 (1H, dd, J=4.4, 17.4 Hz), 2.70 (1H, dd, J=4.8, 17.4 Hz), 1.41 (9H, s).

Example 5(104)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxyphenylthio)tetrazol-1-yl)p entanoic acid•t-butylester ##STR1291##

TLC: Rf 0.38 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.52-7.31 (7H, m), 6.99-6.85 (2H, m), 5.96 (1H, d, J=8.8 Hz), 5.64 (1H, d, J=18.2 Hz), 5.45 (1H, d, J=18.2 Hz), 5.19 (2H, s), 4.64-4.55 (1H, m), 3.75 (3H, s), 3.01 (1H, dd, J=4.4, 17.4 Hz), 2.70 (1H, dd, J=4.8, 17.4 Hz), 1.42 (9H, s).

Example 5(105)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophenylt hio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1292##

TLC: Rf 0.59 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.40-7.30 (5H, m), 6.72 (2H, s), 5.95 (1H, d, J=8.8 Hz), 5.72 (1H, d, J=18 Hz), 5.57 (1H, d, J=18 Hz), 5.16 (2H, s), 4.63 (1H, m), 3.02-2.93 (7H, m), 2.69 (1H, dd, J=4.6, 17 Hz), 1.41 (9H, s).

Example 5(106)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophenylt hio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1293##

TLC: Rf 0.50 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.42-7.30 (5H, m), 6.69 (2H, s), 5.99 (1H, d, J=8.8 Hz), 5.62 (1H, d, J=18 Hz), 5.47 (1H, d, J=18 Hz), 5.20 (2H, s), 4.65 (1H, m), 3.12-2.98 (7H, m), 2.72 (1H, dd, J=4.8, 17 Hz), 1.43 (9H, s).

Example 5(107)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiophen-2-yl)tetrazol-2-yl)pentano ic acid•t-butylester ##STR1294##

TLC: Rf 0.27 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.40-7.32 (5H, m), 7.19-7.16 (1H, m), 6.94-6.90 (2H, m), 5.97 (1H, d, J=8.4 Hz), 5.80 and 5.63 (each 1H, each d, J=17.6 Hz), 5.17 (2H, s), 4.71-4.62 (1H, m), 4.46 (2H, s), 3.00 (1H, dd, J=4.6 and 17.4 Hz), 2.71 (1H, dd, J=4.8 and 17.4 Hz), 1.42 (9H, s).

Example 5(108)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiophen-2-yl)tetrazol-1-yl)pentano ic acid•t-butylester ##STR1295##

TLC: Rf 0.12 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.37 (5H, m), 7.22-7.19 (1H, m), 6.95-6.92 (2H, m), 5.84 (1H, d, J=8.4 Hz), 5.45 and 5.34 (each 1H, each d, J=18.6 Hz), 5.16 (2H, s), 4.62-4.53 (1H, m), 4.43 and 4.27 (each 1H, each d, J=16.6 Hz), 3.06 (1H, dd, J=4.4 and 17.6 Hz), 2.74 (1H, dd, J=4.8 and 17.6 Hz), 1.44 (9H, s).

Example 5(109)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiophen-3-yl)tetrazol-2-yl)pentano ic acid•t-butylester ##STR1296##

TLC: Rf 0.23 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.40-7.31 (5H, m), 7.28-7.24 (1H, m), 7.12-7.10 (1H, m), 7.03 (1H, dd, J=1.2 and 5.0 Hz), 5.97 (1H, d, J=9.2 Hz), 5.80 and 5.62 (each 1H, each d, J=17.6 Hz), 5.17 (2H, s), 4.71-4.62 (1H, m), 4.28 (2H, s), 3.00 (1H, dd, J=4.4 and 17.6 Hz), 2.71 (1H, dd, J=5.0 and 17.6 Hz), 1.42 (9H, s).

Example 5(110)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiophen-3-yl)tetrazol-1-yl)pentano ic acid•t-butylester ##STR1297##

TLC: Rf 0.09 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.40-7.33 (5H, m), 7.31-7.27 (1H, m), 7.18 (1H, brs), 6.94-6.91 (1H, m), 5.82 (1H, d, J=8.8 Hz), 5.35 (2H, s), 5.16 (2H, s), 4.59-4.50 (1H, m), 4.24 and 4.07 (each 1H, each d, J=16.2 Hz), 3.05 (1H, dd, J=4.4 and 17.4 Hz), 2.73 (1H, dd, J=5.0 and 17.4 Hz), 1.44 (9H, s).

Example 5(111)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-imidazol-1-ylpropyl)tetrazol-2-yl )pentanoic acid•t-butylester ##STR1298##

TLC: Rf 0.44 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.49 (1H, s), 7.40-7.30 (5H, m), 7.05 (1H, s), 6.94 (1H, s), 6.10 (1H, d, J=8.8 Hz), 5.81 (1H, d, J=18 Hz), 5.64 (1H, d, J=18 Hz), 5.18 (2H, s), 4.67 (1H, m), 4.03 (2H, t, J=7.0 Hz), 3.02 (1H, dd, J=4.6, 17 Hz), 2.90 (2H, t, J=7.0 Hz), 2.72 (1H, dd, J=5.0, 17 Hz), 2.27 (2H, m), 1.42 (9H, s).

Example 5(112)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-imidazol-1-ylpropyl)tetrazol-1-yl )pentanoic acid•t-butylester ##STR1299##

TLC: Rf 0.36 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.45 (1H, s), 7.40-7.30 (5H, m), 7.04 (1H, s), 6.92 (1H, s), 6.10 (1H, d, J=8.8 Hz), 5.46 (2H, s), 5.18 (2H, s), 4.60 (1H, m), 4.09 (2H, t, J=6.8 Hz), 3.03 (1H, dd, J=4.4, 18 Hz), 2.78 (1H, dd, J=5.4, 18 Hz), 2.57 (2H, t, J=6.8 Hz), 2.27 (2H, m), 1.41 (9H, s).

Example 5(113)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3-dichlorophenylthio)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1300##

TLC: Rf 0.60 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.44-7.11 (8H, m), 5.94 (1H, d, J=10.8 Hz), 5.86 (1H, d, J=17.8 Hz), 5.68 (1H, d, J=17.8 Hz), 4.73-4.62 (1H, m), 3.04 (1H, dd, J=4.0, 17.2 Hz), 2.73 (1H, dd, J=4.8, 17.2 Hz), 1.42 (9H, s).

Example 5(114)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3-dichlorophenylthio)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1301##

TLC: Rf 0.49 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.48-7.15 (8H, m), 5.94 (1H, d, J=10.6 Hz), 5.69 (1H, d, J=18.4 Hz), 5.52 (1H, d, J=18.4 Hz), 4.73-4.63 (1H, m), 3.06 (1H, dd, J=4.4, 17.6 Hz), 2.73 (1H, dd, J=4.8, 17.6 Hz), 1.41 (9H, s).

Example 5(115)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylthio)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1302##

TLC: Rf 0.56 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.37 (5H, s), 7.25-7.10 (3H, m), 5.91 (1H, d, J=9.1 Hz), 5.73 (1H, d, J=17.8 Hz), 5.54 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.70-4.55 (1H, m), 2.99 (1H, dd, J=17.5, 4.5 Hz), 2.67 (1H, dd, J=17.5, 4.8 Hz), 2.48 (6H, s), 1.41 (9H, s).

Example 5(116)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylthio)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1303##

TLC: Rf 0.44 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.45-7.35 (5H, m), 7.31-7.14 (3H, m), 5.96 (1H, d, J=9.1 Hz), 5.56 (1H, d, J=18.5 Hz), 5.38 (1H, d, J=18.5 Hz), 5.21 (2H, s), 4.70-4.54 (1H, m), 3.06 (1H, dd, J=17.5, 4.4 Hz), 2.71 (1H, dd, J=17.5, 4.9 Hz), 2.42 (6H, s), 1.42 (9H, s).

Example 5(117)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-t-butylphenylthio)tetraz ol-2-yl)pentanoic acid•t-butylester ##STR1304##

TLC: Rf 0.65 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 87.46 (1H, d, J=2.1 Hz), 7.43-7.30 (6H, m), 7.25 (1H, dd, J=8.3, 2.1 Hz), 5.94 (1H, d, J=9.3 Hz), 5.82 (1H, d, J=17.8 Hz), 5.64 (1H, d, J=17.8 Hz), 5.17 (2H, s), 4.73-4.58 (1H, m), 3.02 (1H, dd, J=17.4, 4.4 Hz), 2.70 (1H, dd, J=17.4, 4.9 Hz), 1.42 (9H, s), 1.30 (9H, s).

Example 5(118)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-t-butylphenylthio)tetraz ol-1-yl)pentanoic acid•t-butylester ##STR1305##

TLC: Rf 0.55 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.53 (1H, d, J=8.4 Hz), 7.45 (1H, d, J=2.2 Hz), 7.43-7.33 (5H, m), 7.29 (1H, dd, J=8.4, 2.2 Hz), 5.96 (1H, d, J=9.2 Hz), 5.67 (1H, d, J=18.4 Hz), 5.49 (1H, d, J=18.4 Hz), 5.20 (2H, s), 4.72-4.60 (1H, m), 3.05 (1H, dd, J=17.5, 4.4 Hz), 2.71 (1H, dd, J=17.5, 4.9 Hz), 1.43 (9H, s), 1.30 (9H, s).

Example 5(119)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,2,6,6-tetramethylpiperidin-2-ylme thyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1306##

TLC: Rf 0.52 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.40-7.30 (5H, m), 5.98 (1H, d, J=8.6 Hz), 5.79 (1H, d, J=18 Hz), 5.61 (1H, d, J=18 Hz), 5.17 (2H, s), 4.66 (1H, m), 4.00 (2H, s), 2.99 (1H, dd, J=4.2, 17 Hz), 2.70 (1H, dd, J=4.6, 17 Hz), 1.60-1.44 (6H, m), 1.42 (9H, s), 1.07 (12H, s).

Example 5(120)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,2,6,6-tetramethylpiperidin-1-ylme thyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1307##

TLC: Rf 0.31 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.40-7.30 (5H, m), 6.04 (1H, d, J=9.0 Hz), 5.95 (1H, d, J=18 Hz), 5.76 (1H, d, J=18 Hz), 5.20 (2H, s), 4.68 (1H, m), 4.01 (2H, s), 3.05 (1H, dd, J=4.4, 17 Hz), 2.73 (1H, dd, J=4.8, 17 Hz), 1.62-1.46 (6H, m), 1.43 (9H, s), 0.99 and 0.94 (total 12H, each s).

Example 5(121)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N-phenyl-N-methylamino)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1308##

TLC: Rf 0.17 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.47-7.31 (9H, m), 7.12-7.05 (1H, m), 5.96 (1H, d-like), 5.66 and 5.49 (each 1H, each d, J=17.6 Hz), 5.16 (2H, s), 4.70-4.60 (1H, m), 3.56 (3H, s), 3.00 (1H, dd, J=4.4 and 17.4 Hz), 2.70 (1H, dd, J=5.0 and 17.4 Hz), 1.42 (9H, s).

Example 5(122)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N-phenyl-N-methylamino)tetrazol-1-y l)pentanoic acid•t-butylester ##STR1309##

TLC: Rf 0.04 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.41-7.19 (8H, m), 6.98-6.94 (2H, m), 5.60 (1H, d-like), 5.08 (2H, s), 4.89 and 4.69 (each 1H, each d, J=18.6 Hz), 4.11-3.99 (1H, m), 3.49 (3H, s), 2.74 (1H, dd, J=4.6 and 17.4 Hz), 2.49 (1H, dd, J=4.8 and 17.4 Hz), 1.40 (9H, s).

Example 5(123)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-diisopropylphenylthio)tetrazol- 2-yl)pentanoic acid•t-butylester ##STR1310##

TLC: Rf 0.41 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.46-7.31 (6H, m), 7.25-7.21 (2H, m), 5.91 (1H, d, J=9.4 Hz), 5.71 and 5.52 (each 1H, each d, J=18.2 Hz), 5.15 (2H, s), 4.65-4.55 (1H, m), 3.84-3.70 (2H, m), 2.97 (1H, dd, J=4.4 and 17.4 Hz), 2.66 (1H, dd, J=5.0 and 17.4 Hz), 1.39 (9H, s), 1.17 (12H, d, J=6.8 Hz).

Example 5(124)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-diisopropylphenylthio)tetrazol- 1-yl)pentanoic acid•t-butylester ##STR1311##

TLC: Rf 0.24 (benzene:diethylether=8:1); NMR (CDCl3): δ 7.50-7.35 (6H, m), 7.28-7.25 (2H, m), 5.98 (1H, d-like), 5.60 and 5.44 (each 1H, each d, J=18.2 Hz), 5.21 (2H, s), 4.75-4.64 (1H, m), 3.60-3.47 (2H, m), 3.11 (1H, dd, J=4.4 and 17.6 Hz), 2.75 (1H, dd, J=5.0 and 17.6 Hz), 1.44 (9H, s), 1.19 and 1.16 (each 6H, each d, J=6.8 Hz).

Example 5(125)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methyl-4-t-butylphenylthio)tetraz ol-2-yl)pentanoic acid•t-butylester ##STR1312##

TLC: Rf 0.52 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.50 (1H, d, J=8.2 Hz), 7.43-7.3,2 (5H, m), 7.29 (1H, d, J=2.2 Hz), 7.21 (1H, dd, J=8.2, 2.2 Hz), 5.94 (1H, d, J=9.0 Hz), 5.77 (1H, d, J=17.8 Hz), 5.58 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.72-4.56 (1H, m), 3.00 (1H, dd, J=17.3, 4.4 Hz), 2.69 (1H, dd, J=17.3, 4.8 Hz), 2.43 (3H, s), 1.41 (9H, s), 1.30 (9H, s).

Example 5(126)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methyl-4-t-butylphenylthio)tetraz ol-1-yl)pentanoic acid•t-butylester ##STR1313##

TLC: Rf 0.42 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.55-7.15 (8H, m), 5.94 (1H, d, J=9.0 Hz), 5.57 (1H, d, J=18.6 Hz), 5.40 (1H, d, J=18.6 Hz), 5.20 (2H, s), 4.68-4.52 (1H, m), 3.03 (1H, dd, J=17.6, 4.4 Hz), 2.69 (1H, dd, J=17.6, 4.8 Hz), 2.41 (3H, s), 1.42 (9H, s), 1.30 (9H, s).

Example 5(127)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio)te trazol-2-yl)pentanoic acid•t-butylester ##STR1314##

TLC: Rf 0.63 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.37 (5H, s), 7.16 (2H, s), 5.93 (1H, d, J=9.1 Hz), 5.73 (1H, d, J=17.7 Hz), 5.55 (1H, d, J=17.7 Hz), 5.15 (2H, s), 4.70-4.56 (1H, m), 2.99 (1H, dd, J=17.3, 4.4 Hz), 2.68 (1H, dd, J=17.3, 4.8 Hz), 2.48 (6H, s), 1.41 (9H, s), 1.30 (9H, s).

Example 5(128)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio)te trazol-1-yl)pentanoic acid•t-butylester ##STR1315##

TLC: Rf 0.50 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.45-7.32 (5H, m), 7.18 (2H, s), 5.97 (1H, d, J=9.2 Hz), 5.57 (1H, d, J=18.5 Hz), 5.39 (1H, d, J=18.5 Hz), 5.20 (2H, s), 4.68-4.54 (1H, m), 3.06 (1H, dd, J=17.5, 4.3 Hz), 2.71 (1H, dd, J=17.5, 4.9 Hz), 2.41 (3H, s), 1.43 (9H, s), 1.30 (9H, s).

Example 5(129)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophenylt hio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1316##

TLC: Rf 0.56 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.40-7.30 (5H, m), 6.49 (2H, s), 5.93 (1H, d, J=9.0 Hz), 5.71 (1H, d, J=18 Hz), 5.53 (1H, d, J=18 Hz), 5.15 (2H, s), 4.62 (1H, m), 3.02-2.92 (7H, m), 2.67 (1H, dd, J=5.0, 17 Hz), 2.44 (6H, s), 1.40 (9H, s).

Example 5(130)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophenylt hio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1317##

TLC: Rf 0.43 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.42-7.32 (5H, m), 6.48 (2H, s), 5.96 (1H, d, J=8.8 Hz), 5.51 (1H, d, J=18 Hz), 5.33 (1H, d, J=18 Hz), 5.20 (2H, s), 4.61 (1H, m), 3.07-2.96 (7H, m), 2.70 (1H, dd, J=4.8, 18 Hz), 2.37 (6H, s), 1.43 (9H, s).

Example 5(131)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(benzoimizazol-2-ylmethyl)tetrazol-2 -yl)pentanoic acid•t-butylester ##STR1318##

TLC: Rf 0.16 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 11.70-10.25 (1H, br), 7.73-7.11 (9H, m), 6.36-6.15 (1H, m), 5.90 (1H, d, J=18.6 Hz), 5.67 (1H, d, J=18.6 Hz), 5.18 (2H, s), 4.82-4.58 (1H, m), 4.54 (2H, s), 2.96 (1H, dd, J=17.2 and 5.0 Hz), 2.72 (1H, dd, J=17.2 and 5.0 Hz), 1.34 (9H, s).

Example 5(132)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(benzoimizazol-2-ylmethyl)tetrazol-1 -yl)pentanoic acid•t-butylester ##STR1319##

TLC: Rf 0.11 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 10.80-9.90 (1H, br), 7.94-7.08 (9H, m), 6.05 (1H, d, J=9.8 Hz), 5.73 (2H, brs), 5.15 (2H, s), 4.80-4.52 (1H, m), 4.66 (2H, s), 3.03 (1H, dd, J=17.8 and 5.0 Hz), 2.70 (1H, dd, J=17.8 and 5.0 Hz), 1.42 (9H, s).

Example 5(133)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-isopropylphenylthio)tetrazol-2-yl )pentanoic acid•t-butylester ##STR1320##

TLC: Rf 0.45 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.50 (2H, d, J=10.6 Hz), 7.40-7.30 (5H, m), 7.23 (2H, d, J=10.6 Hz), 5.94 (1H, d, J=9.0 Hz), 5.79 (1H, d, J=17.6 Hz), 5.61 (1H, d, J=17.6 Hz), 5.17 (2H, s), 4.70-4.60 (1H, m), 3.06-2.83 (2H, m), 2.71 (1H, dd, J=4.8, 17.2 Hz), 1.41 (9H, s), 1.24 (6H, d, J=7.0 Hz).

Example 5(134)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-isopropylphenylthio)tetrazol-1-yl )pentanoic acid•t-butylester ##STR1321##

TLC: Rf 0.32 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.49-7.34 (7H, m), 7.23 (2H, d, J=8.4 Hz), 5.96 (1H, d, J=9.0 Hz), 5.58 (1H, d, J=18.4 Hz), 5.42 (1H, d, J=18.4 Hz), 5.20 (2H, s), 4.68-4.58 (1H, m), 3.09-2.83 (2H, m), 2.69 (1H, dd, J=4.8, 17.6 Hz), 1.43 (9H, s), 1.23 (6H, d, J=6.8 Hz).

Example 5(135)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(benzothiazol-2-ylmethyl)tetrazol-2- yl)pentanoic acid•t-butylester ##STR1322##

TLC: Rf 0.60 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.09-7.94 (1H, m), 7.92-7.74 (1H, m), 7.53-7.28 (7H, m), 5.98 (1H, d, J=9.6 Hz), 5.85 (1H, d, J=17.8 Hz), 5.68 (1H, d, J=17.8 Hz), 5.17 (2H, s), 4.80 (2H, s), 4.74-4.57 (1H, m), 3.01 (1H, dd, J=17.6 Hz and 4.6 Hz), 2.72 (1H, dd, J=17.6 and 4.8 Hz), 1.41 (9H, s).

Example 5(136)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(benzothiazol-2-ylmethyl)tetrazol-1- yl)pentanoic acid•t-butylester ##STR1323##

TLC: Rf 0.54 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.02-7.76 (2H, m), 7.54-7.22 (7H, m), 6.04-5.08 (1H, m), 5.96 (1H, d, J=18.6 Hz), 5.73 (1H, d, J=18.6 Hz), 5.12 (2H, s), 4.80-4.51 (3H, m), 3.01 (1H, dd, J=17.6 Hz and 5.0 Hz), 2.74 (1H, dd, J=17.6 and 4.8 Hz), 1.38 (9H, s).

Example 5(137)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiazol-2-ylthio)tetrazol-2-yl)pent anoic acid•t-butylester ##STR1324##

TLC: Rf 0.70 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.80 (1H, d, J=3.4 Hz), 7.42 (1H, d, J=3.4 Hz), 7.38 (5H, m), 6.00 (1H, d, J=9 Hz), 5.87 (1H, d, J=18.0 Hz), 5.70 (1H, d, J=18.0 Hz), 5.20 (2H, m), 5.67 (1H, m), 3.03 (1H, dd, J=17.4 Hz, 4.2 Hz), 2.72 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.42 (9H, s).

Example 5(138)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiazol-2-ylthio)tetrazol-1-yl)pent anoic acid•t-butylester ##STR1325##

TLC: Rf 0.56 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.75 (1H, d, J=3.4 Hz), 7.46 (1H, d, J=3.4 Hz), 7.38 (5H, m), 6.00 (1H, d, J=8.8 Hz), 5.81 (1H, d, J=18.4 Hz), 5.64 (1H, d, J=18.4 Hz,), 5.19 (2H, m), 4.72 (1H, m), 3.03 (1H, dd, J=17.6 Hz, 4.2 Hz), 2.74 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.42 (9H, s).

Example 5(139)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4,6-trichlorophenylthio)tetrazol- 2-yl)pentanoic acid•t-butylester ##STR1326##

TLC: Rf 0.48 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.47 (2H, s), 7.37 (5H, brs), 5.82 (1H, d, J=8.8 Hz), 5.76 (1H, d, J=17.6 Hz), 5.58 (1H, d, J=17.6 Hz), 5.16 (2H, s), 4.70-4.54 (1H, m), 3.06 (1H, dd, J=17.5, 4.4 Hz), 2.69 (1H, dd, J=17.5, 5.0 Hz), 1.41 (9H, s).

Example 5(140)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4,6-trichlorophenylthio)tetrazol- 1-yl)pentanoic acid•t-butylester ##STR1327##

TLC: Rf 0.31 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.47 (2H, s), 7.39 (5H, brs), 5.96 (1H, d, J=8.4 Hz), 5.67 (1H, d, J=18.3 Hz), 5.50 (1H, d, J=18.3 Hz), 5.21 (2H, s), 4.75-4.60 (1H, m), 3.01 (1H, dd, J=17.6, 4.3 Hz), 2.74 (1H, dd, J=17.6, 4.9 Hz), 1.43 (9H, s).

Example 5(141)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-(1,1-dimethylpropyl) phenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1328##

TLC: Rf 0.51 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.42-7.30 (7H, m), 5.92 (1H, d, J=8.8 Hz), 5.76 (1H, d, J=17.7 Hz), 5.57 (1H, d, J=17.7 Hz), 5.16 (2H, s), 4.70-4.55 (1H, m), 2.99 (1H, dd, J=17.2, 4.6 Hz), 2.69 (1H, dd, J=17.2, 4.6 Hz), 1.63 (2H, q, J=7.5 Hz), 1.41 (9H, s), 1.27 (6H, s), 0.72 (3H, t, J=7.5 Hz).

Example 5(142)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-(1,1-dimethylpropyl) phenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1329##

TLC: Rf 0.42 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.43-7.28 (7H, m), 5.97 (1H, d, J=8.8 Hz), 5.68 (1H, d, J=18.1 Hz), 5.51 (1H, d, J=18.1 Hz), 5.21 (2H, s), 4.75-4.60 (1H, m), 3.08 (1H, dd, J=17.6, 4.5 Hz), 2.73 (1H, dd, J=17.6, 4.7 Hz), 1.62 (2H, q, J=7.5 Hz), 1.43 (9H, s), 1.26 (6H, s), 0.72 (3H, t, J=7.5 Hz).

Example 5(143)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1,1-diphenylmethyl)tetrazol-2-yl)pe ntanoic acid•t-butylester ##STR1330##

TLC: Rf 0.31 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.47-7.15 (15H, m), 5.95 (1H, d, J=8.6 Hz), 5.83 (1H, s), 5.82 (1H, d, J=17.4 Hz), 5.46 (1H, d, J=17.4 Hz), 5.16 (2H, s), 4.76-4.56 (1H, m), 3.01 (1H, dd, J=17.4 and 4.4 Hz), 2.70 (1H, dd, J=17.4 and 4.8 Hz), 1.41 (9H, s).

Example 5(144)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1,1-diphenylmethyl)tetrazol-1-yl)pe ntanoic acid•t-butylester ##STR1331##

TLC: Rf 0.21 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.46-7.13 (15H, m), 5.72 (1H, d, J=9.0 Hz), 5.55-5.26 (3H, m), 5.15 (2H, s), 4.68-4.45 (1H, m), 3.11 (1H, dd, J=17.2 and 3.8 Hz), 2.75 (1H, dd, J=17.2 and 4.6 Hz), 1.42 (9H, s).

Example 5(145)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-fluorophenylthio)tetrazo l-2-yl)pentanoic acid•t-butylester ##STR1332##

TLC: Rf 0.35 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.58 (1H, dd, J=8.8 and 5.8 Hz), 7.48-7.27 (5H, m), 7.27-7.17 (1H, m), 7.07-6.92 (1H, m), 5.95 (1H, d, J=9.2 Hz), 5.81 (1H, d, J=17.6 Hz), 5.63 (1H, d, J=17.6 Hz), 5.17 (2H, s), 4.76-4.54 (1H, m), 3.03 (1H, dd, J=17.4 and 4.8 Hz), 2.70 (1H, dd, J=17.4 and 5.0 Hz), 1.41 (9H, s).

Example 5(146)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-fluorophenylthio)tetrazo l-1-yl)pentanoic acid•t-butylester ##STR1333##

TLC: Rf 0.25 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.68 (1H, dd, J=8.8 and 5.6 Hz), 7.52-7.27 (5H, m), 7.23 (1H, dd, J=8.4 and 2.8 Hz), 7.12-6.95 (1H, m), 5.97 (1H, d, J=9.4 Hz), 5.68 (1H, d, J=18.2 Hz), 5.50 (1H, d, J=18.2 Hz), 5.20 (2H, s), 4.79-4.52 (1H, m), 3.07 (1H, dd, J=17.6 and 4.4 Hz), 2.73 (1H, dd, J=17.6 and 4.8 Hz), 1.42 (9H, s).

Example 5(147)

N-benzyloxycarbanyl-3-amino-4-oxo-5-(5-(5-imidazol-1-ylpentyl)tetrazol-2-yl )pentanoic acid•t-butylester ##STR1334##

TLC: Rf 0.40 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.44 (1H, s), 7.48-7.25 (5H, m), 7.03 (1H, s), 6.88 (1H, s), 6.38 (1H, d, J=9.2 Hz), 5.79 (1H, d, J=17.6 Hz), 5.62 (1H, d, J=17.6 Hz), 5.18 (2H, s), 4.78-4.60 (1H, m), 3.92 (2H, t, J=7.2 Hz), 3.07-2.83 (3H, m), 2.75 (1H, dd, J=17.4 and 5.4 Hz), 1.97-1.57 (6H, m), 1.42 (9H, s).

Example 5(148)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(5-imidazol-1-ylpentyl)tetrazol-1-yl )pentanoic acid•t-butylester ##STR1335##

TLC: Rf 0.31 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.46 (1H, s), 7.45-7.20 (5H, m), 7.03 (1H, s), 6.89 (1H, s), 6.22 (1H, d, J=8.6 Hz), 5.49 (2H, brs), 5.18 (2H, s), 4.72-4.52 (1H, m), 3.93 (2H, t, J=7.2 Hz ), 3.12 (1H, dd, J=17.6 and 4.8 Hz), 2.78 (1H, dd, J=17.4 and 5.2 Hz), 2.61 (2H, t, J=7.2 Hz), 1.96-1.57 (6H, m), 1.42 (9H, s).

Example 5(149)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-dimethylaminoethyl)tetrazol-2-yl) pentanoic acid•t-butylester ##STR1336##

TLC: Rf 0.43 (chloroform:methanol=9:1).

Example 5(150)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-dimethylaminoethyl)tetrazol-1-yl) pentanoic acid•t-butylester ##STR1337##

TLC: Rf 0.43 (chloroform:methanol=9:1).

Example 5(151)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(4-fluorophenyl)thiazol-2-ylmethy l)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1338##

TLC: Rf 0.30 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.92-7.76 (2H, m), 7.46-7.28 (5H, m), 7.34 (1H, s), 7.17-7.01 (2H, m), 5.95 (1H, d, J=9.2 Hz), 5.85 (1H, d, J=17.6 Hz), 5.68 (1H, d, J=17.6 Hz), 5.18 (2H, s), 4.77-4.60 (1H, m), 4.73 (2H, s), 3.02 (1H, dd, J=17.6 and 4.6 Hz), 2.72 (1H, dd, J=17.6 and 4.8 Hz), 1.42 (9H, s).

Example 5(152)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(4-fluorophenyl)thiazol-2-ylmethy l)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1339##

TLC: Rf 0.16 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.89-7.68 (2H, m), 7.44-7.24 (5H, m), 7.36 (1H, s), 7.16-7.00 (2H, m), 5.85 (1H, d, J=8.6 Hz), 5.98 (1H, d, J=18.6 Hz), 5.75 (1H, d, J=18.6 Hz), 5.22-4.99 (2H, m), 4.76-4.46 (3H, m), 3.00 (1H, dd, J=17.6 and 4.6 Hz), 2.71 (1H, dd, J=17.6 and 4.8 Hz), 1.39 (9H, s).

Example 5(153)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(4-chlorophenyl)thiazol-2-ylmethy l)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1340##

TLC: Rf 0.36 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.86-7.74 (2H, m), 7.46-7.28 (8H, m), 5.96 (1H, d, J=9.2 Hz), 5.85 (1H, d, J=17.8 Hz), 5.68 (1H, d, J=17.8 Hz), 5.17 (2H, s), 4.78-4.58 (1H, m), 4.73 (2H, s), 3.02 (1H, dd, J=17.4 and 4.4 Hz), 2.72 (1H, dd, J=17.4 and 4.8 Hz), 1.42 (9H, s).

Example 5(154)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(4-chlorophenyl)thiazol-2-ylmethy l)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1341##

TLC: Rf 0.20 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.84-7.74 (2H, m), 7.49-7.21 (8H, m), 5.98 (1H, d, J=18.6 Hz), 5.87 (1H, d, J=9.0 Hz), 5.75 (1H, d, J=18.6 Hz), 5.14 (1H, d, J=12.2 Hz), 5.06 (1H, d, J=2.2 Hz), 4.76-4.44 (3H, m), 3.01 (1H, dd, J=17.6 and 4.6 Hz), 2.72 (1H, dd, J=17.6 and 5.0 Hz), 1.39 (9H, s).

Example 5(155)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(3-nitrophenyl)thiazol-2-ylmethyl )tetrazol-2-yl)pentanoic acid•t-butylester ##STR1342##

TLC: Rf 0.27 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.76-8.66 (1H, m), 8.30-8.06 (2H, m), 7.66-7.50 (2H, m), 7.46-7.22 (5H, m), 5.97 (1H, d, J=8.8 Hz), 5.87 (1H, d, J=17.6 Hz), 5.70 (1H, d, J=17.6 Hz), 5.18 (2H, s), 4.80-4.56 (1H, m), 4.76 (2H, s), 3.03 (1H, dd, J=17.6 and 4.4 Hz), 2.73 (1H, dd, J=7.6 and 5.0 Hz), 1.42 (9H, s).

Example 5(156)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(3-nitrophenyl)thiazol-2-ylmethyl )tetrazol-1-yl)pentanoic acid•t-butylester ##STR1343##

TLC: Rf 0.18 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.73 (1H, brs), 8.23-8.04 (2H, m), 7.64-7.44 (2H, m), 7.44-7.14 (5H, m), 6.06 (1H, d, J=18.8 Hz), 5.94 (1H, d, J=8.0 Hz), 5.76 (1H, d, J=18.8 Hz), 5.08 (2H, brs), 4.77-4.46 (3H, m), 3.09 (1H, dd, J=17.6 and 4.4 Hz, 2.78 (1H, dd, J=17.6 and 5.0 Hz), 1.41 (9H, s).

Example 5(157)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylcarbonylaminopheny lthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1344##

TLC: Rf 0.64 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.01 (1H, brs), 7.53 (4H, brs), 7.37 (5H, brs), 5.96 (1H, d, J=9.0 Hz), 5.81 (1H, d, J=17.8 Hz), 5.63 (1H, d, J=17.8 Hz), 5.16 (2H, s), 4.76-4.52 (1H, m), 3.00 (1H, dd, J=17.6 and 4.4 Hz), 2.71 (1H, dd, J=17.6 and 5.0 Hz), 1.41 (9H, s).

Example 5(158)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylcarbonylaminopheny lthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1345##

TLC: Rf 0.08 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 8.81-8.62 (1H, br), 7.65-7.25 (9H, m), 5.94 (1H, d, J=8.8 H z), 5.62 (1H, d, J=18.4 Hz), 5.46 (1H, d, J=18.4 Hz), 5.20 (2H, s), 4.75-4.50 (1H, m), 3.07 (1H, dd, J=18.0 and 4.4 Hz), 2.73 (1H, dd, J=18.0 and 5.2 Hz), 1.43 (9H, s).

Example 5(159)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imizazol-4-ylmethyl)tetrazol-2-yl)p entanoic acid•t-butylester ##STR1346##

TLC: Rf 0.35 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.50 (1H, s), 7.38-7.30 (5H, m), 6.85 (1H, s), 6.32 (1H, d, J=9.0 Hz), 5.74 (1H, d, J=18 Hz), 5.63 (1H, d, J=18 Hz), 5.14 (2H, s), 4.68 (1H, m), 4.24 (2H, s), 2.93 (1H, dd, J=4.8, 17 Hz), 2.73 (1H, dd, J=5.0, 17 Hz), 1.40 (9H, s).

Example 5(160)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imizazol-4-ylmethyl)tetrazol-1-yl)p entanoic acid•t-butylester ##STR1347##

TLC: Rf 0.35 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.41 (1H, s), 7.38-7.30 (5H, m), 6.86 (1H, s), 6.43 (1H, d, J=8.8 Hz), 5.74 (1H, d, J=19 Hz), 5.53 (1H, d, J=19 Hz), 5.16 (2H, s), 4.69 (1H, m), 4.11 (2H, s), 2.98 (1H, dd, J=5.0, 17 Hz), 2.76 (1H, dd, J=5.4, 17 Hz), 1.40 (9H, s).

Example 6(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1 -yl)pentanoic acid ##STR1348##

To a solution of compound prepared in example 5(1) (119 mg) in m-cresole (0.9 ml) was added trifluoroacetic acid (9 ml). The reaction mixture was stirred for 1 h at room temperature. To the reaction mixture was added toluene, and then the mixture was concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol:acetic acid=30:1:1) to give the compound of the present invention (68 mg) having the following physical data.

TLC: Rf 0.22 (chloroform:methanol:acetic acid=28:1:1); NMR (CDCl3): δ 7.67 (1H, brs), 7.40-7.00 (8H, m), 6.31 (1H, brs), 5.54 (1H, brd, J=17 Hz), 5.34 (1H, d, J=17 Hz), 5.10 (2H, s), 4.52 (1H, brs), 4.24 (2H, brs) 2.94 (1H, brd, J=16 Hz), 2.65 (1H, brd, J=16 Hz).

EXAMPLES 6(2)-6(160)

By the same procedure as provided in example 6(1), and if necessary, by known methods converting the same to a corresponding salt, using the compound prepared in examples 5(2)-5(160), compounds of the present invention having the following physical data were obtained.

Example 6(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2 -yl)pentanoic acid ##STR1349##

TLC: Rf 0.37 (chloroform:methanol:acetic acid=28:1:1); NMR (CDCl3): δ 8.53 (1H, brs), 7.60-7.10 (8H, m), 6.20 (1H, brs), 5.90-5.30 (2H, m), 5.08 (2H, s), 4.73-4.35 (3H, m), 2.97 (1H, brd, J=17 Hz), 2.69 (1H, brd, J=17 Hz).

Example 6(3)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1350##

TLC: Rf 0.44 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.05-7.95 (1H, m), 7.42-7.17 (10H, m), 5.81-5.60 (2H, m), 5.09 (2H, s), 4.67-4.52 (1H, m), 4.13 (2H, s), 2.87-2.56 (2H, m).

Example 6(4)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol-2-yl)pentanoic acid ##STR1351##

TLC: Rf 0.60 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.98-7.86 (1H, m), 7.41-7.12 (10H, m), 5.96-5.74 (2H, m), 5.07 (2H, s), 4.67-4.50 (1H, m), 4.23 (2H, s), 2.85-2.53 (2H, m).

Example 6(5)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenoxy)tetrazol-1-yl)penta noic acid ##STR1352##

TLC: Rf 0.30 (chloroform:methanol:acetic acid=30:1:1); NMR (CDCl3): δ 7.41-7.22 (5H, m), 7.20-7.03 (4H, m), 6.20 (1H, brs), 5.46 (1H, d, J=18 Hz), 5.20-4.98 (3H, m), 4.67-4.52 (1H, m), 3.06 (1H, brd, J=18 Hz), 2.74 (1H, brd, J=18 Hz), 2.31 (3H, s).

Example 6(6)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenoxy)tetrazol-2-yl)penta noic acid ##STR1353##

TLC: Rf 0.34 (chloroform:methanol:acetic acid=30:1:1); NMR (CDCl3): δ 7.43-7.23 (5H, m), 7.22-7.00 (4H, m), 6.06 (1H, brs), 5.57 (1H, d, J=18 Hz), 5.38 (1H, d, J=18 Hz), 5.11 (2H, s), 4.72-4.55 (1H, m), 3.05 (1H, brd, J=18 Hz), 2.73 (1H, brd, J=18 Hz), 2.31 (3H, s).

Example 6(7)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-t-butylphenoxy)tetrazol-1-yl)pent anoic acid ##STR1354##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=30:1:1); NMR (CDCl3): δ 7.35-7.18 (8H, m), 7.15-6.98 (1H, m), 6.30-6.13 (1H, m), 5.48 (1H, d, J=18 Hz), 5.25-4.95 (3H, m), 4.71-4.55 (1H, m), 2.98 (1H, brd, J=18 Hz), 2.77 (1H, brd, J=18 Hz), 1.29 (9H, s).

Example 6(8)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-t-butylphenoxy)tetrazol-2-yl)pent anoic acid ##STR1355##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=18:1:1); NMR (CDCl3): δ 7.40-7.16 (8H, m), 7.03 (1H, d, J=8.0 Hz), 5.88 (1H, brs), 5.42 (2H, brs), 5.14 (2H, s), 4.73-4.58 (1H, m), 3.09 (1H, dd, J=18.0, 6.0 Hz), 2.76 (1H, dd, J=18.0, 6.0 Hz), 1.29 (9H, s).

Example 6(9)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-styryltetrazol-1-yl)pentanoic acid ##STR1356##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.14 (1H, d, J=8.0 Hz), 7.85-7.68 (3H, m), 7.50-7.24 (8H, m), 7.16 (1H, d, J=16.2 Hz), 5.90 (2H, s), 5.13 (2H, s), 4.76-4.58 (1H, m), 2.84 (1H, dd, J=16.0, 6.0 Hz), 2.70 (1H, dd, J=16.0, 6.6 Hz).

Example 6(10)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-styryltetrazol-2-yl)pentanoic acid ##STR1357##

TLC: Rf 0.45 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 7.94-7.51 (3H, m), 7.51-7.13 (10H, m), 5.98 (2H, s), 5.09 (2H, s), 4.67-4.50 (1H, m), 2.65 (2H, d, J=5.5 Hz).

Example 6(11)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylethyltetrazol-1-yl)pentanoic acid ##STR1358##

TLC: Rf 0.26 (chloroform:methanol:acetic acid=28:1:1); NMR (DMSO-d6): δ 8.03 (1H, d, J=7.4 Hz), 7.40-7.10 (10H, m), 5.64 (2H, s), 5.07 (2H, s), 4.67-4.52 (1H, m), 2.99 (4H, s), 2.80 (1H, dd, J=17.0, 6.0 Hz), 2.66 (1H, dd, J=17.0, 6.8 Hz).

Example 6(12)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-phenylethyltetrazol-1-yl)pentanoic acid ##STR1359##

TLC: Rf 0.42 (chloroform:methanol:acetic acid=28:1:1); NMR (DMSO-d6): δ 7.91 (1H, d, J=7.2 Hz), 7.45-7.08 (10H, m), 5.88 (2H, s), 5.09 (2H, s), 4.66-4.50 (1H, m), 3.20-2.96 (4H, m), 2.76 (1H, dd, J=16.8, 6.0 Hz), 2.63 (1H, dd, J=16.8, 7.2 Hz).

Example 6(13)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-methoxytetrazol-1-yl)pentanoic acid ##STR1360##

TLC: Rf 0.25 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.55 (1H, m), 7.38 (5H, m), 5.55-5.27 (2H, m), 5.08 (2H, s), 4.49 (1H, m), 4.10 (3H, s), 2.56 (2H, m).

Example 6(14)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-methoxytetrazol-2-yl)pentanoic acid ##STR1361##

TLC: Rf 0.31 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.94 (1H, m), 7.37 (5H, m), 5.82 (2H, brs), 5.09 (2H, s), 4.60 (1H, m), 4.03 (3H, s), 2.88-2.55 (2H, m).

Example 6(15)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N,N-dibenzylamino)tetrazol-2-yl)pen tanoic acid•hydrochloric acid salt ##STR1362##

TLC: Rf 0.34 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.01-7.87 (1H, m), 7.42-7.12 (15H, m), 5.80-5.65 (2H, m), 5.70 (2H, s), 4.70-4.50 (1H, m), 4.57 (4H, s), 2.90-2.52 (2H, m).

Example 6(16)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trifluoromethyltetrazol-1-yl)pentano ic acid ##STR1363##

HPTLC: Rf 0.28 (chloroform:methanol=4:1); NMR (CDCl3): δ 7.35 (5H, m), 5.96 (1H, m), 5.88-5.43 (2H, m), 5.17 (2H, s), 4.70 (1H, m), 4.0 (1H, brs), 3.25-3.03 and 2.96-2.73 (total 2H, m).

Example 6(17)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trifluoromethyltetrazol-2-yl)pentano ic acid ##STR1364##

HPTLC: Rf 0.38 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.62 (1H, m), 7.37 (5H, m), 6.24 (2H, brs), 5.08 (2H, s), 4.56 (1H, m), 2.61 (2H, m).

Example 6(18)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(ethoxycarbonylmethyl)tetrazol-2-yl) pentanoic acid ##STR1365##

TLC: Rf 0.35 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.67 (1H, m), 7.36 (5H, m), 5.97 (2H, brs), 5.07 (2H, s), 4.52 (1H, m), 4.19-3.96 (4H, m), 2.60 (2H, d, J=5.0 Hz), 1.20 (3H, t, J=7.0 Hz).

Example 6(19)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylthiotetrazol-1-yl)pentanoic acid ##STR1366##

TLC: Rf 0.27 (chloroform:methanol:acetic acid=30:1:1); NMR (DMSO-d6): δ 7.99 (1H, m), 7.36 (5H, m), 5.56 (2H, m), 5.10 (2H, s), 4.60 (1H, m), 3.20 (2H, q, J=7.5 Hz), 2.72 (2H, m), 1.31 (3H, t, J=7.5 Hz).

Example 6(20)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylthiotetrazol-2-yl)pentanoic acid ##STR1367##

TLC: Rf 0.41 (chloroform:methanol:acetic acid=30:1:1); NMR (DMSO-d6): δ 7.98 (1H, m), 7.38 (5H, m), 5.93 (2H, m), 5.09 (2H, s), 4.63 (1H, m), 3.19 (2H, q, J=7.5 Hz), 2.73 (2H, m), 1.34 (3H, t, J=7.5 Hz).

Example 6(21)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(ethoxycarbonylmethyl)tetrazol-1-yl) pentanoic acid ##STR1368##

TLC: Rf 0.56 (chloroform:ethanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 7.66 (1H, m), 7.37 (5H, m), 5.79 (2H, brs), 5.07 (2H, s), 4.49 (1H, m), 4.23-3.94 (4H, m), 2.61 (2H, m), 1.18 (3H, t, J=6.5 Hz).

Example 6(22)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-((4-chlorophenyl)thiomethyl)tetrazol -2-yl)pentanoic acid ##STR1369##

TLC: Rf 0.55 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.94 (1H, m), 7.38 (9H, m), 5.90 (2H, m), 5.10 (2H, s), 4.60 (1H, m), 4.52 (2H, s), 2.70 (2H, m).

Example 6(23)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-((4-chlorophenyl)thiomethyl)tetrazol -1-yl)pentanoic acid ##STR1370##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.98 (1H, m), 7.38 (9H, m), 5.79 (2H, m), 5.10 (2H, s), 4.60 (1H, m), 4.48 (2H, m), 2.74 (2H, m).

Example 6(24)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-phenylpropyl)tetrazol-2-yl)pentan oic acid ##STR1371##

TLC: Rf 0.51 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.05-7.90 (1H, m), 7.43-7.09 (10H, m), 6.01-5.78 (2H, m), 5.09 (2H, s), 4.68-4.53 (1H, m), 2.90-2.72 and 2.72-2.54 (4H, m), 2.07-1.88 (2H, m).

Example 6(25)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-phenylpropyl)tetrazol-1-yl)pentan oic acid ##STR1372##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.10-8.00 (1H, m), 7.43-7.08 (10H, m), 5.77-5.58 (2H, m), 5.10 (2H, s), 4.69-4.53 (1H, m), 2.88-2.54 (4H, m), 2.03-1.92 (2H, m).

Example 6(26)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyloxy)tetrazol-2-yl )pentanoic acid ##STR1373##

HPTLC: Rf 0.38 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.92 (1H, br), 7.67 (2H, d, J=7.5 Hz), 7.51-7.24 (6H, m), 5.88 (2H, br), 5.08 (2H, s), 4.59 (1H, m), 2.87-2.54 (2H, m).

Example 6(27)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyloxy)tetrazol-1-yl )pentanoic acid ##STR1374##

HPTLC: Rf 0.30 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 8.00 (1H, m), 7.79 and 7.58-7.16 (total 8H, m), 5.73 (2H, br), 5.08 (2H, brs), 4.66 (1H, m), 2.96-2.60 (2H, m).

Example 6(28)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenyloxymethyl)tetrazol-2- yl)pentanoic acid ##STR1375##

TLC: Rf 0.58 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 8.00 (1H, m), 7.38 (8H, m), 7.00 (1H, m), 6.01 (2H, br), 5.50 (2H, s), 5.10 (2H, s), 4.64 (1H, m), 2.74 (2H, m).

Example 6(29)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenyloxymethyl)tetrazol-1- yl)pentanoic acid ##STR1376##

TLC: Rf 0.53 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 8.08 (1H, m), 7.34 (8H, m), 7.02 (1H, m), 5.88 (2H, br), 5.48 (2H, s), 5.01 (2H, s), 4.62 (1H, m), 2.72 (2H, m).

Example 6(30)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxycarbonylethyl)tetrazol-2-y l)pentanoic acid ##STR1377##

TLC: Rf 0.63 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.92 (1H, d, J=7.2 Hz), 7.46-7.23 (5H, m), 5.88 (2H, s), 5.09 (2H, s), 4.68-4.49 (1H, m), 3.60 (3H, s), 3.12 (2H, t, J=7.0 Hz), 2.93-2.51 (4H, m).

Example 6(31)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxycarbonylethyl)tetrazol-1-y l)pentanoic acid ##STR1378##

TLC: Rf 0.46 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.87-7.69 (1H, m), 7.48-7.24 (5H, m), 5.75 (2H, s), 5.09 (2H, s), 4.64-4.45 (1H, m), 3.60 (3H, s), 3.05-2.56 (6H, m).

Example 6(32)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-methoxylpyrrol-2-ylmethyl)tetrazo l-2-yl)pentanoic acid ##STR1379##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 13.10-11.90 (1H, br), 8.00 (1H, d-like, J=7.0 Hz), 7.50-7.21 (5H, m), 6.68-6.60 (1H, m), 6.06-5.71 (4H, m), 5.09 (2H, s), 4.74-4.52 (1H, m), 4.22 (2H, s), 3.53 (3H, s), 2.91-2.54 (2H, m).

Example 6(33)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-methoxylpyrrol-2-ylmethyl)tetrazo l-2-yl)pentanoic acid ##STR1380##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 13.22-11.20 (1H, br), 8.06-7.92 (1H, m), 7.46-7.16 (6H, m), 6.87 (1H, brs), 6.28 (1H, brs), 5.06 (3H, brs), 4.51 (1H, d, J=17.0 Hz), 4.20 (1H, d, J=17.0 Hz), 3.69 (3H, s), 2.74-2.46 (2H, m).

Example 6(34)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-2-ylmethoxyl)tetrazol-2-yl) pentanoic acid•hydrochloric acid salt ##STR1381##

TLC: Rf 0.29 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.71 (1H, d, J=4.4 Hz), 8.27-8.09 (1H, m), 8.03 (1H, d, J=7.8 Hz), 7.77-7.55 (2H, m), 7.48-7.20 (5H, m), 5.98 (2H, s), 5.09 (2H, s), 4.64 (3H, brs), 2.83 (1H, dd, J=16.8 and 5.8 Hz), 2.64 (1H, dd, J=16.8 and 6.8 Hz).

Example 6(35)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-2-ylmethyl)tetrazol-1-yl)pe ntanoic acid•hydrochloric acid salt ##STR1382##

TLC: Rf 0.14 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.64-8.52 (1H, m), 8.13 (1H, d, J=7.8 Hz), 8.00 (1H, td, J=7.8 and 1.8 Hz), 7.65-7.44 (2H, m), 7.44-7.23 (5H, m), 5.90 (2H, s), 5.06 (2H, s), 4.78-4.55 (1H, m), 4.47 (2H, s), 2.83 (1H, dd, J=17.0 and 6.0 Hz), 2.67 (1H, dd, J=17.0 and 6.8 Hz).

Example 6(36)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-3-ylmethyl)tetrazol-2-yl)pe ntanoic acid•hydrochloric acid salt ##STR1383##

TLC: Rf 0.37 (chloroform:methanol:acetic acid=89:10:1); NMR (DMSO-d6): δ 8.76 (1H, brs), 8.72-8.61 (1H, m), 8.19-8.05 (1H, m), 8.05-7.96 (1H, m), 7.78-7.64 (1H, m), 7.50-7.22 (5H, m), 5.95 (2H, s), 5.08 (2H, s), 4.70-4.52 (1H, m), 4.45 (2H, s), 2.90-2.50 (2H, m).

Example 6(37)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-3-ylmethyl)tetrazol-1-yl)pe ntanoic acid•hydrochloric acid salt ##STR1384##

TLC: Rf 0.18 (chloroform:methanol:acetic acid=89:10:1); NMR (DMSO-d6): δ 8.70-8.52 (2H, m), 8.20-8.09 (1H, m), 7.92-7.78 (1H, m), 7.55-7.43 (1H, m), 7.43-7.21 (5H, m), 5.86 (2H, s), 5.10 (2H, s), 4.70-4.58 (1H, m), 4.21 (2H, s), 2.95-2.60 (2H, m).

Example 6(38)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-difluorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1385##

TLC: Rf 0.54 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.10-7.90 (1H, m), 7.63-7.03 (8H, m), 5.93 (2H, brs), 5.08 (2H, s), 4.72-4.53 (1H, m), 4.27 (2H, s), 2.90-2.55 (2H, m).

Example 6(39)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-difluorophenylmethyl) tetrazol-1-yl)pentanoic acid ##STR1386##

TLC: Rf 0.36 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.07 (1H, brs), 7.60-7.08 (8H, m), 5.84 (2H, brs), 5.10 (2H, s), 4.73-4.56 (1H, m), 4.13 (2H, s), 2.90-2.60 (2H, m).

Example 6(40)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylthio)tetrazol-2-yl) pentanoic acid ##STR1387##

TLC: Rf 0.39 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.76 (1H, m), 7.58-7.22 (10H, m), 6.00 (2H, brs), 5.06 (2H, s), 4.54 (1H, m), 2.62 (2H, m).

Example 6(41)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylthio)tetrazol-1-yl) pentanoic acid ##STR1388##

TLC: Rf 0.33 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.99 (1H, br), 7.60-7.23 (total 10H, m), 5.73 (2H, brs), 5.09 (2H, s), 4.60 (1H, m), 2.71 (2H, m).

Example 6(42)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1389##

TLC: Rf 0.41 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.98 (1H, d, J=7.5 Hz), 7.69 and 7.68 (each 1H, each d, J=9.0, 7.5 Hz), 7.55 (1H, dd, J=9.0, 7.5 Hz), 7.44-7.24 (5H, m), 5.98 (2H, brs), 5.07 (2H, s), 4.61 (1H, m), 2.80 and 2.62 (each 1H, each dd, J=16.5, 6.0 Hz).

Example 6(43)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1390##

TLC: Rf 0.32 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.78 (1H, m), 7.67 and 7.66 (each 1H, each d, J=9.0, 7.0 Hz), 7.56 (1H, dd, J=9.0, 7.5 Hz), 7.41-7.17 (5H, m), 5.80 (2H, br), 5.13 and 5.03 (each 1H, each d, J=12.0 Hz), 4.54 (1H, m), 2.63 (2H, m).

Example 6(44)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1391##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=95:4:1); NMR (DMSO-d6): δ 12.47 (1H, brs), 8.02-7.88 (1H, m), 7.56-7.15 (5H, m), 7.10-6.80 (3H, m), 5.88 (2H, brs), 5.07 (2H, s), 4.70-4.47 (1H, m), 4.20 (2H, s), 2.88-2.50 (2H, m), 2.33 (6H, s).

Example 6(45)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylmethyl) tetrazol-1-yl)pentanoic acid ##STR1392##

TLC: Rf 0.09 (chloroform:methanol:acetic acid=95:4:1); NMR (DMSO-d6): δ 8.05 (1H, d, J=8.0 Hz), 7.42-7.20 (5H, m), 7.16-6.92 (3H, m), 5.82 (2H, brs), 5.10 (2H, s), 4.72-4.55 (1H, m), 3.98 (2H, s) 2.90-2.63 (2H, m), 2.12 (6H, s).

Example 6(46)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylmethyl)tetrazol-2-yl)pent anoic acid ##STR1393##

TLC: Rf 0.26 (chloroform:methanol:acetic acid=95:4:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 7.94 (1H, brs), 7.60-7.10 (5H, m), 5.88 (2H, brs), 5.09 (2H, s), 4.70-4.51 (1H, m), 2.89-2.47 (4H, m), 1.82-1.40 (6H, m), 1.35-0.74 (5H, m).

Example 6(47)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylmethyl)tetrazol-1-yl)pent anoic acid ##STR1394##

TLC: Rf 0.11 (chloroform:methanol:acetic acid=95:4:1); NMR (DMSO-d6): δ 8.04 (1H, d, J=7.4 Hz), 7.41-7.23 (5H, m), 5.67 (2H, brs), 5.09 (2H, s), 4.67-4.50 (1H, m), 2.88-2.60 (2H, m), 2.58 (2H, d, J=6.6 Hz) 1.82-1.41 (6H, m), 1.36-0.78 (5H, m).

Example 6(48)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenylthio) tetrazol-2-yl)pentanoic acid ##STR1395##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=95:4:1); NMR (DMSO-d6): δ 7.95 (1H, brs), 7.60-7.10 (9H, m), 5.93 (2H, brs), 5.08 (2H, s), 4.73-4.51 (1H, m), 2.83-2.54 (2H, m), 2.31 (3H, s).

Example 6(49)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methylphenylthio) tetrazol-1-yl)pentanoic acid ##STR1396##

TLC: Rf 0.14 (chloroform:methanol:acetic acid=95:4:1); NMR (DMSO-d6): δ 8.10-7.93 (1H, brs), 7.47-7.16 (9H, m), 5.72 (2H, brs), 5.11 (2H, s), 4.73-4.55 (1H, m), 2.90-2.59 (2H, m), 2.32 (3H, s).

Example 6(50)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1397##

TLC: Rf 0.26 (chloroform:methanol:acetic acid=95:4:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 8.01 (1H, d, J=7.4 Hz), 7.60-7.42 (4H, m), 7.42-7.23 (5H, m), 6.03 (2H, s), 5.09 (2H, s), 4.78-4.48 (1H, m), 2.90-2.57 (2H, m).

Example 6(51)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1398##

TLC: Rf 0.22 (chloroform:methanol:acetic acid=95:4:1); NMR (DMSO-d6): δ 12.47 (1H, brs), 8.15-7.96 (1H, m), 7.70-7.41 (4H, m), 7.41-7.23 (5H, m), 5.77 (2H, s), 5.10 (2H, s), 4.75-4.52 (1H, m), 2.90-2.55 (2H, m).

Example 6(52)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-4-yl)tetrazol-2-yl) pentanoic acid•hydrochloric acid salt ##STR1399##

TLC: Rf 0.35 (chloroform:methanol:acetic acid=10:1:1); NMR (DMSO-d6): δ 13.36-11.90 (1H, br), 8.81 (2H, d, J=5.3 Hz), 8.08 (1H, d, J=7.5 Hz), 7.82 (2H, d, J=5.3 Hz), 7.52-7.14 (5H, m), 6.00 (2H, s), 5.09 (2H, s), 4.80-4.45 (3H, m), 2.97-2.57 (2H, m).

Example 6(53)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(pyridin-4-yl)tetrazol-1-yl) pentanoic acid•hydrochloric acid salt ##STR1400##

TLC: Rf 0.11 (chloroform:methanol:acetic acid=10:1:1); NMR (DMSO-d6): δ 8.85 (2H, d, J=6.4 Hz), 8.17 (1H, d, J=7.4 Hz), 7.88 (2H, d, J=6.4 Hz), 7.52-7.09 (5H, m), 6.06-5.74 (2H, m), 5.11 (2H, s), 4.73-4.56 (1H, m), 4.51 (2H, s), 2.92-2.59 (2H, m).

Example 6(54)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,5-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1401##

TLC: Rf 0.40 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 8.01 (1H, m), 7.64 (1H, d, J=1.5 Hz), 7.52 (2H, d, J=1.5 Hz), 7.37 (5H, m), 6.08 (2H, br), 5.08 (2H, s), 4.64 (1H, m), 2.89-2.56 (2H, m).

Example 6(55)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,5-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1402##

TLC: Rf 0.30 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 8.06 (1H, m), 7.69 (1H, d, J=1.5 Hz), 7.58 (2H, brs), 7.36 (5H, m), 5.82 (2H, br), 5.10 (2H, s), 4.64 (1H, m), 2.75 (2H, m).

Example 6(56)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-methylpyrimidin-2,4-dion-3-ylmeth yl)tetrazol-2-yl)pentanoic acid ##STR1403##

TLC: Rf 0.36 (chloroform:methanol:acetic acid=20:2:1); NMR (DMSO-d6): δ 7.82 (1H, d, J=8 Hz), 7.76 (1H, d, J=8 Hz), 7.38 (5H, m), 5.92 (2H, br), 5.75 (1H, d, J=8 Hz), 5.22 (2H, s), 5.08 (2H, s), 4.58 (1H, q, J=8 Hz), 3.28 (3H, s), 2.82-2.50 (2H, m).

Example 6(57)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-methylpyrimidin-2,4-dion-3-ylmeth yl)tetrazol-1-yl)pentanoic acid ##STR1404##

TLC: Rf 0.18 (chloroform:methanol:acetic acid=20:2:1); NMR (DMSO-d6): δ 7.78 (1H, d, J=8 Hz), 7.60 (1H, d, J=8 Hz), 7.36 (5H, m), 6.00 (1H, d, J=17 Hz), 5.88 (1H, d, J=17 Hz), 5.56 (1H, d, J=8 Hz), 5.20-4.96 (4H, m), 4.46 (1H, J=8 Hz), 3.30 (3H, s), 2.80-2.55 (2H, m).

Example 6(58)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloroethyl)tetrazol-2-yl) pentanoic acid ##STR1405##

TLC: Rf 0.52 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 7.84-7.61 (1H, m), 7.52-7.16 (5H, m), 6.07-5.80 (2H, m), 5.08 (2H, s), 4.63-4.42 (1H, m), 3.99 (2H, t, J=6.6 Hz), 3.35 (2H, t, J=6.6 Hz), 2.62 (2H, d-like, J=5.6 Hz).

Example 6(59)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloroethyl)tetrazol-1-yl) pentanoic acid ##STR1406##

TLC: Rf 0.22 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.06-7.86 (1H, m), 7.56-7.20 (5H, m), 5.76 (2H, brs), 5.10 (2H, s), 4.68-4.49 (1H, m), 3.94 (2H, t, J=6.8 Hz), 3.25 (2H, t, J=6.8 Hz), 2.85-2.60 (2H, m).

Example 6(60)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylcarbonyl)tetrazol-2-yl)pentan oic acid ##STR1407##

TLC: Rf 0.37 (chloroform:ethanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.21 (2H, d, J=7.0 Hz), 7.84-7.56 (4H, m), 7.35 (5H, m), 6.21 (2H, br), 5.08 (2H, s), 4.58 (1H, m), 2.64 (2H, br).

Example 6(61)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(phenylcarbonyl)tetrazol-1-yl)pentan oic acid ##STR1408##

TLC: Rf 0.45 (chloroform:ethanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.25 (2H, d, J=7.0 Hz), 8.00-7.58 (4H, m), 7.48-7.20 (5H, m), 6.09-5.81 (2H, m), 5.10 (2H, s), 4.65 (1H, m), 2.66 (2H, m).

Example 6(62)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-fluorophenylmethyl)tetra zol-2-yl)pentanoic acid ##STR1409##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=45:4:1); NMR (DMSO-d6): δ 12.45 (1H, brs), 8.02-7.78 (1H, m), 7.50-7.20 (8H, m), 5.90 (2H, s), 5.07 (2H, s), 4.70-4.50 (1H, m), 4.36 (2H, s), 2.90-2.53 (2H, m).

Example 6(63)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-fluorophenylmethyl)tetra zol-1-yl)pentanoic acid ##STR1410##

TLC: Rf 0.39 (chloroform:methanol:acetic acid=45:4:1); NMR (DMSO-d6): δ 12.40 (1H, brs), 8.13-7.99 (1H, m), 7.50-7.15 (8H, m), 5.85 (2H, s), 5.10 (2H, s), 4.74-4.56 (1H, m), 4.19 (2H, s), 2.90-2.60 (2H, m).

Example 6(64)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylthio)tetrazol-2-yl) pentanoic acid ##STR1411##

TLC: Rf 0.63 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 8.05-7.90 (1H, m), 7.63-7.42 (5H, m), 5.95 (2H, s), 5.09 (2H, s), 4.70-4.57 (1H, m), 3.63-3.45 (1H, m), 2.90-2.60 (2H, m), 2.10-1.10 (10H, m).

Example 6(65)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(cyclohexylthio)tetrazol-1-yl) pentanoic acid ##STR1412##

TLC: Rf 0.54 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.43 (1H, brs), 8.07-7.91 (1H, m), 7.42-7.21 (5H, m), 5.60 (2H, s), 5.10 (2H, s), 4.70-4.51 (1H, m), 3.70-3.52 (1H, m), 2.89-2.53 (2H, m), 2.10-1.11 (10H, m).

Example 6(66)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methoxyphenylthio) tetrazol-2-yl)pentanoic acid ##STR1413##

TLC: Rf 0.55 (chloroform:methanol:acetic acid=45:4:1); NMR (DMSO-d6): δ 12.49 (1H, brs), 8.04-7.83 (1H, m), 7.52 (2H, d, J=8.5 Hz), 7.45-7.22 (5H, m), 7.00 (2H, d, J=8.5 Hz), 5.94 (2H, s), 5.07 (2H, s), 4.70-4.50 (1H, m), 3.78 (3H, s), 2.90-2.53 (2H, m).

Example 6(67)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-methoxyphenylthio) tetrazol-1-yl)pentanoic acid ##STR1414##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=45:4:1); NMR (DMSO-d6): δ 8.08-7.97 (1H, m), 7.51 (2H, d, J=8.9 Hz), 7.42-7.25 (5H, m), 6.92 (2H, d, J=8.5 Hz), 5.69 (2H, s), 5.11 (2H, s), 4.71-4.53 (1H, m), 3.78 (3H, s), 2.90-2.53 (2H, m).

Example 6(68)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1415##

TLC: Rf 0.53 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 12.52 (1H, brs), 8.02 (1H, d, J=8 Hz), 7.70-7.52 (1H, m), 7.52-7.20 (8H, m), 6.06 (2H, s), 5.09 (2H, s), 4.78-4.49 (1H, m), 2.83 (1H, dd , J=17 and 6 Hz), 2.65 (1H, dd, J=17 and 7 Hz).

Example 6(69)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1416##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.07-7.79 (1H, m), 7.75-7.12 (9H, m), 5.78 (2H, brs), 5.08 (2H, s), 4.71-4.41 (1H, m), 2.87-2.55 (2H, m).

Example 6(70)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1417##

TLC: Rf 0.57 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.85-12.15 (1H, br), 8.10 (1H, d, J=7 Hz), 7.82 (1H, d, J=7 Hz), 7.58-7.20 (7H, m), 6.05 (2H, s), 5.09 (2H, s), 4.82-4.46 (1H, m), 2.82 (1H, dd, J=17 and 6 Hz), 2.65 (1H, dd, J=17 and 7 Hz).

Example 6(71)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1418##

TLC: Rf 0.53 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.03 (1H, d, J=7 Hz), 7.82 (1H, s-like), 7.66-7.12 (7H, m), 5.76 (2H, brs), 5.09 (2H, s), 4.78-4.44 (1H, m), 2.95-2.53 (2H, m).

Example 6(72)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-methylphenylthio)tetrazo l-2-yl)pentanoic acid ##STR1419##

TLC: Rf 0.56 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.5 (1H, brs), 7.96 (1H, d, J=7.6 Hz), 7.51-7.28 (8H, m), 5.95 (2H, brs), 5.08 (2H, s), 4.67-4.56 (1H, m), 2.80 (1H, dd, J=5.4, 17 Hz), 2.63 (1H, dd, J=7.0, 17 Hz), 2.47 (3H, s).

Example 6(73)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-6-methylphenylthio)tetrazo l-1-yl)pentanoic acid ##STR1420##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.5 (1H, brs), 8.08 (1H, d, J=9.6 Hz), 7.51-7.23 (8H, m), 5.75 (2H, brs), 5.12 (2H, s), 4.71-4.61 (1H, m), 2.92-2.67 (2H, m), 2.46 (3H, s).

Example 6(74)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylphenylthio) tetrazol-2-yl)pentanoic acid ##STR1421##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=40:1:1); NMR (DMSO-d6): δ 7.99 (d, J=8.0 Hz, 1H), 7.76 (d, J=8.6 Hz, 2H), 7.62 (d, J=8.6 Hz, 2H), 7.4-7.2 (m, 5H), 6.07 (s, 2H), 5.09 (s, 2H), 4.8-4.6 (m, 1H), 2.78 (dd, J=6.0, 17.0 Hz, 1H), 2.65 (dd, J=7.0,17.0 Hz, 1H).

Example 6(75)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylphenylthio) tetrazol-1-yl)pentanoic acid ##STR1422##

TLC: Rf 0.45 (chloroform:methanol:acetic acid=40:1:1); NMR (DMSO-d6): δ 8.0-7.9 (m, 1H), 7.78 (d, J=8.5 Hz, 2H), 7.67 (d, J=8.5 Hz, 2H), 7.4-7.3 (m, 5H), 5.79 (s, 2H), 5.09 (s, 2H), 4.7-4.5 (m, 1H), 2.8-2.6 (m, 2H).

Example 6(76)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-2-ylthio) tetrazol-2-yl)pentanoic acid ##STR1423##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 8.12 (1H, s), 8.00-7.86 (4H, m), 7.62-7.45 (3H, m), 7.43-7.20 (5H, m), 5.99 (2H, s), 5.07 (2H, s), 4.73-4.53 (1H, m), 2.90-2.55 (2H, m).

Example 6(77)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-2-ylthio) tetrazol-1-yl)pentanoic acid ##STR1424##

TLC: Rf 0.31 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 12.57 (1H, brs), 8.15 (1H, s), 8.10-7.87 (4H, m), 7.69-7.44 (3H, m), 7.42-7.23 (5H, m), 5.78 (2H, s), 5.10 (2H, s), 4.73-4.5 (1H, m), 2.90-2.55 (2H, m).

Example 6(78)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-t-butylphenylthio)tetrazol-2-yl)p entanoic acid ##STR1425##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 12.48 (1H, brs), 7.96 (1H, brs), 7.60-7.40 (9H, m), 5.98 (2H, brs), 5.06 (2H, s), 4.70-4.50 (1H, m), 2.88-2.53 (2H, m), 1.26 (9H, s).

Example 6(79)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-t-butylphenylthio)tetrazol-1-yl)p entanoic acid ##STR1426##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 8.10-7.90 (1H, m), 7.60-7.25 (9H, m), 5.70 (2H, brs), 5.09 (2H, s), 4.70-4.53 (1H, m), 2.90-2.53 (2H, m), 1.27 (9H, s).

Example 6(80)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethyloxyphenylthio)tetr azol-1-yl)pentanoic acid ##STR1427##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=30:1:1); NMR (DMSO-d6): δ 8.1-8.0 (m, 1H), 7.66 (d, J=8.8 Hz, 2H), 7.43 (d, J=8.8 Hz, 2H), 7.5-7.3 (m, 5H), 5.76 (brs, 2H), 5.10 (s, 2H), 4.7-4.6 (m, 1H), 2.9-2.6 (m, 2H).

Example 6(81)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethyloxyphenylthio)tetr azol-2-yl)pentanoic acid ##STR1428##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 8.1-7.9 (m, 1H), 7.63 (d, J=8.8 Hz, 2H), 7.43 (d, J=8.8 Hz, 2H), 7.5-7.2 (m, 5H), 6.2-5.9 (m, 2H), 5.09 (s, 2H), 4.7-4.5 (m, 1H), 2.9-2.6 (m, 2H).

Example 6(82)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1429##

TLC: Rf 0.61 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 11.9 (1H, brs), 7.96 (1H, d, J=7.8 Hz), 7.84 (1H, d, J=8.8 Hz), 7.71 (1H, d, J=8.8 Hz), 7.39-7.30 (5H, m), 5.97 (2H, brs), 5.09 (2H, s), 4.68-4.58 (1H, m), 2.80 (1H, dd, J=5.6, 16.6 Hz), 2.64 (1H, dd, J=7.0, 16.6 Hz).

Example 6(83)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1430##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.08 (1H, d, J=7.4 Hz), 7.86 (1H, d, J=8.8 Hz), 7.71 (1H, d, J=8.8 Hz), 7.42-7.26 (5H, m), 5.78 (2H, brs), 5.12 (2H, s), 4.75-4.60 (1H, m), 2.93-2.70 (2H, m).

Example 6(84)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dimethylphenylthio) tetrazol-2-yl)pentanoic acid ##STR1431##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=94:3:3); NMR (DMSO-d6): δ 8.02-7.89 (1H, m), 7.43-7.22 (6H, m), 7.19 (1H, s), 7.06 (1H, d, J=8.0 Hz), 5.92 (2H, brs), 5.07 (2H, s), 4.70-4.50 (1H, m), 2.90-2.53 (2H, m), 2.32 (3H, s), 2.29 (3H, s).

Example 6(85)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-dimethylphenylthio) tetrazol-1-yl)pentanoic acid ##STR1432##

TLC: Rf 0.29 (chloroform:methanol:acetic acid=94:3:3); NMR (DMSO-d6): δ 8.10-7.96 (1H, m), 7.43-7.25 (6H, m), 7.20 (1H, s), 7.07 (1H, d, J=7.4 Hz), 5.69 (2H, brs), 5.10 (2H, s), 4.70-4.53 (1H, m), 2.90-2.53 (2H, m), 2.30 (6H, s).

Example 6(86)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,5-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1433##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=96:3:1); NMR (DMSO-d6): δ 8.08-7.90 (1H, m), 7.65 (1H, dd, J=8.7, 2.9 Hz), 7.48 (1H, d, J=8.7 Hz), 7.42-7.23 (6H, m), 6.05 (2H, brs), 5.09 (2H, s), 4.70-4.52 (1H, m), 2.90-2.55 (2H, m).

Example 6(87)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,5-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1434##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=96:3:1); NMR (DMSO-d6): δ 8.05 (1H, brs), 7.70-7.58 (1H, m), 7.55-7.45 (2H, m), 7.45-7.21 (5H, m), 5.83 (2H, brs), 5.09 (2H, s), 4.75-4.55 (1H, m), 2.90-2.55 (2H, m).

Example 6(88)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-bromophenylthio) tetrazol-2-yl)pentanoic acid ##STR1435##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=30:1:1); NMR (DMSO-d6): δ 12.53 (brs, 1H), 8.00 (d, J=8.0 Hz, 1H), 7.62 (d, J=8.6 Hz, 2H), 7.46 (d, J=8.6 Hz, 2H), 7.5-7.3 (s, 4H), 6.03 (s, 2H), 5.09 (s, 2H), 4.8-4.6 (m, 1H), 3.0-2.6 (m, 2H).

Example 6(89)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-bromophenylthio) tetrazol-1-yl)pentanoic acid ##STR1436##

TLC: Rf 0.26 (chloroform:methanol:acetic acid=30:1:1); NMR (DMSO-d6): δ 12.57 (brs, 1H), 8.07 (d, J=7.4 Hz, 1H),7.63 (d, J=8.6 Hz, 2H), 7.46 (d, J=8.6 Hz, 2H), 7.5-7.2 (m, 4H), 5.79 (s, 2H), 5.11 (s, 2H), 4.8-4.6 (m, 1H), 3.0-2.6 (m, 2H).

Example 6(90)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio)tet razol-2-yl)pentanoic acid ##STR1437##

TLC: Rf 0.60 (chloroform:methanol:acetic acid=96:3:1); NMR (DMSO-d6): δ 7.95 (1H, d, J=7.6 Hz), 7.53 (2H, s), 7.40-7.25 (5H, m), 5.96 (2H, s), 5.08 (2H, s), 4.70-4.50 (1H, m), 2.79 (1H, dd, J=16.8, 6.0 Hz), 2.61 (1H, dd, J=16.8, 6.8 Hz), 2.36 (3H, s).

Example 6(91)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio)tet razol-1-yl)pentanoic acid ##STR1438##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=96:3:1); NMR (DMSO-d6): δ 8.04 (1H, brs), 7.52 (2H, s), 7.45-7.20 (5H, m), 5.74 (2H, s), 5.11 (2H, s), 4.76-4.56 (1H, m), 2.90-2.65 (2H, m), 2.36 (3H, s).

Example 6(92)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,4-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1439##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=36:1:1); NMR (CDCl3): δ 7.99 (1H, d, J=7.6 Hz), 7.75 (1H, d, J=2.2 Hz), 7.67 (1H, d, J=8.6 Hz), 7.46 (1H, dd, J=2.2, 8.6 Hz), 7.40-7.30 (5H, m), 6.00 (2H, brs), 5.09 (2H, s),4.69-4.59 (1H, m), 2.87-2.61 (2H, m).

Example 6(93)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3,4-dichlorophenylthio)tetrazol-1-y l)pentanoic acid ##STR1440##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=36:1:1); NMR (CDCl3): δ 8.06 (1H, d, J=7.4 Hz), 7.80 (1H, d, J=2.2 Hz), 7.68 (1H, d, J=8.6 Hz), 7.50 (1H, dd, J=2.2, 8.6 Hz), 7.40-7.29 (5H, m), 5.77 (2H, br s), 5.11 (2H, s), 4.69-4.59 (1H, m), 2.88-2.64 (2H, m).

Example 6(94)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-bromotetrazol-2-yl) pentanoic acid ##STR1441##

TLC: Rf 0.51 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.93 (1H, d, J=7.4 Hz), 7.56-7.13 (5H, m), 6.01 (2H, brs), 5.09 (2H, s), 4.73-4.49 (1H, m), 2.92-2.52 (2H, m).

Example 6(95)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-nitrophenylthio)tetrazol-2-yl)pen tanoic acid ##STR1442##

TLC: Rf 0.53 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.80-10.36 (1H, br), 8.22 (2H, d, J=9.0 Hz), 8.00 (1H, d, J=7.8 Hz), 7.61 (2H, d, J=9.0 Hz), 7.47-7.18 (5H, m), 6.05 (2H, brs), 5.09 (2H, s), 4.80-4.52 (1H, m), 2.93-2.56 (2H, m).

Example 6(96)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-nitrophenylthio)tetrazol-1-yl)pen tanoic acid ##STR1443##

TLC: Rf 0.37 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.22 (2H, d, J=9.0 Hz), 7.98 (1H, d, J=7.8 Hz), 7.66 (2H, d, J=9.0 Hz), 7.46-7.19 (5H, m), 5.79 (2H, brs), 5.09 (2H, s), 4.74-4.46 (1H, m), 2.87-2.54 (2H, m).

Example 6(97)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-1-ylthio) tetrazol-2-yl)pentanoic acid ##STR1444##

TLC: Rf 0.47 (chloroform:methanol:acetic acid=96:3:1); NMR (DMSO-d6): δ 12.43 (1H, brs), 8.26 (1H, d, J=8.6 Hz), 8.16-7.80 (4H, m), 7.74-7.47 (3H, m), 7.42-7.22 (5H, m), 5.94 (2H, s), 5.06 (2H, s), 4.75-4.50 (1H, m), 2.87-2.52 (2H, m).

Example 6(98)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(naphthalen-1-ylthio) tetrazol-1-yl)pentanoic acid ##STR1445##

TLC: Rf 0.37 (chloroform:methanol:acetic acid=96:3:1); NMR (DMSO-d6): δ 12.56 (1H, brs), 8.32-7.97 (4H, m), 7.93 (1H, d, J=7.0 Hz), 7.70-7.49 (3H, m) 7.41-7.10 (5H, m), 5.86 (2H, brs), 5.12 (2H, s), 4.78-4.58 (1H, m), 2.94-2.62 (2H, m).

Example 6(99)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-di-t-butylphenylthio) tetrazol-2-yl)pentanoic acid ##STR1446##

TLC: Rf 0.26 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.60 (1H, d, J=7 Hz), 7.46 (1H, d, J=2 Hz), 7.37-7.19 (7H, m), 5.97 (2H, dd, J=17 and 24 Hz), 5.04 (2H, s), 4.48 (1H, m), 2.65-2.52 (2H, m), 1.49 and 1.27 (each 9H, each s).

Example 6(100)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4-di-t-butylphenylthio) tetrazol-1-yl)pentanoic acid ##STR1447##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.79 (1H, d, J=8 Hz), 7.48 (1H, s), 7.35-7.18 (7H, m), 5.77 (2H, brs), 5.06 (2H, s), 4.52 (1H, m), 2.61 (2H, d-like), 1.46 and 1.29 (each 9H, each s).

Example 6(101)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imidazol-1-ylmethyl) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1448##

TLC: Rf 0.44 (chloroform:methanol:acetic acid=10:5:1); NMR (DMSO-d6): δ 9.28 (1H, s), 8.02 (1H, d, J=7.0 Hz), 7.80 (1H, s), 7.71 (1H, s), 7.42-7.30 (5H, m), 6.04 (2H, s), 5.91 (2H, s), 5.09 (2H, s), 4.62 (1H, m), 2.90-2.58 (2H, m).

Example 6(102)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imidazol-1-ylmethyl) tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1449##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=10:5:1); NMR (DMSO-d6): δ 9.22 (1H, s), 8.20 (1H, d, J=7.0 Hz), 7.72 (1H, s), 7.68 (1H, s), 7.40-7.26 (5H, m), 6.10-5.88 (2H, m), 5.81 (2H, s), 5.12 (2H, s), 4.72 (1H, m), 2.92-2.62 (2H, m).

Example 6(103)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxyphenylthio) tetrazol-2-yl)pentanoic acid ##STR1450##

TLC: Rf 0.34 (chloroform:methanol:acetic acid=36:1:1); NMR (DMSO-d6): δ 7.98 (1H, d, J=7.6 Hz), 7.42-7.30 (6H, m), 7.25 (1H, d, J=7.4 Hz), 7.10 (1H, d, J=7.4 Hz), 7.00-6.92 (1H, m), 5.97 (2H, brs), 5.09 (2H, s), 4.68-4.58 (1H, m), 3.80 (3H, s), 2.87-2.60 (2H, m).

Example 6(104)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methoxyphenylthio) tetrazol-1-yl)pentanoic acid ##STR1451##

TLC: Rf 0.29 (chloroform:methanol:acetic acid=36:1:1); NMR (DMSO-d6): δ 8.03 (1H, d, J=6.8 Hz), 7.46-7.31 (7H, m), 7.09 (1H, d, J=7.8 Hz), 7.03-6.95 (1H, m), 5.72 (2H, brs), 5.10 (2H, s), 4.68-4.58 (1H, m), 3.75 (3H, s), 2.87-2.62 (2H, m).

Example 6(105)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophenylt hio)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1452##

TLC: Rf 0.38 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 7.97 (1H, d, J=7.8 Hz), 7.40-7.26 (5H, m), 6.88 (2H, s), 5.95 (2H, brs), 5.08 (2H, s), 4.60 (1H, m), 2.77 (6H, s), 2.84-2.72 (2H, m).

Example 6(106)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophenylt hio)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1453##

TLC: Rf 0.29 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 8.02 (1H, m), 7.40-7.24 (5H, m), 6.87 (2H, s), 5.73 (2H, brs), 5.11 (2H, s), 4.62 (1H, m), 3.00 (6H, s), 2.92-2.62 (2H, m).

Example 6(107)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiophen-2-yl)tetrazol-2-yl) pentanoic acid ##STR1454##

TLC: Rf 0.46 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.61 (1H, d, J=8 Hz), 7.40-7.32 (6H, m), 6.96-6.94 (2H, m), 5.96 (2H, brs), 5.07 (2H, s), 4.57-4.47 (1H, m), 4.46 (2H, s), 2.60 (2H, d-like).

Example 6(108)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiophen-2-yl)tetrazol-1-yl) pentanoic acid ##STR1455##

TLC: Rf 0.34 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.08 (1H, d, J=8 Hz), 7.43-7.37 (6H, m), 6.97-6.94 (2H, m), 5.77 (2H, s), 5.10 (2H, s), 4.64 (1H, m), 4.38 (2H, s), 2.76 (2H, m).

Example 6(109)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiophen-3-yl)tetrazol-2-yl) pentanoic acid ##STR1456##

TLC: Rf 0.49 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.97 (1H, d, J=7 Hz), 7.48 (1H, dd, J=3 and 5 Hz), 7.37-7.33 (5H, m), 7.28-7.26 (1H, m), 7.02 (1H, d, J=5 Hz), 5.90 (2H, brs), 5.09 (2H, s), 4.67-4.57 (1H, m), 4.25 (2H, s), 2.81 and 2.64 (each 1H, each dd, J=7 and 17 Hz).

Example 6(110)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiophen-3-yl)tetrazol-1-yl) pentanoic acid ##STR1457##

TLC: Rf 0.37 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.06 (1H, d, J=7 Hz), 7.48 (1H, dd, J=3 and 5 Hz), 7.40-7.31 (6H, m), 6.98 (1H, d, J=5 Hz), 5.72 (2H, brs), 5.10 (2H, s), 4.67-4.58 (1H, m), 4.14 (2H, s), 2.81 and 2.69 (each 1H, each dd, J=7 and 17 Hz).

Example 6(111)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-imidazol-1-ylpropyl) tetrazol-2-yl)pentanoic acid ##STR1458##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 7.97 (1H, d, J=7.8 Hz), 7.62 (1H, brs), 7.40-7.30 (5H, m), 7.19 (1H, brs), 6.92 (1H, brs), 5.87 (2H, s), 5.09 (2H, s), 4.61 (1H, m), 4.04 (2H, t, J=7.0 Hz), 2.88-2.58 (4H, m), 2.14 (2H, m).

Example 6(112)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-imidazol-1-ylpropyl) tetrazol-1-yl)pentanoic acid ##STR1459##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 8.04 (1H, d, J=7.8 Hz), 7.62 (1H, brs), 7.40-7.30 (5H, m), 7.17 (1H, s), 6.89 (1H, s), 5.69 (2H, s), 5.10 (2H, s), 4.60 (1H, m), 4.10-3.98 (2H, m), 2.90-2.62 (4H, m), 2.10 (2H, m).

Example 6(113)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1460##

TLC: Rf 0.19 (chloroform:methanol:acetic acid=36:1:1); NMR (DMSO-d6): δ 7.99 (1H, d, J=7.4 Hz), 7.64 (1H, d, J=8.0 Hz), 7.40-7.31 (6H, m), 7.24 (1H, d, J=8.0 Hz), 6.05 (2H, brs), 5.10 (2H, s), 4.70-4.60 (1H, m), 2.89-2.62 (2H, m).

Example 6(114)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,3-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1461##

TLC: Rf 0.16 (chloroform:methanol:acetic acid=36:1:1); NMR (DMSO-d6): δ 8.05 (1H, d, J=7.6 Hz), 7.71-7.66 (1H, m), 7.41-7.18 (7H, m), 5.81 (2H, brs), 5.09 (2H, s), 4.69-4.59 (1H, m), 2.88-2.63 (2H, m).

Example 6(115)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylthio) tetrazol-2-yl)pentanoic acid ##STR1462##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 12.40 (1H, brs), 7.92 (1H, d, J=8.8 Hz), 7.40-7.05 (8H, m) 5.90 (2H, brs), 5.05 (2H, s), 4.70-4.50 (1H, m), 2.84-2.50 (2H, m), 2.40 (6H, s).

Example 6(116)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethylphenylthio) tetrazol-1-yl)pentanoic acid ##STR1463##

TLC: Rf 0.41 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 8.04 (1H, d, J=8.6 Hz), 7.42-7.10 (8H, m) 5.70 (2H, brs), 5.11 (2H, s), 4.70-4.52 (1H, m), 2.91-2.60 (2H, m), 2.35 (6H, s).

Example 6(117)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-t-butylphenylthio)tetraz ol-2-yl)pentanoic acid ##STR1464##

TLC: Rf 0.25 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 7.98 (1H, d, J=8.0 Hz), 7.56 (1H, d, J=1.6 Hz), 7.43-7.20 (7H, m) 6.02 (2H, brs), 5.07 (2H, s), 4.70-4.55 (1H, m), 2.80 (1H, dd, J=16.6, 5.7 Hz), 2.62 (1H, dd, J=16.6, 6.6 Hz), 1.26 (9H, s).

Example 6(118)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-t-butylphenylthio)tetraz ol-1-yl)pentanoic acid ##STR1465##

TLC: Rf 0.19 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 8.10-7.95 (1H, m), 7.58 (1H, d, J=1.4 Hz), 7.53-7.21 (7H, m) 5.76 (2H, brs), 5.10 (2H, s), 4.70-4.54 (1H, m), 2.90-2.60 (2H, m), 1.29 (9H, s).

Example 6(119)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,2,6,6-tetramethylpiperidin-2-ylme thyl)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1466##

TLC: Rf 0.45 (chloroform:methanol:acetic acid=10:2:1); NMR (DMSO-d6): δ 9.32 (1H, brs), 8.08 (1H, d, J=7.6 Hz), 7.40-7.30 (5H, m), 6.07 (2H, s), 5.10 (2H, s), 4.80-4.58 (3H, m), 2.92-2.58 (2H, m), 2.10-1.40 (18H, m).

Example 6(120)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,2,6,6-tetramethylpiperidin-1-ylme thyl)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1467##

TLC: Rf 0.66 (chloroform:methanol:acetic acid=10:2:1); NMR (DMSO-d6): δ 8.36 (1H, d, J=7.4 Hz), 7.40-7.24 (5H, m), 6.20-5.90 (2H, m), 5.11 (2H, s), 4.80-4.60 (3H, m), 2.96-2.60 (2H, m), 2.00-1.20 (18H, m).

Example 6(121)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N-phenyl-N-methylamino) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1468##

TLC: Rf 0.25 (chloroform:methanol:water=90:10:1); NMR (DMSO-d6): δ 7.96 (1H, d, J=8 Hz), 7.48-7.32 (9H, m), 7.08 (1H, t, J=7 Hz), 5.81 (2H, s), 5.09 (2H, s), 4.67-4.57 (1H, m), 3.49 (3H, s), 2.82 and 2.62 (each 1H, each dd, J=7 and 17 Hz).

Example 6(122)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(N-phenyl-N-methylamino) tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1469##

TLC: Rf 0.19 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.79 (1H, d, J=8 Hz), 7.42-7.28 (7H, m), 7.17-7.09 (1H, m), 6.96 (2H, d, J=8 Hz), 5.06 (2H, q-like), 5.01 (2H, s), 4.26-4.16 (1H, m), 3.30 (3H, s), 2.64-2.37 (2H, m).

Example 6(123)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-diisopropylphenylthio) tetrazol-2-yl)pentanoic acid ##STR1470##

TLC: Rf 0.24 (chloroform:methanol:water=90:10:1); NMR (DMSO-d6): δ 7.90 (1H, d, J=8 Hz), 7.51-7.27 (8H, m), 5.87 (2H, brs), 5.07 (2H, s), 4.62-4.52 (1H, m), 3.75-3.62 (2H, m), 2.97-2.62 (2H, m), 1.13 (12H, d, J=7 Hz).

Example 6(124)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-diisopropylphenylthio) tetrazol-1-yl)pentanoic acid ##STR1471##

TLC: Rf 0.21 (chloroform:methanol:water=90:10:1); NMR (DMSO-d6): δ 8.06 (1H, d, J=7 Hz), 7.55-7.28 (8H, m), 5.73 (2H, brs), 5.11 (2H, s), 4.71-4.61 (1H, m), 3.60-3.42 (2H, m), 3.04-2.66 (2H, m), 1.11 (12H, d, J=7 Hz).

Example 6(125)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methyl-4-t-butylphenylthio)tetraz ol-2-yl)pentanoic acid ##STR1472##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 12.47 (1H, brs), 7.98 (1H, J=7.6 Hz), 7.60-7.10 (8H, m) 5.98 (2H, s), 5.08 (2H, s), 4.70-4.50 (1H, m), 2.81 (1H, dd, J=16.8, 5.8 Hz), 2.62 (1H, dd, J=16.8, 6.8 Hz), 2.36 (3H, s), 1.28 (9H, s).

Example 6(126)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-methyl-4-t-butylphenylthio)tetraz ol-1-yl)pentanoic acid ##STR1473##

TLC: Rf 0.32 (chloroform:methanol:acetic acid=46:3:1); NMR (DMSO-d6): δ 12.57 (1H, brs), 8.08 (1H, d, J=7.4 Hz), 7.60-7.10 (8H, m) 5.75 (2H, s), 5.11 (2H, s), 4.70-4.55 (1H, m), 2.86 (1H, dd, J=17.6, 5.8 Hz), 2.68 (1H, dd, J=17.6, 7.0 Hz), 2.35 (3H, s), 1.28 (9H, s).

Example 6(127)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio)te trazol-2-yl)pentanoic acid ##STR1474##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=47:2:1); NMR (DMSO-d6): δ 12.48 (1H, brs), 7.94 (1H, d, J=7.6 Hz), 7.35 (5H, brs), 7.24 (2H, s), 5.92 (2H, s), 5.07 (2H, s), 4.70-4.50 (1H, m), 2.90-2.50 (2H, m), 2.41 (6H, s), 1.28 (9H, s).

Example 6(128)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio)te trazol-1-yl)pentanoic acid ##STR1475##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=47:2:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 8.11-7.90 (1H, m), 7.46-7.20 (5H, m), 7.25 (2H, s), 5.71 (2H, s), 5.11 (2H, s), 4.72-4.53 (1H, m), 2.93-2.57 (2H, m), 2.35 (6H, s), 1.29 (9H, s).

Example 6(129)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophenylt hio)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1476##

TLC: Rf 0.39 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 7.99 (1H, d, J=7.8 Hz), 7.40-7.30 (5H, m), 6.79 (2H, s), 5.92 (2H, s), 5.07 (2H, s), 4.60 (1H, m), 2.96 (6H, s), 2.88-2.54 (2H, m), 2.38 (6H, s).

Example 6(130)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophenylt hio)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1477##

TLC: Rf 0.36 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 8.10 (1H, d, J=7.8 Hz), 7.40-7.26 (5H, m), 6.74 (2H, s), 5.69 (2H, s), 5.11 (2H, s), 4.62 (1H, m), 2.97 (6H, s), 2.92-2.62 (2H, m), 2.30 (6H, s).

Example 6(131)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(benzoimizazol-2-ylmethyl) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1478##

TLC: Rf 0.30 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.28-8.01 (1H, m), 7.62 (2H, dd, J=5.8 and 3.0 Hz), 7.50-7.28 (7H, m), 5.97 (2H, brs), 5.02 (2H, s), 4.67 (3H, brs), 2.92-2.54 (2H, m).

Example 6(132)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(benzoimizazol-2-ylmethyl) tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1479##

TLC: Rf 0.20 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.04 (1H, d, J=7.6 Hz), 7.79 (2H, dd, J=6.0 and 3.2 Hz), 7.51 (2H, dd, J=6.0 and 3.2 Hz), 7.42-7.20 (5H, m), 6.04 (2H, s), 5.08 (2H, s), 4.95 (2H, s), 4.77-4.99 (1H, m), 2.84 (1H, dd, J=16.8 and 6.4 Hz), 2.65 (1H, dd, J=16.8 and 6.8 Hz).

Example 6(133)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-isopropylphenylthio) tetrazol-2-yl)pentanoic acid ##STR1480##

TLC: Rf 0.34 (chloroform:methanol:acetic acid=36:1:1); NMR (DMSO-d6): δ 7.99 (1H, d, J=6.4 Hz), 7.47-7.25 (9H, m), 5.99 (2H, brs), 5.09 (2H, s), 4.69-4.58 (1H, m), 2.98-2.60 (3H, m), 1.20 (6H, d, J=6.8 Hz).

Example 6(134)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-isopropylphenylthio) tetrazol-1-yl)pentanoic acid ##STR1481##

TLC: Rf 0.27 (chloroform:methanol:acetic acid=36:1:1); NMR (DMSO-d6): δ 8.05 (1H, d, J=7.0 Hz), 7.49-7.28 (9H, m), 5.72 (2H, brs), 5.12 (2H, s), 4.69-4.59 (1H, m), 2.98-2.63 (3H, m), 1.21 (6H, d, J=6.8 Hz).

Example 6(135)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(benzothiazol-2-ylmethyl) tetrazol-2-yl)pentanoic acid ##STR1482##

TLC: Rf 0.15 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.80-11.40 (1H, br), 8.20-7.86 (3H, m), 7.62-7.22 (7H, m), 6.29-5.68 (2H, brs), 5.09 (2H, s), 4.87 (2H, s), 4.78-4.46 (1H, m), 2.82 (1H, dd, J=17.0 and 6.5 Hz), 2.65 (1H, dd, J=17.0 and 7.0 Hz).

Example 6(136)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(benzothiazol-2-ylmethyl) tetrazol-1-yl)pentanoic acid ##STR1483##

TLC: Rf 0.10 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.50-11.40 (1H, br), 8.19-7.84 (3H, m), 7.70-7.18 (7H, m), 6.15-5.60 (2H, brs), 5.03 (2H, s), 4.98-4.50 (3H, m), 2.90-2.57 (2H, m).

Example 6(137)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiazol-2-ylthio)tetrazol-2-yl)pent anoic acid ##STR1484##

TLC: Rf 0.29 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.89 (2H, m), 7.78 (1H, m), 7.36 (5H, s), 6.07 (2H, s), 5.08 (2H, s), 4.55 (1H, m), 2.66 (2H, m).

Example 6(138)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(thiazol-2-ylthio)tetrazol-1-yl)pent anoic acid ##STR1485##

TLC: Rf 0.24 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.89 (2H, m), 7.73 (1H, m), 7.35 (5H, s), 5.87 (2H, s), 5.07 (2H, s), 4.53 (1H, m), 2.61 (2H, m).

Example 6(139)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4,6-trichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1486##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=48:1:1); NMR (DMSO-d6): δ 12.49 (1H, brs), 8.05-7.84 (3H, m), 7.45-7.20 (5H, m), 5.98 (2H, s), 5.07 (2H, s), 4.70-4.50 (1H, m), 2.90-2.50 (2H, m).

Example 6(140)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,4,6-trichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1487##

TLC: Rf 0.17 (chloroform:methanol:acetic acid=48:1:1); NMR (DMSO-d6): δ 12.57 (1H, brs), 8.10-8.00 (1H, m), 7.93 (2H, s), 7.43-7.20 (5H, m), 5.80 (2H, s), 5.10 (2H, s), 4.80-4.55 (1H, m), 2.93-2.65 (2H, m).

Example 6(141)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-(1,1-dimethylpropyl) phenylthio)tetrazol-2-yl)pentanoic acid ##STR1488##

TLC: Rf 0.26 (chloroform:methanol:acetic acid=48:1:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 7.96 (1H, d, J=8.5 Hz), 7.59 (2H, s), 7.35 (5H, s), 5.98 (2H, s), 5.07 (2H, s), 4.70-4.52 (1H, m), 2.90-2.50 (2H, m), 1.63 (2H, q, J=7.5 Hz), 1.25 (6H, s), 0.64 (3H, t, J=7.5 Hz).

Example 6(142)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-(1,1-dimethylpropyl) phenylthio)tetrazol-1-yl)pentanoic acid ##STR1489##

TLC: Rf 0.17 (chloroform:methanol:acetic acid=48:1:1); NMR (DMSO-d6): δ 12.56 (1H, brs), 8.09 (1H, d, J=8.5 Hz), 7.59 (2H, s), 7.42-7.08 (5H, s), 5.80 (2H, s), 5.10 (2H, s), 4.75-4.60 (1H, m), 2.90-2.50 (2H, m), 1.63 (2H, q, J=7.5 Hz), 1.25 (6H, s), 0.64 (3H, t, J=7.5 Hz).

Example 6(143)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1,1-diphenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1490##

TLC: Rf 0.29 (chloroform:methanol:acetic acid=38:1:1); NMR (DMSO-d6): δ 7.94 (1H, d, J=7.0 Hz), 7.50-7.12 (15H, m), 5.93 (3H, m), 5.08 (2H, s), 4.72-4.51 (1H, m), 2.92-2.53 (2H, m).

Example 6(144)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1,1-diphenylmethyl) tetrazol-1-yl)pentanoic acid ##STR1491##

TLC: Rf 0.16 (chloroform:methanol:acetic acid=38:1:1); NMR (DMSO-d6): δ 8.05 (1H, d, J=7.0 Hz,), 7.53-7.08 (15H, m), 5.92-5.57 (3H, m), 5.10 (2H, s), 4.72-4.46 (1H, m), 2.94-2.55 (2H, m).

Example 6(145)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-fluorophenylthio)tetrazo l-2-yl)pentanoic acid ##STR1492##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=38:1:1); NMR (DMSO-d6): δ 12.80-12.10 (1H, br), 7.99 (1H, d, J=8.0 Hz), 7.75-7.52 (2H, m), 7.52-7.18 (6H, m), 6.02 (2H, brs), 5.09 (2H, s), 4.80-4.45 (1H, m), 2.95-2.52 (2H, m).

Example 6(146)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-chloro-4-fluorophenylthio)tetrazo l-1-yl)pentanoic acid ##STR1493##

TLC: Rf 0.28 (chloroform:methanol:acetic acid=38:1:1); NMR (DMSO-d6): δ 8.02 (1H, d, J=7.0 Hz,), 7.82-7.54 (2H, m), 7.54-7.16 (6H, m), 5.76 (2H, brs), 5.10 (2H, s), 4.75-4.45 (1H, m), 2.92-2.55 (2H, m).

Example 6(147)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(5-imidazol-1-ylpentyl) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1494##

TLC: Rf 0.39 (chloroform:methanol:water=90:10:1); NMR (DMSO-d6): δ 9.08 (1H, s), 8.15 (1H, d, J=7.0 Hz), 7.75 (1H, s), 7.59 (1H, s), 7.80-6.90 (5H, brs), 5.91 (2H, brs), 5.12 (2H, s), 4.88-4.51 (1H, m), 4.40-4.00 (2H, m), 3.05-2.60 (4H, m), 2.08-1.47 (4H, m), 1.47-1.04 (2H, m).

Example 6(148)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(5-imidazol-1-ylpentyl) tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1495##

TLC: Rf 0.13 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 9.21 (1H, s), 8.14 (1H, d, J=7.0 Hz), 7.79 (1H, s), 7.67 (1H, s), 7.52-7.20 (5H, brs), 5.74 (2H, brs), 5.10 (2H, s), 4.79-4.48 (1H, m), 4.33-4.03 (2H, m), 3.00-2.56 (4H, m), 2.04-1.48 (4H, m), 1.48-1.08 (2H, m).

Example 6(149)

N-benzyloxycarbonyl-3amino-4-oxo-5-(5-(2-dimethylaminoethyl) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1496##

TLC: Rf 0.29 (chloroform:methanol:water=24:8:1); NMR (DMSO-d6): δ 11.80-9.42 (1H, br), 8.26-8.05 (1H, m), 7.49-7.24 (5H, m), 5.98-5.70 (2H, br), 5.11 (2H, s), 4.80-4.50 (1H, m), 3.55-3.05 (4H, m), 2.96-2.60 (2H, m), 2.82 (6H, s).

Example 6(150)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-dimethylaminoehtyl)tetrazol-1-yl) pentanoic acid•hydrochloric acid salt ##STR1497##

TLC: Rf 0.18 (chloroform:methanol:water=24:8:1); NMR (DMSO-d6): δ 13.30-11.65 (1H, br), 11.10-10.60 (1H, br), 8.05 (1H, d, J=8.0 Hz), 7.55-7.20 (5H, m), 5.99 (2H, s), 5.10 (2H, s), 4.70-4.50 (1H, m), 3.60-3.30 (4H, m), 2.96-2.55 (2H, m), 2.82 (6H, s).

Example 6(151)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(4-fluorophenyl)thiazol-2-ylmethy l)tetrazol-2-yl)pentanoic acid ##STR1498##

TLC: Rf 0.28 (chloroform:methanol:acetic acid=38:1:1); NMR (DMSO-d6): δ 13.40-11.50 (1H, br), 8.04 (1H, s), 8.19-7.94 (3H, m), 7.48-7.14 (7H, m), 6.00 (2H, brs), 5.09 (2H, s), 4.77 (2H, s), 4.80-4.47 (1H, m), 2.94-2.53 (2H, m).

Example 6(152)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(4-fluorophenyl)thiazol-2-ylmethy l)tetrazol-1-yl)pentanoic acid ##STR1499##

TLC: Rf 0.21 (chloroform:methanol:acetic acid=38:1:1); NMR (DMSO-d6): δ 8.07 (1H, s), 8.24-7.80 (3H, m), 7.46-7.15 (7H, m), 5.92 (2H, brs), 5.04 (2H, s), 4.84-4.51 (3H, m), 2.93-2.55 (2H, m).

Example 6(153)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(4-chlorophenyl)thiazol-2-ylmethy l)tetrazol-2-yl)pentanoic acid ##STR1500##

TLC: Rf 0.20 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.10-11.30 (1H, br), 8.11 (1H, s), 8.12-7.80 (3H, m), 7.58-7.20 (7H, m), 6.01 (2H, brs), 5.09 (2H, s), 4.78 (2H, s), 4.77-4.46 (1H, m), 2.92-2.53 (2H, m).

Example 6(154)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(4-chlorophenyl)thiazol-2-ylmethy l)tetrazol-1-yl)pentanoic acid ##STR1501##

TLC: Rf 0.16 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 12.90-11.20 (1H, br), 8.15 (1H, s), 8.11 (1H, d, J=8.0 Hz), 7.93 (2H, d, J=8.5 Hz), 7.48 (2H, d, J=8.5 Hz), 7.44-7.16 (5H, m), 5.92 (2H, brs), 5.04 (2H, s), 4.87-4.50 (3H, m), 2.92-2.58 (2H, m).

Example 6(155)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(3-nitrophenyl)thiazol-2-ylmethyl )tetrazol-2-yl)pentanoic acid ##STR1502##

TLC: Rf 0.28 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.30-11.70 (1H, br), 8.74 (1H, t, J=2.0 Hz), 8.40 (1H, s), 8.46-8.29 (1H, m), 8.27-8.10 (1H, m), 8.09-7.91 (1H, m), 7.74 (1H, t, J=8.0 Hz), 7.50-7.15 (5H, m), 6.00 (2H, brs), 5.09 (2H, s), 4.83 (2H, s), 4.78-4.50 (1H, m), 2.94-2.55 (2H, m).

Example 6(156)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(3-nitrophenyl)thiazol-2-ylmethyl )tetrazol-1-yl)pentanoic acid ##STR1503##

TLC: Rf 0.13 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 8.72 (1H, t, J=2.0 Hz), 8.43 (1H, s), 8.45-8.29 (1H, m), 8.25-8.02 (2H, m), 7.73 (1H, t, J=8.0 Hz), 7.50-7.12 (5H, m), 5.90 (2H, brs), 5.05 (2H, s), 4.90-4.50 (3H, m), 2.95-2.55 (2H, m).

Example 6(157)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylcarbonylaminopheny lthio)tetrazol-2-yl)pentanoic acid ##STR1504##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.10-10.50 (1H, br), 7.90 (1H, d, J=7.2 Hz), 7.75 (2H, d, J=8.8 Hz), 7.55 (2H, d, J=8.8 Hz), 7.48-7.38 (6H, m), 5.94 (2H, brs), 5.09 (2H, s), 4.70-4.47 (1H, m), 2.90-2.53 (2H, m).

Example 6(158)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-trifluoromethylcarbonylaminopheny lthio)tetrazol-1-yl)pentanoic acid ##STR1505##

TLC: Rf 0.31 (chloroform:methanol:acetic acid=18:1:1).

Example 6(159)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imizazol-4-ylmethyl) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1506##

TLC: Rf 0.37 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 9.07 (1H, s), 8.02 (1H, d, J=8.6 Hz), 7.51 (1H, s), 7.40-7.30 (5H, m), 5.98 (2H, s), 5.09 (2H, s), 4.62 (1H, m), 4.43 (2H, s), 2.90-2.60 (2H, m).

Example 6(160)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imizazol-4-ylmethyl) tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1507##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 9.04 (1H, s), 8.13 (1H, d, J=8.6 Hz), 7.52 (1H, s), 7.40-7.30 (5H, m), 5.86 (2H, brs), 5.11 (2H, s), 4.67 (1H, m), 4.31 (2H, s), 2.94≧2.84 (2H, m).

Example 7

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(carboxymethyl)tetrazol-2-yl)pentano ic acid ##STR1508##

To a solution of the compound prepared in example 5(18) (59 mg) in dimethoxyethane (1 ml) was added a 1N aqueous solution of sodium hydroxide (0.36 ml). The reaction mixture was stirred for 4 h at room temperature. The reaction mixture was quenched by addition of a 1N aqueous solution of hydrochloric acid, and extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol:acetic acid=18:1:1) to give the compound of the present invention (32 mg) having the following physical data.

TLC: Rf 0.32 (chloroform:ethanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 7.99 (1H, m), 7.42-7.24 (5H, m), 5.97 (2H, brs), 5.09 (2H, s), 4.62 (1H, m), 3.94 (2H, s), 2.91-2.54 (2H, m).

EXAMPLES 7(1)-7(3)

By the same procedure as provided in example 7, using the compounds prepared in examples 5(21), 5(30) or 5(31) instead of the compound prepared in example 5(18), compounds of the present invention having the following physical data were obtained.

Example 7(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(carboxymethyl)tetrazol-1-yl)pentano ic acid ##STR1509##

TLC: Rf 0.30 (chloroform:ethanol:acetic acid=4:1:1); NMR (DMSO-d6): δ 8.07 (1H, m), 7.45-7.17 (5H, m), 5.73 (2H, br), 5.09 (2H, s), 4.63 (1H, m), 4.10-3.85 (2H, m), 2.88-2.58 (2H, m).

Example 7(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-carboxyethyl)tetrazol-2-yl)pentan oic acid ##STR1510##

TLC: Rf 0.54 (chloroform:methanol:acetic acid=10:1:1); NMR (DMSO-d6): δ 13.50-11.12 (2H, br), 7.96 (1H, d, J=7.6 Hz), 7.44-7.21 (5H, m), 5.89 (2H, brs), 5.10 (2H, s), 4.74-4.52 (1H, m), 3.07 (2H, t, J=7.2 Hz), 2.88-2.54 (4H, m).

Example 7(3)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-carboxyethyl)tetrazol-1-yl)pentan oic acid ##STR1511##

TLC: Rf 0.44 (chloroform:methanol:acetic acid=10:1:1); NMR (DMSO-d6): δ 8.03-7.82 (1H, m), 7.52-7.17 (5H, m), 5.90-5.56 (2H, m), 5.10 (2H, s), 4.71-4.40 (1H, m), 3.05-2.80 (2H, m), 2.80-2.37 (4H, M).

Example 8(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfinyltetrazol-1-yl) pentanoic acid•t-butylester ##STR1512##

To a solution of the compound prepared in example 5(19) (50 mg) in methanol (2.1 ml) and water (0.4 ml) was added a 20% aqueous solution of titanium (III) chloride (0.2 ml). To the mixture was added dropwise a solution of a 30% aqueous solution of hydrogen peroxide (0.1 ml) in methanol (0.5 ml). The reaction mixture was stirred for 15 min at room temperature. The reaction mixture was quenched by addition of water, and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=4:1→1:1) to give the compound of the present invention (38 mg) having the following physical data.

TLC: Rf 0.39 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.39 (5H, m), 6.05-5.60 (3H, m), 5.19 (2H, s), 4.75 (1H, m), 3.35 (2H, m), 2.98 (1H, m), 2.74 (1H, m), 1.35 (12H, m).

EXAMPLES 8(2)-8(4)

By the same procedure as provided in example 8(1), using the compounds prepared in examples 5(20), 5(22) or 5(23) instead of the compound prepared in example 5(19), compounds of the present invention having the following physical data were obtained.

Example 8(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfinyltetrazol-2-yl) pentanoic acid•t-butylester ##STR1513##

TLC: Rf 0.25 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.39 (5H, m), 6.01 (1H, m), 5.88 (2H, m), 5.18 (2H, s), 4.69 (1H, m), 3.33 (2H, m), 3.03 (1H, m), 2.73 (1H, m), 1.38 (12H, m).

Example 8(3)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfinylmethyl)tetraz ol-2-yl)pentanoic acid•t-butylester ##STR1514##

TLC: Rf 0.12 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.40 (9H, m), 5.98 (1H, d, J=10.0 Hz), 5.82 (1H, m), 5.64 (1H, m), 5.18 (2H, s), 4.65 (1H, m), 4.44 (1H, d, J=17.5 Hz), 4.32 (1H, d, J=17.5 Hz), 3.01 (1H, m), 2.72 (1H, m), 1.42 (9H, m).

Example 8(4)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfinylmethyl)tetraz ol-1-yl)pentanoic acid•t-butylester ##STR1515##

TLC: Rf 0.23 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.40 (9H, m), 6.05-5.68 (3H, m), 5.20 (2H, s), 4.62 (1H, m), 4.40 (1H, m), 4.12 (1H, m), 3.06 (1H, m), 2.79 (1H, m), 1.42 and 1.38 (total 9H, each s).

Example 9(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfonyltetrazol-1-yl) pentanoic acid•t-butylester ##STR1516##

To a solution of the compound prepared in example 5(19) (50 mg) in dichloromethane (3 ml) and chloroform (3 ml) was added 80% m-chloroperbenzoic acid (48 mg) at 0°C The reaction mixture was stirred for 18 h at room temperature. The reaction mixture was quenched by addition of water (10 ml), and extracted with chloroform. The extract was washed with a saturated aqueous solution of sodium hydrocarbonate, water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=4:1→1:1) to give the compound of the present invention (25 mg) having the following physical data.

TLC: Rf 0.69 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.39 (5H, m), 6.01 (1H, m), 5.95 (1H, d, J=16 Hz), 5.74 (1H, d, J=16 Hz), 5.20 (2H, s), 4.73 (1H, m), 3.50 (2H, q, J=7 Hz), 3.00 (1H, dd, J=17.5, 5 Hz), 2.73 (1H, dd, J=17.5, 5 Hz), 1.42 (12H, m).

EXAMPLES 9(2)-9(4)

By the same procedure as provided in example 9(1), using the compounds prepared in examples 5(20), 5(22) or 5(23) instead of the compound prepared in example 5(19), compounds of the present invention having the following physical data were obtained.

Example 9(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfonyltetrazol-2-yl) pentanoic acid•t-butylester ##STR1517##

TLC: Rf 0.73 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.40 (5H, m), 6.00 (1H, d, J=16 Hz), 5.95 (1H, m), 5.80 (1H, d, J=16 Hz), 5.18 (2H, s), 4.69 (1H, m), 3.46 (2H, q, J=7 Hz), 3.05 (1H, dd, J=17.5, 5 Hz), 2.73 (1H, dd, J=17.5, 5 Hz), 1.41 (12H, m).

Example 9(3)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfonylmethyl)tetraz ol-2-yl)pentanoic acid•t-butylester ##STR1518##

TLC: Rf 0.30 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.68 (2H, d, J=9.0 Hz), 7.48 (2H, d, J=9.0 Hz), 7.40 (5H, m), 5.92 (1H, d, J=10.0 Hz), 5.88 (1H, d, J=17.5 Hz), 5.66 (1H, d, J=17.5 Hz), 5.20 (2H, s), 4.70 (2H, s), 4.65 (1H, m), 3.01 (1H, dd, J=17.5 Hz and 5.0 Hz), 2.72 (1H, dd, J=17.5 Hz and 5.0 Hz), 1.42 (9H, s).

Example 9(4)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfonylmethyl)tetraz ol-1-yl)pentanoic acid•t-butylester ##STR1519##

TLC: Rf 0.39 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.60-7.30 (9H, m), 6.10-5.75 (3H, m), 5.20 (2H, s), 4.65 (3H, m), 3.10 (1H, dd, J=17.5 Hz and 5.0 Hz), 2.82 (1H, dd, J=17.5 Hz and 5.0 Hz), 1.42 (9H, s).

EXAMPLES 10(1)-10(8)

By the same procedure as provided in example 6(1), using the compounds prepared in examples 8(1)-8(4) or 9(1)-9(4), compounds of the present invention having the following physical data were obtained.

Example 10(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfinyltetrazol-1-yl) pentanoic acid ##STR1520##

TLC: Rf 0.54 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.90 (1H, m), 7.35 (5H, m), 5.90 (2H, m), 5.10 (2H, s), 4.60 (1H, m), 3.35 (2H, m), 2.70 (2H, m), 1.20 (3H, m).

Example 10(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfonyltetrazol-1-yl) pentanoic acid ##STR1521##

TLC: Rf 0.58 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.90 (1H, m), 7.38 (5H, m), 5.95 (2H, m), 5.10 (2H, s), 4.60 (1H, m), 3.70 (2H, m), 2.70 (2H, m), 1.25 (3H, m).

Example 10(3)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfinyltetrazol-2-yl) pentanoic acid ##STR1522##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.98 (1H, m), 7.35 (5H, m), 6.10 (2H, brs), 5.10 (2H, s), 4.63 (1H, m), 3.35 (2H, m), 2.70 (2H, m), 1.19 (3H, m).

Example 10(4)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-ethylsulfonyltetrazol-2-yl) pentanoic acid ##STR1523##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 8.00 (1H, m), 7.35 (5H, m), 6.15 (2H, brs), 5.10 (2H, s), 4.65 (1H, m), 3.64 (2H, m), 2.74 (2H, m), 1.21 (3H, m).

Example 10(5)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfinylmethyl)tetraz ol-2-yl)pentanoic acid ##STR1524##

TLC: Rf 0.41 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.73 (1H, m), 7.60 (4H, m), 7.38 (5H, m), 5.99 (2H, br), 5.08 (2H, s), 4.60 (3H, m), 2.64 (2H, m).

Example 10(6)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfinylmethyl)tetraz ol-1-yl)pentanoic acid ##STR1525##

TLC: Rf 0.41 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.75 (1H, m), 7.60 (4H, m), 7.38 (5H, m), 5.85 (2H, m), 5.08 (2H, m), 4.90 (1H, m), 4.58 (2H, m), 2.61 (2H, m).

Example 10(7)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfonylmethyl)tetraz ol-2-yl)pentanoic acid ##STR1526##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.73 (4H, m), 7.60 (1H, m), 7.38 (5H, m), 6.01 (2H, br), 5.21 (2H, s), 5.08 (2H, s), 4.55 (1H, m), 2.60 (2H, m).

Example 10(8)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-chlorophenylsulfonylmethyl)tetraz ol-1-yl)pentanoic acid ##STR1527##

TLC: Rf 0.51 (chloroform:methanol:acetic acid=15:1:1); NMR (DMSO-d6): δ 7.79 (5H, m), 7.35 (5H, m), 5.88 (2H, m), 5.40 (2H, m), 5.08 (2H, s), 4.52 (1H, m), 2.65 (2H, m).

Example 11

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trimethylsilyltetrazol-2-yl) pentanoic acid•t-butylester ##STR1528##

To a solution of (S)-N-benzyloxycarbonyl-3-amino-3-methoxycarbonyl propanic acid•t-butylester (1.69 g) in tetrahydrofuran (10 ml) was added dropwise a 2M lithium diisopropylamide [LDA] in heptane/tetrahydrofuran/ethylbenzene solution (2.5 ml) at 0°C under an atmosphere of argon. To the mixture was added dropwise the solution prepared in the mixture of trimethyldiazomethane (in 10% hexane solution, 13.7 g) and 2M lithium diisopropylamide in heptane/tetrahydrofuran/ethylbenzene solution (6 ml) at 0°C under an atmosphere of argon using cannula. The reaction mixture was stirred for 3.5 h at 0°C The mixture was poured into ice water, and extracted with diethylether. The extract was washed with water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=2:1) to give the compound of the present invention (633 mg) having the following physical data.

TLC: Rf 0.55 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.36 (5H, m), 5.97 (1H, m), 5.87 and 5.68 (each 1H, both d, J=17.5 Hz), 5.16 (2H, brs), 4.67 (1H, m), 3.00 (1H, dd, J=16.0, 4.5 Hz), 2.70 (1H, dd, J=16.0, 5.0 Hz), 1.41 (9H, s), 0.39 (9H, s).

Example 12

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-trimethylsilyltetrazol-2-yl) pentanoic acid ##STR1529##

By the same procedure as provided in example 6(1), using the compound prepared in example 11, compound of the present invention having the following physical data was obtained.

TLC: Rf 0.29 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 7.56 (1H, m), 7.34 (5H, m), 5.98 (2H, m), 5.06 (2H, s), 4.52 (1H, m), 2.58 (2H, m), 0.34 (9H, s).

Reference Example 8

N-benzyoxycarbonyl-3-amino-4-oxo-5-(5-(2-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)ethenyl)tetrazol-2-yl)pentanoic acid•t-butylester (1) and N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)ethenyl)tetrazol-1-yl)pentanoic acid•t-butylester (2) ##STR1530##

To a solution of N-benzyloxycarbonyl-3-amino-4-oxo-5-bromopentanoic acid•t-butylester (300 mg) in N,N-dimethylformamide (5 ml) was added potassium carbonate (414 mg) and 5-(2-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)ethenyl)tetrazole (438 mg). The reaction mixture was stirred for 4 h at room temperature. The reaction mixture was quenched by addition of a saturated aqueous solution of sodium hydrocarbonate, and extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=1:1) to give the compound of reference example 8(1) (297 mg) and reference example 8(2) (110 mg), respectively.

Reference Example 8(1)

TLC: Rf 0.61 (hexane:ethyl acetate=1:4); NMR (CDCl3): δ 7.67 (1H, d, J=16 Hz), 7.61 (1H, d, J=16 Hz), 7.38 (5H, m), 7.17 (1H, d, J=1.2 Hz), 7.07 (1H, d, J=1.2 Hz), 5.99 (1H, d, J=8.8 Hz), 5.83 (1H, d, J=18 Hz), 5.67 (1H, d, J=18 Hz), 5.38 (2H, s), 5.19 (2H, s), 4.66 (1H, m), 3.53 (2H, t, J=8.0 Hz), 3.03 (1H, dd, J=4.6, 18 Hz), 2.73 (1H, dd, J=4.8, 18 Hz), 1.43 (9H, s), 0.91 (2H, t, J=8.0 Hz), -0.03 (9H, s).

Reference Example 8(2)

TLC: Rf 0.50 (hexane:ethyl acetate=1:4); NMR (CDCl3): δ 7.83 (1H, d, J=16 Hz), 7.40-7.08 (8H, m), 6.02 (1H, d, J=9.0 Hz), 5.73 (1H, d, J=19 Hz), 5.52 (1H, d, J=19 Hz), 5.38 (2H, s), 5.21 (2H, s), 4.70 (1H, m), 3.51 (2H, t, J=8.2 Hz), 3.06 (1H, dd, J=4.8, 17 Hz), 2.74 (1H, dd, J=4.8, 17 Hz), 1.39 (9H, s), 0.91 (2H, t, J=8.2 Hz), -0.03 (9H, s).

Reference Example 8(3)-8(12)

By the same procedure as provided in reference example 8, using the corresponding tetrazole compound instead of 5-(2-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)ethenyl)tetrazole, the title compounds having the following physical data were obtained.

Reference Example 8(3)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)ethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1531##

TLC: Rf 0.58 (chloroform:t-butanol=10:1); NMR (CDCl3): δ 7.38 (5H, m), 6.94 (1H, d, J=1.2 Hz), 6.90 (1H, d, J=1.2 Hz), 6.29 (1H, d, J=8.6 Hz), 5.71 (1H, d, J=18 Hz), 5.61 (1H, d, J=18 Hz), 5.21 (2H, s), 5.17 (2H, s), 4.60 (1H, m), 3.54-3.38 (4H, m), 3.30-3.18 (2H, m), 2.96 (1H, dd, J=4.6, 17 Hz), 2.75 (1H, dd, J=4.8, 17 Hz), 1.42 (9H, s), 0.90 (2H, t), J=8.2 Hz), -0.02 (9H, s).

Reference Example 8(4)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)ethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1532##

TLC: Rf 0.50 (chloroform:t-butanol=10:1); NMR (CDCl3): δ 7.38 (5H, m), 6.85 (1H, d, J=1.2 Hz), 6.82 (1H, d, J=1.2 Hz), 6.17 (1H, d, J=9.0 Hz), 5.81 (1H, d, J=19 Hz), 5.60 (1H, d, J=19 Hz), 5.20 (2H, s), 5.16 (2H, s), 4.66 (1H, m), 3.44 (2H, t, J=8.2 Hz), 3.30-3.18 (4H, m), 3.03 (1H, dd, J=4.8, 17 Hz), 2.74 (1H, dd, J=4.8, 17 Hz), 1.40 (9H, s), 0.88 (2H, t, J=8.2 Hz), -0.02 (9H, s).

Reference Example 8(5)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)phenylmethyi)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1533##

TLC: Rf 0.45 (chloroform:t-butanol=15:1); NMR (CDCl3): δ 7.70-7.60 (2H, m), 7.40-7.28 (7H, m), 7.12-7.08 (2H, m), 6.04 (1H, m), 5.80-5.74 (2H, m,), 5.25 (2H, s), 5.16 (2H, s), 4.32 (1H, m), 4.32 (2H, s), 3.54 (2H, t, J=8.0 Hz), 3.04-2.62 (2H, m), 1.41 (9H, s), 0.91 (2H, t, J=8.0 Hz), 0.00 (9H, s).

Reference Example 8(6)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)phenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1534##

TLC: Rf 0.38 (chloroform:t-butanol:acetic acid=15:1); NMR (CDCl3): δ 7.86 (1H, m), 7.70-7.60 (2H, m), 7.42-7.28 (7H, m), 7.10 (2H, m), 5.44-5.20 (4H, m), 5.13 (2H, s), 4.64 (1H, m), 4.23 (2H, s), 3.56 (2H, t, J=8.0 Hz), 2.80-2.70 (2H, m), 1.40 (9H, s), 0.93 (2H, t, J=8.0 Hz), 0.00 (9H, s).

Reference Example 8(7)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)phenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1535##

TLC: Rf 0.51 (chloroform:methanol=15:1); NMR (CDCl3): δ 7.73 (2H, d, J=8.2 Hz), 7.40-7.32 (7H, m), 7.12 (1H, d, J=1.4 Hz), 7.09 (1H, d, J=1.4 Hz), 6.02 (1H, d, J=9.2 Hz), 5.78 (1H, d, J=18 Hz), 5.63 (1H, d, J=18 Hz), 5.25 (2H, s), 5.16 (2H, s), 4.64 (1H, m), 4.31 (2H, s), 3.56 (2H, t, J=8.2 Hz), 3.05 (1H, dd, J=4.4, 17 Hz), 2.96 (1H, dd, J=4.4, 17 Hz), 1.42 (9H, s), 0.90 (2H, t, J=8.2 Hz), -0.02 (9H, s).

Reference Example 8(8)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)phenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1536##

TLC: Rf 0.46 (chloroform:methanol=15:1); NMR (CDCl3): δ 7.77 (2H, d, J=8.2 Hz), 7.40-7.29 (7H, m), 7.13 (1H, d, J=1.2 Hz), 7.10 (1H, d, J=1.2 Hz), 5.81 (1H, d, J=9.2 Hz), 5.38 (2H, s), 5.24 (2H, s), 5.14 (2H, s), 4.58 (1H, m), 4.26 (1H, d, J=16 Hz), 4.09 (1H, d, J=16 Hz), 3.58 (2H, t, J=8.2 Hz), 3.07 (1H, dd, J=4.4, 18 Hz), 2.74 (1H, dd, J=4.4, 17 Hz), 1.43 (9H, s), 0.92 (2H, t, J=8.2 Hz), -0.01 (9H, s).

Reference Example 8(9)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)phenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1537##

TLC: Rf 0.51 (chloroform:methanol=15:1); NMR (CDCl3): δ 7.54-7.20 (11H, m), 6.36 (1H, m), 5.80-5.44 (2H, m), 5.15 (2H, s), 5.02-4.96 (2H, m), 4.62 (1H, m), 4.50-4.40 (2H, m), 3.54 (2H, t, J=8.2 Hz), 2.98-2.74 (2H, m), 1.41 (9H, s), 0.90 (2H, t, J=8.2 Hz), 0.00 (9H, s).

Reference Example 8(10)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-yl)phenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1538##

TLC: Rf 0.64 (chloroform:methanol=15:1); NMR (CDCl3): δ 7.62-7.15 (11H, m), 6.90 (1H, m), 5.86-5.46 (2H, m), 5.23-5.20 (4H, m), 4.84 (1H, m), 4.60-4.20 (2H, m), 3.66 (2H, t, J=8.2 Hz), 3.02-2.78 (2H, m), 1.41 (9H, s), 0.98 (2H, t, J=8.2 Hz), 0.02 (9H, s).

Reference Example 8(11)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-ylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1539##

TLC: Rf 0.47 (chloroform:methanol=15:1); NMR (CDCl3): δ 7.40-7.30 (5H, m), 6.95 (2H, br-s), 6.10 (1H, d, J=8.0 Hz), 5.80-5.58 (2H, m), 5.30 (2H, s), 5.15 (2H, s), 4.60 (1H, m), 4.47 (2H, s), 3.48 (2H, t, J=8.2 Hz), 2.96 (1H, dd, J=4.8, 17 Hz), 2.71 (1H, dd, J=5.0, 17 Hz), 1.41 (9H, s), 0.88 (2H, t, J=8.2 Hz), -0.01 (9H, s).

Reference Example 8(12)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(1-(2-(trimethylsilyl) ethoxymethyl)imidazol-2-ylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1540##

TLC: Rf 0.57 (chloroform:methanol=15:1); NMR (CDCl3): δ 7.40-7.30 (5H, m), 6.92 (1H, d, J=1.2 Hz), 6.87 (1H, d, J=1.2 Hz), 6.38 (1H, d, J=8.0 Hz), 5.82 (1H, d, J=18 Hz), 5.82 (1H, d, J=18 Hz), 5.36-5.18 (4H, m), 4.76 (1H, m), 4.40 (2H, s), 3.43 (2H, t, J=8.2 Hz), 2.93 (1H, dd, J=4.6, 17 Hz), 2.72 (1H, dd, J=5.2, 17 Hz), 1.40 (9H, s), 0.87 (2H, t, J=8.2 Hz), -0.02 (9H, s).

Example 13(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(imidazol-2-yl)ethenyl) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1541##

By the same procedure as provided in example 6(1), using the compound prepared in reference example 8(1), compound of the present invention having the following physical data was obtained.

TLC: Rf 0.28 (chloroform:methanol:acetic acid=10:2:1); NMR (DMSO-d6): δ 8.18-8.04 (2H, m), 7.69 (2H, s), 7.63 (1H, d, J=17 Hz), 7.42-7.30 (5H, m), 6.07 (2H, s), 5.10 (2H, s), 4.64 (1H, m), 2.92-2.60 (2H, m).

EXAMPLES 13(2)-13(12)

By the same procedure as provided in reference example 8→example 13(1), and if necessary, by known methods converted to accommodate the corresponding salts, using the corresponding tetrazole compound instead of 5-(2-(1-((2-trimethylsilyl)ethoxymethyl)imidazol-2-yl)ethenyl)tetrazole, compounds of the present invention having the following physical data were obtained.

Example 13(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(imidazol-2-yl)ethenyl) tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1542##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=10:2:1); NMR (DMSO-d6): δ 8.16-8.02 (2H, m), 7.70-7.60 (3H, m), 7.42-7.30 (5H, m), 6.02-5.80 (2H, m), 5.12 (2H, s), 4.84 (1H, m), 3.00-2.60 (2H, m).

Example 13(3)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(imidazol-2-yl)ethyl) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1543##

TLC: Rf 0.29 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 8.02 (1H, m), 7.53 (2H, s), 7.40-7.30 (5H, m), 5.82 (2H, brs), 5.09 (2H, s), 4.60 (1H, m), 3.50-3.40 (4H, m), 2.90-2.60 (2H, m).

Example 13(4)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(imidazol-2-yl)ethyl) tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1544##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 8.10 (1H, d, J=8.6 Hz), 7.52 (2H, s), 7.40-7.30 (5H, m), 5.79 (2H, brs), 5.09 (2H, s), 4.64 (1H, m), 3.42-3.32 (4H, m), 2.92-2.60 (2H, m).

Example 13(5)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-(imidazol-2-yl) phenylmethyl)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1545##

TLC: Rf 0.51 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 8.04-7.96 (3H, m), 7.52-7.28 (9H, m), 5.90 (2H, m), 5.08 (2H, s), 4.60 (1H, m), 4.32 (2H, s), 2.90-2.60 (2H, m).

Example 13(6)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(3-(imidazol-2-yl) phenylmethyl)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1546##

TLC: Rf 0.60 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 8.12 (1H, m), 8.02-7.90 (2H, m), 7.50-7.20 (9H, m), 5.79 (2H, m), 5.09 (2H, s), 4.64 (1H, m), 4.20 (2H, s), 2.90-2.62 (2H, m).

Example 13(7)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(imidazol-2-yl) phenylmethyl)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1547##

TLC: Rf 0.46 (chloroform:methanol:acetic acid=10:4:1); NMR (DMSO-d6): δ 8.18 (2H, d, J=8.6 Hz), 8.04 (1H, d, J=7.8 Hz), 7.77 (2H, s), 7.54 (2H, d, J=8.6 Hz), 7.42-7.26 (5H, m), 5.70 (2H, brs), 5.09 (2H, s), 4.62 (1H, m), 4.39 (2H, brs), 2.90-2.56 (2H, m).

Example 13(8)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-(imidazol-2-yl) phenylmethyl)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1548##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=10:4:1); NMR (DMSO-d6): δ 8.22-8.12 (3H, m), 7.77 (2H, s), 7.52 (2H, d, J=8.6 Hz), 7.42-7.30 (5H, m), 5.86 (2H, brs), 5.10 (2H, s), 4.64 (1H, m), 4.25 (2H, brs), 2.92-2.64 (2H, m).

Example 13(9)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(imidazol-2-yl) phenylmethyl)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1549##

TLC: Rf 0.44 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 8.02 (1H, m), 7.72-7.24 (11H, m), 5.85 (2H, brs), 5.08 (2H, s), 4.62-4.52 (3H, m), 2.88-2.58 (2H, m).

Example 13(10)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(2-(imidazol-2-yl) phenylmethyl)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1550##

TLC: Rf 0.58 (chloroform:methanol:acetic acid=10:3:1); NMR (DMSO-d6): δ 8.12 (1H, m), 7.68-7.30 (11H, m), 5.82 (2H, brs), 5.11 (2H, s), 4.70-4.58 (3H, m), 2.92-2.60 (2H, m).

Example 13(11)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imidazol-2-ylmethyl) tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1551##

TLC: Rf 0.41 (chloroform:methanol:water=10:5:1); NMR (DMSO-d6): δ 8.04 (1H, m), 7.59 (2H, s), 7.40-7.30 (5H, m), 6.01 (2H, brs), 5.08 (2H, s), 4.73 (2H, s), 4.62 (1H, m), 2.92-2.58 (2H, m).

Example 13(12)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(imidazol-2-ylmethyl) tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1552##

TLC: Rf 0.55 (chloroform:methanol:water=10:5:1); NMR (DMSO-d6): δ 8.14 (1H, m), 7.60 (2H, s), 7.40-7.30 (5H, m), 5.91 (2H, brs,), 5.11 (2H, s,), 4.80-4.60 (3H, m), 2.92-2.62 (2H, m).

EXAMPLES 14(1)-14(106)

By the same procedure as provided in example 1, using the corresponding tetrazole compounds and the corresponding bromo compounds instead of N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-bromopentanoi c acid•t-butylester, compounds of the present invention having the following physical data were obtained.

Example 14(1)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazo l-2-yl)pentanoic acid•t-butylester ##STR1553##

TLC: Rf 0.36 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.40-7.12 (8H, m), 6.62 (1H, d, J=9.5 Hz), 5.69 and 5.49 (each 1H, d, J=17.8 Hz), 4.95-4.78 (1H, m), 4.60 (4H, s), 4.19 (2H, s), 2.98 (1H, dd, J=17.5 Hz, 4.4 Hz), 2.66 (1H, dd, J=17.5 Hz, 4.8 Hz), 1.41 (3H, s).

Example 14(2)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazo l-1-yl)pentanoic acid•t-butylester ##STR1554##

TLC: Rf 0.15 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.41-7.15 (8H, m), 6.52 (1H, d, J=9.5 Hz), 5.58 and 5.46 (each 1H, d, J=18.0 Hz), 4.92-4.74 (1H, m), 4.33 and 4.23 (each 1H, d, J=17.5 Hz), 4.22 (2H, s), 3.07 (1H, dd, J=17.5 Hz, 5.0 Hz), 2.75 (1H, dd, J=17.5 Hz, 5.5 Hz), 1.41 (3H, s).

Example 14(3)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1555##

TLC: Rf 0.72 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.45 (2H, d, J=6.8 Hz), 7.35-7.20 (6H, m), 6.61 (1H, d, J=8.8 Hz), 5.67 (1H, d, J=17.8 Hz), 5.48 (1H, d, J=17.8 Hz), 4.90-4.80 (1H, m), 4.19 (2H, s), 2.99 (1H, dd, J=4.4, 17.4 Hz), 2.67 (1H, dd, J=5.0, 17.6 Hz), 1.41 (9H, s).

Example 14(4)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1556##

TLC: Rf 0.57 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.47-7.20 (8H, m), 6.66 (1H, d, J=8.8 Hz), 5.58 (1H, d, J=18.2 Hz), 5.42 (1H, d, J=18.2 Hz), 4.95-4.83 (1H, m), 4.23 (2H, s), 3.06 (1H, dd, J=4.4, 17.6 Hz), 2.73 (1H, dd, J=4.6, 17.6 Hz), 1.44 (9H, s).

Example 14(5)

N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid•t-butylester ##STR1557##

TLC: Rf 0.22 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.37-7.11 (8H, m), 5.80 (1H, d, J=9.4 Hz), 5.65 (1H, d, J=17.9 Hz), 5.44 (1H, d, J=17.9 Hz), 4.61-4.14 (4H, m), 3.05-2.93 (3H, m), 2.65 (1H, dd, J=4.6, 17.2 Hz), 1.41 (9H, s).

Example 14(6)

N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-1-yl)pentanoic acid•t-butylester ##STR1558##

TLC: Rf 0.77 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.39-7.17 (8H, m), 5.74 (1H, d, J=9.0 Hz), 5.59 (1H, d, J=18.8 Hz), 5.43 (1H, d, J=18.8 Hz), 4.54-4.28 (4H, m), 3.14-2.97 (3H, m), 2.73 (1H, dd, J=5.0, 19.0 Hz), 1.42 (9H, s).

Example 14(7)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1559##

TLC: Rf 0.58 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.37-7.09 (8H, m), 6.58 (1H, d, J=8.8 Hz), 5.67 (1H, d, J=17.8 Hz), 5.45 (1H, d, J=17.8 Hz), 4.89-4.80 (1H, m), 4.61 (2H, s), 3.28-3.19 (2H, m), 3.03-2.87 (3H, m), 2.65 (1H, dd, J=4.6, 17.4 Hz), 1.42 (9H, s).

Example 14(8)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1560##

TLC: Rf 0.35 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.15 (8H, m), 6.53 (1H, d, J=8.6 Hz), 5.61 (1H, d, J=18.7 Hz), 5.46 (1H, d, J=18.7 Hz), 4.87-4.78 (1H, m), 4.37 (1H, d, J=14.9 Hz), 4.26 (1H, d, J=18.7 Hz), 3.31-3.23 (2H, m), 3.13-2.90 (3H, m), 2.74 (1H, dd, J=4.9, 17.6 Hz), 1.43 (9H, s).

Example 14(9)

N-(2,6-dichlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol-1 -yl)pentanoic acid•t-butylester ##STR1561##

TLC: Rf 0.50 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.41-7.20 (8H, m), 5.76 (1H, d, J=9.0 Hz), 5.66-5.11 (4H, m), 4.60-4.50 (1H, m), 4.32-4.03 (2H, m), 3.07 (1H, dd, J=4.4, 17.6 Hz), 2.73 (1H, dd, J=4.8, 17.6 Hz), 1.44 (9H, s).

Example 14(10)

N-(2,6-dichlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmet hyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1562##

TLC: Rf 0.44 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.39-7.13 (6H, m), 5.92 (1H, d, J=8.4 Hz), 5.86-5.47 (4H, m), 4.68-4.55 (1H, m), 4.60 (2H, s), 3.03 (1H, dd, J=4.2, 17.0 Hz), 2.71 (1H, dd, J=4.6, 17.0 Hz), 1.40 (9H, s).

Example 14(11)

N-(3-phenylpropyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1563##

TLC: Rf 0.50 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.36-7.13 (8H, m), 5.83 (1H, d, J=8.8 Hz), 5.79 (1H, d, J=17.8 Hz), 5.60 (1H, d, J=17.8 Hz), 4.15 (2H, t, J=6.6 Hz), 2.98 (1H, dd, J=4.7, 17.5 Hz), 2.74-2.63 (3H, m), 2.04-1.94 (2H, m), 1.43 (9H, s).

Example 14(12)

N-(3-phenylpropyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1564##

TLC: Rf 0.24 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.17 (8H, m), 5.77 (1H, d, J=8.6 Hz), 5.72 (1H, d, J=18.8 Hz), 5.57 (1H, d, J=18.8 Hz), 4.37 (1H, d, J=15.6 Hz), 4.26 (1H, d, J=15.6 Hz), 4.19 (2H, t, J=6.6 Hz), 3.11 (1H, dd, J=4.6, 17.4 Hz), 2.82-2.69 (3H, m), 2.08-1.94 (2H, m), 1.43 (9H, s).

Example 14(13)

N-(4-phenylbutyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid•t-butylester ##STR1565##

TLC: Rf 0.51 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.37-7.13 (8H, m), 5.82 (1H, d, J=8.8 Hz), 5.78 (1H, d, J=17.8 Hz), 5.59 (1H, d, J=17.8 Hz), 4.18-4.10 (2H, br), 2.99 (1H, dd, J=4.6, 11.5 Hz), 2.74-2.62 (3H, m), 1.72-1.66 (4H, m), 1.42 (9H, s).

Example 14(14)

N-(4-phenylbutyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-1-yl)pentanoic acid•t-butylester ##STR1566##

TLC: Rf 0.28 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.15 (8H, m), 5.76 (1H, d, J=8.8 Hz), 5.72 (1H, d, J=18.8 Hz), 5.57 (1H, d, J=18.8 Hz), 4.37 (1H, d, J=15.6 Hz), 4.26 (1H, d, J=15.6 Hz), 4.22-4.14 (2H, br), 3.08 (1H, dd, J=4.6, 17.4 Hz), 2.81-2.63 (3H, m), 1.75-1.68 (4H, m), 1.42 (9H, s).

Example 14(15)

N-(2-(thiophen-2-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1567##

TLC: Rf 0.38 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.35 (2H, m), 7.27-7.14 (2H, m), 6.97-6.89 (2H, m), 5.85 (1H, d, J=9.2 Hz), 5.73 (1H, d, J=17.8 Hz), 5.53 (1H, d, J=17.8 Hz), 4.64-4.21 (5H, m), 3.21 (2H, t, J=6.6 Hz), 3.09 (1H, dd, J=4.5, 17.6 Hz), 2.75 (1H, dd, J=4.8, 17.6 Hz), 1.42 (9H, s).

Example 14(16)

N-(2-(thiophen-2-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1568##

TLC: Rf 0.17 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.35 (2H, m), 7.26-7.14 (2H, m), 6.97-6.89 (2H, m), 5.85 (1H, d, J=9.2 Hz), 5.67 (1H, d, J=18.8 Hz), 5.51 (1H, d, J=18.8 Hz), 4.64-4.22 (5H, m), 3.21 (2H, t, J=6.6 Hz), 3.09 (1H, dd, J=4.5, 17.6 Hz), 2.75 (1H, dd, J=4.8, 17.6 Hz), 1.42 (9H, s).

Example 14(17)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1569##

TLC: Rf 0.36 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.37-7.32 (2H, m), 7.21-7.12 (3H, m), 6.86-6.79 (2H, m), 5.82 (1H, d, J=9.2 Hz), 5.69 (1H, d, J=17.9 Hz), 5.49 (1H, d, J=17.9 Hz), 4.61-4.54 (3H, m), 4.45-4.21 (2H, m), 3.73 (3H, s), 3.02-2.86 (3H, m), 2.66 (1H, dd, J=4.6, 17.2 Hz), 1.42 (9H, s).

Example 14(18)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1570##

TLC: Rf 0.19 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.35 (2H, m), 7.26-7.13 (3H, m), 6.88-6.81 (2H, m), 5.76 (1H, d, J=8.4 Hz), 5.62 (1H, d, J=18.8 Hz), 5.45 (1H, d, J=18.8 Hz), 4.64-4.23 (5H, m), 3.74 (3H, s), 2.93 (2H, t, J=7.0 Hz), 3.07 (1H, dd, J=4.4, 17.6 Hz), 2.66 (1H, dd, J=4.6, 17.6 Hz), 1.42 (9H, s).

Example 14(19)

N-(2-(4-fluorophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1571##

TLC: Rf 0.38 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.37-7.31 (2H, m), 7.21-7.13 (3H, m), 7.02-6.94 (2H, m), 5.81 (1H, d, J=8.6 Hz), 5.71 (1H, d, J=17.8 Hz), 5.53 (1H, d, J=17.8 Hz), 4.61-4.55 (3H, m), 4.43-4.23 (2H, m), 3.01-2.89 (3H, m), 2.66 (1H, dd, J=4.9, 17.6 Hz), 1.42 (9H, s).

Example 14(20)

N-(2-(4-fluorophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1572##

TLC: Rf 0.17 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.35 (2H, m), 7.24-7.16 (3H, m), 7.05-6.95 (2H, m), 5.76 (1H, d, J=8.4 Hz), 5.66 (1H, d, J=18.8 Hz), 5.51 (1H, d, J=18.8 Hz), 4.65-4.55 (1H, m), 4.43-4.23 (4H, m), 3.12-2.93 (3H, m), 2.74 (1H, dd, J=4.7, 17.5 Hz), 1.42 (9H, s).

Example 14(21)

N-(2-(phenylmethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1573##

TLC: Rf 0.40 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.36-7.13 (8H, m), 5.95 (1H, d, J=8.7 Hz), 5.79 (1H, d, J=18.0 Hz), 5.57 (1H, d, J=18.0 Hz), 4.66-4.57 (5H, m), 4.37-4.27 (2H, m), 3.69 (2H, t, J=4.6 Hz), 3.01 (1H, dd, J=4.2, 17.5 Hz), 2.67 (1H, dd, J=4.3, 17.5 Hz), 1.42 (9H, s).

Example 14(22)

N-(2-(phenylmethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1574##

TLC: Rf 0.22 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.18 (8H, m), 5.90 (1H, d, J=8.8 Hz), 5.71 (1H, d, J=18.8 Hz), 5.56 (1H, d, J=18.8 Hz), 4.65-4.56 (3H, m), 4.38-4.21 (4H, m), 3.73 (2H, t, J=4.4 Hz), 3.14 (1H, dd, J=4.2, 17.7 Hz), 2.75 (1H, dd, J=4.8, 17.7 Hz), 1.42 (9H, s).

Example 14(23)

N-(2-(4-dimethylaminophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1575##

TLC: Rf 0.60 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.36-7.07 (5H, m), 6.65 (2H, d, J=8.8 Hz), 5.80 (1H, d, J=10.2 Hz), 5.67 (1H, d, J=17.8 Hz), 5.45 (1H, d, J=17.8 Hz), 4.60 (2H, s), 4.62-4.55 (1H, m), 4.50-4.18 (2H, m), 2.94-2.60 (4H, m), 2.84 (6H, s), 1.41 (9H, s).

Example 14(24)

N-(2-(4-dimethylaminophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1576##

TLC: Rf 0.41 (benzene:diethylether=2:1); NMR (CDCl3): δ 7.38-7.07 (5H, m), 6.68 (2H, d, J=8.8 Hz), 5.80 (1H, d, J=10.2 Hz), 5.67 (1H, d, J=17.8 Hz), 5.45 (1H, d, J=17.8 Hz), 4.60 (2H, s), 4.62-4.55 (1H, m), 4.50-4.18 (2H, m), 2.94-2.60 (4H, m), 2.84 (6H, s), 1.41 (9H, s).

Example 14(25)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1577##

NMR (CDCl3): δ 7.49 (1H, d, J=8.8 Hz), 7.40 (1H, d, J=8.8 Hz), 7.36-7.22 (5H, m), 6.64 (1H, d, J=8.8 Hz), 5.70 (1H, d, J=17.8 Hz), 5.50 (1H, d, J=17.8 Hz), 4.87 (1H, m), 4.20 (2H, s), 2.99 (1H, dd, J=17.4 Hz, 4.5 Hz), 2.68 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.41 (9H, s).

Example 14(26)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1578##

NMR (CDCl3): δ 7.51 (1H, d, J=8.7 Hz), 7.40 (1H, d, J=8.7 Hz), 7.39-7.23 (5H, m), 6.67 (1H, d, J=8.4 Hz), 5.61 (1H, d, J=18.5 Hz), 5.51 (1H, d, J=18.5 Hz), 4.92 (1H, m), 4.24 (2H, s), 3.08 (1H, dd, J=17 Hz, 4.0 Hz), 2.73 (1H, dd, J=17 Hz, 4.8 Hz), 1.44 (9H, s).

Example 14(27)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1579##

TLC: Rf 0.53 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.36-7.22 (7H, m), 6.64 (1H, d, J=8.5 Hz), 5.68 (1H, d, J=17.8 Hz), 5.49 (1H, d, J=17.8 Hz), 4.88 (1H, m), 4.20 (2H, s), 2.98 (1H, dd, J=17.3 Hz, 4.4 Hz), 2.67 (1H, dd, J=17.3 Hz, 4.7 Hz), 2.34 (3H, s), 1.41 (9H, s).

Example 14(28)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1580##

TLC: Rf 0.41 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.23 (7H, m), 6.69 (1H, d, J=8.7 Hz), 5.58 (1H, d, J=18.4 Hz), 5.42 (1H, d, J=18.4 Hz), 4.91 (1H, m), 4.24 (2H, s), 3.07 (1H, dd, J=17.5 Hz, 4.3 Hz), 2.72 (1H, dd, J=17.5 Hz, 4.7 Hz), 2.34 (3H, s), 1.43 (9H, s).

Example 14(29)

N-(3-phenylpropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid•t-butylester ##STR1581##

TLC: Rf 0.54 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.36-7.13 (8H, m), 6.59 (1H, d, J=8.8 Hz), 5.77 (1H, d, J=17.8 Hz), 5.57 (1H, d, J=17.8 Hz), 4.91-4.82 (1H, m), 4.60 (2H, s), 3.04-2.91 (3H, m), 2.75-2.62 (3H, m), 2.05-1.90 (2H, m), 1.42 (9H, s).

Example 14(30)

N-(3-phenylpropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-1-yl)pentanoic acid•t-butylester ##STR1582##

TLC: Rf 0.24 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.17 (8H, m), 6.53 (1H, d, J=8.6 Hz), 5.68 (1H, d, J=18.7 Hz), 5.54 (1H, d, J=18.7 Hz), 4.89-4.81 (1H, m), 4.38 (1H, d, J=16.3 Hz), 4.27 (1H, d, J=16.3 Hz), 3.31-2.97 (3H, m), 2.82-2.70 (3H, m), 2.07-1.93 (2H, m), 1.43 (9H, s).

Example 14(31)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophen ylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1583##

TLC: Rf 0.38 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.41-7.16 (5H, m), 6.72 (2H, s), 6.66 (1H, d, J=8.6 Hz), 5.66 (1H, d, J=17.6 Hz), 5.48 (1H, d, J=17.6 Hz), 4.95-4.76 (1H, m), 4.19 (2H, s), 2.99 (6H, s), 2.97 (1H, dd, J=17.2 and 4.6 Hz), 2.68 (1H, dd, J=17.2 and 4.8 Hz), 1.41 (9H, s).

Example 14(32)

N-benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminopheny lthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1584##

TLC: Rf 0.28 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.43-7.18 (5H, m), 6.70 (2H, s), 6.76-6.60 (1H, m), 5.55 (1H, d, J=18.2 Hz), 5.37 (1H, d, J=18.2 Hz), 4.99-4.80 (1H, m), 4.24 (2H, s), 3.15-2.96 (2H, m), 2.99 (6H, s), 2.71 (1H, dd, J=17.4 and 4.8 Hz), 1.43 (9H, s).

Example 14(33)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylythi o)tetrazol-2-tl)pentanoic acid•t-butylester ##STR1585##

TLC: Rf 0.58 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.49 (1H, d, J=8.8 Hz), 7.40 (1H, d, J=8.8 Hz), 7.30-7.21 (5H, m), 6.62 (1H, d, J=9 Hz), 5.68 (1J=17.8 Hz), 5.46 (1H, d, J=17.8 Hz), 4.84 (1H, m), 3.30-3.13 (2H, m), 3.05-2.90 (3H, m), 2.80-2.61 (1H, m), 1.42 (9H, s).

Example 14(34)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio )tetrazol-1-yl)pentanoic acid•t-butylester ##STR1586##

TLC: Rf 0.47 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.52 (1H, d, J=8.8 Hz), 7.40 (1H, d, J=8.8 Hz), 7.35-7.19 (5H, m), 6.65 (1H, d, J=8.7 Hz), 5.61 (1H, d, J=18.5 Hz), 5.43 (1H, d, J18.5 Hz), 4.91 (1H, m), 3.33-3.25 (2H, m), 3.09 (1H, dd, J=17.6 Hz, 4.7 Hz), 3.01-2.93 (2H, m), 2.72 (1H, dd, J=17.6 Hz, 4.7 Hz), 1.45 (9H, s).

Example 14(35)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphen ylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1587##

TLC: Rf 0.56 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.32-7.14 (7H, m), 6.60 (1H, d, J=7.0 Hz), 5.65 (1H, d, J=17.9 Hz), 5.44 (1H, d, J=17.9 Hz), 4.83 (1H, m), 3.29-3.20 (2H, m), 3.04-2.89 (3H, m), 2.65 (1H, dd, J=17.4 Hz, 4.7 Hz), 2.35 (3H, s), 1.42 (9H, s).

Example 14(36)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphen ylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1588##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.31-7.19 (7H, m), 6.64 (1H, d, J=8.8 Hz), 5.58 (1H, d, J=18.5 Hz), 5.39 (1H, d, J=18.5 Hz), 4.90 (1H, m), 3.33-3.24 (2H, m), 3.12-2.93 (3H, m), 2.71 (1H, dd, J=17.5 Hz, 4.8 Hz), 2.34 (3H, s), 1.44 (9H, s).

Example 14(37)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophen ylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1589##

TLC: Rf 0.65 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.36-7.18 (5H, m), 6.63 (2H, d, J=8.8 Hz), 6.49 (2H, s), 5.64 (1H, d, J=18 Hz), 5.45 (1H, d, J=18 Hz), 4.85 (1H, m), 4.18 (2H, s), 3.01-2.89 (7H, m), 2.65 (1H, dd, J=4.6, 17 Hz), 2.44 (6H, s), 1.40 (9H, s).

Example 14(38)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophen ylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1590##

TLC: Rf 0.50 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.40-7.20 (5H, m), 6.58 (2H, d, J=8.8 Hz), 6.49 (2H, s), 5.41 (1H, d, J=18 Hz), 5.24 (1H, d, J=18 Hz), 4.83 (1H, m), 4.23 (2H, s), 3.05-2.94 (7H, m), 2.67 (1H, dd, J=4.6, 17 Hz), 2.37 (6H, s), 1.43 (9H, s).

Example 14(39)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio )tetrazol-2-yl)pentanoic acid•t-butylester ##STR1591##

TLC: Rf 0.61 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.37-7.19 (5H, m), 7.16 (2H, s), 6.62 (1H, d, J=8.8 Hz), 5.65 (1H, d, J=17.7 Hz), 5.46 (1H, d, J=17.7 Hz), 4.94-4.78 (1H, m), 4.19 (2H, s), 2.98 (1H, dd, J=17.5, 4.3 Hz), 2.65 (1H, dd, J=17.5, 4.7 Hz), 2.48 (6H, s), 1.41 (9H, s), 1.30 (9H, s).

Example 14(40)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio )tetrazol-1-yl)pentanoic acid•t-butylester ##STR1592##

TLC: Rf 0.47 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.42-7.13 (7H, m), 6.75-6.59 (1H, m), 5.48 (1H, d, J=18.5 Hz), 5.30 (1H, d, J=18.5 Hz), 4.92-4.76 (1H, m), 4.24 (2H, s), 3.04 (1H, dd, J=17.5, 4.3 Hz), 2.68 (1H, dd, J=17.5, 4.5 Hz), 2.41 (3H, s), 1.43 (9H, s), 1.30 (9H, s).

Example 14(41)

N-(2-(pyridin-2-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1593##

TLC: Rf 0.33 (hexane:ethyl acetate=1:2); NMR (CDCl3): δ 8.53 (1H, d, J=5.0 Hz), 7.64-7.56 (1H, m), 7.36-7.08 (5H, m), 5.85 (1H, d, J=9.2 Hz), 5.74 (1H, d, J=17.8 Hz), 5.53 (1H, d, J=17.8 Hz), 4.68-4.42 (5H, m), 3.14 (2H, t, J=6.4 Hz), 2.97 (1H, dd, J=4.0, 17.4 Hz), 2.67 (1H, dd, J=5.0, 17.4 Hz), 1.40 (9H, s).

Example 14(42)

N-(2-(pyridin-2-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1594##

TLC: Rf 0.22 (hexane:ethyl acetate=1:2); NMR (CDCl3): δ 8.55 (1H, d, J=5.0 Hz), 7.68-7.60 (1H, m), 7.39-7.12 (5H, m), 5.82 (1H, d, J=8.0 Hz), 5.69 (1H, d, J=18.8 Hz), 5.53 (1H, d, J=18.8 Hz), 4.75-4.45 (3H, m), 4.40-4.20 (2H, m), 3.17 (2H, t, J=6.6 Hz), 3.13-3.02 (1H, m), 2.75 (1H, dd, J=4.8, 17.4 Hz), 1.41 (9H, s).

Example 14(43)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylam inophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1595##

TLC: Rf 0.79 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.38-7.06 (5H, m), 6.73 (2H, s), 6.57 (1H, d, J=8.4 Hz), 5.63 (1H, d, J=17.8 Hz), 5.43 (1H, d, J=17.8 Hz), 4.92-4.72 (1H, m), 3.36-3.12 (2H, m), 3.12-3.09 (3H, m), 2.99 (6H, s), 2.65 (1H, dd, J=17.4 and 4.6 Hz), 1.42 (9H, s).

Example 14(44)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylam inophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1596##

TLC: Rf 0.67 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.41-7.09 (5H, m), 6.70 (2H, s), 6.63 (1H, d, J=8.6 Hz), 5.54 (1H, d, J=18.4 Hz), 5.34 (1H, d, J=18.4 Hz), 4.98-4.74 (1H, m), 3.38-3.15 (2H, m), 3.15-2.80 (3H, m), 2.99 (6H, s), 2.69 (1H, dd, J=17.6 and 4.8 Hz), 1.44 (9H, s).

Example 14(45)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichloro phenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1597##

TLC: Rf 0.46 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.49 (1H, d, J=8.7 Hz), 7.39 (1H, d, J=8.7 Hz), 7.15 (2H, d, J=8.7 Hz), 6.83 (2H, d, J=8.7 Hz), 5.82 (1H, d, J=9.2 Hz), 5.73-5.44 (2H, m), 4.58 (1H, m), 4.48-4.22 (2H, m), 3.74 (3H, s), 3.00 (1H, dd, J=17 Hz, 5 Hz), (2H, t, J=6.9 Hz), 2.66 (1H, dd, J=17 Hz, 4.7 Hz), 1.42 (9H, s).

Example 14(46)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichloro phenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1598##

TLC: Rf 0.38 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.51 (1H, d, J=8.8 Hz), 7.39 (1H, d, J=8.8 Hz), 7.16 (2H, d, J=8.6 Hz), 6.85 (2H, d, J=8.6 Hz), 5.86 (1H, d, J=9.4 Hz), 5.66-5.38 (2H, m), 4.63 (1H, m), 4.51-4.26 (2H, m), 3.75 (3H, s), 3.08 (1H, dd, J=18 Hz, 4.0 Hz), 2.93 (2H, t, 6.9 Hz), 2.70 (1H, dd, J=18 Hz, 4.6 Hz), 1.43 (9H, s).

Example 14(47)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- methylphenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1599##

TLC: Rf 0.41 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.21 (2H, s), 7.08 (2H, d, J=8.4 Hz), 6.77 (2H, d, J=8.4 Hz), 5.74 (1H, d, J=9.5 Hz), 5.65-5.36 (2H, m), 4.51 (1H, m), 4.42-416 (2H, m), 3.68 (3H, s), 2.98-2.81 (3H, m), 2.64 (1H, dd, J=17 Hz, 4.8 Hz), 2.28 (3H, s), 1.36 (9H, s).

Example 14(48)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- methylphenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1600##

TLC: Rf 0.33 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.27 (2H, s), 7.17 (2H, d, J=8.7 Hz), 6.85 (2H, d, J=8.7 Hz), 5.88 (1H, d, J=9.2 Hz), 5.65-5.36 (2H, m), 4.63 (1H, m), 4.51-4.26 (2H, m), 3.75 (3H, s), 3.06 (1H, dd, J=17.6 Hz, 4.2 Hz), 2.93 (2H, t, J=7.0 Hz), 2.70 (1H, dd, J=17.6 Hz, 4.7 Hz), 2.34 (3H, s), 1.44 (9H, s).

Example 14(49)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1601##

TLC: Rf 0.79 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.14 (2H, d, J=8.5 Hz), 6.83 (2H, d, J=8.5 Hz), 6.72 (2H, s), 5.81 (1H, d, J=9 Hz), 5.62-5.42 (2H, m), 4.57 (1H, m), 4.47-4.21 (2H, m), 3.74 (3H, s), 2.99 (6H, s), 2.90 (3H, m), 2.66 (1H, dd, J=17 Hz, 4.5 Hz), 1.42 (9H, s).

Example 14(50)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1602##

TLC: Rf 0.69 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.16 (2H, d, J=8.4 Hz), 6.85 (2H, d, J=8.4 Hz), 6.70 (2H, s), 5.88 (1H, d, J=9 Hz), 5.61-5.32 (2H, m), 4.62 (1H, m), 4.50-4.26 (2H, m), 3.75 (3H, s), 3.09-2.90 (3H, m), 2.99 (6H, s), 2.70 (1H, dd, J=17 Hz, 4.4 Hz), 1.44 (9H, s).

Example 14(51)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4- dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1603##

TLC: Rf 0.61 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.13 (2H, d, J=8.6 Hz), 6.81 (2H, d, J=8.6 Hz), 6.49 (2H, s), 5.81 (1H, d, J=9.0 Hz), 5.61 (1H, d, J=17.9 Hz), 5.41 (1H, d, J=17.9 Hz), 4.63-4.15 (3H, m), 3.73 (3H, s), 3.05-2.80 (3H, m), 2.96 (6H, s), 2.64 (1H, dd, J=17.3, 4.7 Hz), 2.44 (6H, s), 1.42 (9H, s).

Example 14(52)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4- dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1604##

TLC: Rf 0.45 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.16 (2H, d, J=8.7 Hz), 6.84 (2H, d, J=8.7 Hz), 6.49 (2H, s), 5.84 (1H, d, J=9.2 Hz), 5.41 (1H, d, J=18.4 Hz), 5.20 (1H, d, J=18.4 Hz), 4.63-4.20 (3H, m), 3.73 (3H, s), 3.05-2.85 (3H, m), 2.97 (6H, s), 2.65 (1H, dd, J=17.5, 4.8 Hz), 2.38 (6H, s), 1.43 (9H, s).

Example 14(53)

N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichloro phenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1605##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.49 (1H, d, J=8.8 Hz), 7.39 (1H, d, J=8.8 Hz), 7.09 (2H, d, J=8.5 Hz), 6.82 (2H, d, J=8.5 Hz), 5.80 (1H, d, J=17.9 Hz), 5.80 (1H, m), 5.61 (1H, d, J=17.9 Hz), 4.64 (1H, m), 4.14 (2H, m), 3.78 (3H, s), 3.01 (1H, dd, J=17.5 Hz, 4.4 Hz), 2.69 (1H, dd, J=17.5 Hz, 4.8 Hz), 2.59 (2H, m), 1.65 (4H, m), 1.42 (9H, s).

Example 14(54)

N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichloro phenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1606##

TLC: Rf 0.34 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.52 (1H, d, J=8.8 Hz), 7.40 (1H, d, J=8.8 Hz), 7.10 (2H, d, J=8.4 Hz), 6.83 (2H, d, J=8.4 Hz), 5.88 (1H, d, J=8.4 Hz), 5.73 (1H, d, J=8.4 Hz), 5.56 (1H, d, J=18.9 Hz), 4.68 (1H, m), 4.19 (2H, m), 3.78 (3H, s), 3.10 (1H, dd, J=17.6 Hz, 4.4 Hz), 2.74 (1H, dd, J=17.6 Hz, 4.8 Hz), 2.61 (2H, m), 1.69 (4H, 1.45 (9H, s).

Example 14(55)

N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1607##

TLC: Rf 0.35 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.09 (2H, d, J=8.6 Hz), 6.82 (2H, d, J=8.6 Hz), 6.72 (2H, s), 5.81 (1H, m), 5.75 (1H, d, J=17.8 Hz), 5.57 (1H, d, J=17.8 Hz), 4.60 (1H, m), 4.14 (2H, m), 3.78 (3H, s), 2.99 (6H, s), 2.95 (1H, m), 2.74-2.66 (1H, m), 2.59 (2H, m), 1.67 (4H, m), 1.42 (9H, s).

Example 14(56)

N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1608##

TLC: Rf 0.24 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.10 (2H, d, J=8.6 Hz), 6.82 (2H, d, J=8.6 Hz), 6.70 (2H, s), 5.88 (1H, m), 5.66 (1H, d, J=18.4 Hz), 5.47 (1H, d, J=18.4 Hz), 4.65 (1H, m), 4.14 (2H, m), 3.78 (3H, s), 3.05 (1H, dd, J=17.2 Hz, 4.4 Hz), 2.99 (6H, s), 2.72 (1H, dd, J=17.2 Hz, 4.8 Hz), 2.59 (2H, m), 1.69 (4H, m), 1.44 (9H, s).

Example 14(57)

N-(2-(4-methylthiazol-5-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1609##

TLC: Rf 0.60 (hexane:ethyl acetate=1:2); NMR (CDDl3): δ 8.59 (1H, s), 7.48-7.28 (3H, m), 5.99 (1H, m), 5.76 (1H, d, J=17.8 Hz), 5.59 (1H, d, J=17.8 Hz), 4.64 (1H, m), 4.29 (2H, t, J=6.6 Hz), 3.12 (2H, t, J=6.6 Hz), 2.97 (1H, dd, J=18 Hz, 4.4 Hz), 2.71 (1H, dd, J=18 Hz, 5.0 Hz), 2.41 (3H, s), 1.42 (9H, s).

Example 14(58)

N-(2-(4-methylthiazol-5-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1610##

TLC: Rf 0.51 (hexane:ethyl acetate=1:2); NMR (CDCl3): δ 8.60 (1H, s), 7.48-7.27 (3H, m), 5.99 (1H, m), 5.69 (1H, d, J=18.2 Hz), 5.52 (1H, d, J=18.2 Hz), 4.66 (1H, m), 4.36 (2H, t, J=6.2 Hz), 3.16 (2H, t, J=6.2 Hz), 3.08 (1H, dd, J=17.6 Hz, 4.4 Hz), 2.74 (1H, dd, J=17.6 Hz, 5.0 Hz), 2.44 (3H, s), 1.45 (9H, s).

Example 14(59)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-2-yl)pentanoic acid•t-butylester ##STR1611##

TLC: Rf 0.49 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.47-7.43 (2H, m), 7.34-7.14 (6H, m), 6.57 (1H, d, J=8.8 Hz), 5.66 (1H, d, J=17.8 Hz), 5.44 (1H, d, J=17.8 Hz), 4.82 (1H, m), 3.29-3.20 (2H, m), 3.04-2.89 (3H, m), 2.65 (1H, dd, J=17.4 Hz, 4.6 Hz), 1.42 (9H, s).

Example 14(60)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-1-yl)pentanoic acid•t-butylester ##STR1612##

TLC: Rf 0.35 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.36-7.18 (6H, m), 6.64 (1H, d, J=8 (Hz), 5.60 (1H, d, J=18.6 Hz), 5.41 (1H, d, J=18.6 Hz), 4.89 (1H, m), 3.31-3.24 (2H, m), 3.12-2.93 (3H, m), 2.70 (1H, dd, J=17 Hz, 4.6 Hz), 1.45 (9H, s).

Example 14(61)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(4-(pyrrolidin-1-ylmethyl) phenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1613##

TLC: Rf 0.45 (chloroform:methanol=9:1), NMR (CDCl3): δ 7.62 (2H, d, J=8.8 Hz), 7.55 (2H, d, J=8.8 Hz), 7.38-7.10 (5H, m), 6.79 (1H, d, J=8.4 Hz), 5.78 (1H, d, J=17.7 Hz), 5.57 (1H, d, J=17.7 Hz), 4.98-4.83 (1H, m), 4.13 (2H, s), 3.30-2.63 (10H, m), 2.23-2.00 (4H, m), 1.44 (9H, s).

Example 14(62)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(4-(pyrrolidin-1-ylmethyl) phenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1614##

TLC: Rf 0.43 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.62 (2H, d, J=8.3 Hz), 7.51 (2H, d, J=8.3 Hz), 7.41-7.10 (6H, m), 5.68 (1H, d, J=18.6 Hz), 5.45 (1H, d, J=18.6 Hz), 4.98-4.80 (1H, m), 4.30 (1H, d, J=12.7 Hz), 3.94 (1H, d, J=12.7 Hz), 3.33-2.66 (10H, m), 2.30-2.00 (4H, m), 1.41 (9H, s).

Example 14(63)

N-(2-(4-methylthiazol-5-yl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1615##

TLC: Rf 0.67 (hexane:ethyl acetate=1:2); NMR (CDCl3): δ 8.58 (1H, s), 7.47-7.41 (2H, m), 7.34-7.24 (2H, m), 6.69 (1H, d, J=8.8 Hz), 5.74 (1H, d, J=17.6 Hz), 5.56 (1H, d, J=17.6 Hz), 4.86 (1H, m), 3.14 (4H, m), 2.98 (1H, dd, J=17.6 Hz, 4.4 Hz), 2.69 (1H, dd, J=17.6 Hz, 4.8 Hz), 2.43 (1H, s), 1.43 (9H, s).

Example 14(64)

N-(2-(4-methylthiazol-5-yl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1616##

TLC: Rf 0.58 (hexane:ethyl acetate=1:2); NMR (CDCl3): δ 8.59 (1H, s), 7.48-7.43 (2H, m), 7.37-7.27 (2H, m), 6.83 (1H, d, J=8.8 Hz), 5.67 (1H, d, J=18.6 Hz), 5.50 (1H, d, J=18.6 Hz), 492 (1H, m), 3.18 (4H, m), 3.05 (1H, dd, J=17.4 Hz, 4.6 Hz), 2.76 (1H, dd, J=17.4 Hz, 5.0 Hz), 2.44 (1H, s), 1.43 (9H, s).

Example 14(65)

N-(butylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1617##

TLC: Rf 0.68 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.37-7.16 (3H, m), 6.50 (1H, d, J=9.0 Hz), 5.67 (1H, d, J=17.8 Hz), 5.47 (1H, d, J=17.8 Hz), 4.76 (1H, m), 2.89 (1H, dd, J=17.4 Hz, 4.8 Hz), 2.86 (2H, t, J=7.2 Hz), 2.59 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.57 (2H, m), 1.34 (2H, m), 1.33 (9H, s), 0.83 (3H, t, J=7.2 Hz).

Example 14(66)

N-(butylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1618##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.39-7.18 (3H, m), 6.59 (1H, d, J=8.6 Hz), 5.61 (1H, d, J=18.2 Hz), 5.44 (1H, d, J=18.2 Hz), 4.85 (1H, m), 3.00 (1H, dd, J=17.4 Hz, 4.6 Hz), 2.93 (2H, t, J=7.3 Hz), 2.66 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.58 (2H, m), 1.41 (2H, m), 1.37 (9H, s), 0.86 (3H, t, J=7.3 Hz).

Example 14(67)

N-(2-(4-methoxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1619##

TLC: Rf 0.39 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.34-7.29 (1H, m), 7.14 (2H, d, J=8.6 Hz), 6.83 (2H, d, J=8.6 Hz), 6.58 (1H, d, J=8.6 Hz), 5.70 (1H, d, J=17.8 Hz), 5.49 (1H, J=17.8 Hz), 4.85 (1H, m), 3.75 (3H, s), 3.23-3.09 (2H, m), 3.04-2.86 (3H, m), 2.66 (1H, dd, J=18 Hz, 4.6 Hz), 1.42 (9H, s).

Example 14(68)

N-(2-(4-methoxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1620##

TLC: Rf 0.27 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.36-7.28 (1H, m), 7.16 (2H, d, J=8.8 Hz), 6.84 (2H, d, J=8.8 Hz), 6.13 (1H, d, J=8.8 Hz), 5.63 (1H, d, J=18.4 Hz), 5.45 (1H, d, J=18.4 Hz), 4.90 (1H, m), 3.76 (3H, s), 3.24 (2H, m), 3.07 (1H, dd, J=18 Hz, 4.4 Hz), 2.92 (2H, m), 2.71 (1H, dd, J=18 Hz, 4.6 Hz), 1.45 (9H, s).

Example 14(69)

N-(3-(pyrimidin-2-yl)propyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1621##

HPTLC: Rf 0.51 (chloroform:t-butanol=20:1); NMR (CDCl3): δ 8.66 (2H, d, J=5.0 Hz), 7.44 (2H, d, J=6.5 Hz), 7.30 (1H, m), 7.14 (1H, t, J=5.0 Hz), 5.92-5.56 (3H, m), 4.60 (1H, m), 4.22 (2H, t, J=6.0 Hz), 3.13-2.85 (3H, m), 2.69 (1H, dd, J=17.0, 5.0 Hz), 2.22 (2H, m), 1.44 (9H, s).

Example 14(70)

N-(3-(pyrimidin-2-yl)propyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1622##

HPTLC: Rf 0.45 (chloroform:t-butanol=20:1); NMR (CDCl3): δ 8.78 (2H, d, J=5.0 Hz), 7.45 (2H, d, J=7.0 Hz), 7.32 (1H, m), 7.15 (1H, t, J=5.0 Hz), 5.93 (1H, d, J=8.5 Hz), 5.75 and 5.59 (each 1H, each d, J=18.0 Hz), 4.66 (1H, m), 4.28 (2H, t, J=6.5 Hz), 3.10 (3H, m), 2.74 (1H, dd, J=17.0, 5.0 Hz), 2.25 (2H, m), 1.46 (9H, s).

Example 14(71)

N-(2-(4-acetylaminophenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1623##

TLC: Rf 0.66 (hexane:ethyl acetate=3:7); NMR (CDCl3): δ 7.53-7.08 (8H, m), 6.58 (1H, d, J=8.6 Hz), 5.64 (1H, d, J=17.7 Hz), 5.44 (1H, d, J=17.7 Hz), 4.86-4.73 (1H, m), 3.30-2.55 (6H, m), 2.14 (3H, s), 1.42 (9H, s).

Example 14(72)

N-(2-(4-acetylaminophenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1624##

TLC: Rf 0.57 (hexane:ethyl acetate=3:7); NMR (CDCl3): δ 7.54 (1H, s), 7.50-7.23 (5H, m), 7.17 (2H, d, J=8.4 Hz),6.82 (1H, d, J=8.4 Hz), 5.59 (1H, d, J=18.5 Hz), 5.38 (1H, d, J=18.5 Hz), 4.95-4.81 (1H, m), 3.40-2.62 (6H, m), 2.10 (3H, s), 1.44 (9H, s).

Example 14(73)

N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1625##

TLC: Rf 0.48 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.47-7.43 (2H, m), 7.34-7.27 (1H, m), 5.80 (1H, d, J=18.0 Hz), 5.79 (1H, m), 5.61 (1H, d, J=18.0 Hz), 4.62 (1H, m), 4.14 (2H, m), 2.99 (1H, dd, J=17.4 Hz, 4.6 Hz), 2.70 (1H, dd, J=17.4 Hz, 5.0 Hz), 1.64 (2H, m), 1.43 (9H, s), 1.37 (2H, m), 0.94 (3H, t, J=7.4 Hz).

Example 14(74)

N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1626##

TLC: Rf 0.38 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.36-7.27 (1H, m), 5.89 (1H, d, J=8.8 Hz), 5.73 (1H, d, J=18.4 Hz), 5.55 (1H, d, J=18.4 Hz), 4.68 (1H, m), 4.20 (2H, m), 3.08 (1H, dd, J=17.6 Hz, 4.4 Hz), 2.75 (1H, dd, J=17.6 Hz, 5.0 Hz), 1.63 (2H, m), 1.45 (9H, s), 1.41 (2H, m), 0.96 (3H, t, J=7.2 Hz).

Example 14(75)

N-(propylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1627##

TLC: Rf 0.57 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.50-7.21 (3H, m), 6.59 (1H, d, J=8.6 Hz), 5.77 (1H, d, J=17.6 Hz), 5.57 (1H, d, J=17.6 Hz), 4.92-4.78 (1H, m), 3.08-2.87 (3H, m), 2.69 (1H, dd, 17.5, 4.7 Hz), 1.80-1.55 (2H, m), 1.43 (9H, s), 1.00 (3H, t, J=7.3 Hz).

Example 14(76)

N-(propylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1628##

TLC: Rf 0.43 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.50-7.25 (3H, m), 6.65 (1H, d, J=8.8 Hz), 5.69 (1H, d, J=18.2 Hz), 5.51 (1H, d, J=18.2 Hz), 5.00-4.85 (1H, m), 3.16-2.93 (3H, m), 2.74 (1H, dd, 17.5, 4.9 Hz), 1.81-1.57 (2H, m), 1.45 (9H, s), 1.02 (3H, t, J=7.3 Hz).

Example 14(77)

N-(isopropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1629##

TLC: Rf 0.34 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.50-7.23 (3H, m), 6.52 (1H, d, J=8.8 Hz), 5.78 (1H, d, J=17.7 Hz), 5.58 (1H, d, J=7.7 Hz), 4.92-4.78 (1H, m), 3.69 (1H, sep, J=6.8 Hz), 2.99 (1H, dd, 17.5, 4.4 Hz), 2.69 (1H, dd, 17.5, 4.7 Hz), 1.43 (9H, s), 1.37 (6H, t, J=6.8 Hz).

Example 14(78)

N-(isopropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1630##

TLC: Rf 0.12 (hexane:ethyl acetate=3:2); NMR (CDCl3): δ 7.50-7.25 (3H, m), 6.58 (1H, d, J=8.8 Hz), 5.69 (1H, d, J=18.6 Hz), 5.52 (1H, d, J=18.6 Hz), 5.00-4.83 (1H, m), 3.73 (1H, sep, J=7.0 Hz), 3.08 (1H, dd, 17.5, 4.6 Hz), 2.73 (1H, dd, 17.5, 4.9 Hz), 1.45 (9H, s), 1.40 (6H, t, J=6.8 Hz).

Example 14(79)

N-(2-methoxyethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-2-yl)pentanoic acid•t-butylester ##STR1631##

TLC: Rf 0.45 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.47-7.43 (2H, m), 7.34-7.26 (1H, m), 5.96 (1H, d, J=9.2 Hz), 5.81 (1H, d, J=17.8 Hz), 5.62 (1H, d, J=17.8 Hz), 4.60 (1H, m), 4.30 (2H, m), 3.61 (2H, t, J=4.4 Hz), 3.40 (3H, s), 3.02 (1H, dd, J=17.4 Hz, 4.2 Hz), 2.69 (1H, dd, J=17.4 Hz, 4.6 Hz), 1.42 (9H, s).

Example 14(80)

N-(2-methoxyethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-1-yl)pentanoic acid•t-butylester ##STR1632##

TLC: Rf 0.40 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.37-7.28 (1H, m), 6.06 (1H, d, J=7.6 Hz), 5.75 (1H, d, J=18.0 Hz), 5.57 (1H, d, J=18.0 Hz), 4.68 (1H, m), 4.35 (2H, m), 3.65 (2H, t, J=4.4 Hz), 3.42 (3H, s), 3.12 (1H, dd, J=17.4 Hz, 4.4 Hz), 2.74 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.44 (9H, s).

Example 14(81)

N-(2-cyclohexylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio )tetrazol-2-yl)pentanoic acid•t-butylester ##STR1633##

NMR (CDCl3): δ 7.50-7.28 (3H, m), 5.80 (1H, d, J=l 7.8 Hz), 5.79 (1H, d, J=9.0 Hz), 5.61 (1H, d, J=17.8 Hz), 4.70-4.55 (1H, m), 4.17 (2H, t, J=6.8 Hz), 2.99 (1H, dd, 17.4, 4.4 Hz), 2.70 (1H, dd, 17.4, 4.8 Hz), 1.80-1.46 (7H, m), 1.43 (9H, s), 1.38-0.80 (6H, m).

Example 14(82)

N-(2-cyclohexylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio )tetrazol-1-yl)pentanoic acid•t-butylester ##STR1634##

TLC: Rf 0.30 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.50-7.28 (3H, m), 5.86 (1H, d, J=9.0 Hz), 5.73 (1H, d, J=18.5 Hz), 5.55 (1H, d, J=18.5 Hz), 4.75-4.60 (1H, m), 4.22 (2H, t, J=6.8 Hz), 3.08 (1H, dd, 17.5, 4.5 Hz), 2.75 (1H, dd, 17.5, 4.8 Hz), 1.80-1.50 (7H, m), 1.45 (9H, s), 1.40-0.80 (6H, m).

Example 14(83)

N-cyclohexylmethyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-2-yl)pentanoic acid•t-butylester ##STR1635##

TLC: Rf 0.43 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.50-7.28 (3H, m), 5.81 (1H, d, J=9.4 Hz), 5.80 (1H, d, J=17.8 Hz), 5.61 (1H, d, J=17.8 Hz), 4.70-4.55 (1H, m), 3.94 (2H, d, J=6.4 Hz), 2.99 (1H, dd, 17.4, 4.6 Hz), 2.70 (1H, dd, 17.4, 4.7 Hz), 1.80-1.50 (5H, m), 1.43 (9H, s), 1.40-0.80 (6H, m).

Example 14(84)

N-cyclohexylmethyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-1-yl)pentanoic acid•t-butylester ##STR1636##

TLC: Rf 0.29 (hexane:ethyl acetate=7:3); NMR (CDCl3): δ 7.50-7.28 (3H, m), 5.87 (1H, d, J=8.8 Hz), 5.73 (1H, d, J=18.4 Hz), 5.55 (1H, d, J=18.4 Hz), 4.75-4.60 (1H, m), 4.30-3.90 (2H, m), 3.08 (1H, dd, 17.3, 4.6 Hz), 2.75 (1H, dd, 17.3, 4.8 Hz), 1.85-1.50 (5H, m), 1.45 (9H, s), 1.40-0.80 (6H, m).

Example 14(85)

N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tet razol-2-yl)pentanoic acid•t-butylester ##STR1637##

TLC: Rf 0.46 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.44 (2H, d, J=6.8 Hz), 7.33-7.15 (6H, m), 5.86 (1H, d, J=8.8 Hz), 5.64 (1H, d, J=17.8 Hz), 5.34 (1H, d, J=17.8 Hz), 4.58 (1H, m), 4.48-4.25 (2H, m), 2.99-2.87 (3H, m), 2.66 (1H, dd, J=17.6 Hz, 5.0 Hz), 1.41 (9H, s).

Example 14(86)

N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tet razol-1-yl)pentanoic acid•t-butylester ##STR1638##

TLC: Rf 0.34 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.47-7.43 (2H, m), 7.36-7.19 (6H, m), 5.91 (1H, d, J=9 Hz), 5.59 (1H, d, J=19.2 Hz), 5.39 (1H, d, J=19.2 Hz), 4.63 (1H, m), 4.50-4.30 (2H, m), 3.11-2.96 (3H, m), 2.70 (1H, dd, J=17 Hz, 4.6 Hz), 1.44 (9H, s).

Example 14(87)

N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-acetylaminophenylthio )tetrazol-2-yl)pentanoic acid•t-butylester ##STR1639##

TLC: Rf 0.43 (hexane:ethyl acetate=2:3); NMR (CDCl3): δ 8.47 (1H, s), 7.58 (2H, s), 5.90-5.75 (1H, m), 5.88 (1H, d, J=17.7 Hz), 5.69 (1H, d, J=17.7 Hz), 4.73-4.58 (1H, m), 4.14 (2H, t, J=6.9 Hz), 3.01 (1H, dd, 17.4, 4.6 Hz), 2.73 (1H, dd, 17.4, 4.9 Hz), 2.07 (3H, s), 1.70-1.30 (4H, m), 1.43 (9H, s), 0.95 (3H, t, J=7.2 Hz).

Example 14(88)

N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-acetylaminophenylthio )tetrazol-1-yl)pentanoic acid•t-butylester ##STR1640##

TLC: Rf 0.35 (hexane:ethyl acetate=2:3); NMR (CDCl3): δ 9.44 (1H, s), 7.53 (2H, s), 5.83 (1H, d, J=9.2 Hz), 5.75 (1H, d, J=18.4 Hz), 5.61 (1H, d, J=18.4 Hz), 4.75-4.62 (1H, m), 4.19 (2H, t, J=6.7 Hz), 3.13 (1H, dd, 17.5, 4.5 Hz), 2.77 (1H, dd, 17.5, 4.7 Hz), 2.08 (3H, s), 1.75-1.30 (4H, m), 1.45 (9H, s), 0.96 (3H, t, J=7.3 Hz).

Example 14(89)

N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1641##

HPTLC: Rf 0.20 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.62 (2H, d, J=8.0 Hz), 7.48-7.24 (5H, m), 5.83 (1H, d, J=8.0 Hz), 5.72 and 5.56 (each 1H, each d, J=18.0 Hz), 4.58 (1H, m), 4.36 (2H, t, J=6.5 Hz), 3.09-2.86 (3H, m), 2.69 (1H, dd, J=17.5, 5.0 Hz), 1.41 (9H, s).

Example 14(90)

N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1642##

HPTLC: Rf 0.13 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.62 (2H, d, J=8.0 Hz), 7.49-7.23 (5H, m), 5.90 (1H, d, J=8.5 Hz), 5.66 and 5.51 (each 1H, each d, J=17.5 Hz), 4.64 (1H, m), 4.41 (2H, t, J=6.5 Hz), 3.13-2.96 (3H, m), 2.72 (1H, dd, J=17.0, 5.0 Hz), 1.44 (9H, s).

Example 14(91)

N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-me thylphenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1643##

HPTLC: Rf 0.21 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.62 (2H, d, J=8.0 Hz), 7.33 (2H, d, J=8.0 Hz), 7.27 (2H, s), 5.83 (1H, d, J=8.0 Hz), 5.70 and 5.55 (each 1H, each d, J=17.5 Hz), 4.58 (1H, m), 4.36 (2H, t, J=6.5 Hz), 3.08-2.85 (3H, m), 2.67 (1H, dd, J=17.0, 5.0 Hz), 2.34 (3H, s), 1.41 (9H, s).

Example 14(92)

N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-me thylphenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1644##

HPTLC: Rf 0.15 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.62 (2H, d, J=8.0 Hz), 7.36 (2H, d, J=8.0 Hz), 7.28 (2H, s), 5.90 (1H, d, J=7.5 Hz), 5.65 and 5.49 (each 1H, each d, J=18.5 Hz), 4.65 (1H, m), 4.40 (2H, t, J=6.5 Hz), 3.14-2.93 (3H, m), 2.72 (1H, dd, J=17.0, 5.0 Hz), 2.35 (3H, s), 1.44 (9H, s).

Example 14(93)

N-(2-methoxyethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-2-yl)pentanoic acid•t-butylester ##STR1645##

TLC: Rf 0.65 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.47-7.43 (2H, m), 7.28 (1H, dd, J=6.8 Hz, 2.2 Hz), 6.81 (1H, d, J=8.6 Hz), 5.78 (1H, d, J=18.0 Hz), 5.58 (1H, d, J=18.0 Hz), 4.87 (1H, m), 3.59 (2H, t, J=6.2 Hz), 3.36 (3H, s), 3.17 (2H, t, J=6.2 Hz), 2.98 (1H, dd, J=17.4 Hz, 4.4 Hz), 2.70 (1H, dd, J=17.4 Hz, 4.4 Hz), 1.43 (9H, s).

Example 14(94)

N-(2-methoxyethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-1-yl)pentanoic acid•t-butylester ##STR1646##

TLC: Rf 0.52 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.30 (1H, dd, J=9.2 Hz, 2.6 Hz), 6.89 (1H, d, J=8.8 Hz), 5.70 (1H, d, J=18.6 Hz), 5.52 (1H, d, J=18.6 Hz), 4.91 (1H, m) 3.63 (2H, t, J=6.0 Hz), 3.40 (3H, s), 3.18 (2H, t, J=6.0 Hz), 3.08 (1H, dd, J=17.6 Hz, 4.4 Hz), 2.75 (1H, dd, J=17.6 Hz, 4.8 Hz), 1.45 (9H, s).

Example 14(95)

N-(2-(2-methoxyethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1647##

TLC: Rf 0.54 (hexane:ethyl acetate=1:2); NMR (CDCl3): δ 7.47-7.43 (2H, m), 7.34-7.29 (1H, m), 6.00 (1H, d, J=8.8 Hz), 5.83 (1H, d, J=17.6 Hz), 5.62 (1H, d, J=17.6 Hz), 4.62 (1H, m), 4.30 (2H, m), 3.72 (2H, t, J=4.8 Hz), 3.64 (2H, m), 3.56 (2H, m), 3.36 (3H, s), 3.00 (1H, dd, J=17.6 Hz, 4.6 Hz), 2.70 (1H, dd, J=17.6 Hz, 5.0 Hz), 1.42 (9H, s).

Example 14(96)

N-(2-(2-methoxyethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1648##

TLC: Rf 0.42 (hexane:ethyl acetate=1:2); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.36-7.27 (1H, m), 6.05 (1H, d, J=9.4 Hz), 5.75 (1H, d, J=18.2 Hz), 5.56 (1H, d, J=18.2 Hz), 4.66 (1H, m), 4.34 (2H, m), 3.76 (2H, t, J=4.6 Hz), 3.67 (2H, m), 3.57 (2H, m), 3.38 (3H, s), 3.13 (1H, dd, J=17.4 Hz, 4.0 Hz), 2.74 (1H, dd, J=17.4 Hz, 5.0 Hz), 1.45 (9H, s).

Example 14(97)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetraz ol-2-yl)pentanoic acid•t-butylester ##STR1649##

TLC: Rf 0.55 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.33-7.15 (7H, m), 6.60 (1H, d, J=8.8 Hz), 5.73 (1H, d, J=17.8 Hz), 5.53 (1H, d, J=17.8 Hz), 4.86 (1H, m), 3.24 (2H, m), 3.00 (1H, dd, J=17.4 Hz, 4.4 Hz), 2.97 (2H, m), 2.67 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.43 (9H, s).

Example 14(98)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetraz ol-1-yl)pentanoic acid•t-butylester ##STR1650##

TLC: Rf 0.40 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.57-7.43 (2H, m), 7.33-7.17 (7H, m), 6.62 (1H, d, J=8.4 Hz), 5.78 (1H, d, J=18.6 Hz), 5.39 (1H, d, J=18.6 Hz), 4.87 (1H, m), 3.26 (2H, m), 3.03 (1H, dd, J=17.4 Hz, 4.4 Hz), 2.97 (2H, m), 2.68 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.43 (9H, s).

Example 14(99)

N-(2-acetylaminoethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylth io)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1651##

TLC: Rf 0.69 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.50-7.28 (3H, m), 6.89 (1H, d, J=8.0 Hz), 6.25-6.07 (1H, m), 5.76 (1H, d, J=17.7 Hz), 5.60 (1H, d, J=17.7 Hz), 4.93-4.75 (1H, m), 3.48 (2H, q, J=6.2 Hz), 3.08 (2H, t, J=6.2 Hz), 2.95 (1H, dd, 17.4, 4.9 Hz), 2.73 (1H, dd, 17.4, 5.0 Hz), 1.97 (3H, s), 1.43 (9H, s).

Example 14(100)

N-(2-acetylaminoethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylth io)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1652##

TLC: Rf 0.65 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.50-7.28 (3H, m), 6.93 (1H, d, J=8.8 Hz), 6.20-6.06 (1H, m), 5.70 (1H, d, J=18.4 Hz), 5.53 (1H, d, J=18.4 Hz), 5.00-4.85 (1H, m), 3.52 (2H, q, J=6.4 Hz), 3.12 (2H, t, J=6.4 Hz), 3.06 (1H, dd, 17.4, 4.6 Hz), 2.75 (1H, dd, 17.4, 5.2 Hz), 1.99 (3H, s), 1.45 (9H, s).

Example 14(101)

N-(2-acetylaminoethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthi o)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1653##

TLC: Rf 0.50 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.35-7.32 (1H, m), 6.16 (1H, brs), 5.01 (1H, d, J=8.6 Hz), 5.78 (1H, d, J=17.6 Hz), 5.63 (1H, d, J=17.6 Hz), 4.60 (1H, m), 4.20 (2H, m), 3.50 (2H, m), 3.00-2.85 (1H, m), 2.75 (1H, dd, J=17.6 Hz, 5.0 Hz), 1.98 (3H, s), 1.43 (9H, s).

Example 14(102)

N-(2-acetylaminoethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthi o)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1654##

TLC: Rf 0.48 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.49-7.44 (2H, m), 7.37-7.33 (1H, m), 6.06 (2H, m), 5.74 (1H, d, J=18.6 Hz), 5.55 (1H, d, J=18.6 Hz), 4.68 (1H, m), 4.26 (2H, m), 3.54 (2H, m), 3.06 (1H, dd, J=17.6 Hz, 4.4 Hz), 2.77 (1H, dd, J=17.6 Hz, 5.0 Hz), 2.00 (3H, s), 1.45 (9H, s).

Example 14(103)

N-(2-(2-methoxyethyloxy)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1655##

TLC: Rf 0.49 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.50-7.28 (3H, m), 6.76 (1H, d, J=8.4 Hz), 5.77 (1H, d, J=17.8 Hz), 5.58 (1H, d, J=17.8 Hz), 4.90-4.75 (1H, m), 3.80-3.50 (6H, m), 3.37 (3H, s), 3.18 (2H, t, J=6.1 Hz), 2.98 (1H, dd, 17.4, 4.5 Hz), 2.69 (1H, dd, 17.4, 4.9 Hz), 1.43 (9H, s).

Example 14(104)

N-(2-(2-methoxyethyloxy)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1656##

TLC: Rf 0.39 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.50-7.28 (3H, m), 6.83 (1H, d, J=9.0 Hz), 5.69 (1H, d, J=18.4 Hz), 5.51 (1H, d, J=18.4 Hz), 5.00-4.85 (1H, m), 3.80-3.50 (6H, m), 3.38 (3H, s), 3.23 (2H, t, J=6.3 Hz), 3.07 (1H, dd, 17.5, 4.6 Hz), 2.75 (1H, dd, 17.5, 4.9 Hz), 1.45 (9H, s).

Example 14(105)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(phenylthio) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1657##

TLC: Rf 0.57 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.59-7.55 (2H, m), 7.37-7.15 (8H, m), 6.62 (1H, d, J=8.8 Hz), 5.71 (1H, d, J=17.8 Hz), 5.50 (1H, d, J=17.8 Hz), 4.85 (1H, m), 3.23 (2H, m), 3.05-2.90 (3H, m), 2.67 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.43 (9H, s).

Example 14(106)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(phenylthio) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1658##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.57-7.51 (2H, m), 7.39-7.15 (8H, m), 6.63 (1H, d, J=8.6 Hz), 5.49 (1H, d, J=18.4 Hz), 5.30 (1H, d, J=18.4 Hz), 4.82 (1H, m), 3.27 (2H, m), 3.07-2.91 (3H, m), 2.67 (1H, dd, J=17.6 Hz, 4.8 Hz), 1.44 (9H, s).

EXAMPLES 15(1)-15(106)

By the same procedure as provided in example 6(1), and if necessary, by known methods converted to accommodate the corresponding salts, using the compound prepared in examples 14(1)-14(106), compounds of the present invention having the following physical data were obtained.

Example 15(1)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazo l-2-yl)pentanoic acid ##STR1659##

TLC: Rf 0.61 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.65-12.30 (1H, br), 8.96-8.82 (1H, m), 7.52 (2H, d, J=7.5 Hz), 7.45-7.13 (6H, m), 6.05-5.70 (2H, m), 4.87-4.72 (1H, m), 4.52 (2H, s), 4.11 (2H, s), 2.90-2.55 (2H, m).

Example 15(2)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazo l-1-yl)pentanoic acid ##STR1660##

TLC: Rf 0.19 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 9.05-8.95 (1H, m), 7.54 (2H, d, J=7.5 Hz), 7.46-7.10 (6H, m), 6.00-5.75 (2H, m), 4.92-4.75 (1H, m), 4.33 (2H, s), 4.11 (2H, s), 2.88-2.70 (2H, m).

Example 15(3)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1661##

TLC: Rf 0.58 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.88 (1H, d, J=6.2 Hz), 7.69-7.50 (3H, m), 7.33-7.12 (5H, m), 5.89 (2H, brs), 4.85-4.73 (1H, m), 4.10 (2H, s), 2.80 (1H, dd, J=6.0, 17 Hz), 2.64 (1H, dd, J=7.2, 17 Hz).

Example 15(4)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1662##

TLC: Rf 0.36 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.99 (1H, d, J=6.4 Hz), 7.70-7.52 (3H, m), 7.35-7.13 (5H, m), 5.71 (2H, brs), 4.90-4.79 (1H, m), 4.12 (2H, s), 2.92-2.68 (2H, m).

Example 15(5)

N-(2-phenylethoyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy)t etrazol-2-yl)pentanoic acid ##STR1663##

TLC: Rf 0.57 (chloroform:methanol:acetic acid=19:1:0.1); NMR (CDCl3): δ 12.70-12.10 (10H, br), 7.80 (1H, d, J=6.4 Hz), 7.55-7.15 (8H, m), 5.82 (2H, s), 4.59-451 (3H, m), 4.23 (2H, t, J=7.0 Hz), 2.92-2.48 (4H, m).

Example 15(6)

N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-1-yl)pentanoic acid ##STR1664##

TLC: Rf 0.52 (chloroform:methanol:acetic acid=19:1:0.1); NMR (CDCl3): δ 7.61-7.15 (9H, m), 5.90 (2H, s), 4.58-4.44 (1H, m), 4.35 (2H, s), 4.30-4.16 (2H, m), 2.88 (2H, t, J=7.5 Hz), 2.63 (2H, d, J=5.6 Hz).

Example 15(7)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1665##

TLC: Rf 0.57 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 8.62 (1H, d, J=6.0 Hz), 7.50 (2H, d, J=7.2 Hz), 7.40-7.09 (6H, m), 5.88 (2H, d, J=2.8 Hz), 4.74-4.63 (1H, m), 4.50 (2H, s), 3.07 (2H, t, J=7.2 Hz), 2.82 (2H, t, J=7.2 Hz), 2.63-2.50 (2H, m).

Example 15(8)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid ##STR1666##

TLC: Rf 0.42 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 8.89 (1H, d, J=6.4 Hz), 7.52 (2H, d, J=7.0 Hz), 7.39 (1H, dd, J=6.6, 9.0 Hz), 7.25-7.13 (5H, m), 5.91 (2H, s), 4.78-4.69 (1H, m), 4.38 (2H, s), 3.17-3.01 (2H, m), 2.82-2.69 (4H, m).

Example 15(9)

N-(2,6-dichlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(5-phenylmethyltetrazol-1 -yl)pentanoic acid ##STR1667##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=36:1:1); NMR (DMSO-d6): δ 8.12 (1H, d, J=7.6 Hz), 7.54-7.12 (8H, m), 5.76 (2H, s), 5.34 (2H, s), 4.70-4.58 (1H, m), 4.15 (2H, s), 2.87-2.63 (2H, m).

Example 15(10)

N-(2,6-dichlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(-(2,6-dichlorophenylmeth yl)tetrazol-2-yl)pentanoic acid ##STR1668##

TLC: Rf 0.31 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 7.60 (1H, d, J=7.6 Hz), 7.57-7.31 (6H, m), 6.00-5.80 (2H, m), 5.30 (2H, s), 4.55-4.43 (1H, m), 4.51 (2H, s), 2.60-2.54 (2H, m).

Example 15(11)

N-(3-phenylpropyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1669##

TLC: Rf 0.45 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.82 (1H, d, J=7.5 Hz), 7.51 (2H, d, J=7.6 Hz), 7.40-7.14 (6H, m), 6.00-5.76 (2H, br), 4.62-4.51 (3H, m), 3.98 (2H, t, J=3.6 Hz), 2.38-2.5 (4H, m), 1.94-1.80 (2H, m).

Example 15(12)

N-(3-phenylpropyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid ##STR1670##

TLC: Rf 0.42 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.97 (1H, d, J=7.5 Hz), 7.56-7.12 (8H, m), 5.92-5.83 (2H, br), 4.67-4.58 (1H, m), 4.35 (2H, s), 4.02 (2H, t, J=6.6 Hz), 2.92-2.60 (4H, m), 1.95-1.80 (2H, m).

Example 15(13)

N-(4-phenylbutyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid ##STR1671##

TLC: Rf 0.45 (chloroform:methanol:acetic acid=90:0:1); NMR (DMSO-d6):: δ 7.75 (1H, d, J=7.6 Hz), 7.52 (2H, d, J=7.2 Hz), 7.40-7.10 (6H, m), 5.87 (2H, s), 4.61-4.51 (3H, m), 4.05-3.97 (2H, br),2.77 (1H, dd, J=6.3, 17.0 Hz), 2.64-2.56 (3H, m), 1.65-1.50 (4H, br).

Example 15(14)

N-(4-phenylbutyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-1-yl)pentanoic acid ##STR1672##

TLC: Rf 0.42 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.91 (1H, d, J=6.8 Hz), 7.54 (2H, d, J=6.6 Hz), 7.41 (1H, dd, J=6.6, 9.4 Hz), 7.30-7.16 (5H, m), 5.87 (2H, s), 4.69-4.58 (1H, m), 4.35 (2H, s), 4.08-4.00 (2H, br), 2.91-2. 55 (4H, m), 1.68-1.52 (4H, br).

Example 15(15)

N-(2-(thiophen-2-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-2-yl)pentanoic acid ##STR1673##

TLC: Rf 0.39 (chloroform:methanol:acetic acid=19:1:0.1); NMR (DMSO-d6): δ 7.87 (1H, d, J=7.6 Hz), 7.54-7.50 (2H, m), 7.41-7.30 (2H, m), 6.93 (2H, d, J=3.2 Hz), 5.93-5.81 (2H, br), 4.62-4.51 (3H, m), 4.18 (2H, t, J=6.6 Hz), 3.11 (2H, t, J=6.6 Hz), 2.77 (1H, dd, J=6.0, 16.8 Hz), 2.58 (1H, dd, J=7.2, 16.4 Hz).

Example 15(16)

N-(2-(thiophen-2-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-1-yl)pentanoic acid ##STR1674##

TLC: Rf 0.27 (chloroform:methanol:acetic acid=19:1:0.1); NMR (DMSO-d6): δ 8.02 (1H, d, J=7.2 Hz), 7.57-7.52 (2H, m), 7.45-7.31 (2H, m), 6.94 (2H, d, J=3.8 Hz), 5.91-5.80 (2H, br), 4.70-4.60 (1H, m), 4.35 (2H, s), 4.18 (2H, t, J=6.6 Hz), 3.13 (2H, t, J=6.6 Hz), 2.84 (1H, dd, J=6.6, 16.6 Hz), 2.70 (1H, dd, J=6.6, 16.6 Hz).

Example 15(17)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-2-yl)pentanoic acid ##STR1675##

TLC: Rf 0.51 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.78 (1H, d, J=6.8 Hz), 7.54-7.50 (2H, m), 7.37 (1H, dd, J=7.1, 9.1 Hz), 7.17 (2H, d, J=8.5 Hz), 6.83 (2H, d, J=8.5 Hz), 5.90-5.85 (2H, br), 4.60-4.51 (3H, m), 4.17 (2H, t, J=6.6 Hz), 3.67 (3H, s), 2.85-2.52 (4H, m).

Example 15(18)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-1-yl)pentanoic acid ##STR1676##

TLC: Rf 0.47 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.92 (1H, d, J=6.8 Hz), 7.56-7.52 (2H, m), 7.40 (1H, dd, J=6.8, 9.2 Hz), 7.17 (2H, d, J=8.2 Hz), 6.83 (2H, d, J=8.2 Hz), 5.83 (2H, s), 4.66-4.56 (1H, m), 4.35 (2H, s), 4.19 (2H, t, J=6.9 Hz), 3.69 (3H, s), 2.86-2.63 (4H, m).

Example 15(19

N-(2-(4-fluorophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-2-yl)pentanoic acid ##STR1677##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.78 (1H, d, J=8.0 Hz), 7.51 (2H, d, J=7.6 Hz), 7.40-7.26 (3H, m), 7.08 (2H, t, J=9.0 Hz), 5.82 (2H, s), 4.58-4.51 (3H, m), 4.20 (2H, t, J=6.5 Hz), 2.90-2.52 (4H, m).

Example 15(20)

N-(2-(4-fluorophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-1-yl)pentanoic acid ##STR1678##

TLC: Rf 0.44 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.93 (1H, d, J=7.2 Hz), 7.56-7.25 (5H, m), 7.08 (2H, t, J=9.0 Hz), 5.84 (2H, s), 4.66-4.57 (1H, m), 4.34 (2H, s), 4.21 (2H, t, J=6.9 Hz), 2.92-2.63 (4H, m).

Example 15(21)

N-(2-(phenylmethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-2-yl)pentanoic acid ##STR1679##

TLC: Rf 0.53 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 7.91 (1H, d, J=7.4 Hz), 7.54-7.50 (2H, m), 7.40-7.23 (6H, m), 5.96-5.74 (2H, br), 4.61-4.50 (5H, m), 4.18 (2H, t, J=4.4 Hz), 3.62 (2H, t, J=4.4 Hz), 2.78 (1H, dd, J=6.0, 17.2 Hz), 2.59 (1H, dd, J=7.0, 16.6 Hz).

Example 15(22)

N-(2-(phenylmethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylmethyl)tetrazol-1-yl)pentanoic acid ##STR1680##

TLC: Rf 0.47 (chloroform:methanol:acetic acid=90:10:1); NMR (DMSO-d6): δ 8.07 (1H, d, J=7.2 Hz), 7.56-7.23 (8H, m), 5.87 (2H, s), 4.69-4.59 (1H, m), 4.50 (2H, s), 4.35 (2H, s), 4.20 (2H, t, J=4.5 Hz), 3.64 (2H, t, J=4.5 Hz), 2.91-2.66 (2H, m).

Example 15(23)

N-(2-(4-dimethylaminophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylmethyl)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1681##

TLC: Rf 0.37 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.82 (1H, d, J=7.4 Hz), 7.52-7.32 (7H, m), 5.87 (2H, s), 4.59-4.52 (1H, m), 4.52 (2H, s), 4.27-4.19 (2H, m), 3.05 (6H, s), 2.94-2.84 (2H, m), 2.94-2.61 (2H, m).

Example 15(24)

N-(2-(4-dimethylaminophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylmethyl)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1682##

TLC: Rf 0.36 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.99 (1H, d, J=7.4 Hz), 7.54-7.31 (7H, m), 5.88 (2H, s), 4.66-4.63 (1H, m), 4.36 (2H, m), 4.28-4.20 (2H, m), 3.01 (6H, s), 2.93-2.74 (4H, m).

Example 15(25)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1683##

TLC: Rf 0.51 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.70 (1H, d, J=6 Hz), 7.82 (1H, d, J=8.8 Hz), 7.69 (1H, d, J=8.8 Hz), 7.32-7.22 (5H, m), 5.94 (2H, m), 4.73 (1H, m), 4.08 (2H, s), 2.60 (2H, m).

Example 15(26)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1684##

TLC: Rf 0.43 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.83 (1H, d, J=7 Hz), 7.84 (1H, d, J=8.8 Hz), 7.69 (1H, d, J=8.8 Hz), 7.33-7.08 (5H, m), 5.84 (2H, m), 4.75 (1H, m), 4.09 (2H, m), 2.64 (2H, m).

Example 15(27)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio) tetrazol-2-yl)pentanoic acid ##STR1685##

TLC: Rf 0.51 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.69 (1H, d, J=6.4 Hz), 7.52 (2H, s), 7.32-7.19 (5H, m), 5.92 (2H, m), 4.71 (1H, m), 4.08 (2H, s), 2.56 (2H, m), 2.36 (3H, s).

Example 15(28)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphenylthio) tetrazol-1-yl)pentanoic acid ##STR1686##

TLC: Rf 0.45 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.77 (1H, m), 7.51 (2H, s), 7.33-7.13 (5H, m), 5.82 (2H, m), 4.75 (1H, m), 4.10 (2H, m), 2.62 (2H, m), 2.37 (3H, s).

Example 15(29)

N-(3-phenylpropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid ##STR1687##

TLC: Rf 0.54 (chloroform:methanol:acetic acid=19:1:0.1); NMR (DMSO-d6): δ 8.81 (1H, d, J=6.4 Hz), 7.51 (2H, d, J=7.2 Hz), 7.40-7.14 (6H, m), 6.00-5.74 (2H, br), 4.83-4.73 (1H, m), 4.50 (2H, s), 2.87-2.56 (6H, m), 1.91-1.77 (2H, m).

Example 15(30)

N-(3-phenylpropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-1-yl)pentanoic acid ##STR1688##

TLC: Rf 0.41 (chloroform:methanol:acetic acid=19:1:0.1); NMR (DMSO-d6): δ 8.97 (1H, d, J=6.8 Hz), 7.55-7.36 (3H, m), 7.27-7.11 (5H, m), 5.87 (2H, s), 4.87-4.78 (1H, m), 4.34 (2H, s), 2.92-2.58 (6H, 1.91-1.78 (2H, m).

Example 15(31)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophen ylthio)tetrazol-2-yl)pentanoic acid ##STR1689##

TLC: Rf 0.56 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.28-11.40 (1H, br), 9.03-8.77 (1H, m), 7.42-7.06 (5H, m), 6.88 (2H, s), 6.10-5.66 (2H, br), 4.90-4.68 (1H, m), 4.11 (2H, s), 3.00 (6H, s), 2.92-2.53 (2H, m).

Example 15(32)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylaminophen ylthio)tetrazol-1-yl)pentanoic acid ##STR1690##

TLC: Rf 0.31 (chloroform:methanol:acetic acid=30:1:1); NMR (DMSO-d6): δ 13.08-11.40 (1H, br), 9.13-8.86 (1H, m), 7.44-7.08 (5H, m), 6.88 (2H, s), 5.90-5.45 (2H, br), 4.95-4.71 (1H, m), 4.13 (2H, s), 3.00 (6H, s), 2.93-2.62 (2H, m).

Example 15(33)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio )tetrazol-2-yl)pentanoic acid ##STR1691##

TLC: Rf 0.60 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.69 (1H, m), 7.83 (1H, d, J=8.8 Hz), 7.70 (1H, d, J=8.8 Hz), 7.31-7.15 (5H, m), 5.91 (2H, m), 4.73 (1H, m), 3.06 (2H, m), 2.84 (2H, m), 2.62 (2H, m).

Example 15(34)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichlorophenylthio )tetrazol-1-yl)pentanoic acid ##STR1692##

TLC: Rf 0.51 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.87 (1H, m), 7.82 (1H, d, J=8.8 Hz), 7.67 (1H, d, J=8.8 Hz), 7.27-7.14 (5H, m), 5.85 (2H, m), 4.77 (1H, m), 3.05 (2H, m), 2.83 (2H, m), 2.65 (2H, m).

Example 15(35)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphen ylthio)tetrazol-2-yl)pentanoic acid ##STR1693##

TLC: Rf 0.63 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.56 (1H, d, J=6 Hz), 7.49 (2H, s), 7.26-7.15 (5H, m), 5.92 (2H, m), 4.73 (1H, m), 3.04 (2H, m), 2.84 (2H, m), 2.59 (2H, m), 2.35 (3H, s).

Example 15(36)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-methylphen ylthio)tetrazol-1-yl)pentanoic acid ##STR1694##

TLC: Rf 0.53 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.82 (1H, d, J=6.8 Hz), 7.49 (2H, s), 7.24-7.14 (5H, m), 5.81 (2H, s), 4.77 (1H, m), 3.05 (2H, m), 2.82 (2H, m), 2.66 (2H, m), 2.34 (3H, s).

Example 15(37)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophen ylthio)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1695##

TLC: Rf 0.43 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 8.96 (1H, d, J=7.0 Hz), 7.34-7.18 (5H, m), 6.79 (2H, s), 5.88 (2H, m), 4.79 (1H, m), 4.10 (2H, s), 2.96 (6H, s), 2.90-2.58 (2H, m), 2.38 (6H, s).

Example 15(38)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-dimethylaminophen ylthio)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1696##

TLC: Rf 0.36 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 9.05 (1H, d, J=7.0 Hz), 7.38-7.16 (5H, m), 6.71 (2H, s), 5.67 (2H, s), 4.82 (1H, m), 4.13 (2H, s), 2.97 (6H, s), 2.95-2.62 (2H, m), 2.31 (6H, s).

Example 15(39)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio )tetrazol-2-yl)pentanoic acid ##STR1697##

HPTLC: Rf 0.41 (chloroform:methanol:acetic acid=48:1:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 8.88 (1H, d, J=7.6 Hz), 7.35-7.12 (7H, m), 5.92 (1H, d, J=17.8 Hz), 5.71 (1H, d, J=17.8 Hz), 4.87-4.70 (1H, m), 4.09 (2H, s), 2.81 (1H, dd, J=17.3, 5.6 Hz), 2.63 (1H, dd, J=17.3, 7.1 Hz), 2.41 (6H, s), 1.28 (9H, s).

Example 15(40)

N-(benzylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4-t-butylphenylthio )tetrazol-1-yl)pentanoic acid ##STR1698##

TLC: Rf 0.31 (chloroform:methanol:acetic:acid=47:2:1); NMR (DMSO-d6): δ 12.57 (1H, brs), 8.98 (1H, d, J=7.0 Hz), 7.40-7.00 (1H, m), (7H, m), 5.69 (2H, s), 4.90-4.72 (1H, m), 4.12 (2H, s), 2.90-2.60 (2H, m), 2.35 (6H, s), 1.29 (9H, s).

Example 15(41)

N-(2-(pyridin-2-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid ##STR1699##

TLC: Rf 0.23 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.46 (1H, d, J=5.2 Hz), 7.71-7.62 (1H, m), 7.51-7.14 (6H, m), 5.97-5.75 (2H, m), 4.51 (2H, s), 4.51-4.34 (3H, m), 3.05 (2H, t, J=6.6 Hz), 2.61-2.52 (2H, m).

Example 15(42)

N-(2-(pyridin-2-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-1-yl)pentanoic acid ##STR1700##

TLC: Rf 0.14 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.48 (1H, d, J=5.4 Hz), 7.74-7.64 (2H, m), 7.54-7.17 (5H, m), 5.88 (2H, br s), 4.58-4.54 (1H, m), 4.44-4.36 (4H, m), 3.07 (2H, t, J=6.6 Hz), 2.71-2.68 (2H, m).

Example 15(43)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylam inophenylthio)tetrazol-2-yl)pentanoic acid ##STR1701##

TLC: Rf 0.27 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.76-11.14 (1H, br), 8.82 (1H, d, J=6.4 Hz), 7.40-7.07 (5H, m), 6.88 (2H, s), 6.02-5.61 (2H, br), 4.90-4.65 (1H, m), 3.20-2.54 (6H, m), 2.99 (6H, s).

Example 15(44)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-dimethylam inophenylthio)tetrazol-1-yl)pentanoic acid ##STR1702##

TLC: Rf 0.16 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.80-11.30 (1H, br), 8.95 (1H, d, J=6.3 Hz), 7.35-7.07 (5H, m), 6.86 (2H, s), 5.87-5.45 (2H, br), 4.91-4.72 (1H, m), 3.20-2.53 (6H, m), 2.99 (6H, s).

Example 15(45)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichloro phenylthio)tetrazol-2-yl)pentanoic acid ##STR1703##

TLC: Rf 0.46 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.85 (1H, d, J=8.8 Hz), 7.72 (1H, d, J=8.8 Hz), 7.63 (1H, d, J=9 Hz), 7.16 (2H, d, J=8.4 Hz), 6.83 (2H, d, J=8.4 Hz), 5.88 (2H, s), 4.50 (1H, m), 4.16 (2H, m), 3.69 (3H, s), 2.81 (2H, m), 2.62 (2H, m).

Example 15(46)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichloro phenylthio)tetrazol-1-yl)pentanoic acid ##STR1704##

TLC: Rf 0.39 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.86 (1H, d, J=8.8 Hz), 7.71 (1H, d, J=8.8 Hz), 7.67 (1H, m), 7.15 (2H, d, J=8.4 Hz), 6.81 (2H, d, J=8.4 Hz), 5.78 (2H, m), 4.52 (1H, m), 4.17 (2H, m), 3.68 (3H, s), 2.82 (2H, m), 2.62 (2H, m).

Example 15(47)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- methylphenylthio)tetrazol-2-yl)pentanoic acid ##STR1705##

TLC: Rf 0.47 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.49 (1H, brs), 7.82 (1H, d, J=8.0 Hz), 7.53 (2H, s), 7.17 (2H, d, J=8.4 Hz), 6.83 (2H, d, J=8.4 Hz), 5.88 (2H, m), 4.56 (1H, m), 4.18 (2H, t, J=6.6 Hz), 3.69 (3H, s), 2.82 (2H, t, J=6.6 Hz), 2.74-2.51 (2H, m), 2.36 (3H, s).

Example 15(48)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- methylphenylthio)tetrazol-1-yl)pentanoic acid ##STR1706##

TLC: Rf 0.43 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.67 (1H, d, J=8 Hz), 7.53 (2H, s), 7.15 (2H, d, J=8.6 Hz), 6.81 (2H, d, J=8.6 Hz), 5.74 (2H, m), 4.52 (1H, m), 4.16 (2H, m), 3.68 (3H, m), 2.81 (2H, m), 2.63 (2H, m), 2.35 (3H, s).

Example 15(49)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid ##STR1707##

TLC: Rf 0.50 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.64 (1H, m), 7.14 (2H, d, J=8.2 Hz), 6.85 (2H, s), 6.80 (2H, d, J=8.2 Hz), 5.81 (2H, s), 4.49 (1H, m), 4.15 (2H, m), 3.66 (3H, s), 2.97 (6H, s), 2.76 (2H, m), 2.60 (2H, m).

Example 15(50)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid ##STR1708##

TLC: Rf 0.48 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.65 (1H, m), 7.12 (2H, d, J=8.4 Hz), 6.84 (2H, s), 6.79 (2H, d, J=8.4 Hz), 5.68 (2H, s), 4.49 (1H, m), 4.15 (2H, m), 3.66 (3H, s), 2.96 (6H, s), 2.79 (2H, m), 2.61 (2H, m).

Example 15(51)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4- dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid•hydrochloric salt ##STR1709##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=48:1:1); NMR (DMSO-d6): δ 7.78 (1H, d, J=8.0 Hz), 7.16 (2H, d, J=8.5 Hz), 6.81 (2H, d, J=8.5 Hz), 6.72 (2H, s), 5.79 (2H, s), 4.60-4.40 (1H, m), 4.17 (2H, t, J=6.5 Hz), 3.68 (3H, s), 3.00-2.50 (2H, m), 2.96 (6H, s), 2.81 (2H, t, J=6.5 Hz), 2.35 (6H, s).

Example 15(52)

N-(2-(4-methoxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dimethyl-4- dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1710##

TLC: Rf 0.25 (chloroform:methanol:acetic acid=48:1:1); NMR (DMSO-d6): δ 7.88 (1H, d, J=8.0 Hz), 7.16 (2H, d, J=8.5 Hz), 6.81 (2H, d, J=8.5 Hz), 6.64 (2H, s), 5.57 (2H, s), 4.62-4.43 (1H, m), 4.28-4.10 (2H, m), 3.68 (3H, s), 3.00-2.60 (2H, m), 2.96 (6H, s), 2.84 (2H, t, J=7.0 Hz), 2.31 (6H, s).

Example 15(53)

N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichloro phenylthio)tetrazol-2-yl)pentanoic acid ##STR1711##

TLC: Rf 0.67 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.82 (1H, d, J=8.8 Hz), 7.69 (1H, d, J=8.8 Hz), 7.49 (1H, m), 7.06 (2H, d, J=8.6 Hz), 6.78 (2H, d, J=8.6 Hz), 5.93 (2H, m), 4.46 (1H, m), 3.97 (2H, m), 3.68 (3H, s), 2.57 (2H, m), 2.49 (2H, m), 1.53 (4H, m).

Example 15(54)

N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,3,6-trichloro phenylthio)tetrazol-2-yl)pentanoic acid ##STR1712##

TLC: Rf0.56 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.87 (1H, d, J=8.8 Hz), 7.71 (1H, d, J=8.8 Hz), 7.63 (1H, m), 7.06 (2H, d, J=8.6 Hz), 6.80 (2H, d, J=8.6 Hz), 5.80 (2H, m), 4.57 (1H, m), 4.05 (2H, m), 3.70 (3H, s), 2.67 (2H, m), 2.50 (2H, m), 1.57 (4H, m).

Example 15(55)

N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- dimethylaminophenylthio)tetrazol-2-yl)pentanoic acid ##STR1713##

TLC: Rf 0.61 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.68 (1H, d, J=8 Hz), 7.08 (2H, d, J=8.4 Hz), 6.86 (2H, s), 6.80 (2H, d, J=8.4 Hz), 5.86 (2H, s), 4.54 (1H, m), 4.01 (2H, m), 3.70 (3H, s), 2.99 (6H, s), 2.80-2.48 (4H, m), 1.57 (4H, m).

Example 15(56)

N-(4-(4-methoxyphenyl)butyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4- dimethylaminophenylthio)tetrazol-1-yl)pentanoic acid ##STR1714##

TLC: Rf 0.53 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.61 (1H, d, J=8 Hz), 7.04 (2H, d, J=8.4 Hz), 6.84 (2H, s), 6.78 (2H, d, J=8.4 Hz), 5.71 (2H, s), 4.52 (1H, m), 4.02 (2H, m), 3.69 (3H, s), 2.98 (6H, s), 2.63 (2H, m), 2.49 (2H, m), 1.56 (4H, m).

Example 15(57)

N-(2-(4-methylthiazol-5-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylthio)tetrazol-2-yl)pentanoic acid ##STR1715##

TLC: Rf 0.42 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.40 (1H, brs), 8.81 (1H, s), 7.88 (1H, d, J=7.6 Hz), 7.70-7.51 (3H, m), 5.94 (2H, s), 4.59 (1H, m), 4.18 (2H, t, J=6.2 Hz), 3.08 (2H, t, J=6.2 Hz), 2.79 (1H, dd, J=l7 Hz, 5.8 Hz), 2.58 (1H, dd, J=17 Hz, 7.2 Hz), 2.33 (3H, s).

Example 15(58)

N-(2-(4-methylthiazol-5-yl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylthio)tetrazol-1-yl)pentanoic acid ##STR1716##

TLC: Rf 0.35 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.79 (1H, s), 7.83 (1H, d, J=8 Hz), 7.70-7.52 (3H, m), 5.75 (2H, m), 4.60 (1H, m), 4.19 (2H, m), 3.10 (2H, t, J=6.4 Hz), 2.71 (2H, m), 2.32 (3H, s).

Example 15(59)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-2-yl)pentanoic acid ##STR1717##

TLC: Rf 0.63 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.69 (1H, m), 7.70-7.53 (3H, m), 7.32-7.16 (5H, m), 5.91 (2H, s), 4.73 (1H, m), 3.09 (2H, m), 2.84 (2H, m), 2.55 (2H, m).

Example 15(60)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-1-yl)pentanoic acid ##STR1718##

TLC: Rf 0.51 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.85 (1H, m), 7.68-7.50 (3H, m), 7.23-7.14 (5H, m), 5.84 (2H, s), 4.76 (1H, m), 3.04 (2H, m), 2.82 (2H, m), 2.65 (2H, m).

Example 15(61)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(4-(pyrrolidin-1-ylmethyl) phenylthio)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1719##

TLC: Rf 0.39 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 9.02-8.80 (1H, m), 7.66 (2H, d, J=8.5 Hz), 7.50 (2H, d, J=8.5 Hz), 7.40-7.10 (5H, m), 5.98 (2H, s), 4.90-4.75 (1H, m), 4.32 (2H, s), 3.60-2.93 (6H, m), 2.93-2.55 (4H, m), 2.00-1.80 (4H, m).

Example 15(62)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(4-(pyrrolidin-1-ylmethyl) phenylthio)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR1720##

TLC: Rf 0.36 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 9.04-8.95 (1H, m), 7.65 (2H, d, J=8.2H), 7.57 (2H, d, J=8.2 Hz), 7.33-7.10 (5H, m), 5.76 (2H, s), 4.90-4.70 (1H, m), 4.32 (2H, s), 3.60-2.95 (6H, m), 2.95-2.54 (4H, m), 2.05-1.90 (4H, m).

Example 15(63)

N-(2-(4-methylthiazol-5-yl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylthio)tetrazol-2-yl)pentanoic acid ##STR1721##

TLC: Rf 0.38 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.53 (1H, brs), 8.95 (1H, d, J=7.4 Hz), 8.79 (1H, s), 7.70-7.50 (3H, m), 5.99 (1H, d, J=18.0 Hz), 5.88 (1H, d, J=18.0 Hz), 4.82 (1H, m), 3.04 (4H, s), 2.83 (1H, dd, J=17.0 Hz, 5.6 Hz), 2.65 (1H, dd, J=17.0 Hz, 7.0 Hz), 2.32 (3H, s).

Example 15(64)

N-(2-(4-methylthiazol-5-yl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichl orophenylthio)tetrazol-1-yl)pentanoic acid ##STR1722##

TLC: Rf 0.31 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 9.07 (1H, d, J=7 Hz), 8.79 (1H, s), 7.69-7.52 (3H, m), 5.87 (1H, d, J=17 Hz), 5.74 (1H, d, J=17 Hz), 4.86 (1H, m), 3.06 (4H, s), (1H, dd, J=17 Hz, 5.8 Hz), 2.75 (1H, dd, J=17 Hz, 7 Hz), 2.28 (3H, s).

Example 15(65)

N-(butylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1723##

TLC: Rf 0.58 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.74 (1H, d, J=6.8 Hz), 7.70-7.51 (3H, m), 5.90 (2H, s), 4.75 (1H, m), 2.82 (2H, t, J=7.2 Hz), 2.67 (2H, m), 1.51 (2H, m), 1.33 (2H, m), 0.87 (3H, t, J=7.2 Hz).

Example 15(66)

N-(butylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1724##

TLC: Rf 0.43 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.80 (1H, d, J=6.6 Hz), 7.69-7.51 (3H, m), 5.82 (2H, m), 4.76 (1H, m), 2.82 (2H, m), 2.67 (2H, m), 1.49 (2H, m), 1.31 (2H, m), 0.80 (3H, t, J=7.2 Hz).

Example 15(67)

N-(2-(4-methoxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylthio)tetrazol-2-yl)pentanoic acid ##STR1725##

TLC: Rf 0.52 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.05 (1H, brs), 8.82 (1H, m), 7.70-7.66 (3H, m), 7.59-7.54 (1H, m), 7.14 (2H, d, J=8.4 Hz), 6.83 (2H, d, J=8.4 Hz), 5.81 (2H, m), 4.78 (1H, m), 3.70 (3H, s), 3.05 (2H, m), 2.86-2.75 (3H, m), 2.62 (1H, dd, J=17 Hz, 8 Hz).

Example 15(68)

N-(2-(4-methoxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylthio)tetrazol-1-yl)pentanoic acid ##STR1726##

TLC: Rf 0.40 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.36 (1H, brs), 8.99 (1H, d, J=7.4 Hz), 7.70-7.65 (2H, m), 7.59-7.51 (1H, m), 7.11 (2H, d, J=8.6 Hz), 6.79 (2H, d, J=8.6 Hz), 5.89-5.69 (2H, m), 4.84 (1H, m), 3.69 (3H, s), 3.09-3.02 (2H, m), 2.94-2.61 (4H, m).

Example 15(69)

N-(3-(pyrimidin-2-yl)propyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylthio)tetrazol-2-yl)pentanoic acid ##STR1727##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.71 (2H, d, J=5.0 Hz), 7.75-7.48 (3H, m), 7.40 (1H, m), 7.32 (1H, t, J=5.0 Hz), 5.99 (2H, br), 4.48 (1H, m), 4.07 (2H, m), 2.94 (2H, m), 2.59 (2H, br), 2.06 (2H, m).

Example 15(70)

N-(3-(pyrimidin-2-yl)propyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylthio)tetrazol-1-yl)pentanoic acid ##STR1728##

TLC: Rf 0.36 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.66 (2H, m), 7.74-7.46 (4H, m), 7.29 (1H, m), 5.83 (2H, br), 4.50 (1H, m), 4.09 (2H, m), 2.94 (2H, m), 2.63 (2H, m), 2.06 (2H, m).

Example 15(71)

N-(2-(4-acetylaminophenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylthio)tetrazol-2-yl)pentanoic acid ##STR1729##

TLC: Rf 0.30 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 9.86 (1H, s), 8.77 (1H, d, J=7.4 Hz), 7.75-7.40 (5H, m), 7.13 (2H, d, J=8.2 Hz), 5.90 (2H, brs), 4.83-4.63 (1H, m), 3.04 (2H, t, J=7.3 Hz), 2.77 (2H, t, J=7.3 Hz), 2.70-2.50 (2H, m), 2.01 (3H, s).

Example 15(72)

N-(2-(4-acetylaminophenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylthio)tetrazol-1-yl)pentanoic acid ##STR1730##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 9.85 (1H, s), 8.88-8.76 (1H, m), 7.70-7.50 (3H, m), 7.44 (2H, d, J=8.2 Hz), 7.09 (2H, d, J=8.2 Hz), 5.82 (2H, brs), 4.82-4.64 (1H, m), 3.13-2.90 (2H, m), 2.90-2.68 (2H, m), 2.68-2.54 (2H, m), 2.01 (3H, s).

Example 15(73)

N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1731##

TLC: Rf 0.55 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.70-7.51 (3H, m), 5.93 (2H, s), 4.54 (1H, m), 4.00 (2H, t, J=6.6 Hz), 2.77-2.55 (2H, m), 1.55 (2H, m), 1.29 (2H, m), 0.89 (3H, t, J=7.4 Hz).

Example 15(74)

N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1732##

TLC: Rf 0.48 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.70-7.52 (3H, m), 5.80 (2H, s), 4.56 (1H, m), 4.01 (2H, m), 2.67 (2H, m), 1.55 (2H, m), 1.30 (2H, m), 0.86 (3H, t, J=7.4 Hz).

Example 15(75)

N-(propylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1733##

TLC: Rf 0.39 (chloroform:methanol:acetic acid=94:3:3); NMR (DMSO-d6): δ 8.61 (1H, d, J=7.0 Hz), 7.70-7.49 (3H, m), 5.95 (2H, brs), 4.75-4.58 (1H, m), 2.78 (2H, t, J=7.2 Hz), 2.57 (2H, brs), 1.63-1.40 (2H, m), 0.90 (3H, t, J=7.4 Hz).

Example 15(76)

N-(propylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1734##

TLC: Rf 0.30 (chloroform:methanol:acetic acid=94:3:3); NMR (DMSO-d6): δ 8.85-8.68 (1H, m), 7.70-7.50 (3H, m), 5.83 (2H, brs), 4.80-4.58 (1H, m), 2.90-2.68 (2H, m), 2.63-2.54 (2H, m), 1.65-1.40 (2H, m), 0.86 (3H, t, J=7.2 Hz).

Example 15(77)

N-(isopropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-2-yl)pentanoic acid ##STR1735##

TLC: Rf 0.36 (chloroform:methanol:acetic acid=94:3:3); NMR (DMSO-d6): δ 8.75 (1H, d, J=7.0 Hz), 7.80-7.50 (3H, m), 6.05-5.80 (2H, m), 4.90-4.71 (1H, m), 3.49 (1H, sep, J=6.8 Hz), 2.92-2.53 (2H, m), 1.27 (6H, d, J=6.8 Hz).

Example 15(78)

N-(isopropylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio) tetrazol-1-yl)pentanoic acid ##STR1736##

TLC: Rf 0.30 (chloroform:methanol:acetic acid=94:3:3); NMR (DMSO-d6): δ 9.03-8.75 (1H, m), 7.80-7.50 (3H, m), 5.76 (2H, brs), 4.90-4.70 (1H, m), 3.52 (1H, sep, J=6.6 Hz), 2.95-2.63 (2H, m), 1.28 (6H, d, J=6.6 Hz).

Example 15(79)

N-(2-methoxyethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-2-yl)pentanoic acid ##STR1737##

TLC: Rf 0.43 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.50 (1H, s), 7.93 (1H, d, J=7.8 Hz), 7.71-7.66 (2H, m), 7.59-7.51 (1H, m), 5.97 (2H, s), 4.58 (1H, m), 4.13 (2H, m), 3.51 (2H, t, J=4.4 Hz), 3.22 (3H, s), 2.80 (1H, dd, J=16.8 Hz, 5.8 Hz), 2.58 (1H, dd, J=16.8 Hz, 4.8 Hz).

Example 15(80)

N-(2-methoxyethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-1-yl)pentanoic acid ##STR1738##

TLC: Rf 0.34 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.00 (1H, s), 7.92 (1H, d, J=7 Hz), 7.70-7.66 (2H, m), 7.60-7.53 (1H, m), 5.77 (2H, m), 4.60 (1H, m), 4.15 (2H, m), 3.53 (2H, m), 3.25 (3H, s), 2.74 (2H, m).

Example 15(81)

N-(2-cyclohexylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio )tetrazol-2-yl)pentanoic acid ##STR1739##

TLC: Rf 0.35 (chloroform:methanol:acetic acid=95:3:2); NMR (DMSO-d6): δ 12.46 (1H, s), 7.78 (1H, d, J=7.6 Hz), 7.73-7.50 (3H, m), 5.96 (2H, s), 4.65-4.46 (1H, m), 4.04 (2H, t, J=6.4 Hz), 2.88-2.50 (2H, m), 1.80-0.78 (13H, m).

Example 15(82)

N-(2-cyclohexylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio )tetrazol-1-yl)pentanoic acid ##STR1740##

TLC: Rf 0.25 (chloroform:methanol:acetic acid=95:3:2); NMR (DMSO-d6): δ 12.53 (1H, s), 7.92 (1H, d, J=7.6 Hz), 7.77-7.50 (3H, m), 5.80 (2H, s), 4.73-4.50 (1H, m), 4.13-3.92 (2H, m), 2.85 (1H, dd, J=17.0, 5.4 Hz), 2.29 (1H, dd, J=17.0, 6.6 Hz), 1.80-0.70 (13H, m).

Example 15(83)

N-cyclohexylmethyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-2-yl)pentanoic acid ##STR1741##

TLC: Rf 0.31 (chloroform:methanol:acetic acid=95:3:2); NMR (DMSO-d6): δ 12.40 (1H, brs), 7.77 (1H, d, J=7.6 Hz), 7.75-7.50 (3H, m), 5.95 (2H, s), 4.65-4.45 (1H, m), 3.82 (2H, d, J=5.8 Hz), 2.90-2.50 (2H, m), 1.80-0.80 (11H, m).

Example 15(84)

N-cyclohexylmethyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)te trazol-1-yl)pentanoic acid ##STR1742##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=95:3:2); NMR (DMSO-d6): δ 12.53 (1H, brs), 7.92 (1H, d, J=7.6 Hz), 7.74-7.52 (3H, m), 5.80 (2H, s), 4.70-4.56 (1H, m), 3.96-3.73 (2H, m), 2.85 (1H, dd, J=17.0, 6.2 Hz), 2.70 (1H, dd, J=17.0, 6.5 Hz), 1.80-0.80 (11H, m).

Example 15(85)

N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tet razol-2-yl)pentanoic acid ##STR1743##

TLC: Rf 0.49 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.69-7.50 (4H, m), 7.32-7.13 (5H, m), 5.85 (2H, s), 4.52 (1H, m), 4.22 (2H, m), 2.88 (2H, t, J=7.0 Hz), 2.64 (2H, m).

Example 15(86)

N-(2-phenylethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)tet razol-1-yl)pentanoic acid ##STR1744##

TLC: Rf 0.29 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.83 (1H, d, J=7.0 Hz), 7.70-7.66 (2H, m), 7.60-7.52 (1H, m), 7.27-7.16 (5H, m), 5.71 (2H, s), 4.59 (1H, m), 4.27 (2H, m), 2.91 (2H, t, J=6.8 Hz), 2.70 (2H, m).

Example 15(87)

N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-acetylaminophenylthio )tetrazol-2-yl)pentanoic acid ##STR1745##

TLC: Rf 0.25 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 10.49 (1H, s), 7.87 (2H, s), 7.68 (1H, d, J=7.4 Hz), 5.91 (2H, s), 4.62-4.45 (1H, m), 3.99 (2H, t, J=6.4 Hz), 2.80-2.50 (2H, m), 2.10 (3H, s), 1.64-1.20 (4H, m), 0.88 (3H, t, J=7.2 Hz).

Example 15(88)

N-butyloxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-acetylaminophenylthio )tetrazol-1-yl)pentanoic acid ##STR1746##

TLC: Rf 0.15 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 10.60 (1H, s), 7.87 (2H, s), 7.69 (1H, d, J=8.4 Hz), 5.76 (2H, s), 4.60-4.45 (1H, m), 4.07-3.92 (2H, m), 2.73-2.53 (2H, m), 2.10 (3H, s), 1.65-1.20 (4H, m), 0.86 (3H, t, J=7.2 Hz).

Example 15(89)

N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lthio)tetrazol-2-yl)pentanoic acid ##STR1747##

TLC: Rf 0.44 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.47 (1H, br), 7.84 (1H, d, J=7.0 Hz), 7.79-7.37 and 7.17 (total 7H, m), 5.94 and 5.87 (each 1H, each d, J=l 6.0 Hz), 4.55 (1H, m), 4.25 (2H, t, J=7.0 Hz), 3.00 (2H, t, J=7.0 Hz), 2.76 and 2.60 (each 1H, each dd, J=16.5, 6.0 Hz).

Example 15(90)

N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lthio)tetrazol-1-yl)pentanoic acid ##STR1748##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.91 (1H, d, J=7.5 Hz), 7.79-7.41 and 7.30-7.08 (total 7H, m) 5.71 (2H, brs), 4.59 (1H, m), 4.28 (2H, t, J=6.5 Hz), 3.01 (2H, t, J=6.5 Hz), 2.73 (2H, m).

Example 15(91)

N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-me thylphenylthio)tetrazol-2-yl)pentanoic acid ##STR1749##

TLC: Rf 0.56 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.6-12.3 (1H, br), 7.82 (1H, m), 7.74 (2H, d, J=8.0 Hz), 7.53 (2H, s), 7.48 (2H, d, J=8.0 Hz), 5.90 (2H, brs), 4.53 (1H, m), 4.26 (2H, t, J=6.5 Hz), 2.99 (2H, t, J=6.5 Hz), 2.65 (2H, m), 2.35 (3H, s).

Example 15(92)

N-(2-(4-cyanophenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro-4-me thylphenylthio)tetrazol-1-yl)pentanoic acid ##STR1750##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.86 (1H, m), 7.72 (2H, d, J=8.0 Hz), 7.52 (2H, s), 7.47 (2H, d, J=8.0 Hz), 5.71 (2H, br), 4.58 (1H, m), 4.28 (2H, t, J=6.5 Hz), 3.00 (2H, t, J=6.5 Hz), 2.72 (2H, m), 2.36 (3H, s).

Example 15(93)

N-(2-methoxyethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-2-yl)pentanoic acid ##STR1751##

TLC: Rf 0.53 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 8.89 (1H, d, J=7.0 Hz), 7.70-7.66 (2H, m), 7.55 (1H, dd, J=9.2 Hz, 6.6 Hz), 6.00 (1H, d, J=18.0 Hz), 5.89 (1H, d, J=18.0 Hz), 4.79 (1H, m), 3.45 (2H, t, J=6.6 Hz), 3.24 (3H, s), 2.98 (2H, t, J=6.6 Hz), 2.82 (1H, dd, J=17.2 Hz, 5.6 Hz), 2.64 (1H, dd, J=17.2 Hz, 7.0 Hz).

Example 15(94)

N-(2-methoxyethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthio)t etrazol-1-yl)pentanoic acid ##STR1752##

TLC: Rf 0.34 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.88 (1H, d, J=6.2 Hz), 7.70-7.51 (3H, m), 5.80 (2H, s), 4.79 (1H, m), 3.43 (2H, t, J=6.8 Hz), 3.20 (3H, s), 3.00 (2H, t, J=6.8 Hz), 2.70 (2H, d, J=5.8 Hz).

Example 15(95)

N-(2-(2-methoxyethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylthio)tetrazol-2-yl)pentanoic acid ##STR1753##

TLC: Rf 0.40 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.85 (1H, m), 7.71-7.67 (2H, m), 7.60-7.52 (1H, m), 5.94 (2H, s), 4.55 (1H, m), 4.12 (2H, m), 3.58 (2H, m), 3.50 (2H, m), 3.43 (2H, m), 3.22 (3H, s), 2.82-2.55 (2H, m).

Example 15(96)

N-(2-(2-methoxyethyloxy)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylthio)tetrazol-1-yl)pentanoic acid ##STR1754##

TLC: Rf 0.31 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 7.76-7.55 (4H, m), 5.81 (2H, s), 4.55 (1H, m), 4.13 (2H, m), 3.59 (2H, m), 3.56 (2H, m), 3.40 (2H, m), 3.21 (3H, s), 2.66 (2H, m).

Example 15(97)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetraz ol-2-yl)pentanoic acid ##STR1755##

TLC: Rf 0.49 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.58 (1H, m), 8.91 (1H, d, J=7.0 Hz), 7.63-7.59 (1H, m), 7.43-7.17 (8H, m), 6.05 (1H, d, J=8.0 Hz),5.94 (1H, d, J=18.0 Hz), 4.83 (1H, m), 3.10 (2H, m),2.89-2.79 (3H, m), 2.67 (1H, dd, J=17.0 Hz, 7.0 Hz).

Example 15(98)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2-chlorophenylthio)tetraz ol-1-yl)pentanoic acid ##STR1756##

TLC: Rf 0.40 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 8.81 (1H, m), 7.58 (1H, d, J=7.0 Hz), 7.53-7.37 (3H, m), 7.24-7.20 (5H, m), 5.80 (2H, s), 4.76 (1H, m), 3.05 (2H, m), 2.81 (2H, m), 2.62 (2H, m).

Example 15(99)

N-(2-acetylaminoethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylth io)tetrazol-2-yl)pentanoic acid ##STR1757##

TLC: Rf 0.41 (chloroform:methanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 8.67 (1H, d, J=6.4 Hz), 8.06 (1H, d, J=5.8 Hz), 7.74-7.50 (3H, m), 5.98 (2H, brs), 4.80-4.55 (1H, m), 3.18 (2H, dt, J=6.4, 5.8 Hz), 2.86 (2H, t, J=5.8 Hz), 2.65-2.50 (2H, m), 1.78 (3H, s).

Example 15(100)

N-(2-acetylaminoethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylth io)tetrazol-1-yl)pentanoic acid ##STR1758##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 8.90-8.73 (1H, m), 8.10-8.00 (1H, m), 7.75-7.48 (3H, m), 5.84 (2H, brs), 4.80-4.60 (1H, m), 3.24-3.10 (2H, m), 3.00-2.75 (2H, m), 2.65-2.50 (2H, m), 1.77 (3H, s).

Example 15(101)

N-(2-acetylaminoethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthi o)tetrazol-2-yl)pentanoic acid ##STR1759##

TLC: Rf 0.49 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 12.40 (1H, m), 7.96 (1H, m), 7.78-7.50 (4H, m), 5.96 (2H, m), 4.57 (1H, m), 4.00 (2H, m), 3.26 (2H, m), 2.70 (2H, m), 1.80 (3H, s).

Example 15(102)

N-(2-acetylaminoethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylthi o)tetrazol-1-yl)pentanoic acid ##STR1760##

TLC: Rf 0.45 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 8.00 (1H, m), 7.70-7.52 (4H, m), 5.81 (2H, m), 4.57 (1H, m), 4.03 (2H, m), 3.29 (2H, m), 2.70 (2H, m), 1.81 (3H, s).

Example 15(103)

N-(2-(2-methoxyethyloxy)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylthio)tetrazol-2-yl)pentanoic acid ##STR1761##

TLC: Rf 0.41 (chloroform:methanol:water=40:10:1); NMR (CDCl3): δ 7.60-7.20 (4H, m), 6.20-5.40 (2H, m), 5.00-4.60 (1H, m), 3.80-3.40 (6H, m), 3.29 (3H, s), 3.20-3.00 (2H, m), 2.60-2.20 (2H, m).

Example 15(104)

N-(2-(2-methoxyethyloxy)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylthio)tetrazol-1-yl)pentanoic acid ##STR1762##

TLC: Rf 0.34 (chloroform:methanol:water=40:10:1); NMR (CDCl3): δ 8.00-7.50 (1H, m), 7.50-7.20 (3H, m), 6.20-5.20 (2H, m), 5.00-4.60 (1H, m), 3.80-3.40 (6H, m), 3.32 (3H, s), 3.20-3.00 (2H, m), 2.80 (2H, brs).

Example 15(105)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(phenylthio) tetrazol-2-yl)pentanoic acid ##STR1763##

TLC: Rf 0.61 (chloroform:methanol:water=40:10:1); NMR (Acetone-d6): δ 7.56-7.51 (2H, m), 7.42-7.38 (3H, m), 7.27 (5H, s), 7.18 (1H, m), 6.05-5.83 (2H, m), 5.01 (1H, m), 3.18 (2H, m), 2.96-2.89 (4H, m).

Example 15(106)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(phenylthio) tetrazol-1-yl)pentanoic acid ##STR1764##

TLC: Rf 0.45 (chloroform:methanol:water=40:10:1); NMR (Acetone-d6): δ 7.60-7.55 (2H, m), 7.42-7.39 (3H, m), 7.25 (5H, s), 7.17 (1H, m), 5.89-5.63 (2H, m), 5.02 (1H, m), 3.20 (2H, m), 2.96-2.88 (4H, m).

EXAMPLES 16(1)-16(4)

By the same procedure as provided in example 1, using the corresponding tetrazole compounds and the corresponding bromo compounds instead of N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-bromopentanoi c acid•t-butylester, compounds of the present invention having the following physical data were obtained.

Example 16(1)

N-(2-(4-methoxymethyloxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-di chlorophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1765##

TLC: Rf 0.60 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.44 (2H, d, J=7.4 Hz), 7.29 (1H, m), 7.14 (2H, d, J=8.4 Hz), 6.96 (2H, d, J=8.4 Hz), 5.83 (1H, m), 5.70 (1H, d, J=17.4 Hz), 5.51 (1H, d, J=17.4 Hz), 5.12 (2H, s), 4.59 (1H, m), 4.35 (2H, m), 3.45 (3H, s), 3.02-2 (3H, m), 2.66 (1H, dd, J=l 7 Hz, 5.0 Hz), 1.42 (9H, s).

Example 16(2)

N-(2-(4-methoxymethyloxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-di chlorophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1766##

TLC: Rf 0.52 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.45 (2H, d, J=7.4 Hz), 7.31 (1H, m), 7.16 (2H, d, J=8.6 Hz), 6.98 (2H, d, J=8.6 Hz), 5.91 (1H, m), 5.65 (1H, d, J=18.2 Hz), 5.46 d, J=18.2 Hz), 5.13 (2H, s), 4.64 (1H, m), 4.39 (2H, m), 3.46 (3H, s), 3.06 (1H, dd, J=17 Hz, 4 Hz), 2.94 (2H, t, J=6.8 Hz), 2.73 (1H, dd, J=17 Hz, 5 Hz), 1.44 (9H, s).

Example 16(3)

N-(2-(4-methoxymethyloxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-d ichlorophenylthio)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1767##

TLC: Rf 0.55 (hexane:ethyl acetate=11); NMR (CDCl3): δ 7.47-7.26 (3H, m), 7.07 (2H, d, J=8.6 Hz), 6.73 (2H, d, J=8.6 Hz), 6.60 (1H, d, J=8.6 Hz), 5.66 (1H, d, J=17.8 Hz), 5.47 (1H, d, J=17.8 Hz), 4.82 (1H, m), 3.19 (2H, m), 3.02-2.80 (3H, m), 2.66 (1H, dd, J=18 Hz, 4.8 Hz), 1.42 (9H, s).

Example 16(4)

N-(2-(4-meythoxymethyoxyphenyl)ethythio)carbonyl-3-amino-4-oxo-5-(5-(2,6-di chlorophenylthio)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1768##

TLC: Rf 0.43 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.47-7.31 (3H, m), 7.08 (2H, d, J=8.6 Hz), 6.76 (2H, d, J=8.6 Hz), 6.66 (1H, d, J=8.8 Hz), 5.99 (1H, d, J=l8 Hz), 5.81 (1H, d, J=18 Hz), 4.88 (1H, m), 3.23 (2H, m), 3.05 (1H, dd, J=17 Hz, 4.4 Hz), 2.89 (2H, m), 2.71 (1H, dd, J=17 Hz, 4.8 Hz), 1.45 (9H, s).

EXAMPLES 17(1)-17(4)

By the same procedure as provided in example 6(1), using the compound prepared in examples 16(1)-16(4), compounds of the present invention having the following physical data were obtained.

Example 17(1)

N-(2-(4-hydroxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylthio)tetrazol-2-yl)pentanoic acid ##STR1769##

TLC: Rf 0.37 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 9.26 (1H, brs), 7.70-7.44 (4H, m), 7.03 (2H, d, J=8.2 Hz), 6.67 (2H, d, J=8.2 Hz), 5.94 (2H, m), 4.51 (1H, m), 4.13 (2H, t, J=6.8 Hz), 2.76 (2H, t, J=6.8 Hz), 2.59 (2H, m).

Example 17(2)

N-(2-(4-hydroxyphenyl)ethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophe nylthio)tetrazol-1-yl)pentanoic acid ##STR1770##

TLC: Rf 0.31 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 9.28 (1H, brs), 7.70-7.55 (4H, m), 7.02 (2H, d, J=8.4 Hz), 6.60 (2H, d, J=8.4 Hz), 5.80 (2H, m), 4.54 (1H, m), 4.17 (2H, m), 2.77 (2H, m), (2H, m), 2.64 (2H, m).

Example 17(3)

N-(2-(4-hydroxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylthio)tetrazol-2-yl)pentanoic acid ##STR1771##

TLC: Rf 0.30 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 9.27 (1H, brs), 8.54 (1H, m), 7.69-7.49 (3H, m), 7.00 (2H, d, J=8.4 Hz), 6.67 (2H, d, J=8.4 Hz), 5.96 (2H, m), 4.75 (1H, m), 3.00 (2H, m), 2.71 (2H, m), 2.59 (2H, m).

Example 17(4)

N-(2-(4-hydroxyphenyl)ethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylthio)tetrazol-1-yl)pentanoic acid ##STR1772##

TLC: Rf 0.24 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 9.24 (1H, brs), 8.73 (1H, d, J=7 Hz), 7.68-7.51 (3H, m), 6.95 (2H, d, J=8.2 Hz), 6.62 (2H, d, J=8.2 Hz), 5.85 (2H, m), 4.77 (1H, m), 2.98 (2H, m), 2.70-2.61 (4H, m).

Reference Example 9(1)

3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester•hydrochloric acid salt ##STR1773##

The mixture of the compound prepared in example 5(1) (8.74 g), ethanol (600 ml), 10% palladium on activated carbon (773 mg) and a 6N aqueous solution of hydrochloric acid (5.37 ml) was stirred for 20 min at room temperature under an atmosphere of hydrogen gas. The reaction mixture was filtered through Celite (trade mark) and the filtrate was concentrated to give the title compound having the following physical data.

TLC: Rf 0.36 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 9.10-8.40 (3H, br), 7.55 (1H, d, J=9.0 Hz), 7.55 (1H, d, J=7.2 Hz), 7.40 (1H, dd, J=9.0 Hz, 7.2 Hz), 6.11 (2H, br), 4.75-4.55 (1H, m), 4.41 (2H, s), 3.50-3.05 (2H, m), 1.44 (9H, s).

Reference Example 9(2) and Reference Example 9(3)

By the same procedure as provided in reference example 9(1), using the compound prepared in example 5(2) or example 5(3), the title compounds having the following physical data were obtained.

Reference Example 9(2)

3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester•hydrochloric acid salt ##STR1774##

TLC: Rf 0.32 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.60-8.35 (3H, br), 7.52 (2H, each d, J=9.0, 6.8 Hz), 7.37 (1H, dd, J=9.0, 6.8 Hz), 6.14 and 6.03 (each 1H, d, J=17.5 Hz), 4.60-4.46 (1H, m), 4.54 (2H, s), 3.28-2.99 (2H, m), 1.41 (9H, s).

Reference Example 9(3)

3-amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester•hydrochloric acid salt ##STR1775##

TLC: Rf 0.54 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 8.66 (2H, brs), 7.31 (5H, s), 5.96 (2H, s), 4.63 (1H, brs), 4.20 (2H, s), 3.17 (2H, m), 1.44 (9H, s).

Example 18(1)

3-(N-(2-(hexahydro-2-oxo-3S-(thiazol-4-ylcarbonylamino)azepin-1-yl)) propionyl)amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentano ic acid•t-butylester ##STR1776##

To a solution of 2-(hexahydro-2-oxo-3S-(thiazol-4-ylcarbonylamino)azepin-1-yl)propionic acid (414 mg) in dichloromethane (4 ml) and dimethylformamide (1 ml) was added 1-hydroxybenzotriazole (306 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (383 mg) at 0°C The mixture was stirred for 15 min at room temperature. To the mixture was added the compound prepared in reference example 9 (1) (600 mg) in dimethylformamide (3 ml) and triethylamine (0.204 ml) at 0°C The reaction mixture was stirred for 1 h at room temperature. The reaction mixture was quenched by addition of water, and extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol=100:1→29:1) to give the compound of the present invention (682 mg) having the following physical data.

TLC: Rf 0.55 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 9.17 (1H, m), 8.94-8.51 (2H, m), 8.30 (1H, m), 7.52-7.25 (3H, m), 5.82 (2H, m), 5.27-4.68 (3H, m), 4.34 (2H, m), 3.65-3.42 (2H, m), 2.91-2.56 (2H, m), 2.08-1.52 (6H, m), 1.39 (9H, s), 1.33 (3H, m).

EXAMPLES 18(2)-18(28)

By the same procedure as provided in example 18(1), using the corresponding carboxylic acid compounds and the compound prepared in reference example 9(1), reference example 9(2) or reference example 9(3), the compounds of the present invention having the following physical data were obtained.

Example 18(2)

3-(N-(2-(hexahydro-2-oxo-3S-(thiazol-4-ylcarbonylamino)azepin-1-yl)) propionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1777##

TLC: Rf 0.65 (chloroform:methanol=9:1); NMR (CDCl3): δ 9.19-9.08 (1H, m), 8.85-8.50 (2H, m), 8.35-8.29 (1H, m), 7.27 (5H, m), 5.67 (2H, m), 5.26-4.69 (3H, m), 4.13 (2H, m), 3.58-3.20 (2H, m), 2.86-2.56 (2H, m), 2.07-1.43 (6H, m), 1.38-1.29 (12H, m).

Example 18(3)

3-(N-(2-(hexahydro-2-oxo-3S-(pyridin-3-ylcarbonylamino)azepin-1-yl))propion yl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1778##

TLC: Rf 0.34 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.92 (1H, m), 8.64 (1H, m), 8.51 (2H, m), 8.08 (1H, m), 7.42 (1H, m), 7.21 (5H, s), 5.59 (2H, s), 5.13-4.57 (3H, m), 4.05 (2H, m), 3.40 (2H, m), 2.71-2.50 (2H, m), 1.82 (6H, m), 1.33 (9H, s), 1.28 (3H, m).

Example 18(4)

3-(N-(2-(hexahydro-2-oxo-3S-(quinolin-2-ylcarbonylamino)azepin-1-yl))propio nyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1779##

TLC: Rf 0.69 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 9.30 (1H, m), 8.86-8.54 (2H, m), 8.19-8.05 (2H, m), 7.99-7.68 (3H, m), 7.24 (5H, m), 5.70 (2H, m), 5.28-4.66 (2H, m), 4.14 (2H, m), 3.62-3.23 (2H, m), 2.82-2.38 (2H, m), 2.21-1.48 (6H, m), 1.37 (12H, m).

Example 18(5)

3-(N-(2-(hexahydro-2-oxo-3S-(pyridin-2-ylcarbonylamino)azepin-1-yl))propion yl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1780##

TLC: Rf 0.61 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 9.11 (1H, m), 8.86-8.51 (2H, m), 8.04 (2H, m), 7.62 (1H, m), 7.27 (5H, m), 5.67 (2H, m), 5.24-4.65 (2H, m), 4.11 (2H, m), 3.52 (1H, m), 3.24 (1H, m), 2.80 (1H, m), 2.56 (1H, m), 2.06-1.45 (6H, m), 1.38 (9H, s), 1.34 (3H, s).

EXAMPLES 18(6) AND 18(7)

3-(N-(2-(hexahydro-2-oxo-3S-(morpholin-1-ylcarbonylamino)azepin-1-yl))propi onyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1781## (wherein represents mixture of R and S stereochemistry. The compounds were separated to the compound of example 19(6) and example 19(7) by hydrolysis of t-butylester)

NMR (DMSO-d6): δ 8.63-8.39 (1H, m), 7.25 (5H, m), 6.35 (1H, t-like), 5.58 (2H, m), 5.11-4.28 (2H, m), 4.08 (2H, s), 3.45 (6H, m), 3.15 (2H, m), 2.76 (1H, m), 2.50 (1H, m), 1.75-1.40 (6H, m), 1.34 (9H, s), 1.26 (3H, m).

Example 18(8)

3-(N-(2-(hexahydro-2-oxo-3S-(pyridin-4-ylcarbonylamino)azepin-1-yl))propion yl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1782##

TLC: Rf 0.57 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 8.66 (4H, m), 7.72 (2H, m), 7.27 (5H, m), 5.65 (2H, m), 5.18-4.63 (2H, m), 3.60-3.34 (2H, m), 2.80 (1H, m), 2.54 (2H, m), 1.93-1.58 (6H, m), 1.39 (9H, m), 1.33 (3H, m).

Example 18(9)

3-(N-(2-(hexahydro-2-oxo-3S-(4-methoxyphenylcarbonylamino)azepin-1-yl))prop ionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1783##

NMR (DMSO-d6): δ 8.55 (1H, d, J=6.5 Hz), 8.02 (1H, d, J=6.5 Hz), 7.80 (2H, dd, J=8.0, 2.0 Hz), 7.40-7.18 (5H, m), 6.98 (2H, d, J=8.0 Hz), 5.66 (2H, s), 5.10 (1H, q, J=6.0 Hz), 4.90-4.60 (2H, m), 4.20-4.10 (2H, m), 3.80 (3H, s), 2.88-2.50 (4H, m), 2.35-1.20 (9H, m), 1.14 (9H, s).

Example 18(10)

3-(N-(2-(hexahydro-2-oxo-3S-(3-methoxyphenylcarbonylamino)azepin-1-yl))prop ionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1784##

NMR (DMSO-d6): δ 8.58 (1H, d, J=7.0 Hz), 8.20 (1H, d, J=7.0 Hz), 7.40-7.40 (8H, m),7.15-7.00 (1H, m), 5.65 (2H, s), 5.34-5.05 (1H, q, J=6.5 Hz), 4.92-4.65 (2H, m), 4.12 (2H, s), 3.80 (3H, s), 2.95-2.50 (4H, m), 2.05-1.20 (9H, m), 1.15 (9H, s).

Example 18(11)

3-(N-(2-(hexahydro-2-oxo-3S-(4-(morpholin-1-ylcarbonyl) phenylcarbonylamino)azepin-1-yl))propionyl)amino-4-oxo-5-(5-phenylmethylte trazol-1-yl)pentanoic acid•t-butylester ##STR1785##

NMR (DMSO-d6): δ 8.60-8.58 (2H, m), 7.92 (2H, t, J=8.0 Hz), 7.52-7.40 (2H, m), 7.32-7.15 (5H, m), 5.82-5.58 (2H, m), 5.20-5.10 (1H, m), 5.00-4.80 (1H, m), 4.70-4.50 (1H, m), 4.15 (2H, brs), 3.80-3.20 (8H, m), 2.78-2.42 (4H, m), 2.00-1.50 (7H, m), 1.45-1.20 (3H, m), 1.20 (9H, s).

EXAMPLES 18(12) AND (13)

3-(N-(2-(hexahydro-2-oxo-3S-(quinolin-3-ylcarbonylamino)azepin-1-yl))propio nyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1786## (wherein * represents mixture of R and S stereochemistry. The compounds were separated to the compound of example 19(12) and example 19(13) by hydrolysis of t-butylester)

TLC: Rf 0.71 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 9.37-9.24 (2H, m), 8.88-8.51 (2H, m), 8.23 (2H, m), 7.96-7.81 (2H, m), 7.26 (5H, m), 5.68 (2H, m), 5.30-4.67 (2H, m), 4.14 (2H, m), 3.56 (1H, m), 3.29 (1H, m), 2.81 (1H, m), 2.58 (1H, m), 2.13-1.49 (6H, m), 1.38 (12H, s).

Example 18(14)

3-(N-(2-(hexahydro-2-oxo-3S-(pyridin-3-ylcarbonylamino)azepin-1-yl))propion yl)amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl) pentanoic acid•t-butylester ##STR1787##

TLC: Rf 0.46 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 8.99 (1H, m), 8.81-8.53 (3H, m), 8.14 (1H, m), 7.48 (4H, m), 5.79 (2H, m), 5.22-4.69 (3H, m), 4.35 (2H, m), 3.63-3.40 (2H, m), 2.86 (1H, m), 2.56 (1H, m), 1.95-1.48 (6H, m), 1.39 (9H, s), 1.33 (3H, m).

Example 18(15)

3-(N-(2-(hexahydro-2-oxo-3S-(4-dimethylaminophenylcarbonylamino)azepin-1-yl ))propionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1788##

NMR (CDCl3): δ 8.75 (1H, m), 7.90-7.50 (4H, m), 7.40-7.10 (8H, m), 6.70 (2H, d, J=10 Hz), 6.54 (1H, d, J=8.5 Hz), 5.60 (2H, m), 5.25-5.10 (1H, m), 4.90-4.60 (5H, m), 3.20-2.50 (3H, m), 2.65 (6H, s), 2.15-1.60 (8H, m), 1.45 (3H, d, J=7.5 Hz), 1.15 (9H, s).

Example 18(16)

3-(N-(2S-(2-phenyl-4R-methyl-4,5-dihydrothiazol-4-ylcarbonylamino) propionyl)amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentano ic acid•t-butylester ##STR1789##

TLC: Rf 0.58 and 0.60 (hexane:ethyl acetate=1:3); NMR (CDCl3): δ 7.90-7.75 (1H, m), 7.60-7.10 (7H, m), 6.90-5.35 (2H, m), 4.90-4.70 (1H, m), 4.60-4.30 (2H, m), 3.90-3.70 (2H, m), 3.40-3.30 (1H, m), 3.10-2.90 (1H, m), 2.80-2.50 (1H, m), 1.60 (9H, s), 1.60-1.35 (6H, m).

Example 18(17)

3-(N-(2S-(2-phenyl-4,5-dihydrothiazol-4-ylcarbonylamino)propionyl) amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1790##

TLC: Rf 0.62 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.90-7.70 (1H, m), 7.60-6.90 (7H, m), 5.90-5.75 (1H, m),5.65-5.40 (1H, m),5.30-5.10 (1H, m),4.95-4.70 (1H, m), 4.65-4.10 (2H, m), 4.00-3.55 (2H, m), 3.40-3.15 (1H, m), 3.15-2.95 (1H, m), 2.85-2.65 (1H, m), 1.60-1.05 (12H, m).

Example 18(18)

N-(thiazol-4-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetra zol-2-yl)pentanoic acid•t-butylester ##STR1791##

TLC: Rf 0.37 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.81 (1H, d, J=2.0 Hz), 8.26 (1H, d, J=2.0 Hz), 7.33 (1H, d, J=8.6 Hz), 7.33 (1H, d, J=7.4 Hz), 7.16 (1H, dd, J=8.6 Hz, 7.4 Hz), 5.85 and 5.63 (each 1H, d, J=18.0 Hz), 5.17-5.02 (1H, m), 4.59 (2H, s), 3.19 (1H, dd, J=17.5 Hz, 4.6 Hz), 2.76 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.45 (9H, s).

Example 18(19)

N-phenylthiomethylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1792##

TLC: Rf 0.58 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.94 (1H, d, J=9.0 Hz), 7.39-7.22 (8H, m), 5.16 (2H, s), 4.81 (1H, dt, J=9.0, 4.6 Hz), 4.58 (2H, s), 3.83 (1h, d, J=17.0 Hz), 3.68 (1h, d, J=17.0 Hz), 2.95 (1H, dd, J=17.5, 4.7 Hz), 2.46 (1H, dd, J=17.5, 4.7 Hz), 1.40 (9H, s).

Example 18(20)

N-(perhydrobenzo-1,4-diazepin-2,5-dion-3-ylcarbonyl)-3-amino-4-oxo-5-(5-(2, 6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1793##

TLC: Rf 0.30 (chloroform:methanol=8:1); NMR (CDCl3): δ 9.50-8.90 (1H, m),8.50-8.10 (1H, m),7.90-7.80 (1H, m), 7.60-7.10 (6H, m), 7.10-6.80 (1H, m), 5.80-5.30 (1H, m), 4.90-4.60 (1H, m), 4.50-4.00 (2H, m), 3.20-2.50 (2H, m), 1.50-1.20 (9H, m).

Example 18(21)

3-(N-(2-(hexahydro-2-oxo-3S-(3-t-butoxycarbonylphenylcarbonylamino)azepin-1 -yl))propionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1794##

TLC: Rf 0.43 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.78-8.48 (2H, m), 8.34 (1H, m), 8.06 (2H, m), 7.58 (1H, m), 7.25 (5H, m), 5.65 (2H, s), 5.23-4.65 (3H, m), 4.12 (2H, m), 3.61-3.35 (2H, m), 2.80 (1H, m), 2.54 (1H, m), 1.94-1.61 (6H, m), 1.57 (9H, s), 1.38 (9H, s), 1.34 (3H, m).

Example 18(22)

3-(N-(2-(hexahydro-2-oxo-3S-(4-t-butoxycarbonylphenylcarbonylamino)azepin-1 -yl))propionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•t-butylester ##STR1795##

TLC: Rf 0.58 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 8.81-8.45 (2H, m), 7.93 (4H, m), 7.26 (5H, m), 5.66 (2H, m), 5.23-4.64 (3H, m), 4.13 (2H, m), 3.61-3.28 (2H, m), 2.81 (1H, m), 2.55 (1H, m), 1.97-1.47 (6H, m), 1.57 (9H, s), 1.38 (9H, s), 1.34 (3H, m).

Example 18(23)

N-(1-benzyloxycarbonylpiperidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1796## (wherein * represent R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 18(24))

TLC: Rf 0.52 (hexane:ethyl acetate=1:1); NMR (DMSO-d6): δ 8.80-8.65 (1H, m), 7.60-7.15 (8H, m), 5.90-5.67 (2H, m), 5.06 (2H, brs), 4.99-4.81 and 4.81-4.65 (each 1H, m), 4.51-4.15 (2H, m), 4.02-3.80 (1H, m), 3.45-2.95 (1H, m), 2.95-2.55 (2H, m), 2.20-2.00 (1H, m), 1.80-1.10 (5H, m), 1.39 (9H, s).

Example 18(24)

N-(1-benzyloxycarbonylpiperidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1797## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 18(23))

TLC: Rf 0.44 (hexane:ethyl acetate=1:1); NMR (DMSO-d6): δ 9.00-8.75 (1H, m), 7.57-7.15 (8H, m), 5.98-5.50 (2H, m), 5.14-4.90 (2H, m), 4.90-4.65 (2H, m), 4.44-4.14 (2H, m), 4.05-3.98 (1H, m), 3.45-2.95 (1H, m), 2.95-2.45 (2H, m), 2.21-2.05 (1H, m), 1.80-1.10 (5H, m), 1.40 (9H, s).

Example 18(25)

N-(1-acetylpiperidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1798##

TLC: Rf 0.40 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.87-8.51 (1H, m), 7.58-7.20 (3H, m), 5.93-5.60 (2H, m), 5.11-4.47 (2H, m), 4.47-4.07 and 3.80-3.60 (3H, m), 3.40-3.13 (1H, m), 2.98-2.56 (2H, m), 2.22-1.90 (1H, m), 2:04 and 1.99 (total 3H, each s), 1.75-1.10 (5H, m), 1.40 (9H, s).

Example 18(26)

N-(1-benzyloxycarbonylpyrrolidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dic hlorophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1799## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 18(27))

TLC: Rf 0.30 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.76-7.55 (1H, br), 7.42-7.14 (8H, m), 5.90-5.33 (2H, m), 5.12 (2H, s), 4.96-4.62 (1H, m), 4.31 (3H, brs), 3.81-3.34 (2H, m), 3.17-2.50 (2H, m), 2.45-1.78 (4H, m), 1.44 (9H, s).

Example 18(27)

N-(1-benzyloxycarbonylpyrrolidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dic hlorophenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1800## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 18(26))

TLC: Rf 0.24 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.86-7.64 (1H, m), 7.45-7.10 (8H, m), 5.95-5.35 (2H, m), 5.31-5.00 (2H, m), 4.95-4.60 (1H, m), 4.52-4.34 (1H, m), 4.27 (2H, s), 3.77-3.33 (2H, br), 3.15-2.50 (2H, m), 2.44-1.73 (4H, m), 1.43 (9H, s).

Example 18(28)

N-(1-acetylpyrrolidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1801##

TLC: Rf 0.19 (ethyl acetate); NMR (CDCl3): δ 9.05 and 8.86 (total 1H, each d, J=7.0 and 7.4 Hz), 7.64-7.30 (3H, m), 6.01-5.64 (2H, m), 4.99-4.54 (1H, m), 4.54-3.98 (1H, m), 4.34 and 4.26 (total 2H, each s), 3.80-3.23 (2H, m), 3.00-2.38 (2H, m), 2.34-1.57 (4H, m), 1.99 and 1.95 (total 3H, each s), 1.41 (9H, s).

EXAMPLES 19(1)-19(26)

By the same procedure as provided in example 6(1), using the compound prepared in examples 18(1)-18(20) or examples 18(23)-18(28), the compounds of the present invention having the following physical data were obtained.

Example 19(1)

3-(N-(2-(hexahydro-2-oxo-3S-(thiazol-4-ylcarbonylamino)azepin-1-yl)) propionyl)amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentano ic acid ##STR1802##

TLC: Rf 0.57 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 9.18-9.08 (1H, m), 8.75-8.50 (2H, m), 8.34-8.29 (1H, m), 7.52-7.26 (3H, m), 6.02-5.69 (2H, m), 5.24-4.63 (3H, m), 4.35 (2H, m), 3.62-3.30 (2H, m), 2.70 (2H, m), 2.07-1.44 (6H, m), 1.39-1.27 (3H, m).

Example 19(2)

3-(N-(2-(hexahydro-2-oxo-3S-(thiazol-4-ylcarbonylamino)azepin-1-yl)) propionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1803##

TLC: Rf 0.57 (chloroform:methanol:water=6:4:1); NMR (CDCl3): δ 12.72 (1H, brs), 9.13 (1H, m), 8.90-8.49 (2H, m), 8.30 (1H, m), 7.27 (5H, m), 5.69 (2H, m), 5.23-4.65 (3H, m), 4.14 (2H, m), 3.48 (2H, m), 2.90-2.54 (2H, m), 2.05-1.41 (6H, m), 1.32 (3H, m).

Example 19(3)

3-(N-(2-(hexahydro-2-oxo-3S-(pyridin-3-ylcarbonylamino)azepin-1-yl))propion yl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1804##

TLC: Rf 0.54 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 12.60 (1H, brs), 8.98 (1H, m), 8.69-8.58 (3H, m), 8.13 (1H, m), 7.47 (1H, m), 7.27 (5H, m), 5.66 (2H, m), 5.20-4.61 (3H, m), 4.11 (2H, m), 3.42 (2H, m), 2.72 (2H, m), 1.87 (6H, m), 1.32 (3H, m).

Example 19(4)

3-(N-(2-(hexahydro-2-oxo-3S-(quinolin-2-ylcarbonylamino)azepin-1-yl))propio nyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1805##

TLC: Rf 0.40 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.51 (1H, m), 9.34 (1H, dd, J=6.4 Hz, 0.8 Hz), 8.66 (1H, m), 8.60 (1H, d, J=8.4 Hz), 8.19 (1H, d, J=8.4 Hz), 8.08 (2H, m),7.88 (1H, m), 7.77 (1H, m), 7.22 (5H, m), 5.70 (2H, s), 5.24 (1H, m), 4.80 (2H, m), 4.13 (2H, m), 3.62-3.22 (2H, m), 2.84 (1H, m), 2.56 (1H, m), 2.14-1.23 (6H, m), 1.37 (3H, d, J=7.0 Hz).

Example 19(5)

3-(N-(2-(hexahydro-2-oxo-3S-(pyridin-2-ylcarbonylamino)azepin-1-yl))propion yl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1806##

TLC: Rf 0.70 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 9.12 (1H, m), 8.64 (2H, m), 8.02 (2H, m), 7.62 (1H, m), 7.27 (5H, m), 5.67 (2H, m), 5.26-4.74 (3H, m), 4.14 (2H, m), 3.40 (2H, m), 2.90-2.59 (2H, m), 2.08-1.43 (6H, m), 1.32 (3H, m).

Example 19(6)

3-(N-(2-(hexahydro-2-oxo-3S-(morpholin-1-ylcarbonylamino)azepin-1-yl))propi onyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1807## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 18(7))

TLC: Rf 0.62 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 12.53 (1H, brs), 8.52 (1H, m), 7.27 (5H, m), 6.43 (1H, m), 5.66 (2H, s), 5.12 (1H, m), 4.74 (1H, m), 4.52 (1H, m), 4.13 (2H, m), 3.52 (4H, m), 3.44 (2H, m), 3.24 (4H, m), 2.81 (1H, m), 2.60 (1H, m), 1.85-1.37 (6H, m), 1.30 (3H, m).

Example 19(7)

3-(N-(2-(hexahydro-2-oxo-3S-(morpholin-1-ylcarbonylamino)azepin-1-yl))propi onyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1808## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 18(6))

TLC: Rf 0.59 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 12.56 (1H, brs), 8.68-8.48 (1H, m), 7.30 (3H, m), 6.42 (1H, m), 5.66 (2H, m), 4.66 (2H, m), 4.41 (1H, m), 4.13 (2H, m), 3.48 (4H, m), 3.42 (2H, m), 3.17 (4H, m), 2.82 (1H, m), 2.61 (1H, m), 1.80-1.42 (6H, m), 1.30 (3H, m).

Example 19(8)

3-(N-(2-(hexahydro-2-oxo-3S-(pyridin-4-ylcarbonylamino)azepin-1-yl))propion yl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1809##

TLC: Rf 0.59 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 8.70 (4H, m), 7.73 (2H, m), 7.26 (5H, m), 5.67 (2H, m), 5.19-4.65 (3H, m), 4.13 (2H, m), 3.55 (2H, m), 2.83 (1H, m), 2.60 (1H, m), 1.94-1.60 (6H, m), 1.32 (3H, m).

Example 19(9)

3-(N-(2-(hexahydro-2-oxo-3S-(4-methoxyphenylcarbonylamino)azepin-1-y))propi onyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1810##

TLC: Rf 0.50 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 8.58 (1H, d, J=6.5 Hz), 8.05 (1H, d, J=6.5 Hz), 7.80 (2H, dd, J=8.0, 2.0 Hz), 7.40-7.18 (5H, m), 6.98 (2H, d, J=8.0 Hz), 5.62 (2H, s), 5.08 (1H, q, J=6.0 Hz), 4.90-4.60 (2H, m), 4.20-4.00 (2H, m) 3.80 (3H, s), 2.88-2.50 (4H, m), 2.05-1.20 (9H, m).

Example 19(10)

3-(N-(2-(hexahydro-2-oxo-3S-(3-methoxyphenylcarbonylamino)azepin-1-yl))prop ionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1811##

TLC: Rf 0.48 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 8.58 (1H, d, J=7.0 Hz), 8.20 (1H, d, J=7.0 Hz), 7.40-7.20 (8H, m),7.15-7.00 (1H, m), 5.65 (2H, s), 5.30-5.10 (1H, q, J=6.5 Hz), 4.92-4.65 (2H, m), 4.12 (2H, s), 3.80 (3H, s), 2.95-2.50 (4H, m), 2.05-1.20 (9H, m).

Example 19(11)

3-(N-(2-(hexahydro-2-oxo-3S-(4-(morpholin-1-ylcarbonyl) phenylcarbonylamino)azepin-1-yl))propionyl)amino-4-oxo-5-(5-phenylmethylte trazol-1-yl)pentanoic acid ##STR1812##

TLC: Rf 0.45 (chloroform:methanol:water=70:30:1); NMR (DMSO-d6): δ 8.60-8.58 (2H, m), 7.92 (2H, t, J=8.0 Hz), 7.52-7.40 (2H, m), 7.32-7.15 (5H, m), 5.82-5.58 (2H, m), 5.20-5.10 (1H, m), 5.00-4.80 (1H, m), 4.70-4.50 (1H, m), 4.15 (2H, brs), 3.80-3.20 (8H, m), 2.78-2.42 (4H, m), 2.00-1.50 (7H, m), 1.45-1.20 (3H, m).

Example 19(12)

3-(N-(2-(hexahydro-2-oxo-3S-(quinolin-3-ylcarbonylamino)azepin-1-yl))propio nyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1813## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet.)

TLC: Rf 0.30 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.40 (1H, brs), 9.38 (1H, s), 9.35 (1H, m), 8.81 (1H, m), 8.57 (1H, s), 8.27 (2H, m), 7.89 (2H, m), 7.26 (5H, m), 5.68 (2H, m), 5.24 (1H, m), 4.82 (2H, m), 4.14 (2H, m), 3.55-3.27 (2H, m), 2.84 (1H, m), 2.58 (1H, m), 2.15-1.46 (6H, m), 1.37 (3H, m).

Example 19(13)

3-(N-(2-(hexahydro-2-oxo-3S-(quinolin-3-ylcarbonylamino)azepin-1-yl))propio nyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1814##

TLC: Rf 0.30 and 0.25 (chloroform:methanol:water=40:10:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 9.25 (2H, m), 8.86-8.67 (1H, m), 8.54 (1H, s), 8.21 (2H, m), 7.85 (2H, m), 7.27 (5H, m), 5.72 (2H, m), 4.81 (3H, m), 4.12 (2H, m), 3.52 (2H, m), 2.87 (1H, m), 2.67 (1H, m), 2.07-1.52 (6H, m), 1.34 (3H, m).

Example 19(14)

3-(N-(2-(hexahydro-2-oxo-3S-(pyridin-3-ylcarbonylamino)azepin-1-yl))propion yl)amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl) pentanoic acid ##STR1815##

TLC: Rf 0.55 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 12.50 (1H, brs), 8.99 (1H, m), 8.81-8.52 (3H, m), 8.19-8.08 (1H, m), 7.55-7.26 (4H, m), 5.98-5.67 (2H, m), 5.24-4.70 (3H, m), 4.32 (2H, m), 3.80-3.37 (2H, m), 2.96-2.61 (2H, m), 1.95-1.57 (6H, m), 1.35 (3H, m).

Example 19(15)

3-(N-(2-(hexahydro-2-oxo-3S-(4-dimethylaminophenylcarbonylamino)azepin-1-yl ))propionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1816##

TLC: Rf 0.24 (chloroform:methanol:water=70:30:1); NMR (CDCl3): δ 8.75 (1H, m), 7.90-7.50 (4H, m), 7.40-7.10 (8H, m), 6.65 (2H, d, J=10 Hz), 6.54 (1H, d, J=8.5 Hz), 5.60 (2H, m), 5.25-5.10 (1H, m), 4.90-4.60 (5H, m), 3.20-2.50 (3H, m), 2.65 (6H, s), 2.15-1.60 (8H, m), 1.35 (3H, d, J=7.5 Hz).

Example 19(16)

3-(N-(2S-(2-phenyl-4R-methyl-4,5-dihydrothiazol-4-ylcarbonylamino) propionyl)amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentano ic acid ##STR1817##

TLC: Rf 0.18 (chloroform:methanol:water=100:20:1); NMR (DMSO-d6): δ 8.93 (d, J=8 Hz) and 8.80 (d, J=8 Hz) total 1H, 7.90-7.70 (3H, m), 7.60-7.20 (6H, m), 5.90-5.60 (2H, m), 4.80-4.60 (1H, m), 4.50-4.10 (3H, m), 2.90-2.70 (2H, brd), 1.45 (3H, s), 1.30 (3H, d, J=8 Hz).

Example 19(17)

3-(N-(2S-(2-phenyl-4,5-dihydrothiazol-4-ylcarbonylamino)propionyl)amino-4-o xo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1818##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=10:1:1); NMR (DMSO-d6): δ 8.90-8.70 (1H, m), 8.50-8.20 (1H, m), 7.85-7.75 (2H, m), 7.60-7.20 (6H, m), 6.10-5.50 (2H, m), 5.30-5.15 (1H, m), 4.60-4.15 (4H, m), 3.80-3.10 (2H, m), 2.80-2.40 (2H, m), 1.40-1.20 (3H, m).

Example 19(18)

N-(thiazol-4-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetra zol-2-yl)pentanoic acid ##STR1819##

TLC: Rf 0.47 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.70-12.20 (1H, br), 9.10-8.90 (1H, m), 8.45 and 8.44 (1H, each s), 8.31 (1H, s), 7.56-7.45 and 7.45-7.27 (total 3H, m), 6.04-5.75 (2H, m), 5.13-4.96 (1H, m), 4.50 (2H, s), 3.05-2.67 (2H, m).

Example 19(19)

N-phenylthiomethylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1820##

TLC: Rf 0.54 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 12.72-12.20 (1H, br), 8.83 (1H, d), 7.54-7.18 (8H, m), 5.69 (2H, s), 4.79-4.70 (1H, m), 4.51 (2H, s), 3.77 (2H, s), 2.80-2.72 (2H, m).

Example 19(20)

N-(perhydrobenzo-1,4-diazepin-2,5-dion-3-ylcarbonyl)-3-amino-4-oxo-5-(5-(2, 6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR1821##

TLC: Rf 0.25 (chloroform:methanol:acetic acid=10:1:1); NMR (DMSO-d6): δ 10.7-10.5 (1H, m), 9.10-8.70 (1H, m), 8.10-7.85 (1H, m), 7.80-7.70 (1H, m), 7.60-7.10 (6H, m), 6.10-5.70 (2H, m), 4.85-4.75 (1H, m), 4.60-4.40 (1H, m), 4.40-4.10 (2H, m), 2.90-2.60 (2H, m).

Example 19(21)

N-(1-benzyloxycarbonylpiperidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1822## (wherein * represents R or S stereochemistry. The above compound has the opposite stereocondiguration as the compound of example 19(22))

TLC: Rf 0.39 (chloroform:methanol:acetic acid=18:1:11); NMR (DMSO-d6): δ 13.40-11.80 (1H, br), 8.94-8.65 (1H, m), 7.58-7.13 (8H, m), 5.92-5.62 (2H, m), 5.06 (2H, brs), 4.90-4.65 (2H, m), 4.42-4.19 (2H, m), 4.01-3.77 (1H, m), 3.47-2.99 (1H, m), 2.99-2.60 (2H, m), 2.21-2.00 (1H, m), 1.75-1.47 and 1.47-1.15 (5H, m).

Example 19(22)

N-(1-benzyloxycarbonylpiperidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1823## (wherein * represents R or S stereochemistry. The above compound has the opposite stereocondiguration as the compound of example 19(21))

TLC: Rf 0.39 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.60-11.90 (1H, br), 8.93-8.65 (1H, m), 7.58-7.07 (8H, m), 5.92-5.60 (2H, m), 5.06 (2H, brs), 4.90-4.65 (2H, m), 4.42-4.19 (2H, m), 4.01-3.77 (1H, m), 3.47-2.99 (1H, m), 2.99-2.60 (2H, m), 2.21-2.00 (1H, m), 1.75-1.47 and 1.47-1.15 (5H, m).

Example 19(23)

N-(1-acetylpiperidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-1-yl)pentanoic acid ##STR1824##

TLC: Rf 0.58 (chloroform:methanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 8.82-8.52 (1H, m), 7.60-7.20 (3H, m), 5.95-5.60 (2H, m), 5.10-4.95, 4.95-4.55 and 4.40-4.10 (5H, m), 3.75-3.60 (1H, m), 3.00-253 (2H, m), 2.33-1.95 (1H, m), 2.03 and 2.00 (total 3H, each s),1.75-1.10 (5H, m).

Example 19(24)

N-(1-benzyloxycarbonylpyrrolidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dic hlorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1825## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 19(25))

TLC: Rf 0.40 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 9.16-8.73 (1H, m), 7.72-7.01 (8H, m), 6.00-5.40 (2H, m), 5.22-4.84 (2H, m), 4.84-4.80 (1H, m), 4.80-4.04 (3H, m), 3.70-3.23 (2H, m), 2.98-2.40 (2H, m), 2.40-1.-57 (4H, m).

Example 19(25)

N-(1-benzyloxycarbonylpyrrolidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dic hlorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1826## (wherein * represents R or S stereochemistry. The stereostructure has not been identified yet. However, the above compound has the opposite stereoconfiguration as the compound of example 19(24))

TLC: Rf 0.40 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 9.22-8.66 (1H, m), 7.75-7.10 (8H, m), 6.06-5.40 (2H, m), 5.21-4.84 (2H, m), 4.84-4.56 (1H, m), 4.56-4.00 (3H, m), 3.70-3.23 (2H, m), 3.00-2.40 (2H, m), 2.40-1.40 (4H, m).

Example 19(26)

N-(1-acetylpyrrolidin-2S-ylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-1-yl)pentanoic acid ##STR1827##

TLC: Rf 0.13 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 9.07-8.54 (1H, m), 7.67-7.23 (3H, m), 6.18-5.59 (2H, m), 4.92-4.02 (4H, m), 3.71-3.20 (2H, m), 2.92-2.39 (2H, m), 2.39-1.50 (4H, m), 1.96 and 1.89 (total 3H, each s).

EXAMPLES 20(1)-20(2)

By the same procedure as provided in example 6(1), using the compound prepared in example 18(21) or 18(22), the compounds of the present invention having the following physical data were obtained.

Example 20(1)

3-(N-(2-(hexahydro-2-oxo-3S-(3-carboxyphenylcarbonylamino)azepin-1-yl))prop ionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1828##

TLC: Rf 0.38 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 12.84 (2H, brs), 8.54 (2H, m), 8.41 (1H, s) 8.07 (2H, m), 7.59 (1H, m), 7.26 (5H, m), 5.66 (2H, m), 5.24-4.62 (3H, m), 4.13 (2H, m), 3.39 (2H, m), 2.83 (1H, m), 2.60 (1H, m) 1.97-1.55 (6H, m), 1.33 (3H, m).

Example 20(2)

3-(N-(2-(hexahydro-2-oxo-3S-(4-carboxyphenylcarbonylamino)azepin-1-yl))prop ionyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1829##

TLC: Rf 0.39 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 8.57 (1H, m), 8.44 (1H, m), 8.04-7.89 (4H, m), 7.27 (5H, m), 5.66 (2H, m), 5.22-4.67 (3H, m), 4.13 (2H, m), 3.53 (2H, m), 2.83 (1H, m), 2.65 (1H, m), 1.99-1.53 (6H, m), 1.34 (3H, m).

Reference Example 10

3-(N-(2-(hexahydro-2-oxo-3S-(1-((2-trimethylsilyl)ethoxymethyl)imizazol-5-y lcarbonylamino)azepin-1-yl))propionyl)amino-4-oxo-5-(5-phenylmethyltetrazol -1-yl)pentanoic acid•t-butylester ##STR1830##

By the same procedure as provided in example 18(1) using the compound prepared in reference example 9(3) and 2-(hexahydro-2-oxo-3S-(1-((2-trimethylsilyl)ethoxymethyl)imizazol-5-ylcarb onylamino)azepin-1-yl)propionic acid instead of 2-(hexahydro-2-oxo-3S-(thiazol-4-ylcarbonylamino)azepin-1-yl)propionic acid, the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.63 (chloroform:methanol=9:1); NMR (DMSO-d6): δ 8.87-8.53 (2H, m), 8.29-8.17 (1H, m), 7.87-7.75 (2H, m), 7.27 (5H, m), 5.67 (2H, m), 5.37 (2H, m), 5.26-4.62 (3H, m), 4.13 (2H, m), 3.48 (2H, t, J=7.7 Hz), 3.28 (2H, m), 2.80 (1H, m), 2.57 (1H, m), 2.02-1.45 (6H, m), 1.38 (9H, s), 1.32 (3H, m), 0.84 (2H, t, J=7.7 Hz), -0.04 (9H, s).

Example 21 (1)

3-(N-(2-(hexahydro-2-oxo-3S-(imizazol-5-ylcarbonylamino)azepin-1-yl))propio nyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid ##STR1831##

By the same procedure as provided in example 6(1), using the compound prepared in reference example 10, the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.69 (chloroform:methanol:water=6:4:1); NMR (DMSO-d6): δ 12.53 (1H, brs), 8.78-8.53 (1H, m), 8.30-8.16 (1H, m), 7.71-7.60 (2H, m), 7.28 (5H, m), 5.67 (2H, m), 5.25-4.60 (3H, m), 4.14 (2H, m), 3.35 (2H, m), 2.85-2.60 (2H, m), 2.04-1.40 (6H, m), 1.32 (3H, m).

Example 22(1) and Example 22(2)

By the same procedure as provided in example 1, using 5-(2,6-dichlorophenylmethyl)tetrazole and N-t-butoxycarbonyl-3-amino-4-oxo-5-bromopentanoic acid•ethylester instead of N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-bromopentanoi c acid•t-butylester, the compounds of the present invention having the following physical data were obtained.

Example 22(1)

N-t-butoxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2- yl)pentanoic acid•ethylester ##STR1832##

TLC: Rf 0.41 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.35 (1H, d, J=8.8 Hz), 7.34 (1H, d, J=7.6 Hz), 7.16 (1H, dd, J=8.8 Hz, 7.6 Hz), 5.82 and 5.61 (each 1H, d, J=17.8 Hz), 5.72-5.59 (1H, m), 4.68-4.53 (1H, m), 4.61 (2H, s), 4.15 (2H, q, J=7.2 Hz), 3.06 (1H, dd, J=17.5 Hz, 5.0 Hz), 2.76 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.47 (9H, s), 1.25 (3H, t, J=7.2 Hz).

Example 22(2)

N-t-butoxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1- yl)pentanoic acid•ethylester ##STR1833##

TLC: Rf 0.23 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.37 (1H, d, J=8.8 Hz), 7.37 (1H, d, J=7.2 Hz), 7.21 (1H, dd, J=8.8 Hz, 7.2 Hz), 5.74 and 5.57 (each 1H, d, J=18.6 Hz), 5.66-5.52 (1H, m), 4.65-4.50 (1H, m), 4.39 and 4.29 (each 1H, d, J=17.5 Hz), 4.17 (2H, q, J=7.0 Hz), 3.13 (1H, dd, J=17.5 Hz, 5.0 Hz), 2.83 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.50 (9H, s), 1.27 (3H, t, J=7.0 Hz).

Example 23(1)

N-t-butoxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2- yl)pentanoic acid ##STR1834##

To a solution of the compound prepared in example 22(1) (72 mg) in 1,2-dimethoxyethane (0.5 ml) was added 1N aqueous solution of sodium hydroxide (0.15 ml) at 0°C The reaction mixture was stirred for 30 min at 0°C The mixture was quenched by addition of 1N aqueous solution oh hydrochloric acid, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, concentrated to give the compound of the present invention (62 mg) having the following physical data.

TLC: Rf 0.49 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.57-7.30 (4H, m), 5.95-5.74 (2H, m), 4.51 (2H, s), 4.58-4.40 (1H, m), 2.82-2.39 (2H, m), 1.40 (9H, s).

Example 23(2)

N-t-butoxycarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1- yl)pentanoic acid ##STR1835##

By the same procedure as provided in example 23(1), using the compound prepared in example 22(2), the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.37 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.68-7.33 (4H, m), 5.92-5.77 (2H, m), 4.60-4.43 (1H, m), 4.34 (2H, s), 2.86-2.58 (2H, m), 1.41 (9H, s).

Reference Example 11 (1)

3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•ethylester•hydrochloric acid salt ##STR1836##

To the compound prepared in example 22(1) (201 mg) was added 4N hydrochloric acid in dioxane (4 ml). The reaction mixture was stirred for 30 min at room temperature. The mixture was concentrated. The residue was removed as toluene azeotrope. The obtained residue was washed with ether, to give the title compound (150 mg) having the following physical data.

TLC: Rf 0.28 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.60-8.20 (3H, br), 7.62 (1H, d, J=9.0 Hz), 7.62 (1H, d, J=6.8 Hz), 7.37 (1H, dd, J=9.0 Hz, 6.8 Hz), 6.21 and 6.02 (each 1H, d, J=18.0 Hz), 4.65-4.55 (1H, m), 4.54 (2H, s), 4.12 (2H, q, J=7.0 Hz), 3.35-3.03 (2H, m), 1.20 (3H, t, J=7.0 Hz).

Reference Example 11(2)

3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid•ethylester•hydrochloric acid salt ##STR1837##

By the same procedure as provided in reference example 11(1), using the compound prepared in example 22(2), the title compound having the following physical data was obtained.

TLC: Rf 0.33 (chloroform:methanol=19:1).

Reference Example 11(3)

3-amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•ethylester•hydrochloric acid salt ##STR1838##

By the same procedure as provided in example 1→reference example 11(1), using 5-phenylmethyltetrazole and N-t-butoxycarbonyl-3-amino-4-oxo-5-bromopentanoic acid•ethylester instead of N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-bromopentanoi c acid•t-butylester, the title compound having the following physical data was obtained.

TLC: Rf 0.50 (chloroform:methanol=19:1).

EXAMPLES 24(1)-24(12)

By the same procedure as provided in example 18(1), using the corresponding carboxylic acid compounds and the compound prepared in reference example 11(1), reference example 11(2) or reference example 11(3) instead of the compound prepared in reference example 9(1), the compounds of the present invention having the following physical data were obtained.

Example 24(1)

N-(N-benzyloxycarbonyl-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-2-yl)pentanoic acid•ethylester ##STR1839##

TLC: Rf 0.43 (chloroform:methanol 19:1); NMR (CDCl3): δ 7.50-7.07 (9H, m), 5.82-5.61 and 5.61-5.39 (2H, m), 5.36 and 5.25 (total 1H, each d, J=5.5 Hz), 5.10 and 5.08 (total 2H, each s), 4.98-4.82 (1H, m), 4.59 (2H, s), 4.33-4.13 (1H, m),4.12 (2H, q, J=7.0 Hz), 3.10-285 and 2.81-2.59 (total 2H, m), 1.41 and 1.40 (total 3H, each d, J=7.0 Hz), 1.23 (3H, t, J=7.0 Hz).

Example 24(2)

N-(N-benzyloxycarbonyl-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-1-yl)pentanoic acid•ethylester ##STR1840##

NMR (CDCl3): δ 7.50-7.10 (8H, m), 5.85-5.60 and 5.60-5.28 (2H, m), 5.25-5.00 (2H, m), 4.90-4.77 (1H, m), 4.35-4.07 (5H, m), 3.19-2.99 and 2.87-2.79 (2H, m), 1.52-1.38 (3H, m), 1.27 (3H, t, J=7.0 Hz).

Example 24(3)

N-(N-benzyloxycarbonyl-L-valyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid•ethylester ##STR1841##

TLC: Rf 0.20 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.92-8.79 and 8.72-8.60 (2H, m), 7.61-7.44 and 7.44-7.15 (8H, m), 5.84 (2H, m), 4.80-4.62 (1H, m)4.51 (2H, s), 4.04 (2H, q, J=7.0 Hz), 3.93 (1H, m), 3.00-2.55 (2H, m), 2.08-1.92 (1H, m), 1.16 (3H, t, J=7.0 Hz), 0.96-0.75 (6H, m).

Example 24(4)

N-(N-benzyloxycarbonyl-N'-t-butyloxycarbonyl-L-lysinyl)-3-amino-4-oxo-5-(5- (2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•ethylester ##STR1842##

TLC: Rf 0.47 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.88-8.75 and 8.72-8.60 (total 1H, m), 7.63-7.45 and 7.45-7.10 (9H, m), 6.82-6.68 (total 1H, m), 5.96-5.72 (2H, m), 4.99 (2H, s), 4.93-4.60 (1H, m), 4.51 (2H, s), 4.15-3.85 (1H, m), 4.05 (2H, q, J=6.8 Hz), 2.96-2.55 (2H, m), 1.68-1.05 (6H, m), 1.36 (9H, s), 1.16 (3H, t, J=6.8 Hz).

Example 24(5)

N-phenylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl )pentanoic acid•ethylester ##STR1843##

TLC: Rf 0.54 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 9.07 (1H, d, J=9.5 Hz), 7.95-7.84 and 7.63-7.25 (8H, m), 5.94 (2H, s), 5.08-4.94 (1H, m), 4.50 (2H, s), 4.06 (2H, q, J=7.2 Hz), 2.96 (1H, dd, J=16.0 Hz, 5.5 Hz), 2.74 (1H, dd, J=16.0 Hz, 7.5 Hz), 1.15 (3H, t, J=7.0 Hz).

Example 24(6)

N-(2-phenylethylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•ethylester ##STR1844##

TLC: Rf 0.24 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.43-6.97 (8H, m), 6.57 (1H, d, J=9.5 Hz), 5.21 and 5.09 (each 1H, d, J=18.0 Hz), 4.94-4.76 (1H, m), 4.59 (2H, s), 4.10 (2H, q, J=7.0 Hz), 3.10-2.85 and 2.79-2.45 (6H, m), 1.23 (3H, t, J=7.0 Hz).

Example 24(7)

N-phenyloxymethylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•ethylester ##STR1845##

TLC: Rf 0.52 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.80-7.66 (1H, m), 7.42-6.87 (8H, m), 5.63 and 5.52 (each 1H, d, J=18.0 Hz), 5.07-4.92 (1H, m), 4.60 (4H, s), 4.13 (2H, q, J=7.0 Hz), 3.07 (1H, dd, J=17.5 Hz, 4.5 Hz), 2.74 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.24 (3H, t, J=7.0 Hz).

Example 24(8)

N-(2-(hexahydro-2-oxo-azepin-1-yl)propionyl)-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylmethyl)tetrazol-1-yl)pentanoic acid•ethylester ##STR1846##

TLC: Rf 0.47 (ethyl acetate); NMR (CDCl3): δ 7.50-7.15 (3H, m), 5.80-5.42 (2H, m), 5.08-4.91 (1H, m), 4.91-4.74 (1H, m), 4.36 and 4.35 (total 2H, each s), 4.22-4.11 (2H, m), 3.46-3.22 (2H, m), 3.11-2.68 (2H, m), 2.69-2.44 (2H, m), 1.98-1.39 (6H, m), 1.63 (9H, s), 1.48-1.34 (3H, m), 1.27 (3H, t, J=7.2 Hz).

Example 24(9)

N-(2S-(tetrahydro-5-oxo-1,4-benzooxsazepin-4-yl)propionyl)-3-amino-4-oxo-5- (5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid•ethylester ##STR1847##

TLC: Rf 0.12 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.85-6.93 (8H, m), 5.84-5.40 (2H, m), 5.35-5.11 (1H, m), 4.98-4.75 (1H, m), 4.51-3.96 (6H, m), 3.72-3.42 (2H, m), 3.25-2.69 (2H, m), 1.71-1.40 (2H, m), 1.40-1.02 (3H, m).

Example 24(10)

N-(2S-(2,3-indol-3,4-tetrahydro-2-oxo-azepin-1-yl)propionyl)-3-amino-4-oxo- 5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid•ethylester ##STR1848##

TLC: Rf 0.16 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 11.18 (1H, s), 8.90-8.69 (1H, m), 7.62-6.89 (1H, m), 5.87 (2H, m), 5.38-5.16 (1H, m), 4.98-4.79 (1H, m) 4.46-4.17 (2H, m), 4.17-3.95 (2H, m), 3.65-2.63 (6H, m), 2.42-1.85 (2H, m), 1.50-1.30 (3H, m), 1.30-0.98 (3H, m).

Example 24(11)

N-(2-(4-fluorophenyl)-4-oxo-5-benzyloxocarbonylaminopyrimidin-3-yl)methylca rbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid•ethylester ##STR1849##

TLC: Rf 0.56 (chloroform:methanol=10:1); NMR (CDCl3): δ 8.77 (1H, brs), 7.70-7.07 (14H, m), 5.90 and 5.52 (each 1H, each d, J=18.5 Hz), 5.18 (2H, s), 4.91 (1H, m), 4.60 and 4.52 (each 1H, each d, J=15.0 Hz), 4.31 (2H, s), 4.11 (2H, q, J=7.0 Hz), 3.06 and 2.82 (each 1H, each dd, J=16.0, 5.0 Hz), 1.22 (3H, t, J=7.0 Hz).

Example 24(12)

3-(N-(2-(hexahydro-2-oxo-3S-(quinolin-3-ylcarbonylamino)azepin-1-yl))propio nyl)amino-4-oxo-5-(5-phenylmethyltetrazol-1-yl)pentanoic acid•ethylester ##STR1850##

TLC: Rf 0.65 (chloroform:methanol=9:1); NMR (CDCl3): δ 9.31-9.22 (1H, m), 9.13 (1H, m), 8.54 (1H, m), 8.02 (2H, m), 7.73 (2H, m), 7.48 (1H, m), 7.32-7.21 (5H, m), 5.60-5.25 (2H, m), 4.97-4.73 (3H, m), 4.24-4.06 (4H, m), 3.55 (2H, m), 3.05-2.72 (2H, m), 2.27-1.84 (6H, m), 1.44 (3H, d, J=7.0 Hz), 1.30-1.18 (3H, m).

EXAMPLES 25(1)-25(11)

By the same procedure as provided in example 23(1), using the compound prepared in examples 24(1)-24(11), the compounds of the present invention having the following physical data were obtained.

Example 25(1)

N-(N-benzyloxycarbonyl-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-2-yl)pentanoic acid ##STR1851##

TLC: Rf 0.29 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.64-12.25 (1H, m), 8.79-8.56 (1H, m), 7.66-7.55 (1H, m), 7.55-7.45 and 7.45-7.12 (8H, m), 6.00-5.55 (2H, m), 5.00 (2H, s), 4.81-4.57 (1H, m), 4.51 (2H, s), 4.14-4.00 (1H, m), 2.86-2.35 (2H, m), 1.23 and 1.21 (total 3H, each d, J=7.4 Hz).

Example 25(2)

N-(N-benzyloxycarbonyl-L-alanyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmeth yl)tetrazol-1-yl)pentanoic acid ##STR1852##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.63-12.35 (1H, m), 9.00-8.72 (1H, m), 7.70-7.20 (9H, m), 5.87-5.73 (2H, m), 5.06-4.87 (2H, s), 4.87-4.60 (1H, m), 4.36-4.22 (2H, s), 4.22-3.95 (1H, m), 2.90-2.55 (2H, m), 1.30-1.05 (3H, m).

Example 25(3)

N-(N-benzyloxycarbonyl-L-valyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid ##STR1853##

TLC: Rf 0.61 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.65-12.25 (1H, br), 8.86-8.55 (1H, m), 7.59-7.15 (9H, m), 6.02-5.50 (2H, m), 5.00 (2H, s), 4.88-4.58 (1H, m), 4.51 (2H, s), 3.93-3.77 (1H, m), 2.92-2.22 (2H, m), 2.06-1.93 (1H, m), 0.95-0.76 (6H, m).

Example 25(4)

N-(N-benzyloxycarbonyl-N'-t-butyloxycarbonyl-L-lysinyl)-3-amino-4-oxo-5-(5- (2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR1854##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.72-8.55 (1H, m), 7.61-7.43 (3H, m), 7.43-7.05 (6H, m), 6.81-6.70 (1H, m), 5.92-5.53 (2H, m), 4.99 (2H, s), 4.72-4.55 (1H, m), 4.50 (2H, s), 4.04-3.87 (1H, m), 2.96-2.79 (4H, m), 2.72-2.56 (2H, m), 1.71-1,12 (15H, m).

Example 25(5)

N-phenylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl) tetrazol-2-yl)pentanoic acid ##STR1855##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=18:1:1); NMR (CDCl3): δ 12.60-12.25 (1H, br), 9.12-9.00 (1H, m), 7.95-7.86 (2H, m), 7.65-7.10 (6H, m), 6.00-5.87 (2H, m), 5.02-4.89 (1H, m), 4.50 (2H, s), 3.00-2.80 and 2.80-2.58 (2H, m).

Example 25(6)

N-(2-phenylethylcarbonyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR1856##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.65-12.30 (1H, br), 8.65-8.52 (1H, m), 7.53 (2H, dd, J=9.0, 7.4 Hz), 7.34 (1H, dd, J=9.0, 7.4 Hz), 7.29-7.00 (6H, m), 5.68-5.52 (2H, m), 4.74-4.58 (1H, m), 4.51 (2H, s), 2.93-2.40 (6H, m).

Example 25(7)

N-phenyloxymethylcarbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR1857##

TLC: Rf 0.61 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 12.62-12.30 (1H, br), 8.77-7.66 (1H, m), 7.52 (2H, d, J=7.5 Hz), 7.44-7.22 (4H, m), 7.02-6.88 (3H, m), 5.91-5.75 (2H, m), 5.00-4.81 (1H, m), 4.61 (2H, s), 4.51 (2H, s), 2.92-2.56 (2H, m).

Example 25(8)

N-(2-(hexahydro-2-oxo-azepin-1-yl)propionyl)-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1858##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=18:11); NMR (DMSO-d6): δ 13.09-11.98 (1H, br), 8.74-8.43 (1H, m), 7.60-7.29 (3H, m), 5.83 (2H, brs), 5.06-4.86 (1H, m), 4.85-4.62 (1H, m), 4.34 (2H, s), 3.35 (2H, brs), 2.97-2.56 (2H, m), 2.47 (2H, brs), 1.95-1.30 (6H, m), 1.27 (3H, d, J=7.2 Hz).

Example 25(9)

N-(2S-(tetrahydro-5-oxo-1,4-benzooxsazepin-4-yl)propionyl)-3-amino-4-oxo-5- (5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1859##

TLC: Rf 0.42 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.98-12.14 (1H, br), 9.12-8.70 (1H, m), 7.75-7.26 (5H, m), 7.10-6.86 (2H, m), 6.07-5.63 (2H, brs), 5.28-4.96 (1H, m), 4.96-4.60 (1H, m), 4.52-4.12 (4H, m), 3.76-3.42 (2H, m), 3.03-2.55 (2H, m), 1.44 (3H, d, J=7.2 Hz).

Example 25(10)

N-(2S-(2,3-indol-3,4-tetrahydro-2-oxo-azepin-1-yl)propionyl)-3-amino-4-oxo- 5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1860##

TLC: Rf 0.30 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.90-12.16 (1H, br), 11.18 (1H, s), 8.97-8.64 (1H, m), 7.68-6.86 (7H, m), 5.88 (1H, brs), 5.43-5.10 (1H, m), 4.98-4.62 (1H, m), 4.49-4.12 (1H, m), 3.70-3.35 (2H, m), 3.15-2.53 (4H, m), 2.36-1.82 (2H, m), 1.55-1.20 (3H, m).

Example 25(11)

N-(2-(4-fluorophenyl)-4-oxo-5-benzyloxocarbonylaminopyrimidin-3-yl)methylca rbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl) pentanoic acid ##STR1861##

TLC: Rf 0.31 (chloroform:methanol=4:1); NMR (DMSO-d6): δ 9.21 (1H, m), 8.86 (1H, brs), 8.48 (1H, s), 7.7014 7.20 (12H, m), 5.82 (2H, br), 5.12 (2H, s), 4.78 (1H, m), 4,.58 (2H, brs), 4.27 (2H, brs), 2.80 (2H, m).

EXAMPLE 26(1) and EXAMPLE 26(2)

By the same procedure as provided in reference example 11(1) and if necessary, by known methods converted to accommodate the corresponding salts, using the compounds prepared in example 24(4) or example 25(4), the compounds of the present invention having the following physical data were obtained.

Example 26(1)

N-(N-benzyloxycarbonyl-L-lysinyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmet hyl)tetrazol-2-yl)pentanoic acid•ethylester•hydrochloric acid salt ##STR1862##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 8.90-8.79 and 8.79-8.66 (1H, m), 7.92-7.65 (3H, br), 7.65-7.55 (1H, m), 7.50 (2H, d, J=7.5 Hz), 7.43-7.10 (6H, m), 5.95-5.53 (2H, m), 5.00 (2H, s), 4.91-4.65 (1H, m), 4.51 (2H, s), 4.13-3.83 (3H, m), 2.93-2.55 (4H, m), 1.75-1.22 (6H, m), 1.16 (3H, t, J=7.2 Hz).

Example 26(2)

N-(N-benzyloxycarbonyl-L-lysinyl)-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmet hyl)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1863##

TLC: Rf 0.11 (chloroform:methanol:water=70:30:3); NMR (DMSO-d6): δ 12.80-12.18 (1H, br), 8.87-8.65 (1H, m), 8.10-7.70 (3H, m), 7.70-7.45 (3H, m), 7.45-7.12 (6H, m), 5.99-5.50 (2H, m), 5.00 (2H, s), 4.84-4.59 (1H, m), 4.51 (2H, s), 4.07-3.87 (1H, m), 2.90-2.55 (4H, m), 1.72-1.19 (6H, m).

EXAMPLES 27(1)-27(9)

By the same procedure as provided in example 1, using the corresponding tetrazole compounds and the corresponding bromo compounds instead of N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-5-bromopentanoi c acid•t-butylester, compounds of the present invention having the following physical data were obtained.

Example 27(1)

N-(2-methylbenzyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•ethylester ##STR1864##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.40-7.09 (7H, m), 6.02-5.86 (1H, m), 5.78 and 5.60 (each 1H, d, J=18.0 Hz), 5.18 (2H, s), 4.76-4.62 (1H, m), 4.59 (2H, s), 4.12 (2H, q, J=7.0 Hz), 3.06 (1H, dd, J=17.5 Hz, 5.0 Hz), 2.77 (1H, dd, J=17.5 Hz, 5.0 Hz), 2.35 (3H, s), 1.23 (3H, t, J=7.0 Hz).

Example 27(2)

N-(pyridin-4-ylmethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmet hyl)tetrazol-2-yl)pentanoic acid•ethylester ##STR1865##

TLC: Rf 0.40 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 8.55 (2H, d, J=5.8 Hz), 8.12 (1H, d, J=9.5 Hz), 7.57-7.28 (3H, m), 7.34 (2H, d, J=5.8 Hz), 5.96 (each 1H, s), 5.14 (2H, s), 4.76-4.60 (1H, m), 4.52 (2H, s), 4.06 (2H, q, J=7.2 Hz), 2.86 (1H, dd, J=17.5 Hz, 5.0 Hz), 2.70 (1H, dd, J=17.5 Hz, 6.0 Hz), 2.35 (3H, s), 1.16 (3H, t, J=7.2 Hz).

Example 27(3)

N-(tetrahydrofuran-3-yloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-2-yl)pentanoic acid•ethylester ##STR1866##

TLC: Rf 0.33 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.34 (1H, d, J=8.8 Hz), 7.34 (1H, d, J=7.6 Hz), 7.18 (1H, dd, J=8.8 Hz, 7.6 Hz), 5.95 (1H, d, J=9.5 Hz), 5.80 and 5.62 (each 1H, d, J=18.0 Hz), 5.41-5.19 (1H, m), 4.73-4.52 (1H, m), 4.60 (2H, s), 4.15 (2H, q, J=7.0 Hz), 4.02-3.75 (4H, m), 3.15-2.98 and 2.78-2.69 (2H, m), 2.32-1.92 (2H, s), 1.25 (3H, t, J=7.0 Hz).

Example 27(4)

N-(3-chlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•ethylester ##STR1867##

TLC: Rf 0.71 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.45-7.10 (7H, m), 6.01-5.86 (1H, m), 5.78 and 5.61 (each 1H, d, J=18.0 Hz), 5.12 (2H, s), 4.74-4.55 (1H, m), 4.60 (2H, s), 4.15 (2H, q, J=7.2 Hz), 3.08 (1H, dd, J=17.5 Hz, 4.5 Hz), 2.76 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.24 (3H, t, J=7.2 Hz).

Example 27(5)

N-(2-propenoxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetraz ol-2-yl)pentanoic acid•ethylester ##STR1868##

TLC: Rf 0.33 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.26 (1H, d, J=8.6 Hz), 7.26 (1H, d, J=7.4 Hz), 7.09 (1H, dd, J=8.6 Hz, 7.4 Hz), 6.00-5.73 (2H, m), 5.75 and 5.56 (each 1H, d, J=18.0 Hz), 5.25 (1H, dd, J=17.2 Hz, 1.0 Hz), 5.18 (1H, dd, J=l 1.2 Hz, 1.0 Hz), 4.68-4.45 m), 4.54 (2H, s), 4.52 (2H, s), 4.06 (2H, q, J=7.0 Hz), 2.98 (1H, dd, J=17.5 Hz, 4.5 Hz), 2.72 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.16 (3H, t, J=7.0 Hz).

Example 27(6)

N-(naphthalen-2-ylmethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid•ethylester ##STR1869##

TLC: Rf 0.41 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.92-7.75 and 7.56-7.41 (7H, m), 7.34 (1H, d, J=8.8 Hz), 7.33 (1H, d, J=7.6 Hz), 7.18 (1H, dd, J=8.8 Hz, 7.6 Hz), 6.02-5.87 (1H, m), 5.78 and 5.59 (each 1H, d, J=18.0 Hz), 5.32 (2H, s), 4.72-4.50 (1H, m), 4.60 (2H, s), 2.99 (1H, dd, J=17.5 Hz, 4.5 Hz), 2.72 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.40 (9H, s).

Example 27(7)

N-(naphthalen-1-ylmethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid•ethylester ##STR1870##

TLC: Rf 0.44 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.11-7.98, 7.95-7.81 and 7.63-7.40 (7H, m), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=7.0 Hz), 7.18 (1H, dd, J=9.0 Hz, 7.0 Hz), 5.96-5.85 (1H, m), 5.76 (1H, d, J=18.0 Hz), 5.64 (2H, s), 5.58 (1H, d, J=18.0 Hz), 4.72-4.50 (1H, m), 4.60 (2H, s), 2.99 (1H, dd, J=17.5 Hz, 4.0 Hz), 2.68 (1H, dd, J=17.5 Hz, 4.5 Hz), 1.38 (9H, s).

Example 27(8)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•ethylester ##STR1871##

TLC: Rf 0.63 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.48-7.42 (2H, m), 7.34-7.14 (6H, m), 6.56 (1H, d, J=8.4 Hz), 5.67 (1H, d, J=17.8 Hz), 5.46 (1H, d, J=17.8 Hz), 4.87 (1H, m), 4.15 (2H, q, J=7.2 Hz), 3.23 (2H, m), 3.08 (1H, dd, J=17.4 Hz, 4.4 Hz), 2.93 (2H, m), 2.74 (1H, dd, J=7.4 Hz, 4.8 Hz), 1.25 (3H, t, J=7.2 Hz).

Example 27(9)

N-(2-phenylethylthio)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid•ethylester ##STR1872##

TLC: Rf 0.54 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.48-7.43 (2H, m), 7.37-7.17 (6H, m), 6.62 (1H, d, J=8.8 Hz), 5.61 (1H, d, J=18.6 Hz), 5.40 (1H, d, J=18.6 Hz), 4.93 (1H, m), 4.18 (2H, q, J=7.2 Hz), 3.28 (2H, m), 3.16 (1H, dd, J=17.6 Hz, 4.4 Hz), 2.96 (2H, m), 2.79 (1H, dd, J=17.4 Hz, 5.0 Hz), 1.28 (3H, t, J=7.2 Hz).

EXAMPLES 28(1)-28(7)

By the same procedure as provided in example 23(1), using the compounds prepared in examples 27(1)-27(7), the compounds of the present invention having the following physical data were obtained.

Example 28(1)

N-(2-methylbenzyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1873##

TLC: Rf 0.25 (chloroform:methanol=50:1); NMR (DMSO-d6): δ 12.65-12.30 (1H, br), 8.02-7.86 (1H, m), 7.51 (2H, d, J=7.5 Hz), 7.42-7.25 (2H, m), 7.25-7.10 (3H, m), 5.98-5.83 (2H, m), 5.07 (2H, s), 4.67-4.53 (1H, m), 4.50 (2H, s), 2.88-2.40 (2H, m), 2.28 (3H, s).

Example 28(2)

N-(pyridin-4-ylmethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmet hyl)tetrazol-2-yl)pentanoic acid ##STR1874##

TLC: Rf 0.46 (chloroform:methanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 12.80-12.25 (1H, br), 8.70-8.45 (2H, m), 8.18-8.01 (1H, m), 7.53 (2H, d, J=7.0 Hz), 7.46-7.28 (3H, m), 6.10-5.80 (2H, m), 5.13 (2H, s), 4.70-4.56 (1H, m), 4.51 (2H, s), 2.91-2.56 (2H, m).

Example 28(3)

N-(tetrahydrofuran-3-yloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-2-yl)pentanoic acid ##STR1875##

TLC: Rf 0.46 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.88-7.76 (1H, m), 7.52 (1H, d, J=8.8 Hz), 7.51 (1H, d, J=6.8 Hz), 7.37 (1H, dd, J=8.8 Hz, 6.8 Hz), 5.95-5.78 (2H, m), 5.20-5.07 (1H, m), 4.61-4.43 (1H, m), 4.50 (2H, s), 3.83-3.60 (4H, m), 2.87-2.20 (2H, m), 2.23-2.00 and 2.00-1.80 (each 1H, m).

Example 28(4)

N-(3-chlorobenzyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1876##

TLC: Rf 0.20 (chloroform:methanol:acetic acid=50:11); NMR (DMSO-d6): δ 8.00-7.87 (1H, m), 7.60-7.27 (7H, m), 6.00-5.80 (2H, m), 5.07 (2H, s), 4.67-4.42 (1H, m), 4.50 (2H, s), 2.86-2.54 (2H, m).

Example 28(5)

N-(2-propenoxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetraz ol-2-yl)pentanoic acid ##STR1877##

TLC: Rf 0.22 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 12.53-12.30 (1H, m), 7.58 and 7.57 (total 2H, each d, J=8.4 Hz and 7.0 Hz), 7.43 (1H, dd, J=8.4 Hz and 7.0 Hz), 6.10-5.84 (3H, m), 5.36 (1H, dd, J=17.4 Hz, 1.4 Hz), 5.25 (1H, dd, J=10.6 Hz, 1.4 Hz), 4.74-4.5 (1H, m), 4.58 (2H, d, J=5.2 Hz), 4.57 (2H, s), 2.93-2.52 (2H, m).

Example 28(6)

N-(naphthalen-2-ylmethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid ##STR1878##

TLC: Rf 0.26 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 8.08-7.81 (5H, m), 7.58-7.42 (5H, m), 7.36 (2H, d, J=9.0 Hz, 7.5 Hz), 6.03-5.80 (2H, m), 5.25 (2H, s), 4.70-4.55 (1H, m), 4.52 (2H, s), 2.91-2.53 (2H, m).

Example 28(7)

N-(naphthalen-1-ylmethyloxy)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid ##STR1879##

TLC: Rf 0.63 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.12-7.84 and 7.65-7.26 (total 11H, m), 6.07-5.78 (2H, m), 5.56 (2H, s), 4.70-4.55 (1H, m), 4.52 (2H, s), 2.9,0-2.55 (2H, m).

Example 29(1)

N-(4-t-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-1-yl)pentanoic acid•t-butylester ##STR1880##

To a solution of the compound prepared in reference example (725 mg) in dichloromethane (5 ml) was added 4-t-butylbenzenesulfonyl cloride (524 mg), triethylamine (0.2 ml) and dimethylaminopyridine (185 mg) at 0°C, successively. The reaction mixture was stirred for 6 h for room temperature. The reaction mixture was quenched by addition of 1N aqueous solution of hydrochloric acid, extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=3:1) to give the compound of the present invention (526 mg) having the following physical data.

TLC: Rf 0.46 (hexane:ethyl acetate=2:1); NMR (DMSO-d6): δ 7.91-7.72 (2H, m), 7.68-7.50 (2H, m), 7.46-7.16 (3H, m), 6.01 (1H, d, J=9.2 Hz), 5.76 (1H, d, J=18.8 Hz), 5.63 (1H, d, J=18.8 Hz), 4.29 (2H, s), 4.21-4.02 (1H, m), 2.96 (1H, dd, J=17.6 and 4.2 Hz), 2.40 (1H, dd, J=17.6 and 4.4 Hz), 1.37 (9H, s), 1.36 (9H, s).

EXAMPLES 29(2)-29(74)

By the same procedure as provided in example 29(1), using the compounds prepared in reference example 9(1) or reference example 9(2) and the corresponding sulfonyl chloride compounds, the compounds of the present invention having the following physical data were obtained.

Example 29(2)

N-phenylmethylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazo l-2-yl)pentanoic acid•t-butylester ##STR1881##

TLC: Rf 0.77 (chloroform:methanol=19:1); NMR (DMSO-d6): δ 7.90 (1H, d, J=9.0 Hz), 7.58-7.29 (8H, m), 5.98 (2H, m), 4.52 (4H, m), 2.77-2.64 (2H, m), 1.38 (9H, s).

Example 29(3)

N-phenylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl )pentanoic acid•t-butylester ##STR1882##

TLC: Rf 0.57 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.93-7.83 and 7.71-7.48 (5H, m), 7.35 (1H, d, J=9.0 Hz), 7.35 (1H, d, J=7.0 Hz), 7.18 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.07 (1H, J=9.5 Hz), 5.83 and 5.62 (each 1H, d, J=18.0 Hz), 4.59 (2H, s), 4.20-4.05 (1H, m), 2.82 (1H, dd, J=17.5 Hz, 4.0 Hz), 2.24 (1H, dd, J=17.5 Hz, 4.5 Hz), 1.37 (9H, s).

Example 29(4)

N-(2-(naphthalen-1-yl)ethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1883##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.11-7.73 and 7.63-7.08 (10H, m), 5.72 and 5.58 (each 1H, d, J=18.0 Hz), 4.58 (2H, s), 4.32-4.19 (1H, m), 3.74-3.55 and 3.53-3.37 (total 4H, m), 2.91 (1H, dd, J=17.5 Hz, 4.5 Hz), 2.52 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.38 (9H, s).

Example 29(5)

N-(naphthalen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid•t-butylester ##STR1884##

TLC: Rf 0.24 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 8.45 (1H, m), 8.07-7.59 (6H, m), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=7.0 Hz), 7.17 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.20 (1H, d, J=9.5 Hz), 5.88 and 5.67 (each 1H, d, J=18.0 Hz), 4.58 (2H, s), 4.26 (1H, m), 2.79 (1H, dd, J=17.5 Hz, 4.0 Hz), 2.20 (1H, dd, J=17.5 Hz, 4.5 Hz), 1.33 (9H, s).

Example 29(6)

N-(naphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid•t-butylester ##STR1885##

TLC: Rf 0.21 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 8.62-8.50, 8.35-8.26, 8.18-8.07, 8.05-7.94 and 7.76-7.46 (7H, m), 7.33 (1H, d, J=9.0 Hz), 7.33 (1H, d, J=7.0 Hz), 7.16 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.50-6.39 (1H, m), 5.84 and 5.56 (each 1H, d, J=18.0 Hz), 4.57 (2H, s), 4.12-3.95 (1H, m), 2.65 (1H, dd, J=17.5 Hz, 4.0 Hz), 1.78 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.24 (9H, s).

Example 29(7)

N-(2-phenylethenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid•t-butylester ##STR1886##

TLC: Rf 0.53 (hexane:ethyl acetate=3:1); NMR (DMSO-d6): δ 7.55 (1H, d, J=15.6 Hz), 7.52-7.40 (5H, m), 7.36-7.17 (3H, m), 6.77 (1H, d, J=15.6 Hz), 5.92 (1H, d, J=18.2 Hz), 5.73 (1H, d, J=18.2 Hz), 4.59 (2H, s), 4.20 (1H, m), 2.98 (1H, dd, J=17.4, 4.2 Hz), 2.70 (1H, dd, J=17.4, 4.2 Hz), 1.39 (9H, s).

Example 29(8)

N-(4-bromophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1887##

TLC: Rf 0.44 (hexane:ethyl acetate=2:1); NMR (DMSO-d6): δ 7.76 and 7.66 (each 2H, d, J=8.5 Hz), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=7.0 Hz), 7.16 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.12 (1H, d, J=9.6 Hz), 5.84 and 5.64 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.19-4.03 (1H, m), 2.82 (1H, dd, J=17.8 Hz, 3.8 Hz), 2.31 (1H, dd, J=17.8 Hz, 4.6 Hz), 1.38 (9H, s).

Example 29(9)

N-butylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl) pentanoic acid•t-butylester ##STR1888##

TLC: Rf 0.60 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.37-7.24 (3H, m), 5.89 (2H, d, J=7.2 Hz), 5.74 (1H, d, J=17.2 Hz), 4.61 (1H, s), 4.38-4.28 (1H, m), 3.12-3.02 (2H, m), 2.98 (1H, dd, J=17.0, 4.6 Hz), 2.74 (1H, dd, J=17.0, 4.6 Hz), 1.91-1.79 (2H, m), 1.63-1.61 (2H, m), 1.43 (9H, s), 0.96 (3H, t, J=7.2 Hz).

Example 29(10)

N-(quinolin-8-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1889##

TLC: Rf 0.46 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 9.02 (1H, dd, J=4.3, 1.7 Hz), 8.47-8.10 (3H, m), 7.73-7.55 (2H, m), 7.44 (1H, d, J=7.5 Hz), 7.37-7.13 (4H, m), 6.02 (1H, d, J=16.6 Hz), 5.87 (1H, d, J=16.6 Hz), 4.60 (2H, s), 4.48-4.41 (1H, m), 2.66 (1H, dd, J=17.0, 4.5 Hz), 2.96 (1H, dd, J=17.0, 4.5 Hz), 1.27 (9H, s).

Example 29(11)

N-(5-dimethylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1890##

TLC: Rf 0.58 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.60 (1H, d, J=8.5 Hz), 8.31-8.19 (2H, m), 7.63-7.52 (2H, m), 7.36-7.13 (5H, m), 6.39 (1H, d, J=9.9 Hz), 5.84 (1H, d, J=18.2 Hz), 5.55 (1H, d, J=18.2 Hz), 4.58 (2H, s), 4.05-3.96 (1H, m), 2.89 (6H, s), 2.66 (1H, dd, J=17.2, 4.5 Hz), 1.79 (1H, dd, J=17.2, 4.5 Hz), 1.25 (9H, s).

Example 29(12)

N-(4-nitrophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1891##

TLC: Rf 0.60 (chloroform:methanol=19:1); NMR (CDCl3): δ 8.38 and 8.05 (each 2H, d, J=9.2 Hz), 7.36 (1H, d, J=8.8 Hz), 7.36 (1H, d, J=7.2 Hz), 7.20 (1H, dd, J=8.8 Hz, 7.2 Hz), 6.25 (1H, d, J=9.6 Hz), 5.71 and 5.56 (each 1H, d, J=18.0 Hz), 4.61 (2H, s), 4.27-4.10 (1H, m), 2.92 (1H, dd, J=17.8 Hz, 4.0 Hz), 2.38 (1H, dd, J=17.8 Hz, 5.0 Hz), 1.38 (9H, s).

Example 29(13)

N-phenylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl )pentanoic acid•t-butylester ##STR1892##

TLC: Rf 0.46 (hexane:ethyl acetate=1:1); NMR (DMSO-d6): δ 8.66 (1H, d, J=10.0 Hz), 7.94-7.89 (2H, m), 7.65-7.33 (6H, m), 6.04-5.79 (2H, m), 4.53-4.42 (1H, m), 4.28 (2H, s), 2.65-2.61 (2H, m), 1.33 (9H, s).

Example 29(14)

N-(2-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1893##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.92 (1H, dt, J=1.8, 7.8 Hz), 7.70-7.59 (1H, m), 7.37-7.14 (5H, m), 6.28 (1H, d, J=9.4 Hz), 5.92 (1H, d, J=18.0 Hz), 5.74 (1H, d, J=18.0 Hz), 4.60 (2H, s), 4.30-4.21 (1H, m), 2.92 (2H, dd, J=17.6, 3.7 Hz), 2.34 (2H, dd, J=l 7.6, 3.7 Hz), 1.40 (9H, s).

Example 29(15)

N-(4-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1894##

TLC: Rf 0.46 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.93-7.86 (2H, m), 7.38-7.15 (5H, m), 6.08 (1H, d, J=8.5 Hz), 5.83 (1H, d, J=18.0 Hz), 5.63 (1H, d, J=18.0 Hz), 4.60 (2H, s), 4.18-4.08 (1H, m), 2.82 (2H, dd, J=17.4, 3.9 Hz), 2.30 (2H, dd, J=17.4, 3.9 Hz), 1.38 (9H, s).

Example 29(16)

N-(3-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1895## TLC: Rf 0.62 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.72-7.46 and 7.42-7.12 (7H, m), 6.23-6.10 (1H, m), 5.84 and 5.64 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.22-4.07 (1H, m), 2.84 (1H, dd, J=17.5 Hz, 4.0 Hz), 2.38 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.37 (9H, s).

Example 29(17)

N-(2-bromophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1896##

TLC: Rf 0.24 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 8.20-8.08 (1H, m), 7.92-7.72 (1H, m), 7.60-7.40 (2H, m), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=7.0 Hz), 7.18 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.68 (1H, d, J=9.6 Hz), 5.98 and 5.80 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.17-4.00 (1H, m), 2.88 (1H, dd, J=17.5 Hz, 4.0 Hz), 2.19 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.40 (9H, s).

Example 29(18)

N-(4-methoxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid•t-butylester ##STR1897##

TLC: Rf 0.38 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.81 (2H, d, J=9.0 Hz), 7.36-7.14 (3H, m), 7.01 (2H, d, J=9.0 Hz), 5.99 (1H, d, J=9.8 Hz), 5.85 (1H, d, J=16.9 Hz), 5.63 (1H, d, J=16.9 Hz), 4.60 (2H, s), 4.14-4.03 (1H, m), 2.81 (2H, dd, J=12.6, 3.7 Hz), 2.26 (2H, dd, J=12.6, 3.7 Hz), 1.37 (9H, s).

Example 29(19)

N-(4-trifluoromethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1898##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (DMSO-d6): δ 8.01 (2H, d, J=8.8 Hz), 7.82 (2H, d, J=8.8 Hz), 7.37-7.15 (3H, m), 6.21 (1H, d, J=9.2 Hz), 5.84 (1H, d, J=17.9 Hz), 5.65 (1H, d, J=17.9 Hz), 4.61 (2H, s), 4.23-4.12 (1H, m), 2.81 (2H, dd, J=16.6, 4.0 Hz), 2.26 (2H, dd, J=16.6, 4.0 Hz), 1.36 (9H, s).

Example 29(20)

N-(thiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1899##

TLC: Rf 0.43 (hexane:ethyl acetate=2:1); NMR (DMSO-d6): δ 7.68-7.65 (2H, m), 7.37-7.14 (3H, m), 7.13 (1H, t, J=4.4 Hz), 6.17 (1H, d, J=9.4 Hz), 5.86 (1H, d, J=18.1 Hz), 5.66 (1H, d, J=18.1 Hz), 4.60 (2H, s), 4.24-4.13 (1H, m), 2.89 (2H, dd, J=17.5, 3.7 Hz), 2.26 (2H, dd, J=17.5, 3.7 Hz), 1.38 (9H, s).

Example 29(21)

N-(3-phenylpropyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1900##

TLC: Rf 0.41 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.40-7.10 (8H, m), 5.82 and 5.66 (each 1H, d, J=18.0 Hz), 4.61 (2H, s), 4.32-4.16 (1H, m), 3.12-2.52 (6H, m), 2.30-2.50 (2H, m), 1.42 (9H, s).

Example 29(22)

N-(2-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-1-yl)pentanoic acid•t-butylester ##STR1901##

HPTLC: Rf 0.34 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.96 (1H, m), 7.68 (1H, m), 7.46-7.10 (5H, m), 6.24 (1H, m), 5.84 and 5.75 (each 1H, each d, J=18.0 Hz), 4.30 (2H, s), 4.28 (1H, m), 3.05 and 2.45 (each 1H, each dd, J=17.5, 5.0 Hz), 1.40 (9H, s).

Example 29(23)

N-(4-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1902##

TLC: Rf 0.61 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.81 and 7.52 (each 2H, d, J=8.0 Hz), 7.35 (1H, d, J=8.0 Hz), 7.35 (1H, d, J=8.2 Hz), 7.19 (1H, dd, J=8.2 Hz, 7.0 Hz), 6.13 (1H, d, J=9.5 Hz), 5.84 and 5.64 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.21-4.05 (1H, m), 2.83 (1H, dd, J=17.5 Hz, 4.5 Hz), 2.33 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.37 (9H, s).

Example 29(24)

N-(3-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1903##

TLC: Rf 0.66 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.95-7.41 (4H, m), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=8.0 Hz), 7.18 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.17 (1H, d, J=9.6 Hz), 5.84 and 5.65 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.23-4.08 (1H, m), 2.84 (1H, dd, J=17.6 Hz, 4.0 Hz), 2.29 (1H, dd, J=17.6 Hz, 4.6 Hz), 1.38 (9H, s).

Example 29(25)

N-(2-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1904##

TLC: Rf 0.64 (chloroform:methanol=19:1); NMR (CDCl3): δ 8.15-8.07 (1H, m), 7.61-7.40 (3H, m), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=7.0 Hz), 7.17 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.58 (1H, d, J=9.6 Hz), 5.97 and 5.79 (each 1H, d, J=18.2 Hz), 4.60 (2H, s), 4.18-4.04 (1H, m), 2.88 (1H, dd, J=17.6 Hz, 3.6 Hz), 2.19 (1H, dd, J=17.6 Hz, 4.4 Hz), 1.40 (9H, s).

Example 29(26)

N-(2-phenyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1905##

TLC: Rf 0.33 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 8.03-7.93, 7.58-6.97 and 6.95-6.85 (1H, m), 6.38 (1H, d, J=9.6 Hz), 5.93 and 5.82 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.38-4.22 (1H, m), 2.94 (1H, dd, J=17.5 Hz, 4.0 Hz), 2.46 (1H, dd, J=17.5 Hz, 5.0 Hz), 1.38 (9H, s).

Example 29(27)

N-(2-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1906##

TLC: Rf 0.45 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.14 (1H, dd, J=1.4, 7.8 Hz), 7.70-7.12 (11H, m), 5.67 (2H, s), 5.18 (1H, d, J=9.4 Hz), 4.58 (2H, s), 3.96 (1H, m), 2.74 (1H, dd, J=4.0, 17 Hz), 2.25 (1H, d, J=4.8, 17 Hz), 1.36 (9H, s).

Example 29(28)

N-(3-phenylpropyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-1-yl)pentanoic acid•t-butylester ##STR1907##

TLC: Rf 0.28 (dichloromethane:ethyl acetate=20:1); NMR (CDCl3): δ 7.41-7.14 (8H, m), 5.78 and 5.68 (each 1H, d, J=19.0 Hz), 5.70 (1H, d, J=9.4 Hz), 4.35-4.19 (1H, m), 4.31 (2H, s), 3.19-2.95 and 2.87-2.60 (6H, m), 2.35-2.07 (2H, m), 1.43 (9H, s).

Example 29(29)

N-(2-methoxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid•t-butylester ##STR1908##

TLC: Rf 0.40 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.95-7.86 (1H, m), 7.63-7.46 (1H, m), 7.38-6.93 (5H, m), 6.38 (1H, d, J=8.5 Hz), 5.78 (2H, s), 4.60 (2H, s), 4.30-4.12 (1H, m), 3.93 (3H, s), 2.85 (1H, dd, J=17.6 Hz, 4.0 Hz), 2.26 (1H, dd, J=17.6 Hz, 5.0 Hz), 1.40 (9H, s).

Example 29(30)

N-(2,6-difluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid•t-butylester ##STR1909##

TLC: Rf 0.33 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.65-7.46 (1H, m), 7.34 (1H, d, J=8.8 Hz), 7.34 (1H, d, J=7.2 Hz), 7.18 (1H, dd, J=8.8 Hz, 7.2 Hz), 7.09 and 7.05 (each 1H, d, J=8.6 Hz), 6.56-6.45 (1H, m), 5.91 and 5.75 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.45-4.53 (1H, m), 2.98 (1H, dd, J=17.8 Hz, 3.6 Hz), 2.45 (1H, dd, J=17.8 Hz, 4.6 Hz), 1.41 (9H, s).

Example 29(31)

N-(4-cyanophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1910##

TLC: Rf 0.63 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.97 (2H, d, J=8.5 Hz), 7.83 (2H, d, J=8.5 Hz), 7.36 (2H, d, J=8.0 Hz), 7.19 (1H, t, J=8.0 Hz), 6.33-6.19 (1H, m), 5.81 and 5.61 (each 1H, d, J=18.0 Hz), 4.61 (2H, s), 4.25-4.13 (1H, m), 2.80 (1H, dd, J=17.5 Hz, 4.0 Hz), 2.38 (1H, dd, J=17.5 Hz, 4.6 Hz), 1.37 (9H, s).

Example 29(32)

N-(2-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1911##

TLC: Rf 0.42 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.04-7.90 (1H, m), 7.58-7.19 (6H, m), 6.33-6.09 (1H, br), 5.81 (1H, dd, J=18.0 Hz), 5.63 (1H, dd, J=18.0 Hz), 4.59 (2H, s), 4.14-3.97 (1H, m), 2.79 (1H, dd, J=17.6 and 3.6 Hz), 2.64 (3H, s), 2.18 (1H, dd, J=17.6 and 4.6 Hz), 1.38 (9H, s).

Example 29(33)

N-(4-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1912##

TLC: Rf 0.35 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.82-7.68 (2H, m), 7.44-7.10 (5H, m), 6.05 (1H, d, J=9.0 Hz), 5.86 (1H, dd, J=18.2 Hz), 5.62 (1H, dd, J=18.2 Hz), 4.60 (2H, s), 4.22-4.02 (1H, m), 2.82 (1H, dd, J=17.6 and 3.8 Hz), 2.48 (3H, s), 2.26 (1H, dd, J=17.6 and 4.6 Hz), 1.37 (9H, s).

Example 29(34)

N-(4-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1913##

TLC: Rf 0.26 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 8.00-7.86 (2H, m), 7.84-7.69 (2H, m), 7.67-7.38 (5H, m), 7.38-7.11 (3H, m, 6.14 (1H, brs), 5.87 (1H, d, J=18.2 Hz), 5.67 (1H, d, J=18.2 Hz), 4.59 (2H, s), 4.27-4.06 (1H, m), 2.85 (1H, dd, J=17.4 and 4.0 Hz), 2.33 (1H, dd, J=17.4 and 4.6 Hz), 1.37 (9H, s).

Example 29(35)

N-(5-dibutylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1914##

TLC: Rf 0.50 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 8.69 (1H, d, J=8.8 Hz), 8.37-8.14 (2H, m), 7.59-7.43 (2H, m), 7.43-7.06 (4H, m), 6.43 (1H, d, J=10.0 Hz), 5.87 (1H, d, J=18.4 Hz), 5.57 (1H, d, J=18.4 Hz), 4.58 (2H, s), 4.10-3.93 (1H, m), 3.11 (4H, t, J=7.2 Hz), 2.65 (1H, dd, J=17.8 and 3.4 Hz), 1.75 (1H, dd, J=17.8 and 4.6 Hz), 1.55-1.05 (8H, m), 1.24 (9H, s), 0.83 (6H, t, J=7.0 Hz).

Example 29(36)

N-(3-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1915##

TLC: Rf 0.67 (chloroform:methanol=19:1); NMR (CDCl3): δ 8.10 (1H, m), 7.90-7.80 (2H, m), 7.67-7.39 (6H, m), 7.34 (1H, d, J=8.8 Hz), 7.34 (1H, d, J=7.0 Hz), 7.17 (1H, dd, J=8.8 Hz, 7.0 Hz), 6.24-6.11 (1H, m), 5.86 and 5.67 (each 1H, d, J=18.0 Hz), 4.58 (2H, s), 4.25-4.12 (1H, m), 2.82 (1H, dd, J=17.6 Hz, 4.0 Hz), 2.26 (1H, dd, J=17.6 Hz, 4.6 Hz), 1.33 (9H, s).

Example 29(37)

N-(4-acetylaminophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1916##

TLC: Rf 0.47 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.80 (2H, d, J=9.2 Hz), 7.74-7.60 (1H, m), 7.69 (2H, d, J=9.2 Hz), 7.33 (1H, d, J=9.2 Hz), 7.33 (1H, d, J=7.0 Hz), 7.17 (1H, dd, J=9.2 Hz, 7.0 Hz), 6.20-6.00 (1H, m), 5.85 and 5.65 (each 1H, d, J=18.0 Hz), 4.59 (2H, s), 4.17-4.04 (1H, m), 2.81 (1H, dd, J=17.4 Hz, 4.0 Hz), 2.21 (1H, dd, J=17.4 Hz, 4.8 Hz), 1.35 (9H, s).

Example 29(38)

N-(4-t-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid•t-butylester ##STR1917##

TLC: Rf 0.23 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.86-7.72 (2H, m), 7.63-7.48 (2H, m), 7.42-7.10 (3H, m), 6.13-5.95 (1H, m, 5.84 (1H, d, J=18.0 Hz), 4.59 (2H, s), 4.22-4.01 (1H, m), 2.84 (1H, dd, J=17.6 and 4.0 Hz), 2.27 (1H, dd, J=17.6 and 4.6 Hz), 1.36 (9H, s), 1.34 (9H, s).

Example 29(39)

N-(5-dimethylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1918##

TLC: Rf 0.29 (hexane:ethyl acetate=2:1); NMR (DMSO-d6): δ 8.63 (1H, d, J=8.6 Hz), 8.30-8.12 (2H, m), 7.72-7.48 (2H, m), 7.48-7.10 (4H, m), 6.42-6.20 (1H, br), 5.67 (1H, d, J=18.8 Hz), 5.46 (1H, d, J=18.8 Hz), 4.32-3.87 (3H, m), 2.90 (6H, s), 2.81 (1H, dd, J=18.0 and 4.0 Hz), 2.01 (1H, dd, J=18.0 and 4.0 Hz), 1.27 (9H, s).

Example 29(40)

N-(5-(pyridin-2-yl)thiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1919##

TLC: Rf 0.28 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.66-8.48 (1H, m), 7.88-7.66 (2H, m), 7.64 (1H, d, J=4.0 Hz), 7.51 (1H, d, J=4.0 Hz), 7.43-7.06 (4H, m), 6.35-6.12 (1H, br), 5.92 (1H, d, J=18.2 Hz), 5.73 (1H, d, J=18.2 Hz), 4.59 (2H, s), 4.31-4.15 (1H, m), 2.92 (1H, dd, J=17.2 and 3.4 Hz), 2.41 (1H, dd, J=17.2 and 4.4 Hz), 1.37 (9H, s).

Example 29(41)

N-(1-(3-chloro-5-trifluoromethylpyridin-2-yl)pyrrol-2-yl)sulfonyl-3-amino-4 -oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1920##

TLC: Rf 0.26 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 8.74-8.64 (1H, m), 8.21-8.11 (1H, m), 8.06 (1H, t, J=2.6 Hz), 7.56 (1H, t, J=2.2 Hz), 7.44-7.04 (3H, m), 6.70-6.59 (1H, m), 607 (1H, d, J=9.4 Hz), 5.90 (1H, d, J=18.4 Hz), 5.71 (1H, d, J=18.4 Hz), 5.10 (2H, s), 4.28-4.04 (1H, m), 2.92 (1H, dd, J=17.2 and 3.8 Hz), 2.50 (1H, dd, J=17.2 and 4.6 Hz), 1.39 (9H, s).

Example 29(42)

N-(4-phenyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1921##

TLC: Rf 0.42 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.85-7.75 and 7.50-7.00 (12H, m), 6.03 (1H, d, J=9.6 Hz), 5.85 and 5.64 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.19-4.03 (1H, m), 2.85 (1H, dd, J=17.4 Hz, 4.0 Hz), 2.33 (1H, dd, J=17.4 Hz, 4.6 Hz), 1.38 (9H, s).

Example 29(43)

N-(4-phenylthiophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid•t-butylester ##STR1922##

TLC: Rf 0.48 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.75-7.60 and 7.60-7.12 (12H, m), 6.15-5.95 (1H, m), 5.84 and 5.62 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.15-4.00 (1H, m), 2.82 (1H, dd, J=17.6 Hz, 4.0 Hz), 2.30 (1H, dd, J=17.6 Hz, 4.6 Hz), 1.37 (9H, s).

Example 29(44)

N-octanylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-y l)pentanoic acid•t-butylester ##STR1923##

TLC: Rf 0.32 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.40-7.10 (3H, m), 5.89 (1H, d, J=17.8 Hz), 5.74 (1H, d, J=17.8 Hz), 4.61 (2H, s), 4.44-4.24 (1H, m), 3.17-2.86 (3H, m), 2.74 (1H, dd, J=17.6 and 4.8 Hz), 1.95-1.70 (2H, m), 1.58-1.14 (10H, m), 1.43 (9H, s), 0.88 (3H, t, J=7.5 Hz).

Example 29(45)

N-(4-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1924##

TLC: Rf 0.17 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 8.06-7.89 (2H, m), 7.89-7.70 (2H, m), 7.70-7.16 (8H, m), 6.10 (1H, d, J=9.2 Hz), 5.80 (1H, d, J=18.8 Hz), 5.68 (1H, d, J=18.8 Hz), 4.29 (2H, s), 4.27-4.09 (1H, m), 2.98 (1H, dd, J=17.8 and 4.2 Hz), 2.44 (1H, dd, J=17.8 and 4.8 Hz), 1.38 (9H, s).

Example 29(46)

N-(4-phenylcarbonylmethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1925##

TLC: Rf 0.79 (chloroform:methanol=19:1); NMR (CDCl3): δ 8.06-7.93, 7.90-7.75 and 7.70-7.10 (12H, m), 6.09 (1H, d, J=8.6 Hz), 5.83 and 5.69 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.39 (2H, s), 4.20-4.05 (1H, m), 2.82 (1H, dd, J=17.6 Hz, 3.6 Hz), 2.27 (1H, dd, J=17.6 Hz, 4.6 Hz), 1.37 (9H, s).

Example 29(47)

N-(2-acetylamino-4-methylthiazol-5-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1926##

TLC: Rf 0.26 (chloroform:methanol=19:1); NMR (CDCl3): δ 9.55-9.35 (1H, m), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=7.0 Hz), 7.17 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.40-6.26 (1H, m), 5.87 and 5.69 (each 1H, d, J=18.0 Hz), 4.60 (2H, s), 4.31-4.15 (1H, m), 2.91 (1H, dd, J=17.6 Hz, 4.0 Hz), 2.52 (3H, s), 2.35 (1H, dd, J=17.6 Hz, 4.4 Hz), 2.30 (3H, s), 1.39 (9H, s).

Example 29(48)

N-(2,2,2-trifluoroethylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1927##

TLC: Rf 0.41 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.51 (1H, d, J=9.0 Hz), 7.51 (1H, d, J=7.0 Hz), 7.17 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.27 (1H, d, J=9.2 Hz), 5.91 and 5.72 (each 1H, d, J=18.0 Hz), 4.61 (2H, s), 4.49-4.35 (1H, m), 4.19-4.82 (2H, m), 2.90-2.73 (2H, m), 1.43 (9H, s).

Example 29(49)

N-(2-trifluoromethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1928##

TLC: Rf 0.33 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.29-8.13 (1H, m), 8.00-7.84 (1H, m), 7.84-7.66 (2H, m), 7.41-7.10 (3H, m), 6.28 (1H, d, J=9.4 Hz), 5,91 (1H, d, J=18.0 Hz), 5.73 (1H, d, J=18.0 Hz), 4.60 (2H, s), 4.25-4.08 (1H, m), 2.86 (1H, dd, J=17.6 and 3.6 Hz), 2.13 (1H, dd, J=17.6 and 4.8 Hz), 1.36 (9H, s).

Example 29(50)

N-(benzofurazan-4-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1929##

TLC: Rf 0.21 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.22-8.00 (2H, m), 7.67-7.47 (1H, d, J=9.0 and 7.0 Hz), 7.47-7.10 (3H, m), 6.52 (1H, d, J=9.0 Hz), 5.94 (1H, d, J=18.0 Hz), 5.78 (1H, d, J=18.0 Hz), 4.70-4.49 (1H, m), 4.60 (2H, s), 2.93 (1H, dd, J=17.8 and 4.2 Hz), 2.35 (1H, dd, J=17.8 and 4.8 Hz), 1.35 (9H, s).

Example 29(51)

N-(3,5-dimethylisooxazol-4-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1930##

TLC: Rf 0.64 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.35 (1H, d, J=9.0 Hz), 7.35 (1H, d, J=7.2 Hz), 7.19 (1H, dd, J=9.0 Hz, J=7.2 Hz), 6.28 (1H, d, J=8.8 Hz), 5.85 and 5.68 (each 1H, d, J=18.0 Hz), 4.61 (2H, s), 4.16-4.00 (1H, m), 2.82 (1H, dd, J=17.4 Hz, J=4.4 Hz), 2.64 (3H, s), 2.46 (1H, dd, J=17.4 Hz, J=4.6 Hz), 2.40 (3H, s), 1.40 (9H, s).

Example 29(52)

N-(2-benzyloxycarbonylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1931##

TLC: Rf 0.52 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.38-7.08 (8H, m), 6.10-5.93 (1H, m), 5.93-5.64 (2H, m), 5.48-5.25 (1H, m), 5.10 (2H, s), 4.60 (2H, s), 4.41-4.21 (1H, m), 3.80-3.55 and 3.55-3.18 (4H, m), 3.03-2.62 (2H, m), 1.42 (9H, s).

Example 29(53)

N-(1,1-dioxotetrahydrothiophen-3-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1932##

TLC: Rf 0.32 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.44-7.08 (3H, m), 6.12-5.87 (1H, m), 5.87-5.57 (2H, m), 4.62 (2H, s), 4.67-4.25 (1H, m), 4.25-3.80 (1H, m), 3.66-2.93 (4H, m), 2.93-2.30 (4H, m), 1.44 (9H, s).

Example 29(54)

N-(5-phenylcarbonylaminomethylthiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2, 6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1933##

TLC: Rf 0.38 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.86-7.70 (2H, m), 7.64-7.06 (7H, m), 7.02 (1H, d, J=3.8 Hz), 6.93-6.76 (1H, m), 6.15 (1H, d, J=9.0 Hz), 5.78 (1H, d, J=18.0 Hz), 5.59 (1H, d, J=18.0 Hz), 4.81 (2H, d, J=6.2 Hz), 4.58 (2H, s), 4.27-4.07 (1H, m), 2.90 (1H, dd, J=17.6 and 4.0 Hz), 2.47 (1H, dd, J=17.6 and 5.0 Hz), 1.38 (9H, s).

Example 29(55)

N-(2,1,3-benzothiadiazol-4-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1934##

TLC: Rf 0.30 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.36-8.21 (2H, m), 7.75 (1H, dd, J=8.8 and 7.2 Hz), 7.42-7.11 (3H, m), 6.59 (1H, d, J=9.4 Hz), 5.90 (1H, d, J=18.0 Hz), 5.73 (1H, d, J=18.0 Hz), 4.72-4.47 (1H, m), 4.59 (2H, s), 2.88 (1H, dd, J=17.6 and 3.6 Hz), 2.19 (1H, dd, J=17.6 and 4.8 Hz), 1.35 (9H, s).

Example 29(56)

N-(4-acetylaminophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1935##

TLC: Rf 0.26 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.9 7 (1H, s), 7.83 and 7.73 (each 2H, d, J=8.5 Hz), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=7.0 Hz), 7.20 (1H, dd, J=9.0 Hz, J=7.0 Hz), 6.10 (1H, d, J=9.2 Hz), 5.77 and 5.65 (each 1H, d, J=19.0 Hz), 4.28 (2H, s), 4.23-4.04 (1H, m), 2.96 (1H, dd, J=17.6 Hz, J=3.8 Hz), 2.46 (1H, dd, J=17.6 Hz, J=5.2 Hz), 1.38 (9H, s).

Example 29(57)

N-(4-phenylthiophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-1-yl)pentanoic acid•t-butylester ##STR1936##

TLC: Rf 0.52 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.72 (2H, d, J=8.8 Hz), 7.59-7.13 (8H, m), 7.23 (2H, d, J=8.8 Hz), 6.20 (1H, d, J=9.0 Hz), 5.88 and 5.66 (each 1H, d, J=18.8 Hz), 4.28 (2H, s), 4.19-4.05 (1H, m), 2.93 (1H, dd, J=17.6 Hz, J=3.8 Hz), 2.44 (1H, dd, J=17.6 Hz, J=4.6 Hz), 1.36 (9H, s).

Example 29(58)

N-(2-nitrophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1937##

TLC: Rf 0.61 (chloroform:methanol=19:1); NMR (CDCl3): δ 8.20-8.06 and 8.05-7.70 (4H, m), 7.34 (1H, d, J=9.0 Hz), 7.34 (1H, d, J=7.0 Hz), 7.18 (1H, dd, J=9.0 Hz, J=7.0 Hz), 6.74 (1H, d, J=9.2 Hz,), 5.93 and 5.75 (each 1H, d, J=18.0 Hz), 4.61 (2H, s), 4.42-4.25 (1H, m), 2.95 (1H, dd, J=17.6 Hz, J=4.2 Hz), 2.40 (1H, dd, J=17.6 Hz, J=4.4 Hz), 1.38 (9H, s).

Example 29(59)

N-(camphor-10-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1938##

TLC: Rf 0.63 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.35 (1H, d, J=9.0 Hz), 7.35 (1H, d, J=6.8 Hz), 7.18 (1H, dd, J=9.0 Hz, J=6.8 Hz), 6.61 (1H, d, J=8.0 Hz), 6.01 and 5.85 (each 1H, d, J=18.5 Hz), 4.64-4.33 (1H, m), 4.61 (2H, s), 3.56-3.40 and 3.15-2.70 (4H, m), 2.53-2.27 and 2.27-1.82 (7H, m), 1.43 (9H, s), 1.02 (3H, s), 0.94 (3H, s).

Example 29(60)

N-(6-chloroimizazo[2,1-B]thiazol-5-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1939##

TLC: Rf 0.19 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.93 (1H, d, J=4.4 Hz), 7.44-7.07 (4H, m), 6.76-6.53 (1H, m), 5.94 (1H, d, J=18.0 Hz), 5.78 (1H, d, J=18.0 Hz), 4.61 (2H, s), 4.36 (1H, m), 2.91 (1H, dd, J17.6 and 4.0 Hz), 2.48 (1H, dd, J=17.6 and 4.6 Hz), 1.39 (9H, s).

Example 29(61)

N-(5-(2-methylthiopyrimidin-4-yl)thiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5- (2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1940##

TLC: Rf 0.19 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.58 (1H, d, J=5.2 Hz), 7.72-7.58 (2H, m), 7.41-7.10 (4H, m), 6.32 (1H, d, J=8.8 Hz), 5.89 (1H, d, J=18.2 Hz), 5.70 (1H, d, J=18.2 Hz), 4.60 (2H, s), 4.35-4.15 (1H, m), 2.92 (1H, dd, J=17.6 and 3.6 Hz), 2.61 (3H, s), 2.41 (1H, dd, J=17.6 and 4.8 Hz), 1.38 (9H, s).

Example 29(62)

N-(4-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid•t-butylester ##STR1941##

TLC: Rf 0.67 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.77 (2H, d, J=8.8 Hz), 7.35 (2H, d, J=8.8 Hz), 7.40-7.12 (3H, m), 6.02 (1H, d, J=9.6 Hz), 5.84 and 5.62 (each 1H, d, J=18.0 Hz), 4.59 (2H, s), 4.18-4.05 (1H, m), 2.82 (1H, dd, J=17.6 Hz, J=3.6 Hz), 2.70 (2H, t, J=7.5 Hz), 2.32 (1H, dd, J=17.6 Hz, J=5.0 Hz), 1.72-1.18 (4H, m), 1.37 (9H, s), 0.93 (3H, s).

Example 29(63)

N-(4-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-1-yl)pentanoic acid•t-butylester ##STR1942##

TLC: Rf 0.57 (chloroform:methanol=19:1); NMR (CDCl3): δ 7.81 (2H, d, J=8.5 Hz), 7.45-7.15 (3H, m), 7.38 (2H, d, J=8.5 Hz), 5.98 (1H, d, J=9.0 Hz), 5.76 and 5.63 (each 1H, d, J=18.6 Hz), 4.28 (2H, s), 4.20-4.03 (1H, m), 2.95 (1H, dd, J=17.6 Hz, J=3.6 Hz), 2.71 (2H, t, J=7.6 Hz), 2.36 (1H, dd, J=17.6 Hz, J=5.0 Hz), 1.74-1.18 (4H, m), 1.37 (9H, s), 0.93 (3H, s).

Example 29(64)

N-(5-(isooxazol-3-yl)thiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlor ophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1943##

TLC: Rf 0.21 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.33 (1H, d, J=2.0 Hz), 7.63 (1H, d, J=3.8 Hz), 7.47 (1H, d, J=3.8 Hz), 7.40-7.11 (3H, m), 6.56 (1H, d, J=2.0 Hz), 6.37 (1H, d, J=8.0 Hz), 5.88 (1H, d, J=17.8 Hz), 5.69 (1H, d, J=17.8 Hz), 4.60 (2H, s), 4.34-4.12 (1H, m), 2.90 (1H, dd, J=17.2 and 3.8 Hz), 2.44 (1H, dd, J=17.2 and 4.8 Hz), 1.38 (9H, s).

Example 29(65)

N-(5-(4-chlorophenylcarbonylaminomethyl)thiophen-2-yl)sulfonyl-3-amino-4-ox o-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1944##

TLC: Rf 0.31 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.82-7.65 (2H, m), 7.55-6.90 (8H, m), 6.18 (1H, d, J=9.0 Hz), 5.75 (1H, d, J=17.8 Hz), 5.56 (1H, d, J=17.8 Hz), 4.78 (2H, d, J=6.0 Hz), 4.57 (2H, s), 4.28-4.10 (1H, m), 2.90 (1H, dd, J=17.4 and 4.0 Hz), 2.51 (1H, dd, J=17.4 and 5.0 Hz), 1.38 (9H, s).

Example 29(66)

N-(4-(pyrrolidin-1-yl)phenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1945##

TLC: Rf 0.43 (hexane:ethyl acetate=1:1); NMR (DMSO-d6): δ 8.27-8.06 (1H, brs), 7.80-7.19 (5H, m), 6.71-6.46 (2H, m), 6.04-5.70 (2H, m), 4.44-3.90 (3H, m), 3.35-3.05 (4H, m), 2.74-2.49 (2H, m), 2.03-1.76 (4H, m), 1.34 (9H, s).

Example 29(67)

N-(4-(morpholin-4-yl)phenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1946##

TLC: Rf 0.19 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.85-7.66 (2H, m), 7.47-7.10 (3H, m), 7.02-6.85 (2H, m), 5.83 (1H, d, J=9.4 Hz), 5.73 (1H, d, J-18.8 Hz), 5.61 (1H, d, J=18.8 Hz), 4.25 (2H, s), 4.15-4.00 (1H, m), 3.94-3.76 (4H, m), 3.40-3.22 (4H, m), 2.98 (1H, dd, J=17.6 and 4.2 Hz), 2.47 (1H, dd, J=17.6 and 4.6 Hz), 1.39 (9H, s).

Example 29(68)

N-(2-diethylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid•t-butylester ##STR1947##

TLC: Rf 0.67 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.34 (1H, d, J=8.8 Hz), 7.34 (1H, d, J=7.0 Hz), 7.17 (1H, dd, J=8.8 Hz, 7.0 Hz), 5.87 and 5.78 (each 1H, d, J=18.0 Hz), 4.61 (2H, s), 4.53-4.43 (1H, m), 3.47-2.41 (10H, m), 1.42 (9H, s), 1.05 (3H, t, J=7.0 Hz).

Example 29(69)

N-(3-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid•t-butylester ##STR1948##

TLC: Rf 0.23 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.74-7.59 (2H, m), 7.51-7.10 (5H, m), 6.06 (1H, d, J=9.6 Hz), 5.83 (1H, d, J=18.2 Hz), 5.62 (1H, d, J=18.2 Hz), 4.59 (2H, s), 4.21-4.05 (1H, m), 2.82 (1H, dd, J=17.4 and 3.8 Hz), 2.44 (3H, s), 2.24 (1H, dd, J=17.4 and 5.0 Hz), 1.37 (9H, s).

Example 29(70)

N-(4-isopropylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid•t-butylester ##STR1949##

TLC: Rf 0.31 (hexane:ethyl acetate=3:1); NMR (CDCl3): δ 7.86-7.71 (2H, m), 7.46-7.10 (5H, m), 6.04 (1H, d, J=9.6 Hz), 5.84 (1H, d, J=18.0 Hz), 5.61 (1H, d, J=18.0 Hz), 4.59 (2H, s), 4.20-4.01 (1H, m, 3.10-2.87 (1H, m), 2.83 (1H, dd, J=17.6 and 3.6 Hz), 2.27 (1H, dd, J=17.6 and 5.0 Hz), 1.36 (9H, s), 1.27 (6H, d, J=7.0 Hz).

Example 29(71)

N-(4-isopropylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid•t-butylester ##STR1950##

TLC: Rf 0.26 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.90-7.73 (2H, m), 7.51-7.15 (5H, m), 5.98 (1H, d, J=9.6 Hz), 5.76 (1H, d, J=18.8 Hz), 5.63 (1H, d, J=18.8 Hz), 4.29 (2H, s), 4.22-4.02 (1H, m), 3.13-2.83 (2H, m), 2.39 (1H, dd, J=17.8 and 4.4 Hz), 1.37 (9H, s), 1.29 (6H, d, J=6.8 Hz).

Example 29(72)

N-(2-diethylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-1-yl)pentanoic acid•t-butylester ##STR1951##

TLC: Rf 0.37 (chloroform:methanol=9:1); NMR (CDCl3): δ 7.43-7.15 (3H, m), 5.81 (2H, s), 4.60-4.47 (1H, m), 4.39-4.26 (2H, m), 3.41-2.45 (10H, m), 1.42 (9H, s), 1.08 (3H, t, J=7.0 Hz).

Example 29(73)

N-(4-butyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid•t-butylester ##STR1952##

TLC: Rf 0.51 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.92-7.69 (2H, m), 7.28-7.10 (3H, m), 7.10-6.89 (2H, m), 6.00 (1H, d, J=8.6 Hz), 5.86 (1H, d, J=18.2 Hz), 5.65 (1H, d, J=18.2 Hz), 4.60 (2H, s), 4.22-3.89 (3H, m), 2.83 (1H, dd, J=17.2 and 3.4 Hz), 2.27 (1H, dd, J=17.2 and 4.8 Hz), 1.94-1.69 (2H, m), 1.64-1.24 (2H, m), 1.37 (9H, s), 0.99 (3H, t, J=7.4 Hz).

Example 29(74)

N-(4-butyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-1-yl)pentanoic acid•t-butylester ##STR1953##

TLC: Rf 0.28 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 7.91-7.74 (2H, m), 7.46-7.14 (3H, m), 7.10-6.93 (2H, m), 6.03-5.82 (1H, brs), 5.76 (1H, d, J=19.2 Hz), 5.64 (1H, d, J=19.2 Hz), 4.27 (2H, s), 4.18-3.97 (1H, m), 4.04 (2H, t, J=6.4 Hz), 2.96 (1H, dd, J=17.4 and 4.0 Hz), 2.39 (1H, dd, J=17.4 and 4.6 Hz), 1.92-1.67 (2H, m), 1.67-1.35 (2H, m), 1.38 (9H, s), 0.99 (3H, t, J=7.4 Hz).

EXAMPLES 30(1)-30(74)

By the same procedure as provided in example 6(1), and if necessary, by known methods converted to accommodate the corresponding salts, using the compound prepared in examples 29(1)-29(74), the compounds of the present invention having the following physical data were obtained.

Example 30(1)

N-(4-t-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-1-yl)pentanoic acid ##STR1954##

TLC: Rf 0.19 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 8.83-8.34 (1H, br), 7.92-7.75 (2H, m), 7.72-7.31 (5H, m), 6.10-5.54 (2H, br), 4.43-4.26 (1H, m), 4.30 (2H, s), 2.82-2.50 (2H, m), 1.30 (9H, s).

Example 30(2)

N-phenylmethylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazo l-2-yl)pentanoic acid ##STR1955##

TLC: Rf 0.14 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 7.99-7.70 (1H, br), 7.52 (2H, d, J=7.5 Hz), 7.45-7.27 (6H, m), 6.01-5.80 (2H, m), 4.52 (total 4H, s), 4.58-4.38 (1H, m), 2.77-2.66 (2H, m).

Example 30(3)

N-phenylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl )pentanoic acid ##STR1956##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=18:1:1); NMR (CDCl3 +DMSO-d6): δ 7.98-7.80 and 7.68-7.10 (total 9H, m), 6.10-5.30 (2H, br), 4.58 (2H, s), 4.30-4.10 (1H, m), 2.76-2.33 (2H, m).

Example 30(4)

N-(2-(naphthalen-1-yl)ethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-2-yl)pentanoic acid ##STR1957##

TLC: Rf 0.59 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.10-7.75 and 7.65-7.13 (total 11H, m), 6.10-5.87 (2H, m), 4.89 (2H, s), 4.55-4.38 (1H, m), 3.60-3.46 (4H, m), 2.75-2.62 (2H,m).

Example 30(5)

N-(naphthalen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid ##STR1958##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.80-12.10 (1H, br), 8.72-8.47 (2H, m), 8.23-8.00 (3H, m), 7.94-7.83 (1H, m), 7.79-7.60 (2H, m), 7.57-7.45 (2H, m), 7.43-7.29 (1H, m), 6.15-5.77 (2H, m), 4.49 (2H, s), 4.43-4.29 (1H, m), 2.64-2.37 (2H, m).

Example 30(6)

N-(naphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid ##STR1959##

TLC: Rf 0.54 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.70-12.20 (1H, br), 8.99-8.75 (1H, m), 8.70-8.57 (1H, m), 8.32-8.15 and 8.15-8.02 (total 3H, m), 7.78-7.56 (3H, m), 7.56-7.46 (2H, m), 7.42-7.30 (1H, m), 6.00-5.70 (2H, m), 4.49 (2H, s), 4.42-4.25 (1H, m), 2.42-2.21 (2H, m).

Example 30(7)

N-(2-phenylethenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid ##STR1960##

TLC: Rf 0.57 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 8.90-8.40 (1H, br), 7.72-7.68 (2H, m), 7.55-7.15 (8H, m), 6.10-5.90 (2H, m), 4.51 (2H, s), 4.45-4.35 (1H, m), 2.80-2.72 (2H, m).

Example 30(8)

N-(4-bromophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR1961##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.85-8.25 (1H, br), 7.86-7.70 (4H, m), 7.56-7.30 (3H, m), 6.07-5.72 (2H, m), 4.51 (2H, s), 4.43-4.27 (1H, m), 2.69-2.52 (2H, m).

Example 30(9)

N-butylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl) pentanoic acid ##STR1962##

TLC: Rf 0.30 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 7.94-7.72 (1H, d), 7.53-7.33 (3H, m), 6.16-5.85 (2H, m), 4.52 (2H, s), 4.50-4.40 (1H, m), 3.18-3.10 (2H, m), 2.77-2.73 (2H, m), 1.75-1.55 (2H, m), 1.48-1.28 (2H, m), 0.90 (3H, t).

Example 30(10)

N-(quinolin-8-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR1963##

TLC: Rf 0.42 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 9.05-9.01 (1H, m), 8.58-8.53 (1H, m), 8.39-8.29 (2H, m), 8.17-8.00 (1H, m), 7.80-7.67 (2H, m), 7.53-7.33 (3H, m), 6.16-5.63 (2H, m), 4.91-4.73 (1H, m), 4.49 (2H, s).

Example 30(11)

N-(5-dimethylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylmethyl)tetrazol-2-yl)pentanoic acid ##STR1964##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=30:1:1); NMR (DMSO-d6): δ 12.84-11.80 (1H, br), 8.94-8.64 (1H, m), 8.52-8.47 (1H, m), 8.30-8.19 (2H, m), 7.66-7.23 (6H, m), 5.93-5.68 (2H, m), 4.49 (2H, s), 4.42-4.26 (1H, m), 2.83 (6H, s), 2.60-2.25 (2H, m).

Example 30(12)

N-(4-nitrophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR1965##

TLC: Rf 0.53 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.40 (2H, d, J=9.0 Hz), 8.10 (2H, d, J=9.0 Hz), 7.51 (1H, d, J=9.0 Hz), 7.50 (1H, d, J=6.8 Hz), 6.10-5.75 (2H, br), 4.50 (2H, s), 4.55-4.37 (1H, m), 2.68-2.55 (2H, m).

Example 30(13)

N-phenylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl )pentanoic acid ##STR1966##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 13.04-12.28 (1H, br), 8.68-8.50 (1H, m), 7.94-7.89 (2H, m), 7.68-7.34 (6H, m), 6.04-5.79 (2H, m), 4.46-4.36 (1H, m), 4.29 (2H, m), 2.79-2.56 (2H, m).

Example 30(14)

N-(2-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1967##

TLC: Rf 0.36 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 12.94-12.36 (1H, br), 8.86-8.70 (1H, m), 7.88-7.33 (7H, m), 5.97 (2H, brs), 4.52 (2H, s), 4.46 (1H, m), 2.78-2.47 (2H, m).

Example 30(15)

N-(4-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1968##

TLC: Rf 0.31 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 13.09-12.00 (1H, br), 8.62-8.46 (1H, m), 7.96-7.89 (2H, m), 7.53-7.32 (5H, m), 6.07-5.83 (2H, m), 4.51 (2H, s), 4.35 (1H, m), 2.56 (2H, m).

Example 30(16)

N-(3-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1969##

TLC: Rf 0.17 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 8.60 (1H, br), 7.75-7.32 (7H, m), 6.20-5.70 (2H, m), 4.51 (2H, s), 4.46-4.32 (1H, m), 2.62-2.53 (2H, m).

Example 30(17)

N-(2-bromophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR1970##

TLC: Rf 0.27 (chloroform:methanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 12.80-12.20 (1H, brs), 8.80-8.40 (1H, m), 8.12-8.00 and 7.90-7.79 (each 1H, m), 7.65-7.46 and 7.46-7.32 (total 5H, m), 6.15-5.75 (2H, m), 4.51 (2H, s), 4.60-4.30 (1H, m), 2.80-2.42 (2H, m).

Example 30(18)

N-(4-methoxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid ##STR1971##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 8.48-8.16 (1H, m), 7.82-7.78 (2H, m), 7.53-7.08 (5H, m), 6.15-5.63 (2H, m), 4.51 (2H, s), 4.33-4.15 (1H, m), 3.85 (3H, s).

Example 30(19)

N-(4-trifluoromethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-2-yl)pentanoic acid ##STR1972##

TLC: Rf 0.35 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 8.07 (2H, d, J=8.5 Hz), 7.96 (2H, t, J=8.5 Hz), 7.53-7.33 (3H, m), 6.08-5.65 (2H, m), 4.51 (2H, s), 4.46-4.55 (1H, m), 2.61-2.58 (2H, m).

Example 30(20)

N-(thiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR1973##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=25:1:1); NMR (DMSO-d6): δ 13.13-11.94 (1H, br), 8.92-8.46 (1H, m), 7.95 (1H, dd, J=5.0, 1.4 Hz), 7.70 (1H, m), 7.53-7.49 (2H, m,), 7.40-7.32 (1H, m), 7.18 (1H, dd, J=5.0, 4.0 Hz), 6.08-5.78 (2H, m), 4.52 (2H, s), 4.39 (1H, m), 2.57 (2H, m).

Example 30(21)

N-(3-phenylpropyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1974##

TLC: Rf 0.57 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.00-7.80 (1H, m), 7.56-7.47 and 7.43-7.13 (8H, m), 6.12-5.82 (2H, m), 4.52 (2H, s), 4.56-4.40 (1H, m), 3.22-3.07 (2H, m), 2.80-2.60 (4H, m), 2.06-1.87 (2H, m).

Example 30(22)

N-(2-fluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-1-yl)pentanoic acid ##STR1975##

TLC: Rf 0.35 (chloroform:ethanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.9 (1H, br), 7.95-7.30 (7H, m), 5.94 (2H, br), 4.54 (1H, m), 4.30 (2H, brs), 2.74 (2H, m).

Example 30(23)

N-(4-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1976##

TLC: Rf 0.15 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.00-12.20 (1H, br), 8.78-8.40 (1H, br), 7.87 and 7.65 (each 2H, d, J=8.6 Hz), 7.52 (1H, d, J=8.6 Hz), 7.51 (1H, d, J=7.4 Hz), 7.41 (1H, dd, J=8.6 Hz, 7.4 Hz), 6.15-5.76 (2H, br), 4.51 (2H, s), 4.45-4.27 (1H, m), 2.67-2.53 (2H, m).

Example 30(24)

N-(3-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1977##

TLC: Rf 0.15 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 12.80-12.40 (1H, brs), 8.64 (1H, d, J=7.4 Hz), 7.90-7.70 and 7.42-7.32 (7H, m), 6.02 and 5.89 (each 1H, d, J=18.4 Hz), 4.51 (2H, s), 4.57-4.38 (1H, m), 2.66-2.55 (2H, m).

Example 30(25)

N-(2-chlorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1978##

TLC: Rf 0.21 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 12.80-11.80 (1H, brs), 8.80-8.50 (1H, m), 8.02 (1H, d, J=7.4 Hz), 7.73-7.45 and 7.45-7.30 (6H, m), 6.10-5.80 (2H, m), 4.51 (2H, s), 4.57-4.32 (1H, m), 2.77-2.40 (2H, m).

Example 30(26)

N-(2-phenyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1979##

TLC: Rf 0.26 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 12.80-12.20 (1H, brs), 8.39-8.27 (1H, m), 7.95-7.85 (1H, m), 7.65-7.05 and 6.99-6.82 (11H, m), 6.03 and 5.91 (each 1H, d, J=18.4 Hz), 4.52 (2H, s), 4.60-4.40 (1H, m), 2.80-2.47 (2H, m).

Example 30(27)

N-(2-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1980##

TLC: Rf 0.38 (chloroform:methanol:water=50:10:1); NMR (DMSO-d6): δ 8.05 (1H, dd, J=1.0, 7.6 Hz), 7.68-7.30 (12H, m), 5.79 (2H, brs), 4.49 (2H, s), 3.96 (1H, m), 2.48-2.28 (2H, m).

Example 30(28)

N-(3-phenylpropyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-1-yl)pentanoic acid ##STR1981##

TLC: Rf 0.43 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.10-12.20 (1H, brs), 8.10-7.90 (1H, m), 7.61-7.13 (8H, m), 6.13-5.75 (2H, br), 4.65-4.47 (1H, m), 4.35 (2H, s), 3.25-3.10 (2H, m), 2.91-2.79 (2H, m) 2.79-2.64 (2H, m), 2.11-1.87 (2H, m).

Example 30(29)

N-(2-methoxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid ##STR1982##

TLC: Rf 0.51 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.90-12.10 (1H, brs), 8.10-7.90 (1H, m), 7.80-7.01 (7H, m), 6.10-5.70 (2H, br), 4.50 (2H, s), 4.53-4.33 (1H, m), 3.85 (3H, s), 2.67-2.39 (2H, m).

Example 30(30)

N-(2,6-difluorophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid ##STR1983##

TLC: Rf 0.48 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.80-7.60, 7.60-7.47 and 7.47-7.17 (6H, m), 6.10-5.80 (2H, br), 4.63-4.52 (1H, m), 4.51 (2H, m), 2.85-2.43 (2H, m).

Example 30(31)

N-(4-cyanophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR1984##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.08 (2H, d, J=8.6 Hz), 8.00 (2H, d, J=8.6 Hz), 7.52 (1H, d, J=9.0 Hz), 7.51 (1H, d, J=6.8 Hz), 7.37 (1H, dd, J=9.0 Hz, 6.8 Hz), 6.10-5.75 (2H, br), 4.51 (2H, s), 4.48 (1H, m), 2.68-2.55 (2H, m).

Example 30(32)

N-(2-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1985##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.95-8.20 (1H, br), 7.90 (1H, d, J=7.6 Hz), 7.70-7.08 (6H, m), 6.30-5.42 (2H, br), 4.52 (2H, s), 4.30 (1H, brs), 2.58 (3H, s), 2.84-2.12 (2H, m).

Example 30(33)

N-(4-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1986##

TLC: Rf 0.44 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.79-8.03 (1H, br), 7.76 (2H, d, J=8.0 Hz), 7.61-7.20 (5H, m), 6.32-5.42 (2H, br), 4.51 (2H, s), 4.43-4.14 (1H, m), 2.71-2.12 (2H, m), 2.39 (3H, s).

Example 30(34)

N-(4-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1987##

TLC: Rf 0.25 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.45-11.25 (1H, br), 8.87-8.27 (1H, br), 8.13-7.80 (4H, m), 7.76 (2H, d, J=6.6 Hz), 7.65-7.23 (6H, m), 6.33-5.55 (2H, br), 4.51 (2H, s), 4.58-4.20 (1H, m), 2.82-2.35 (2H, m).

Example 30(35)

N-(5-dibutylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylmethyl)tetrazol-2-yl)pentanoic acid ##STR1988##

TLC: Rf 0.33 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.20-11.60 (1H, br), 9.10-8.49 (1H, br), 8.57 (1H, d, J=8.4 Hz), 8.33 (1H, d, J=8.2 Hz), 8.20 (1H, d, J=7.0 Hz), 7.75-7.22 (6H, m), 6.09-5.18 (2H, br), 4.47 (2H, s), 4.46-4.18 (1H, m), 3.08 (4H, t, J=7.4 Hz), 2.68-2.20 (2H, m), 1.54-0.97 (8H, m), 0.76 (6H, t, J=6.8 Hz).

Example 30(36)

N-(3-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1989##

TLC: Rf 0.65 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.00-12.10 (1H, br), 8.71-8.40 (1H, br), 8.17-8.10, 8.00-7.79, 7.79-7.60 and 7.60-7.30 (12H, m), 6.15-5.73 (2H, br), 4.49 (2H, s), 4.55-4.35 (1H, m), 2.64-2.40 (2H, m).

Example 30(37)

N-(4-acetylaminophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid ##STR1990##

TLC: Rf 0.32 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.90-12.10 (1H, br), 10.34 (1H, s), 8.43-8.25 (1H, br), 7.83-7.70 (4H, m), 7.53 (1H, d, J=9.0 Hz), 7.52 (1H, d, J=6.8 Hz), 7.37 (1H, dd, J=9.0 Hz, 6.8 Hz), 6.10-5.77 (2H, br), 4.51 (2H, s), 4.39-4.20 (1H, m), 2.62-2.37 (2H, m) 2.09 (3H, s).

Example 30(38)

N-(4-t-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)te trazol-2-yl)pentanoic acid ##STR1991##

TLC: Rf 0.31 (chloroform:methanol:acetic acid=35:1:1); NMR (DMSO-d6): δ 13.15-11.35 (1H, br), 8.86-8.03 (1H, br), 7.79 (2H, d, J=8.6 Hz), 7.61 (2H, d, J=8.6 Hz), 7.56-7.26 (3H, m), 6.24-5.42 (2H, br), 4.50 (2H, s), 4.40-4.20 (1H, m), 2.63-2.37 (2H, m), 1.29 (9H, s).

Example 30(39)

N-(5-dimethylaminonaphthalen-1-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloro phenylmethyl)tetrazol-1-yl)pentanoic acid ##STR1992##

TLC: Rf 0.12 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 9.46-8.63 (1H, br), 8.49 (1H, d, J=8.4 Hz), 8.40-8.16 (2H, m), 7.74-7.15 (6H, m), 5.70 (2H, br), 4.48-4.32 (1H, m), 4.16 (2H, s), 2.81 (6H, s), 2.70-2.40 (2H, m).

Example 30(40)

N-(5-(pyridin-2-yl)thiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylmethyl)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR1993##

TLC: Rf 0.22 (chloroform:methanol:acetic acid=35:1:1); NMR (DMSO-d6) δ 8.84 (1H, d, J=7.8 Hz), 8.59 (1H, d, J=4.4 Hz), 8.06 (1H, d, J=7.8 Hz), 8.00-7.80 (2H, m), 7.71 (1H, d, J=4.2 Hz), 7.58-7.27 (4H, m), 6.05 (2H, d, J=18.1 Hz), 5.91 (1H, d, J=18.1 Hz), 4.61-4.30 (1H, m), 4.49 (2H, s), 2.77-2.46 (2H, m).

Example 30(41)

N-(1-(3-chloro-5-trifluoromethylpyridin-2-yl)pyrrol-2-yl)sulfonyl-3-amino-4 -oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid hydrochloric acid salt ##STR1994##

TLC: Rf 0.16 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.50-11.80 (1H, br), 8.95 (1H, brs), 8.77 (1H, brs), 8.41-8.17 (1H, m), 8.00 (1H, brs), 7.64-7.00 (4H, m), 6.66 (1H, brs), 6.23-5.68 (2H, m), 4.55-4.14 (1H, m), 4.50 (2H, s), 2.75-2.28 (2H, m).

Example 30(42)

N-(4-phenyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1995##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 8.60-8.25 (1H, br), 7.93-7.79 (2H, m), 7.60-7.05 (10H, m), 6.10-5.70 (2H, br), 4.51 (2H, s), 4.40-4.23 (1H, m), 2.65-2.35 (2H, m).

Example 30(43)

N-(4-phenylthiophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-2-yl)pentanoic acid ##STR1996##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 8.67-8.25 (1H, br), 7.83-7.72 (2H, m), 7.60-7.25 (10H, m), 6.12-5.65 (2H, br), 4.51 (2H, s), 4.40-4.23 (1H, m), 2.65-2.33 (2H, m).

Example 30(44)

N-octanylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR1997##

TLC: Rf 0.17 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 8.00-7.64 (1H, br), 7.60-7.30 (3H, m), 6.20-5.63 (2H, br), 4.61-4.33 (1H, m), 4.52 (2H, s), 3.25-3.00 (2H, m), 2.88-2.60 (2H, m), 1.82-1.48 (2H, m), 1.48-1.06 (10H, m), 0.97-0.70 (3H, m).

Example 30(45)

N-(4-phenylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR1998##

TLC: Rf 0.10 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 9.23-8.40 (1H, br), 8.06-7.82 (4H, m), 7.82-7.64 (2H, m), 7.64-7.24 (6H, m), 6.26-5.45 (2H, br), 4.56-4.30 (1H, m), 4.33 (1H, d, J=18.0 Hz), 4.22 (1H, d, J=18.0 Hz), 2.90-2.50 (2H, m).

Example 30(46)

N-(4-phenylcarbonylmethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloroph enylmethyl)tetrazol-2-yl)pentanoic acid ##STR1999##

TLC: Rf 0.61 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.70-8.20 (1H, br), 8.10-7.99, 7.88-7.78 and 7.78-7.33 (total 12H, m), 6.10-5.64 (2H, br), 4.56 (2H, s), 4.51 (2H, s), 4.40-4.27 (1H, m), 2.60-2.38 (2H, m).

Example 30(47)

N-(2-acetylamino-4-methylthiazol-5-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR2000##

TLC: Rf 0.35 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.70-12.35 (1H, br), 7.52 (1H, d, J=9.0 Hz), 7.52 (1H, d, J=7.0 Hz), 7.37 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.12-5.71 (2H, br), 4.51 (2H, s), 4.39-4.23 (1H, m), 2.64-2.38 (2H, m) 2.50 (3H, s), 2.17 (3H, s).

Example 30(48)

N-(2,2,2-trifluoroethylsulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid ##STR2001##

TLC: Rf 0.32 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.52 (1H, d, J=9.4 Hz), 7.52 (1H, d, J=6.8 Hz), 7.37 (1H, dd, J=9.4 Hz, 6.8 Hz), 6.20-5.80 (2H, br), 4.72-4.45 (3H, m), 4.52 (2H, s), 2.89-2.65 (2H, m).

Example 30(49)

N-(2-trifluoromethylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylm ethyl)tetrazol-2-yl)pentanoic acid ##STR2002##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=35:1:1); NMR (DMSO-d6): δ 13.10-11.85 (1H, br), 9.22-8.18 (1H, br), 8.26-8.12 (1H, m), 8.22-7.76 (2H, m), 7.52 (1H, d, J=9.0 Hz), 7.52 (1H, d, J=7.0 Hz), 7.37 (1H, dd, J=9.0 and 7.0 Hz), 6.25-5.60 (2H, br), 4.63-4.34 (1H, m), 4.51 (2H, s), 2.83-2.49 (2H, m).

Example 30(50)

N-(benzofurazan-4-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR2003##

TLC: Rf 0.18 (chloroform:methanol:acetic acid=35:1:1); NMR (DMSO-d6): δ 12.80-11.80 (1H, br), 9.50-8.82 (1H, br), 8.36 (1H, d, J=9.0 Hz), 8.12 (1H, d, J=6.8 Hz), 7.74 (1H, dd, J=9.0 and 6.8 Hz), 7.52 (1H, d, J=9.1 Hz), 7.52 (1H, d, J=7.1 Hz), 7.37 (1H, dd, J=9.1 and 7.1 Hz), 5.98 (2H, s), 4.75-4.41 (1H, m), 4.50 (2H, s), 2.85-2.42 (2H, m).

Example 30(51)

N-(3,5-dimethylisooxazol-4-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-2-yl)pentanoic acid ##STR2004##

TLC: Rf 0.50 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.10-11.90 (1H, br), 9.20-8.40 (1H, br), 7.52 (1H, d, J=8.8 Hz), 7.52 (1H, d, J=7.0 Hz), 7.37 (1H, dd, J=8.8 Hz, 7.0 Hz), 6.15-5.80 (2H, br), 4.52 (2H, s), 4.42-4.30 (1H, m), 2.82-2.35 (2H, m), 2.57 (3H, s), 2.32 (3H, s).

Example 30(52)

N-(2-benzyloxycarbonylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorop henylmethyl)tetrazol-2-yl)pentanoic acid ##STR2005##

TLC: Rf 0.42 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.10-7.65 (1H, br), 7.58-7.20 (8H, m), 6.15-5.80 (2H, br), 5.01 (2H, s), 4.57-4.40 (1H, m), 4.52 (2H, s), 3.80-2.90 (4H, m), 2.90-2.60 (2H, m).

Example 30(53)

N-(1,1-dioxotetrahydrothiophen-3-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlo rophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR2006##

TLC: Rf 0.14 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 7.64-7.22 (3H, m), 5.97 (2H, brs), 4.68-4.14 (2H, m), 4.52 (2H, s), 3.85-3.00 (4H, m), 2.90-2.20 (4H, m).

Example 30(54)

N-(5-phenylcarbonylaminomethylthiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2, 6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR2007##

TLC: Rf 0.16 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 9.30 (1H, t, J=5.8 Hz), 7.88 (2H, d, J=6.6 Hz), 7.66-6.99 (8H, m), 6.06-5.70 (2H, m), 4.66 (2H, d, J=5.8 Hz), 4.50 (2H, s), 4.17 (1H, t, J=6.2 Hz), 2.64-2.23 (2H, m).

Example 30(55)

N-(2,1,3-benzothiadiazol-4-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-2-yl)pentanoic acid ##STR2008##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=40:1:1); NMR (DMSO-d6): δ 13.30-11.70 (1H, br), 9.20-8.00 (1H, br), 8.38 (1H, d, J=9.0 Hz), 8.25 (1H, d, J=6.0 Hz), 7.85 (1H, dd, J=9.0 and 6.0 Hz), 7.52 (2H, m), 7.38 (1H, dd, J=9.0 and 6.8 Hz), 6.25-5.52 (2H, m), 5.00-4.64 (1H, m), 4.49 (2H, s), 2.89-2.35 (2H, m).

Example 30(56)

N-(4-acetylaminophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-1-yl)pentanoic acid ##STR2009##

TLC: Rf 0.39 (chloroform:methanol:acetic acid=8:1:1); NMR (DMSO-d6): δ 10.39 (1H, s), 7.88-7.70 (4H, m), 7.56-7.34 (3H, m), 6.03-5.70 (2H, br), 4.33 and 4.22 (each 1H, d, J=15.0 Hz), 4.12-4.00 (1H, m), 2.55-2.22 (2H, m), 2.07 (3H, s).

Example 30(57)

N-(4-phenylthiophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl )tetrazol-1-yl)pentanoic acid ##STR2010##

TLC: Rf 0.47 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.00-11.90 (1H, br), 9.00-8.40 (1H, br), 7.81 (2H, d, J=8.2 Hz), 7.60-7.38 (8H, m), 7.32 (2H, d, J=8.2 Hz), 6.02-5.65 (2H, br), 4.45-4.31 (1H, m), 4.29 (2H, s), 2.81-2.52 (2H, m).

Example 30(58)

N-(2-nitrophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR2011##

TLC: Rf 0.52 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.90-12.00 (1H, br), 9.20-8.35 (1H, br), 8.15-7.80 (4H, m), 7.52 (1H, d, J=9.0 Hz), 7.52 (1H, d, J=7.0 Hz), 7.37 (1H, dd, J=9.0 Hz, J=7.0 Hz), 6.10-5.70 (2H, br), 4.65-4.45 (1H, m), 4.51 (2H, s), 2.85-2.55 (2H, m).

Example 30(59)

N-(camphor-10-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR2012##

TLC: Rf 0.57 and 0.49 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.10-11.90 (1H, br), 8.00-7.74 (1H, br), 7.52 (1H, d, J=9.0 Hz), 7.52 (1H, d, J=6.8 Hz), 7.37 (1H, dd, J=9.0 Hz, J=6.8 Hz), 6.18-5.79 (2H, br), 4.65-4.45 (1H, m), 4.52 (2H, s), 3.54, 3.45, 3.20 and 3.13 (total 2H, each d, J=14.0 Hz), 2.87-2.68 (2H, m), 2.46-2.36, 2.10-1.81 and 1.62-1.30 (total 7H, m), 1.03 (3H, s), 0.82 and 0.81 (total 3H, each s).

Example 30(60)

N-(6-chloroimizazo[2,1-B]thiazol-5-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR2013##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.01 (1H, d, J=4.6 Hz), 7.59 (1H, d, J=4.6 Hz), 7.56-7.25 (3H, m), 6.12-5.74 (2H, br), 4.51 (2H, s), 4.40 (1H, t, J=6.0 Hz), 2.85-2.46 (2H, m).

Example 30(61)

N-(5-(2-methylthiopyrimidin-4-yl)thiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5- (2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR2014##

TLC: Rf 0.34 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.10-12.20 (1H, br), 9.44-8.40 (1H, br), 8.72 (1H, d, J=5.2 Hz), 8.10 (1H, d, J=4.1 Hz), 7.81 (1H, d, J=5.2 Hz), 7.76 (1H, d, J=4.1 Hz), 7.60-7.23 (3H, m), 6.25-5.70 (2H, br), 4.49 (3H, brs), 2.96-2.33 (2H, m), 2.57 (3H, s).

Example 30(62)

N-(4-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR2015##

TLC: Rf 0.35 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 13.10-11.90 (1H, br), 8.55-8.20 (1H, br), 7.77 (2H, d, J=8.0 Hz), 7.52 (1H, d, J=9.0 Hz), 7.52 (1H, d, J=7.2 Hz), 7.41 (2H, d, J=8.0 Hz), 7.37 (1H, dd, J=9.0 Hz, J=7.2 Hz), 6.10-5.58 (2H, br), 4.51 (2H, s), 4.39-4.20 (1H, m), 2.66 (2H, t, J=7.6 Hz), 2.56-2.32 (2H, m), 1.66-1.45 and 1.37-1.14 (each 2H, m), 0.87 (3H, t, J=7.4 Hz).

Example 30(63)

N-(4-butylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-1-yl)pentanoic acid ##STR2016##

TLC: Rf 0.17 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 12.90-11.50 (1H, br), 8.80-8.10 (1H, br), 7.81 (2H, d, J=8.4 Hz), 7.60-7.32 (3H, m), 7.42 (2H, d, J=8.4 Hz), 6.03-5.60 (2H, br), 4.42-4.12 (3H, m), 2.80-2.58 (4H, m), 1.65-1.43 and 1.40-1.15 (each 2H, m), 0.87 (3H, t, J=7.4 Hz).

Example 30(64)

N-(5-(isooxazol-3-yl)thiophen-2-yl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlor ophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR2017##

TLC: Rf 0.38 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.73 (1H, d, J=1.8 Hz), 7.89-7.64 (2H, m), 7.64-7.23 (3H, m), 7.10 (1H, d, J=1.8 Hz), 6.27-5.55 (2H, br), 4.63-4.30 (3H, m), 2.92-2.47 (2H, m).

Example 30(65)

N-(5-(4-chlorophenylcarbonylaminomethyl)thiophen-2-yl)sulfonyl-3-amino-4-ox o-5-(5-(2,6-dichlorophenylmethyl)tetrazol-2-yl)pentanoic acid ##STR2018##

TLC: Rf 0.18 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 9.36 (1H, t, J=5.8 Hz), 8.03-7.76 (2H, m), 7.76-7.27 (5H, m), 7.09 (1H, d, J=4.0 Hz), 6.06-5.61 (2H, m), 4.66 (2H, d, J=5.8 Hz), 4.50 (2H, s), 4.30 (1H, t, J=6.0 Hz), 2.69-2.37 (2H, m).

Example 30(66) ps N-(4-(pyrrolidin-1-yl)phenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophen ylmethyl)tetrazol-1-yl)pentanoic acid ##STR2019##

TLC: Rf 0.49 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.33-7.94 (1H, br), 7.83-7.18 (5H, m), 6.74-6.45 (2H, m), 6.07-5.51 (2H, br), 4.39-4.00 (3H, m), 3.45-3.00 (4H, m), 2.92-2.58 (2H, m), 2.10-1.70 (4H, m).

Example 30(67)

N-(4-(morpholin-4-yl)phenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenyl methyl)tetrazol-1-yl)pentanoic acid ##STR2020##

TLC: Rf 0.24 (chloroform:methanol:acetic acid=20:1:1); NMR (DMSO-d6): δ 8.62-7.90 (1H, br), 7.81-7.61 (2H, m), 7.61-7.17 (3H, m), 7.17-6.97 (2H, m), 6.02-5.57 (2H, m), 4.44-4.02 (3H, m), 3.95-3.55 (4H, m), 3.30-3.00 (4H, m), 2.78-2.40 (2H, m).

Example 30(68)

N-(2-diethylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-2-yl)pentanoic acid•hydrochloric acid salt ##STR2021##

TLC: Rf 0.40 (chloroform:methanol:acetic acid=6:2:2); NMR (DMSO-d6): δ 8.50-8.10 (1H, br), 7.53 (2H, d, J=8.8 Hz), 7.52 (2H, d, J=7.4 Hz), 7.34 (2H, d, J=8.8 Hz, 7.4 Hz), 6.06 (2H, br), 4.65-4.40 (1H, m), 4.52 (2H, s), 3.84-3.00 (8H, m), 3.00-2.83 (2H, m), 1.22 (6H, t, J=7.0 Hz).

Example 30(69)

N-(3-methylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tet razol-2-yl)pentanoic acid ##STR2022##

TLC: Rf 0.22 (chloroform:methanol:acetic acid=40:1:1); NMR (DMSO-d6): δ 13.45-11.42 (1H, br), 8.79-8.10 (1H, br), 7.83-7.10 (7H, m), 6.20-5.54 (2H, br), 4.51 (2H, s), 4.43-4.20 (1H, m), 2.69-2.22 (2H, m), 2.39 (3H, s).

Example 30(70)

N-(4-isopropylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-2-yl)pentanoic acid ##STR2023##

TLC: Rf 0.31 (chloroform:methanol:acetic acid=40:1:1); NMR (DMSO-d6): δ 13.60-11.40 (1H, br), 8.82-8.03 (1H, br), 7.93-7.65 (2H, m), 7.65-7.10 (5H, m), 6.28-5.39 (2H, br), 4.51 (2H, s), 4.43-4.17 (1H, m), 3.10-2.81 (1H, m), 2.78-2.29 (2H, m), 1.21 (6H, d, J=6.8 Hz).

Example 30(71)

N-(4-isopropylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid ##STR2024##

TLC: Rf 0.41 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.40-11.70 (1H, br), 8.89-8.20 (1H, br), 7.95-7.69 (2H, m), 7.69-7.05 (5H, m), 6.18-5.50 (2H, br), 4.52-4.14 (1H, m), 4.30 (2H, s), 3.07-2.85 (1H, m), 2.85-2.43 (2H, m), 1.21 (6H, d, J=6.8 Hz).

Example 30(72)

N-(2-diethylaminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethy l)tetrazol-1-yl)pentanoic acid•hydrochloric acid salt ##STR2025##

TLC: Rf 0.32 (chloroform:methanol:acetic acid=6:2:2); NMR (DMSO-d6): δ 7.55 (1H, d, J=9.2 Hz), 7.55 (1H, d, J=6.8 Hz), 7.55 (1H, dd, J=9.2 Hz, 6.8 Hz), 6.05-5.87 (2H, br), 4.95-4.54 (1H, m), 4.38 (2H, m), 3.78-2.75 (10H, m), 1.16 (6H, t, J=7.0 Hz).

Example 30(73)

N-(4-butyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-2-yl)pentanoic acid ##STR2026##

TLC: Rf 0.32 (chloroform:methanol:acetic acid=40:1:1l); NMR (DMSO-d6): δ 13.25-11.90 (1H, br), 8.54-8.10 (1H, br), 7.89-7.65 (2H, m), 7.60-7.26 (3H, m), 7.20-6.97 (2H, m), 6.28-5.49 (2H, br), 4.51 (2H, s), 4.40-4.09 (1H, m), 4.06 (2H, t, J=6.2 Hz), 2.74-2.26 (2H, m), 1.87-1.58 (2H, m), 1.58-1.26 (2H, m), 0.93 (3H, t, J=7.2 Hz).

Example 30(74)

N-(4-butyloxyphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)t etrazol-1-yl)pentanoic acid ##STR2027##

TLC: Rf 0.10 (chloroform:methanol:acetic acid=40:1:1); NMR (DMSO-d6): δ 13.52-11.75 (1H, br), 8.74-8.12 (1H, br), 8.00-7.67 (2H, m), 7.67-7.25 (3H, m), 7.25-6.98 (2H, m), 6.15-5.48 (2H, br), 4.48-4.11 (1H, m), 4.26 (2H, s), 4.02 (2H, t, J=6.4 Hz), 2.83-2.37 (2H, m), 1.84-1.55 (2H, m), 1.55-1.24 (2H, m), 0.93 (3H, t, J=7.2 Hz).

Example 31 (1)

N-(4-phenylsulfinylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylme thyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR2028##

By the same procedure as provided in example 8(1), using the compound prepared in example 29(43), the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.12 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.00-7.88 and 7.88-7.75 (4H, m), 7.70-7.56 and 7.53-7.43 (5H, m), 7.40-7.12 (3H, m), 6.30-6.15 (1H, m), 5.80 (1H, d, J=17.8 Hz), 5.59 and 5.58 (total 1H, d, J=17.8 Hz), 4.60 (2H, s), 4.21-4.05 (1H, m), 2.78 (1H, dd, J=17.4 Hz, 4.0 Hz), 2.28 and 2.27 (1H, dd, J=17.4 Hz, 4.6 Hz), 1.36 (9H, s).

Example 32(1)

N-(4-phenylsulfonylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylme thyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR2029##

By the same procedure as provided in example 9(1), using the compound prepared in example 29(43), the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.21 (hexane:ethyl acetate=2:1); NMR (CDCl3): δ 8.10 (2H, d, J=8.0 Hz), 7.97 (2H, d, J=8.0 Hz), 7.98-7.90 (2H, m), 7.70-7.47 (3H, m), 7.36 (1H, d, J=9.0 Hz), 7.36 (1H, d, J=7.0 Hz), 7.18 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.15 (1H, d, J=9.0 Hz), 5.82 and 5.62 (each 1H, d, J=17.8 Hz), 4.60 (2H, s), 4.22-4.08 (1H, m), 2.78 (1H, dd, J=17.6 Hz, 4.0 Hz), 2.29 (1H, dd, J=17.6 Hz, 4.6 Hz), 1.35 (9H, s).

EXAMPLE 33(1) AND EXAMPLE 33(2)

By the same procedure as provided in example 6(1), using the compound prepared in example 31(1) or example 32(1), the compounds of the present invention having the following physical data were obtained.

Example 33(1)

N-(4-phenylsulfinylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylme thyl)tetrazol-2-yl)pentanoic acid ##STR2030##

TLC: Rf 0.10 (chloroform:methanol:acetic acid=50:1:1); NMR (DMSO-d6): δ 8.00 (2H, d, J=8.4 Hz), 7.96 (2H, d, J=8.4 Hz), 7.80-7.67 (2H, m), 7.61-7.46 and 7.42-7.32 (6H, m), 6.00-5.62 (2H, br), 4.50 (2H, s), 4.33-4.22 (1H, m), 2.57-2.37 (2H, m).

Example 33(2)

N-(4-phenylsulfonylphenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylme thyl)tetrazol-2-yl)pentanoic acid ##STR2031##

TLC: Rf 0.14 (chloroform:methanol:acetic acid=50:1:1); NMR (CDCl3): δ 8.17 (2H, d, J=8.4 Hz), 8.06 (2H, d, J=8.4 Hz), 8.01-7.93 (2H, m), 7.78-7.45 and 7.45-7.31 (6H, m), 6.03-5.68 (2H, br), 4.51 (2H, s), 4.45-4.33 (1H, m), 2.65-2.52 (2H, m).

Example 34(1)

N-(4-aminophenyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR2032##

By the same procedure as provided in reference example 9(1), using the compound prepared in example 30(12), the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.29 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 8.50-7.80 (1H, br), 7.80-7.25 (5H, m), 6.61 (2H, d, J=8.8 Hz), 6.15-5.72 (2H, m), 4.50 (2H, s), 3.97-3.81 (1H, m), 2.38-2.05 (2H, m).

Example 35(1)

N-(N,N-dibenzylamino)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid•ethylester ##STR2033##

To a solution of dibenzylamine (0.06 ml) in dimethylformamide (0.5 ml) was added 1,1'-carbonylduimidazole (50 mg) at room,temperature under an atomsphere of argon. The mixture was stirred for 30 min. To the mixture was added the compound prepared in reference example 11(2) (139 mg) in dimethylformamide (0.5 ml) at 0°C The mixture was stirred for room temperature overnight. The reaction mixture was quenched by addition of 1N aqueous solution of hydrochloric acid, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium hydrocarbonate, water, a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane: ethyl acetate=1:1) to give the compound of the present invention (79 mg) having the following physical data.

TLC: Rf 0.46 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.50-7.10 (13H, m), 5.59 (1H, d, J=8.2 Hz), 5.41 (1H, d, J=18.6 Hz), 5.23 (1H, d, J=18.6 Hz), 4.84-4.66 (1H, m), 4.69-4.47 (2H, m), 4.29 (1H, d, J=16.6 Hz), 4.17 (1H, d, J=16.6 Hz), 4.04 (2H, q, J=7.0 Hz), 3.02 (1H, dd, J=17.8 and 5.0 Hz), 2.70 (1H, dd, J=17.8 and 4.8 Hz), 1.21 (3H, t, J=7.0 Hz).

Example 36(1)

N-(N,N-dibenzylamino)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl) tetrazol-1-yl)pentanoic acid ##STR2034##

By the same procedure as provided in example 23(1), using the compound prepared in example 35(1), the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.78 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 12.88-12.00 (1H, br), 7.65-7.06 (14H, m), 5.98-5.62 (2H, m), 4.82-4.62 (1H, m), 4.59-4.13 (6H, m), 2.91 (1H, dd, J=17 and 7 Hz), 2.66 (1H, dd, J=17 and 7 Hz).

Example 37(1)

N-(N-benzyl-N-methylamino)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylme thyl)tetrazol-1-yl)pentanoic acid•t-butylester ##STR2035##

By the same procedure as provided in example 35(1), using the compound prepared in reference example 9(1) instead of the compound prepared in reference example 11(2) and N-benzyl-N-methylamine instead of dibenzylamine, compound of the present invention having the following physical data was obtained.

TLC: Rf 0.37 (hexane:ethyl acetate=1:1); NMR (CDCl3): δ 7.40-7.16 (8H, m), 5.76 (1H, d, J=7.8 Hz), 5.53 (2H, s), 4.73 (1H, m), 4.53 (2H, s), 4.30 (2H, m), 3.00 (3H, s), 2.98-2.67 (2H, m), 1.41 (9H, s).

Example 38(1)

N-(N-benzyl-N-methylamino)carbonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylme thyl)tetrazol-1-yl)pentanoic acid ##STR2036##

By the same procedure as provided in example 6(1), using the compound prepared in example 37(1), the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.28 (chloroform:methanol:acetic acid=10:1:1); NMR (DMSO-d6): δ 7.54-7.18 (9H, m), 5.81 (2H, brs), 4.60 (1H, m), 4.47 (2H, s), 4.32 (2H, m), 2.92-2.56 (5H, m).

Example 39(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-aminophenylthio)tetrazol-2-yl)pen tanoic acid ##STR2037##

To the mixture solution of the compound prepared In example 5(157) (770 mg) in methanol (11 ml) and water (3 ml) was added potassium carbonate (350 mg). The reaction mixture was stirred for 7 h at room temperature. The reaction mixture was added 1N aqueous solution of hydrochloric acid until pH 4, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of ammonium chloride, water, a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate, concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol:acetic acid=18:1:1) to give the compound of the present invention (235 mg) having the following physical data.

TLC: Rf 0.31 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 7.94 (1H, d, J=7.4 Hz), 7.46-7.24 (5H, m), 7.25 (2H, d, J=8.5 Hz), 6.59 (2H, d, J=8.5 Hz), 5.90 (2H, brs), 5.72-5.20 (2H, br), 5.08 (2H, s), 4.74-4.43 (1H, m), 2.90-2.50 (2H, m).

Example 39(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(4-aminophenylthio)tetrazol-1-yl)pen tanoic acid ##STR2038##

By the same procedure as provided in example 39(1), using the compound prepared in example 5(158) instead of the compound prepared in example 5(157), compound of the present invention having the following physical data was obtained.

TLC: Rf 0.22 (chloroform:methanol:acetic acid=18:1:1); NMR (DMSO-d6): δ 13.50-11.50 (1H, br), 8.03 (1H, d, J=7.8 Hz), 7.46-7.22 (5H, m), 7.22 (2H, d, J=8.6 Hz), 6.57 (2H, d, J=8.6 Hz), 5.94-5.30 (4H, br), 5.12 (2H, s), 4.73-4.50 (1H, m), 2.93-2.55 (2H, m).

Example 40(1)

N-(2-aminoethyl)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetra zol-2-yl)pentanoic acid ##STR2039##

By the same procedure as provided in reference example 9(1) using the compound prepared in example 30(52), the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.42 (chloroform:methanol:acetic acid=3:1:1) NMR (DMSO-d6): δ 13.00-12.40 (1H, br), 8.40-8.23 (1H, br), 8.23-8.00 (3H, br) 7.53 (1H, d, J=9.0 Hz), 7.52 (1H, d, J=7.0 Hz), 7.37 (1H, dd, J=9.0 Hz, 7.0 Hz), 6.20-5.95 (2H, br), 4.53 (2H, s), 4.65-4.40 (1H, m), 3.61-3.00 (4H, m), 3.00-2.65 (2H, m).

Reference Example 13

N-(N-t-butyloxycarbonylamino)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichloropheny lmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR2040##

By the same procedure as provided in example 29(1), using the compound prepared in reference example 9(2) instead of the compound prepared in reference example 9(1) and (N-t-butyloxycarbonylamino)sulfonyl chloride instead of 4-t-butylbenzenesulfonyl chloride, title compound having the following physical data was obtained.

TLC: Rf 0.21 (hexane:ethyl acetate=2:1).

Reference Example 14

N-(N-t-butyloxycarbonyl-N-benzylamino)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dich lorophenylmethyl)tetrazol-2-yl)pentanoic acid•t-butylester ##STR2041##

To a solution of the compound prepared in reference example 13 (548 mg) in tetrahydrofuran (7 ml) was added benzyl alcohol (0.14 ml), triphenylphosphine (361 mg) and diethylazodicarboxylate (0.55 ml) at 0°C The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was diluted with ethyl acetate, washed with water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate, concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=5:1-2:1) to give the title compound having the following physical data.

TLC: Rf 0.60 (hexane:ethyl acetate=2:1).

Example 41(1)

N-(N-benzylamino)sulfonyl-3-amino-4-oxo-5-(5-(2,6-dichlorophenylmethyl)tetr azol-2-yl)pentanoic acid ##STR2042##

By the same procedure as provided in example 6(1), using the compound prepared in reference example 14, the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.16 (chloroform:methanol:acetic acid=40:1:1). NMR (DMSO-d6): δ 13.00-11.60 (1H, br), 8.05-7.50 (1H, br), 7.70 (1H, t, J=6.1 Hz), 7.62-7.43 (2H, m), 7.43-7.07 (6H, m), 6.19-5.74 (2H, m), 4.52 (2H, s), 4.42-4.20 (1H, m), 4.10 (2H, d, J=6.1 Hz), 2.89-2.35 (2H, m).

Example 42(1)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(methylaminocarbonylmethyl)tetrazol- 2-yl)pentanoic acid ##STR2043##

To a suspension of the compound prepared in example 5 (18) (190 mg) in methanol (0.2 ml) was added 40% aqueous solution of methylamine (0.4 ml). The reaction mixture was stirred for 5 h at room temperature. The reaction mixture was quenched by addition of 1N aqueous solution of hydrochloric acid, extracted with ethyl acetate. The extract was washed with water, a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol:acetic acid=20:1:1) to give the compound of the present invention (120 mg) having the following physical data.

TLC: Rf 0.11 (chloroform:methanol:acetic acid=18:1:1). NMR (DMSO-d6): δ 8.15 (1H, d, J=5.0 Hz), 7.74 (1H, d, J=7.0 Hz), 7.53-7.13 (5H, m), 5.93 (2H, s), 5.08 (2H, s), 4.64-4.33 (1H, m), 3.74 (2H, s), 2.70-2.48 (5H, m).

Example 42(2)

N-benzyloxycarbonyl-3-amino-4-oxo-5-(5-(methylaminocarbonylmethyl)tetrazol- 1-yl)pentanoic acid ##STR2044##

By the same procedure as provided in example 42(1), using the compound prepared in example 5(21) instead of the compound prepared in example 5(18), the compound of the present invention having the following physical data was obtained.

TLC: Rf 0.08 (chloroform:methanol:acetic acid=8:1:1). NMR (DMSO-d6): δ 8.40 (1H, d, J=4.8 Hz), 7.87 (1H, d, J=7.6 Hz), 7.52-7.12 (5H, m), 5.94-5.61 (2H, m), 5.08 (2H, s), 4.66-4.40 (1H, m), 3.80 (2H, s), 2.85-2.49 (5H, m).

FORMULATION EXAMPLE
PAC Formulation Example 1

The following components were admixed in conventional manner and punched out to obtain 100 tablets each containing 50 mg of active ingredient.

______________________________________
N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-oxo-
5.0 g
5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic acid
Carboxymethylcellulose calcium (disintegrating agent) 0.2 g
Magnesium stearate (lubricating agent) 0.1 g
Microcrystalline cellulose 4.7 g
______________________________________
Formulation Example 2

The following components were admixed in conventional manner. The solution was sterilized in conventional manner, placed 5 ml portion into ampoules and freeze-dried to obtain 100 ampoules each containing 20 mg of the active ingredient.

______________________________________
N-((N-(3-phenylpropionyl)-L-valyl)-L-alanyl)-3-amino-4-
2.0 g
oxo-5-(5-(2,6-dichlorophenylmethyl)tetrazol-1-yl)pentanoic
acid
mannitol 20 g
Distilled water 1000 ml
______________________________________
INVENTORS:

Tanaka, Makoto, Ohno, Hiroyuki, Miyazaki, Tohru, Ohmoto, Kazuyuki

THIS PATENT IS REFERENCED BY THESE PATENTS:
Patent Priority Assignee Title
10478508, Jan 10 2012 KONKUK UNIVERSITY Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
10913790, Aug 26 2003 The Regents of the University of Colorado, a body corporate Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules
6555542, Jan 30 2001 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of FXa and method
7001899, Jun 10 2002 Procter & Gamble Company, The Interleukin converting enzyme inhibitors
7053057, May 23 2000 VERTEX PHARMACEUTICALS INCORPORATED Caspase inhibitors and uses thereof
7074782, Mar 29 2000 VERTEX PHARMACEUTICALS INCORPORATED Carbamate caspase inhibitors and uses thereof
7166586, Jan 30 2001 Bristol Myers Squibb Co. Sulfonamide lactam inhibitors of FXa and method
7417029, May 19 2000 VERTEX PHARMACEUTICALS INCORPORATED Prodrug of an ice inhibitor
7531570, May 27 2004 VERTEX PHARMACEUTICALS INCORPORATED Treatment of diseases using ICE inhibitors
7807781, Mar 05 1999 Regents of the University of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of viral infections
7850970, Aug 26 2003 Regents of the University of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
7858776, Oct 03 2002 AstraZeneca AB Lactams and uses thereof
7863317, Aug 19 2004 Bristol-Myers Squibb Company Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
8022041, May 19 2000 VERTEX PHARMACEUTICALS INCORPORATED Prodrug of an ICE inhibitor
8329662, May 19 2000 Vertexd Pharmaceuticals Incorporated Prodrug of an ICE inhibitor
8633305, Aug 26 2003 Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules
8691848, Mar 19 1998 VERTEX PHARMACEUTICALS INCORPORATED Inhibitors of caspases
9156880, May 19 2000 VERTEX PHARMACEUTICALS INCORPORATED Prodrug of an ice inhibitor
9487555, May 19 2000 VERTEX PHARMACEUTICALS INCORPORATED Prodrug of an ice inhibitor
9499606, Aug 26 2003 The Regents of the University of Colorado, a body corporate Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules
9695229, Aug 26 2003 The Regents of the University of Colorado, a body corporate Compositions of, and methods for, alpha-1 antitrypsin Fc fusion molecules
9938353, Jun 24 2011 KONKUK UNIVERSITY Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
9994613, May 19 2000 VERTEX PHARMACEUTICALS INCORPORATED Prodrug of an ICE inhibitor
THIS PATENT REFERENCES THESE PATENTS:
Patent Priority Assignee Title
EP339549A3,
EP519748A2,
EP761680A2,
EP10644198,
EP20618223,
WO9309135,
WO9526958,
ASSIGNMENT RECORDS    Assignment records on the USPTO
/////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Jun 22 1998OHMOTO, KAZUYUKIONO PHARMACEUTICAL CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0098820840 pdf
Jun 22 1998TANAKA, MAKOTOONO PHARMACEUTICAL CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0098820840 pdf
Jun 22 1998MIYAZAKI, TOHRUONO PHARMACEUTICAL CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0098820840 pdf
Jun 22 1998OHNO, HIROYUKIONO PHARMACEUTICAL CO , LTD ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0098820840 pdf
Jun 29 1998ONO Pharmaceutical Co., Ltd.(assignment on the face of the patent)
MAINTENANCE FEES AND DATES:    Maintenance records on the USPTO
Date Maintenance Fee Events
Mar 17 2004M1551: Payment of Maintenance Fee, 4th Year, Large Entity.
May 05 2008REM: Maintenance Fee Reminder Mailed.
Oct 24 2008EXP: Patent Expired for Failure to Pay Maintenance Fees.


Date Maintenance Schedule
Oct 24 20034 years fee payment window open
Apr 24 20046 months grace period start (w surcharge)
Oct 24 2004patent expiry (for year 4)
Oct 24 20062 years to revive unintentionally abandoned end. (for year 4)
Oct 24 20078 years fee payment window open
Apr 24 20086 months grace period start (w surcharge)
Oct 24 2008patent expiry (for year 8)
Oct 24 20102 years to revive unintentionally abandoned end. (for year 8)
Oct 24 201112 years fee payment window open
Apr 24 20126 months grace period start (w surcharge)
Oct 24 2012patent expiry (for year 12)
Oct 24 20142 years to revive unintentionally abandoned end. (for year 12)